data_2mn7_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mn7 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 1.5 mp . . . . . 0 N--CA 1.468 0.436 0 CA-C-O 120.576 0.227 . . . . 0.0 110.506 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 63.8 m95 -62.65 -49.54 74.73 Favored 'General case' 0 C--O 1.221 -0.432 0 CA-C-O 120.754 0.311 . . . . 0.0 110.576 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.432 ' OE1' ' N ' ' A' ' 8' ' ' GLN . 20.9 mp0 -64.17 -38.52 91.34 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.491 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 3.0 mm? -63.64 -39.33 94.07 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.646 179.284 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 9.1 mt -63.86 -51.0 66.61 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.872 -178.077 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 3.4 mp -66.08 -44.45 91.93 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.396 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 69.3 mt -63.58 -45.01 98.8 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.086 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.285 -179.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.438 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -65.01 -37.83 88.94 Favored 'General case' 0 C--N 1.317 -0.844 0 O-C-N 123.435 0.46 . . . . 0.0 111.245 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 71.4 t -67.86 -43.98 85.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.794 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.8 mt -66.33 -43.47 91.45 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.104 0 CA-C-O 121.59 0.71 . . . . 0.0 109.322 179.435 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.8 t -63.53 -42.41 96.08 Favored 'Isoleucine or valine' 0 CA--C 1.479 -1.788 0 CA-C-N 114.794 -1.094 . . . . 0.0 109.788 -178.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.438 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 60.4 t -66.5 -48.89 79.15 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.046 0 C-N-CA 117.609 -1.636 . . . . 0.0 112.787 -177.227 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -66.99 -44.38 80.55 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 118.863 -1.135 . . . . 0.0 112.042 179.667 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.431 ' C ' ' CD1' ' A' ' 19' ' ' LEU . 0.4 OUTLIER -65.95 -38.47 88.69 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.823 -179.979 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 4.7 m-85 -67.89 -41.03 83.37 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.463 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 108.62 14.58 15.45 Favored Glycine 0 C--N 1.312 -0.803 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 178.392 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.463 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 68.0 p 52.02 39.51 26.47 Favored 'General case' 0 CA--C 1.495 -1.136 0 CA-C-N 114.747 -0.726 . . . . 0.0 112.473 178.283 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 59.5 tttm -112.43 -41.29 3.9 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.935 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.92 -56.28 9.65 Favored 'General case' 0 CA--C 1.509 -0.63 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.271 -179.492 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.509 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.311 -1.07 0 CA-C-O 121.901 0.858 . . . . 0.0 109.989 -177.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 38.7 t . . . . . 0 CA--C 1.517 -0.29 0 N-CA-C 111.699 0.259 . . . . 0.0 111.699 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.9 m-20 -94.24 -35.51 12.43 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 179.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -74.32 -49.35 23.31 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.408 -1.269 . . . . 0.0 111.412 -178.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.57 -42.97 99.86 Favored Glycine 0 CA--C 1.518 0.246 0 N-CA-C 109.304 -1.519 . . . . 0.0 109.304 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.59 -39.28 93.45 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.783 -0.709 . . . . 0.0 110.939 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 75.3 m -62.88 -41.31 99.35 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.137 -0.625 . . . . 0.0 110.709 -178.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.3 mp -68.65 -40.01 81.13 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.861 179.048 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.6 ptmt -59.79 -41.81 91.98 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 -178.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.17 -36.47 90.16 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 177.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 23.0 t80 -71.75 -52.44 17.68 Favored 'General case' 0 CA--C 1.514 -0.428 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.227 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 62.2 mttm -62.81 -40.18 96.56 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.43 179.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 38.9 ttpt -63.43 -38.36 90.84 Favored 'General case' 0 C--N 1.317 -0.846 0 C-N-CA 119.95 -0.7 . . . . 0.0 111.212 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.325 -0.488 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.818 -178.974 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.406 ' CG2' ' N ' ' A' ' 7' ' ' TRP . 3.4 tp . . . . . 0 N--CA 1.442 -0.833 0 CA-C-O 121.754 0.788 . . . . 0.0 111.907 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.427 ' CD1' ' C ' ' A' ' 7' ' ' TRP . 5.6 t-105 -61.91 -39.34 91.67 Favored 'General case' 0 N--CA 1.421 -1.884 0 CA-C-N 114.88 -1.054 . . . . 0.0 108.748 -178.321 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -64.74 -38.85 92.4 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 178.158 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.507 ' O ' ' N ' ' A' ' 13' ' ' ALA . 73.7 mt -62.74 -38.09 89.14 Favored 'General case' 0 CA--C 1.503 -0.851 0 CA-C-N 114.925 -1.034 . . . . 0.0 110.479 178.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.7 mt -62.63 -47.62 82.94 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.235 -177.274 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.457 HD11 ' N ' ' A' ' 11' ' ' ILE . 3.2 mp -69.13 -44.58 80.82 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 178.21 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 77.3 mt -64.02 -44.48 97.82 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.307 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.507 ' N ' ' O ' ' A' ' 9' ' ' LEU . . . -64.9 -36.63 84.97 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.945 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.43 ' O ' ' CD2' ' A' ' 18' ' ' LEU . 48.8 t -67.28 -44.29 87.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.307 -179.026 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 14.1 pt -67.24 -43.9 87.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.831 179.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -64.79 -39.3 85.19 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.07 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.323 -179.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 75.8 t -66.25 -46.99 85.89 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 C-N-CA 118.683 -1.207 . . . . 0.0 112.743 -178.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.43 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 0.8 OUTLIER -68.88 -42.39 77.04 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.419 0.628 . . . . 0.0 110.031 179.046 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.444 ' C ' ' CD1' ' A' ' 19' ' ' LEU . 2.2 tm? -63.88 -39.84 95.14 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.623 -1.171 . . . . 0.0 109.875 -179.306 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -69.17 -37.22 78.09 Favored 'General case' 0 CA--C 1.513 -0.454 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 177.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.509 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 102.3 9.59 41.24 Favored Glycine 0 N--CA 1.462 0.405 0 CA-C-N 115.086 -0.961 . . . . 0.0 110.916 179.135 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.509 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 51.6 p 58.56 22.22 9.5 Favored 'General case' 0 C--N 1.32 -0.713 0 O-C-N 123.935 0.433 . . . . 0.0 111.99 178.774 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -100.96 -15.82 17.38 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.103 -0.499 . . . . 0.0 112.06 -179.599 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 15.2 mmmt -92.29 -57.82 2.58 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.178 0.513 . . . . 0.0 110.718 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.654 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 1.7 mp . . . . . 0 CA--C 1.496 -1.124 0 CA-C-O 122.272 1.034 . . . . 0.0 110.417 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.7 m . . . . . 0 C--O 1.232 0.177 0 CA-C-O 120.657 0.265 . . . . 0.0 111.214 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -70.09 -43.83 70.3 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 179.302 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -65.08 -44.1 90.01 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.064 -0.971 . . . . 0.0 111.249 179.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.6 -45.49 94.51 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 119.208 -1.472 . . . . 0.0 109.863 -179.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.11 -39.65 71.94 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.56 -0.32 . . . . 0.0 111.738 179.22 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 14.5 t -63.03 -42.14 99.7 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.341 -177.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.71 -39.64 80.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.744 178.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 34.5 tttm -59.91 -43.36 94.9 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 -178.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.81 -36.79 91.67 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 177.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 13.7 t80 -71.64 -50.23 32.56 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-O 120.897 0.379 . . . . 0.0 110.221 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 47.8 mtpt -62.86 -38.88 92.6 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.346 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 50.5 mtpt -61.82 -38.85 89.7 Favored 'General case' 0 C--N 1.319 -0.744 0 C-N-CA 119.764 -0.774 . . . . 0.0 110.083 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.324 -0.515 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.778 -179.856 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 34.4 mm . . . . . 0 N--CA 1.444 -0.768 0 CA-C-O 121.092 0.472 . . . . 0.0 110.356 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 94.1 m95 -74.32 -38.93 63.15 Favored 'General case' 0 C--N 1.321 -0.638 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.096 179.595 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.499 ' N ' ' OE1' ' A' ' 8' ' ' GLN . 0.8 OUTLIER -64.23 -38.77 92.22 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -179.686 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.429 ' C ' ' CD1' ' A' ' 9' ' ' LEU . 0.4 OUTLIER -73.31 -38.19 65.93 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.249 179.672 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 13.8 mt -63.41 -46.87 84.4 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.871 0.367 . . . . 0.0 111.278 -177.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.2 mp -67.74 -44.23 85.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.201 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 35.1 mt -65.04 -44.64 95.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.121 -179.27 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.46 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -64.74 -37.54 87.93 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 115.762 -0.653 . . . . 0.0 110.966 -178.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.437 ' O ' ' CD2' ' A' ' 18' ' ' LEU . 54.4 t -66.93 -44.99 88.36 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.426 0 C-N-CA 120.435 -0.506 . . . . 0.0 111.506 -178.764 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 16.7 pt -66.9 -42.65 89.24 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.99 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.147 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.51 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.7 t -63.82 -41.43 92.54 Favored 'Isoleucine or valine' 0 CA--C 1.482 -1.659 0 CA-C-N 115.388 -0.823 . . . . 0.0 109.795 -178.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.46 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 52.2 t -66.29 -50.43 68.15 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.93 0 C-N-CA 117.548 -1.661 . . . . 0.0 113.32 -177.269 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.437 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 1.2 pp -67.04 -44.11 81.03 Favored 'General case' 0 C--N 1.296 -1.727 0 C-N-CA 119.151 -1.02 . . . . 0.0 111.881 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.436 ' C ' ' CD1' ' A' ' 19' ' ' LEU . 0.4 OUTLIER -65.78 -38.43 89.02 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.607 -0.27 . . . . 0.0 111.028 179.8 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.51 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 3.4 m-85 -68.38 -37.13 80.11 Favored 'General case' 0 CA--C 1.515 -0.376 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.819 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.466 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 97.93 13.77 42.04 Favored Glycine 0 CA--C 1.504 -0.601 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.512 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.466 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 46.2 p 53.2 76.95 0.18 Allowed 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 114.083 -1.058 . . . . 0.0 112.121 178.504 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 18.0 ptmt -142.4 -36.46 0.4 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.939 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 11.1 mmmt -77.31 -50.75 12.14 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.39 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.474 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 0.2 OUTLIER . . . . . 0 CA--C 1.503 -0.84 0 CA-C-O 122.12 0.962 . . . . 0.0 110.449 -178.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.4 t . . . . . 0 CA--C 1.523 -0.089 0 CA-C-O 120.692 0.282 . . . . 0.0 111.341 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -73.93 -42.6 60.34 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -66.83 -44.44 81.11 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 114.998 -1.001 . . . . 0.0 111.475 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.41 -44.13 97.24 Favored Glycine 0 N--CA 1.44 -1.051 0 C-N-CA 119.322 -1.418 . . . . 0.0 109.817 -179.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.73 -40.13 69.61 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.529 -0.336 . . . . 0.0 111.346 179.05 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.5 m -63.69 -40.56 97.1 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.223 -178.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.408 HD11 ' N ' ' A' ' 36' ' ' ILE . 1.2 mp -70.19 -39.52 77.04 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.677 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.5 ptmt -59.79 -41.86 92.12 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 -178.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.81 -36.9 87.92 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -71.49 -50.82 27.8 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 53.7 mtpt -63.21 -38.6 91.82 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.506 178.655 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -61.49 -39.2 90.07 Favored 'General case' 0 C--N 1.318 -0.766 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.867 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.323 -0.572 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.705 179.869 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.49 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.5 mp . . . . . 0 N--CA 1.453 -0.287 0 CA-C-O 120.755 0.312 . . . . 0.0 110.463 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 67.6 m95 -62.15 -46.98 86.57 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.43 -38.9 92.63 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.413 ' O ' ' CB ' ' A' ' 13' ' ' ALA . 89.2 mt -66.08 -38.73 89.0 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.306 178.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 16.7 mt -63.43 -50.28 70.41 Favored 'General case' 0 C--N 1.315 -0.919 0 C-N-CA 120.131 -0.628 . . . . 0.0 110.541 -176.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 3.4 mp -66.61 -44.73 89.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.107 178.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 75.5 mt -63.91 -46.79 93.16 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.967 0 C-N-CA 120.294 -0.562 . . . . 0.0 111.432 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.436 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -65.0 -37.68 88.47 Favored 'General case' 0 C--N 1.319 -0.745 0 O-C-N 123.213 0.321 . . . . 0.0 111.349 -179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.2 t -67.8 -43.82 86.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.613 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.448 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 96.6 mt -66.2 -43.53 91.86 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.155 0 O-C-N 123.521 0.513 . . . . 0.0 109.725 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.424 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.6 t -63.72 -42.26 95.38 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.504 0 CA-C-N 115.08 -0.964 . . . . 0.0 109.919 -178.637 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.436 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 59.9 t -66.27 -44.78 91.05 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 C-N-CA 118.217 -1.393 . . . . 0.0 112.79 -176.844 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.2 pp -71.96 -42.9 66.02 Favored 'General case' 0 C--N 1.294 -1.825 0 C-N-CA 120.046 -0.661 . . . . 0.0 109.761 178.177 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.448 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.6 tm? -64.8 -41.75 95.56 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.823 -179.175 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.424 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 6.9 m-85 -69.24 -33.47 73.33 Favored 'General case' 0 CA--C 1.511 -0.558 0 C-N-CA 119.067 -1.053 . . . . 0.0 108.831 178.716 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.475 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 93.93 12.9 56.06 Favored Glycine 0 C--N 1.318 -0.471 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 179.244 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.475 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 43.1 p 55.78 77.73 0.22 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 114.684 -0.758 . . . . 0.0 112.002 178.762 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -146.28 -26.11 0.43 Allowed 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.454 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.65 -39.71 10.65 Favored 'General case' 0 C--O 1.223 -0.315 0 C-N-CA 120.719 -0.393 . . . . 0.0 110.905 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.447 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 0.2 OUTLIER . . . . . 0 CA--C 1.501 -0.931 0 CA-C-O 121.714 0.768 . . . . 0.0 110.001 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.5 t . . . . . 0 CA--C 1.52 -0.177 0 N-CA-C 111.733 0.272 . . . . 0.0 111.733 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -75.54 -42.51 52.25 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.438 0.637 . . . . 0.0 109.487 179.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.8 mp -66.89 -44.66 80.28 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.043 -0.98 . . . . 0.0 111.81 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.32 -44.12 97.4 Favored Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 119.413 -1.375 . . . . 0.0 109.832 -179.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.84 -39.79 69.49 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.66 -0.27 . . . . 0.0 111.394 179.183 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.7 m -63.24 -40.92 98.79 Favored 'General case' 0 CA--C 1.518 -0.287 0 CA-C-O 121.112 0.482 . . . . 0.0 110.477 -178.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.63 -39.36 78.15 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.757 178.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 24.2 tttt -59.97 -44.56 94.37 Favored 'General case' 0 N--CA 1.435 -1.217 0 C-N-CA 119.231 -0.988 . . . . 0.0 108.414 -179.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.97 -36.34 91.91 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 178.005 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 21.0 t80 -71.38 -51.41 24.24 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-O 120.835 0.35 . . . . 0.0 110.456 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -63.08 -38.56 91.66 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.38 178.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -61.36 -36.84 81.33 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.121 -0.632 . . . . 0.0 110.012 -179.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.325 -0.475 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.126 179.663 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 4.6 tp . . . . . 0 N--CA 1.448 -0.557 0 CA-C-O 121.219 0.533 . . . . 0.0 111.986 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 8.1 t-105 -62.2 -37.12 84.12 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 115.459 -0.791 . . . . 0.0 108.91 -178.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -64.35 -38.91 92.71 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 178.318 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 84.0 mt -64.79 -37.58 88.11 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.93 178.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.4 ' O ' ' CG2' ' A' ' 14' ' ' VAL . 3.9 mt -62.47 -43.89 97.71 Favored 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.274 -177.239 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.2 mt -68.35 -45.11 83.02 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 C-N-CA 119.992 -0.683 . . . . 0.0 109.593 178.049 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 72.0 mt -65.98 -44.74 92.19 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.572 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.531 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.466 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -65.22 -37.21 86.56 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.03 -179.517 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.48 ' O ' ' CD2' ' A' ' 18' ' ' LEU . 46.0 t -66.65 -44.78 89.57 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.717 0 C-N-CA 120.599 -0.44 . . . . 0.0 111.485 -179.082 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.439 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 15.2 pt -66.61 -42.64 90.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.209 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.514 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.5 t -63.85 -41.82 93.8 Favored 'Isoleucine or valine' 0 CA--C 1.483 -1.603 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.702 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.466 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 61.5 t -65.8 -45.93 90.21 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 C-N-CA 118.361 -1.335 . . . . 0.0 112.948 -177.216 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.48 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 1.4 pp -72.11 -42.85 65.59 Favored 'General case' 0 C--N 1.288 -2.093 0 CA-C-O 121.333 0.587 . . . . 0.0 109.791 178.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.467 ' C ' ' CD1' ' A' ' 19' ' ' LEU . 2.5 tm? -64.67 -42.3 95.47 Favored 'General case' 0 N--CA 1.44 -0.956 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.164 -179.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.514 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 5.7 m-85 -68.94 -34.37 75.24 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 119.138 -1.025 . . . . 0.0 109.314 179.333 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.487 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 96.32 11.38 54.32 Favored Glycine 0 N--CA 1.466 0.635 0 N-CA-C 110.647 -0.981 . . . . 0.0 110.647 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.487 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 43.4 p 56.53 68.58 0.84 Allowed 'General case' 0 CA--C 1.502 -0.884 0 CA-C-N 115.055 -0.573 . . . . 0.0 112.271 178.199 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -139.87 -24.77 0.83 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.015 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 10.1 mmmt -87.06 -52.09 5.63 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.821 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.508 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 0.1 OUTLIER . . . . . 0 CA--C 1.505 -0.781 0 CA-C-O 121.783 0.801 . . . . 0.0 110.266 -178.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.1 p . . . . . 0 CA--C 1.519 -0.217 0 CA-C-O 120.655 0.265 . . . . 0.0 111.336 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 46.2 t0 -81.36 -39.47 25.02 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.254 0.549 . . . . 0.0 109.694 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.0 mp -69.37 -45.32 69.63 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.193 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.76 -43.94 98.21 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 119.531 -1.319 . . . . 0.0 109.913 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.0 -39.99 79.0 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.538 -0.331 . . . . 0.0 111.372 179.522 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 47.1 t -63.28 -42.26 99.08 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.093 0.473 . . . . 0.0 110.718 -178.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.88 -39.42 79.92 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.154 179.205 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 7.6 ttpt -59.39 -43.65 92.92 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.242 -0.983 . . . . 0.0 108.524 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.73 -36.21 92.0 Favored Glycine 0 N--CA 1.444 -0.821 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 178.439 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -71.08 -52.54 18.84 Favored 'General case' 0 CA--C 1.512 -0.517 0 CA-C-O 120.976 0.417 . . . . 0.0 110.133 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -63.36 -38.86 92.81 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 120.27 -0.572 . . . . 0.0 110.545 178.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 1.9 tmtp? -61.7 -39.15 90.44 Favored 'General case' 0 C--N 1.319 -0.76 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.106 -179.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.325 -0.478 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.953 179.572 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 3.7 tp . . . . . 0 N--CA 1.447 -0.586 0 CA-C-O 121.235 0.54 . . . . 0.0 111.578 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.445 ' CD1' ' C ' ' A' ' 7' ' ' TRP . 0.3 OUTLIER -62.21 -41.62 98.54 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-N 115.365 -0.834 . . . . 0.0 108.967 -179.185 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 18.4 mt-30 -64.08 -38.38 90.87 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 178.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.514 ' O ' ' N ' ' A' ' 13' ' ' ALA . 87.5 mt -65.37 -36.98 85.63 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.326 177.439 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.8 tt -61.84 -50.95 70.19 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.888 -174.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 mp -65.35 -44.73 94.64 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 C-N-CA 119.893 -0.723 . . . . 0.0 109.533 177.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.1 mp -63.77 -44.36 98.23 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.21 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.904 179.49 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.514 ' N ' ' O ' ' A' ' 9' ' ' LEU . . . -64.56 -37.35 87.27 Favored 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 121.086 -0.246 . . . . 0.0 110.836 -179.411 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.451 ' O ' ' CD2' ' A' ' 18' ' ' LEU . 53.0 t -66.93 -45.01 88.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 C-N-CA 120.544 -0.462 . . . . 0.0 111.465 -179.191 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 13.5 pt -66.87 -42.76 89.47 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.989 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 178.59 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.553 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.4 t -63.14 -41.54 93.21 Favored 'Isoleucine or valine' 0 CA--C 1.478 -1.799 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.883 -178.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.461 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 51.7 t -66.14 -51.23 62.11 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.033 0 C-N-CA 117.857 -1.537 . . . . 0.0 113.652 -177.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.451 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 1.4 pp -66.89 -44.36 81.08 Favored 'General case' 0 C--N 1.293 -1.869 0 C-N-CA 119.487 -0.885 . . . . 0.0 111.782 179.764 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.432 ' C ' ' CD1' ' A' ' 19' ' ' LEU . 0.4 OUTLIER -65.77 -38.87 90.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.704 -0.225 . . . . 0.0 110.638 -179.943 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.553 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 3.0 m-85 -68.5 -36.54 79.05 Favored 'General case' 0 CA--C 1.513 -0.476 0 C-N-CA 119.607 -0.837 . . . . 0.0 109.317 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.472 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 96.98 12.01 51.11 Favored Glycine 0 CA--C 1.506 -0.501 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 -179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.472 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 43.3 p 54.74 74.74 0.33 Allowed 'General case' 0 CA--C 1.5 -0.963 0 CA-C-N 114.196 -1.002 . . . . 0.0 112.677 178.055 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 62.1 mttp -139.04 -31.57 0.7 Allowed 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.784 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 6.7 mmpt? -81.6 -54.35 5.48 Favored 'General case' 0 CA--C 1.501 -0.914 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.612 -179.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.467 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.312 -1.024 0 CA-C-O 122.371 1.081 . . . . 0.0 110.701 -176.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.2 p . . . . . 0 N--CA 1.456 -0.168 0 CA-C-O 120.702 0.287 . . . . 0.0 110.944 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -72.96 -43.28 62.48 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.54 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.5 mp -64.97 -44.37 89.58 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.185 179.578 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -64.02 -45.1 94.81 Favored Glycine 0 N--CA 1.44 -1.093 0 C-N-CA 119.251 -1.452 . . . . 0.0 109.765 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.65 -39.71 73.46 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.513 -0.344 . . . . 0.0 111.664 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.9 t -62.89 -41.91 99.59 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.407 -177.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.412 ' CG2' ' HZ3' ' A' ' 40' ' ' LYS . 1.2 mp -69.72 -39.77 78.44 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.145 178.613 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 36.6 tttm -60.07 -41.45 92.42 Favored 'General case' 0 N--CA 1.426 -1.644 0 N-CA-C 108.056 -1.091 . . . . 0.0 108.056 -178.529 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.12 -36.49 90.44 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 109.882 -1.287 . . . . 0.0 109.882 177.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -71.6 -51.92 20.78 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.188 -179.308 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.412 ' HZ3' ' CG2' ' A' ' 36' ' ' ILE . 54.5 mttp -63.72 -39.65 94.81 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.517 178.322 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 61.6 tttm -61.79 -38.79 89.38 Favored 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 120.054 -0.658 . . . . 0.0 110.458 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.322 -0.62 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.701 -179.637 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 40.8 mm . . . . . 0 N--CA 1.45 -0.464 0 CA-C-O 120.848 0.356 . . . . 0.0 111.06 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 82.9 m95 -71.68 -40.69 69.42 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 120.279 -0.568 . . . . 0.0 110.207 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.488 ' N ' ' OE1' ' A' ' 8' ' ' GLN . 1.7 mp0 -64.41 -38.8 92.31 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.055 0.455 . . . . 0.0 110.311 -179.227 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.455 ' C ' ' CD1' ' A' ' 9' ' ' LEU . 0.3 OUTLIER -72.31 -38.0 68.81 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.97 179.7 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 15.8 mt -63.28 -48.78 76.68 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.73 -176.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.2 mp -66.13 -44.33 91.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 178.394 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 69.3 mt -64.06 -44.48 97.74 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.642 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.391 -179.366 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.451 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -64.91 -37.09 86.5 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.867 -179.067 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.496 ' O ' ' CD2' ' A' ' 18' ' ' LEU . 50.2 t -66.93 -45.6 86.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 C-N-CA 120.425 -0.51 . . . . 0.0 111.574 -178.809 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 15.9 pt -66.41 -42.34 90.27 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.916 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.736 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.7 t -63.19 -42.36 96.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.35 -179.626 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.451 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 61.3 t -65.63 -48.96 80.69 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.887 0 C-N-CA 117.245 -1.782 . . . . 0.0 113.69 -176.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.496 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 1.6 pp -68.49 -44.0 75.66 Favored 'General case' 0 C--N 1.289 -2.063 0 C-N-CA 120.094 -0.642 . . . . 0.0 112.156 -179.377 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.448 ' C ' ' CD1' ' A' ' 19' ' ' LEU . 0.4 OUTLIER -66.3 -39.19 89.15 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.99 -179.604 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.736 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 1.8 m-85 -68.45 -37.62 80.37 Favored 'General case' 0 CA--C 1.506 -0.726 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.641 -178.395 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.49 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 101.2 9.53 44.56 Favored Glycine 0 C--N 1.308 -0.974 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.046 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.49 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 44.6 p 55.15 66.66 1.17 Allowed 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 178.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -139.6 -22.57 0.89 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.054 179.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 9.9 mmmt -87.13 -51.41 6.01 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.646 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.484 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.316 -0.866 0 CA-C-O 122.067 0.937 . . . . 0.0 110.556 -178.85 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.2 p . . . . . 0 N--CA 1.454 -0.259 0 CA-C-O 120.796 0.332 . . . . 0.0 111.058 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -76.02 -39.88 54.71 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.078 0.466 . . . . 0.0 109.874 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.7 mp -70.21 -45.59 66.27 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.129 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.55 -43.57 98.83 Favored Glycine 0 N--CA 1.441 -1.007 0 C-N-CA 119.545 -1.312 . . . . 0.0 110.473 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.02 -40.04 71.99 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 120.898 0.38 . . . . 0.0 111.06 179.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 12.4 t -63.99 -41.93 97.36 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 120.559 -0.456 . . . . 0.0 110.98 -178.558 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.44 -39.87 79.2 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.71 -179.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 18.7 pttt -59.58 -40.51 87.62 Favored 'General case' 0 C--N 1.309 -1.195 0 C-N-CA 118.591 -1.243 . . . . 0.0 107.843 -178.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -69.46 -36.82 78.07 Favored Glycine 0 N--CA 1.442 -0.92 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 179.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -71.52 -50.71 28.67 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.552 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 52.7 mtpt -63.65 -38.85 92.66 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.597 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -62.04 -37.97 86.94 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 119.981 -0.687 . . . . 0.0 110.09 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.325 -0.471 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.495 -179.939 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.422 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.4 mp . . . . . 0 CA--C 1.534 0.334 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 70.9 m95 -62.76 -46.97 85.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.692 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 59.1 mm-40 -64.35 -39.05 93.11 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.423 ' O ' ' N ' ' A' ' 13' ' ' ALA . 84.4 mt -65.08 -39.1 92.72 Favored 'General case' 0 CA--C 1.508 -0.649 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.146 178.626 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.0 mt -63.38 -49.16 74.91 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.521 -176.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.486 ' O ' HG12 ' A' ' 15' ' ' ILE . 3.3 mp -67.67 -44.97 85.66 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.775 0 C-N-CA 119.508 -0.877 . . . . 0.0 109.093 178.07 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 77.1 mt -63.36 -44.36 98.98 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.526 -179.165 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.423 ' N ' ' O ' ' A' ' 9' ' ' LEU . . . -63.79 -36.46 83.96 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.203 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.405 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 65.8 t -67.1 -43.06 88.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 C-N-CA 119.779 -0.769 . . . . 0.0 110.457 179.672 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.486 HG12 ' O ' ' A' ' 11' ' ' ILE . 33.5 mm -66.08 -43.04 92.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.127 0.489 . . . . 0.0 110.28 179.26 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -63.75 -38.04 81.27 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.558 -178.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.407 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 95.0 t -65.66 -43.02 93.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 C-N-CA 118.409 -1.316 . . . . 0.0 111.868 -178.308 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.405 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 16.1 mt -62.0 -45.03 95.42 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 118.631 -1.227 . . . . 0.0 111.833 -179.106 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.449 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.78 -38.37 79.97 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -178.528 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.449 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 1.3 m-85 -67.57 -32.44 73.2 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -177.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.472 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 94.45 8.88 59.46 Favored Glycine 0 CA--C 1.5 -0.887 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 178.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.472 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 18.0 p 56.95 27.95 13.94 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 114.27 -0.965 . . . . 0.0 112.502 178.034 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -100.57 -12.84 18.92 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.776 179.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 15.4 mmmt -96.06 -58.43 2.09 Favored 'General case' 0 C--O 1.221 -0.438 0 CA-C-O 121.053 0.454 . . . . 0.0 110.281 179.511 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.684 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 2.0 mp . . . . . 0 CA--C 1.495 -1.144 0 CA-C-O 122.459 1.123 . . . . 0.0 110.468 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 61.9 p . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.731 0.301 . . . . 0.0 111.761 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.412 ' O ' ' OG ' ' A' ' 35' ' ' SER . 29.5 t70 -67.81 -39.87 83.91 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.411 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -65.46 -44.99 85.51 Favored 'General case' 0 CA--C 1.507 -0.694 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.159 179.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.43 -43.43 99.34 Favored Glycine 0 N--CA 1.433 -1.54 0 N-CA-C 108.475 -1.85 . . . . 0.0 108.475 -178.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.97 -40.0 75.63 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.073 -0.564 . . . . 0.0 111.159 178.429 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.412 ' OG ' ' O ' ' A' ' 31' ' ' ASP . 51.6 m -63.53 -43.37 97.33 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 120.408 -0.517 . . . . 0.0 110.87 -178.452 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -67.28 -39.71 83.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.64 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.0 pttt -60.02 -42.08 93.56 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 -179.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.68 -36.83 88.37 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 178.23 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 14.8 t80 -71.94 -50.41 29.27 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 120.956 0.408 . . . . 0.0 110.642 -179.673 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 21.8 mtpp -62.74 -38.55 90.99 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.269 179.066 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -61.76 -38.3 87.49 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.475 -179.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.327 -0.405 0 CA-C-O 121.194 0.521 . . . . 0.0 109.626 179.189 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.578 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.4 mp . . . . . 0 N--CA 1.435 -1.21 0 CA-C-O 121.153 0.501 . . . . 0.0 110.403 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -70.92 -39.71 72.53 Favored 'General case' 0 C--N 1.316 -0.884 0 C-N-CA 120.068 -0.653 . . . . 0.0 109.773 179.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 94.2 mm-40 -64.66 -39.15 93.19 Favored 'General case' 0 N--CA 1.442 -0.85 0 C-N-CA 120.315 -0.554 . . . . 0.0 109.617 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.443 ' O ' ' N ' ' A' ' 13' ' ' ALA . 0.4 OUTLIER -73.05 -38.36 66.51 Favored 'General case' 0 C--O 1.226 -0.176 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.014 179.027 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 15.3 mt -63.31 -47.82 80.66 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.945 -0.302 . . . . 0.0 111.22 -177.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.407 HD13 ' N ' ' A' ' 11' ' ' ILE . 2.1 mp -66.94 -44.48 88.64 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.851 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 53.3 mt -64.42 -44.72 97.09 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.076 0 CA-C-N 115.639 -0.709 . . . . 0.0 111.271 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.443 ' N ' ' O ' ' A' ' 9' ' ' LEU . . . -64.84 -37.39 87.47 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.719 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.47 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 55.3 t -67.67 -45.72 84.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 C-N-CA 119.624 -0.831 . . . . 0.0 110.697 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.5 mt -65.85 -43.88 92.97 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.717 0 CA-C-O 121.172 0.51 . . . . 0.0 111.189 -179.023 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -64.46 -38.74 83.36 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.344 0 CA-C-N 115.284 -0.871 . . . . 0.0 109.616 -178.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.412 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 61.0 t -65.75 -42.79 93.19 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.158 0 C-N-CA 118.571 -1.252 . . . . 0.0 111.389 -177.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.47 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 66.0 mt -61.77 -44.96 95.86 Favored 'General case' 0 C--N 1.312 -1.031 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.751 -179.02 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.434 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.55 -38.29 80.65 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 113.067 0.765 . . . . 0.0 113.067 -178.74 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.434 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 1.2 m-85 -67.61 -31.74 71.97 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -178.224 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.442 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 90.74 2.79 71.84 Favored Glycine 0 C--N 1.318 -0.47 0 N-CA-C 109.211 -1.556 . . . . 0.0 109.211 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.442 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 5.5 p 57.19 9.09 0.63 Allowed 'General case' 0 CA--C 1.511 -0.544 0 CA-C-N 114.727 -0.737 . . . . 0.0 112.178 178.03 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 24.7 mtpp -71.76 -42.26 67.42 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.256 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.57 -25.17 25.14 Favored 'General case' 0 C--O 1.221 -0.41 0 CA-C-N 116.16 -0.473 . . . . 0.0 112.017 -178.705 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.464 ' H ' HD12 ' A' ' 25' ' ' LEU . 9.7 mp . . . . . 0 CA--C 1.49 -1.328 0 CA-C-O 121.852 0.834 . . . . 0.0 109.353 -179.669 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 7.3 t . . . . . 0 C--O 1.232 0.149 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -86.53 -36.19 19.1 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.4 mp -73.03 -46.34 52.48 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.129 -0.942 . . . . 0.0 111.725 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.78 -43.66 98.94 Favored Glycine 0 C--N 1.308 -1.003 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.579 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.0 -40.32 75.34 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.486 -0.357 . . . . 0.0 111.479 179.57 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.5 t -63.61 -42.84 98.17 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.195 0.521 . . . . 0.0 110.857 -178.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.417 ' N ' HD12 ' A' ' 36' ' ' ILE . 1.1 mp -67.09 -39.76 83.92 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.753 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.1 pttp -59.81 -42.71 94.08 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 118.809 -1.156 . . . . 0.0 108.301 -178.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.87 -36.88 87.57 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.495 -1.042 . . . . 0.0 110.495 178.549 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 51.6 t80 -71.91 -53.34 13.45 Favored 'General case' 0 CA--C 1.513 -0.445 0 CA-C-O 120.684 0.278 . . . . 0.0 111.597 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 9.9 pttm -62.75 -38.37 90.3 Favored 'General case' 0 C--N 1.318 -0.773 0 C-N-CA 120.069 -0.652 . . . . 0.0 109.994 -179.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 52.9 tttp -61.47 -37.52 83.91 Favored 'General case' 0 N--CA 1.446 -0.654 0 C-N-CA 120.153 -0.619 . . . . 0.0 110.057 -179.523 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.324 -0.508 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.53 179.389 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 26.1 mm . . . . . 0 N--CA 1.443 -0.777 0 CA-C-O 121.523 0.678 . . . . 0.0 111.315 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -62.74 -42.0 99.46 Favored 'General case' 0 N--CA 1.434 -1.242 0 CA-C-N 115.219 -0.901 . . . . 0.0 108.756 179.338 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.539 ' N ' ' OE1' ' A' ' 8' ' ' GLN . 5.9 mp0 -64.74 -38.73 91.97 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.127 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 32.7 mt -60.03 -37.28 79.3 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.789 178.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.8 mt -61.94 -44.32 97.01 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.077 -176.671 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 4.4 mp -66.65 -45.33 88.62 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.508 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.329 177.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.403 ' N ' ' CD1' ' A' ' 12' ' ' ILE . 1.1 mp -64.96 -44.79 96.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.448 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -64.18 -37.0 85.89 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.971 0.415 . . . . 0.0 110.395 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.578 ' O ' ' CD2' ' A' ' 18' ' ' LEU . 56.0 t -67.4 -43.77 87.43 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.39 0 C-N-CA 119.811 -0.756 . . . . 0.0 110.792 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 4.4 mm -65.53 -43.39 94.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.26 0.552 . . . . 0.0 110.98 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -63.54 -38.16 81.48 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.401 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.536 -178.31 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 73.5 t -64.61 -43.67 96.72 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.381 0 C-N-CA 118.429 -1.309 . . . . 0.0 109.751 -178.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.578 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 0.1 OUTLIER -63.72 -43.63 95.98 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 178.168 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.06 -43.75 94.55 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-N 114.006 -1.452 . . . . 0.0 111.605 -176.519 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -68.92 -33.1 73.19 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.51 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 97.35 14.21 42.37 Favored Glycine 0 CA--C 1.502 -0.733 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 178.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.51 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 70.3 p 57.38 14.51 2.22 Favored 'General case' 0 CA--C 1.508 -0.664 0 CA-C-N 114.57 -0.815 . . . . 0.0 112.408 179.051 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -97.51 -31.35 12.38 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.375 -178.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 13.8 tppt? -70.96 -47.36 59.36 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 121.399 0.618 . . . . 0.0 111.477 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.656 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 1.8 mp . . . . . 0 CA--C 1.489 -1.402 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.232 -179.086 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.2 p . . . . . 0 CA--C 1.521 -0.173 0 CA-C-O 120.575 0.226 . . . . 0.0 111.606 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 45.5 m-20 -87.28 -36.74 17.73 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -73.6 -46.03 49.6 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.456 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.92 -44.46 97.8 Favored Glycine 0 C--N 1.311 -0.854 0 C-N-CA 119.399 -1.382 . . . . 0.0 109.856 -179.105 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.68 -40.17 76.52 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.718 -0.241 . . . . 0.0 111.432 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.9 t -63.1 -42.35 99.56 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.565 -0.454 . . . . 0.0 110.528 -178.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.2 -39.41 81.14 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.042 178.712 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.469 ' CG ' ' HZ3' ' A' ' 40' ' ' LYS . 7.7 ttpt -59.51 -45.56 91.39 Favored 'General case' 0 N--CA 1.435 -1.175 0 C-N-CA 119.252 -0.979 . . . . 0.0 109.043 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.79 -37.11 88.3 Favored Glycine 0 CA--C 1.529 0.946 0 C-N-CA 120.05 -1.071 . . . . 0.0 110.461 178.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -71.6 -51.82 21.32 Favored 'General case' 0 CA--C 1.511 -0.528 0 CA-C-O 120.574 0.226 . . . . 0.0 111.537 -179.478 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.469 ' HZ3' ' CG ' ' A' ' 37' ' ' LYS . 8.9 pttm -62.78 -37.71 87.77 Favored 'General case' 0 C--N 1.318 -0.792 0 C-N-CA 120.207 -0.597 . . . . 0.0 110.144 -179.455 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -61.64 -36.15 79.95 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.25 -178.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.319 -0.727 0 C-N-CA 120.686 -0.405 . . . . 0.0 109.921 179.496 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.9 mm . . . . . 0 N--CA 1.447 -0.583 0 CA-C-O 121.585 0.707 . . . . 0.0 111.35 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 10.8 t-105 -62.6 -38.59 90.76 Favored 'General case' 0 N--CA 1.44 -0.944 0 CA-C-N 115.421 -0.808 . . . . 0.0 109.008 179.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 25.7 mm-40 -64.94 -39.25 93.22 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 29.3 mt -61.39 -38.1 85.8 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.434 178.662 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.41 ' O ' ' CG2' ' A' ' 14' ' ' VAL . 5.6 mt -62.09 -43.3 99.13 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.066 -176.809 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 5.9 mt -66.3 -45.33 89.99 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 C-N-CA 119.928 -0.709 . . . . 0.0 109.588 177.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.1 mp -65.8 -47.39 85.92 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.806 -179.268 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.4 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -64.75 -37.36 87.34 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.543 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.561 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 45.8 t -67.38 -44.28 87.18 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.052 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.709 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 97.0 mt -65.61 -43.13 94.08 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.761 0 CA-C-O 121.33 0.586 . . . . 0.0 110.685 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -63.99 -38.17 81.72 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.589 -178.082 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.4 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 83.2 t -65.61 -42.83 93.73 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.93 0 C-N-CA 118.449 -1.3 . . . . 0.0 111.474 -178.156 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.561 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 19.2 mt -62.49 -45.72 91.73 Favored 'General case' 0 C--N 1.319 -0.76 0 C-N-CA 119.66 -0.816 . . . . 0.0 112.075 -178.469 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.456 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.92 -38.24 79.41 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -179.315 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.456 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 2.0 m-85 -67.79 -36.87 81.21 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 108.804 -0.814 . . . . 0.0 108.804 -178.215 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.479 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 101.65 7.41 48.27 Favored Glycine 0 CA--C 1.501 -0.837 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 178.374 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.479 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 18.0 p 56.41 19.74 4.26 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.77 -0.715 . . . . 0.0 112.135 178.588 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 17.0 mtmt -92.09 -25.13 18.9 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.63 -0.428 . . . . 0.0 111.006 -179.081 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -85.12 -59.85 2.21 Favored 'General case' 0 C--O 1.213 -0.856 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.828 -179.514 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.635 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 2.6 mp . . . . . 0 CA--C 1.492 -1.272 0 CA-C-O 122.503 1.145 . . . . 0.0 110.221 -179.308 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.0 p . . . . . 0 C--O 1.232 0.171 0 CA-C-O 120.692 0.282 . . . . 0.0 111.628 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -76.4 -42.48 44.16 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 179.361 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -66.89 -44.18 81.51 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.587 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.13 -44.31 97.39 Favored Glycine 0 N--CA 1.44 -1.063 0 C-N-CA 119.51 -1.328 . . . . 0.0 109.884 -179.097 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -72.1 -39.92 68.58 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.671 -0.265 . . . . 0.0 111.289 178.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 67.0 m -63.31 -40.7 98.06 Favored 'General case' 0 CA--C 1.515 -0.392 0 C-N-CA 120.528 -0.469 . . . . 0.0 110.551 -178.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.48 -39.15 78.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.007 179.048 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.407 ' O ' ' CB ' ' A' ' 41' ' ' LYS . 20.8 tttt -59.49 -44.98 92.93 Favored 'General case' 0 N--CA 1.432 -1.344 0 C-N-CA 119.358 -0.937 . . . . 0.0 108.598 -178.416 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.04 -36.48 93.08 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 178.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 87.1 t80 -71.35 -54.31 11.2 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 111.66 0.244 . . . . 0.0 111.66 -179.172 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.411 ' CG ' ' N ' ' A' ' 41' ' ' LYS . 18.9 ptmt -64.8 -39.83 94.23 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.974 179.889 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . 0.411 ' N ' ' CG ' ' A' ' 40' ' ' LYS . 88.6 tttt -62.87 -36.84 84.63 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.729 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.325 -0.478 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.421 179.743 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.497 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.5 mp . . . . . 0 N--CA 1.441 -0.877 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 29.0 m95 -62.69 -46.88 86.09 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 120.086 -0.645 . . . . 0.0 110.027 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.522 ' N ' ' OE1' ' A' ' 8' ' ' GLN . 0.7 OUTLIER -64.22 -39.04 93.15 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 -179.385 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.475 ' C ' ' CD1' ' A' ' 9' ' ' LEU . 0.2 OUTLIER -70.37 -37.92 74.66 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.319 178.654 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 19.2 mt -62.82 -46.55 87.41 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.899 -177.467 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 6.2 mt -65.84 -44.31 92.87 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.247 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 56.2 mt -63.44 -44.35 98.83 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.157 -178.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.403 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -64.15 -37.13 86.34 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.454 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.461 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 73.5 t -67.53 -44.31 86.62 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 C-N-CA 119.795 -0.762 . . . . 0.0 110.489 179.58 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 4.5 mm -65.99 -43.43 92.66 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.698 0 CA-C-O 121.129 0.49 . . . . 0.0 111.133 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -63.96 -38.39 82.27 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.072 0 CA-C-N 115.362 -0.835 . . . . 0.0 109.371 -178.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.403 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 79.0 t -65.4 -42.81 94.4 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.024 0 C-N-CA 118.478 -1.289 . . . . 0.0 111.64 -177.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.461 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 29.4 mt -62.42 -45.2 94.17 Favored 'General case' 0 C--N 1.317 -0.821 0 C-N-CA 118.984 -1.086 . . . . 0.0 111.721 -179.159 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.428 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -67.48 -38.46 84.42 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.818 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.428 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 1.4 m-85 -67.73 -31.25 71.04 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -178.819 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.447 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 89.62 8.77 67.35 Favored Glycine 0 CA--C 1.505 -0.541 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.12 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.447 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 14.8 p 56.65 15.6 2.22 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 114.48 -0.86 . . . . 0.0 112.279 178.139 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 13.4 ptpt -82.66 -44.38 15.79 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.296 0.569 . . . . 0.0 109.68 178.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 2.0 mmmm -67.95 -43.97 77.84 Favored 'General case' 0 C--O 1.21 -1.012 0 CA-C-N 115.218 -0.901 . . . . 0.0 112.069 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.532 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 6.7 mp . . . . . 0 CA--C 1.49 -1.331 0 CA-C-O 121.876 0.846 . . . . 0.0 110.568 -178.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 41.8 t . . . . . 0 N--CA 1.453 -0.306 0 CA-C-O 120.884 0.373 . . . . 0.0 111.442 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -76.28 -44.79 35.54 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.371 0.605 . . . . 0.0 109.485 179.651 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 10.6 mp -67.48 -43.87 79.94 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 114.795 -1.093 . . . . 0.0 111.816 -179.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.33 -43.77 98.61 Favored Glycine 0 C--N 1.308 -0.985 0 C-N-CA 119.247 -1.454 . . . . 0.0 109.789 -179.682 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.27 -40.32 71.03 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.461 -0.369 . . . . 0.0 111.25 179.407 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 40.1 t -63.49 -41.98 98.56 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.223 0.535 . . . . 0.0 111.125 -178.71 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.53 -40.12 79.3 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.665 -179.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.2 pttt -60.07 -42.84 95.41 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -179.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.03 -36.59 92.18 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 178.578 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -71.65 -51.89 20.75 Favored 'General case' 0 CA--C 1.516 -0.365 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.18 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 42.7 mmtm -64.0 -38.97 93.01 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.37 178.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -61.63 -36.83 81.89 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.092 -0.643 . . . . 0.0 110.14 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.326 -0.438 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.794 -179.686 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 1.6 mp . . . . . 0 CA--C 1.538 0.483 0 CA-C-O 120.768 0.318 . . . . 0.0 110.548 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 58.6 m95 -62.56 -49.02 76.95 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 -179.456 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.415 ' H ' ' NE2' ' A' ' 8' ' ' GLN . 3.0 mp0 -64.53 -38.94 92.74 Favored 'General case' 0 C--N 1.312 -1.045 0 C-N-CA 120.186 -0.606 . . . . 0.0 109.577 179.625 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.504 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 3.3 mm? -63.82 -39.25 93.8 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.953 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 9.5 mt -63.4 -52.4 61.78 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.894 -178.415 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 3.5 mp -64.86 -44.58 96.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 178.495 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 71.9 mt -63.56 -45.73 96.9 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.101 0 C-N-CA 120.107 -0.637 . . . . 0.0 111.177 -179.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -64.73 -37.37 87.38 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.968 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.544 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 51.6 t -67.54 -43.84 86.89 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 C-N-CA 119.823 -0.751 . . . . 0.0 110.872 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.3 mt -65.4 -42.79 94.34 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.658 0 CA-C-O 121.1 0.476 . . . . 0.0 110.225 -179.009 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -64.5 -38.43 82.59 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.345 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.917 -178.459 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 75.1 t -63.88 -43.07 97.7 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.367 0 C-N-CA 118.544 -1.262 . . . . 0.0 111.002 -177.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.544 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 14.4 mt -60.8 -47.08 87.98 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 120.078 -0.649 . . . . 0.0 112.473 -178.789 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.436 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.95 -37.96 79.17 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -179.515 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.436 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 0.8 OUTLIER -67.45 -35.99 80.28 Favored 'General case' 0 CA--C 1.519 -0.217 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -177.946 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.618 ' C ' ' H ' ' A' ' 23' ' ' LYS . . . 102.69 10.8 36.94 Favored Glycine 0 CA--C 1.501 -0.837 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 178.298 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.539 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 44.8 p 56.52 -1.94 0.04 OUTLIER 'General case' 0 CA--C 1.497 -1.081 0 CA-C-O 121.073 0.463 . . . . 0.0 112.138 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.618 ' H ' ' C ' ' A' ' 21' ' ' GLY . 12.6 tmtt? -84.41 -36.22 22.55 Favored 'General case' 0 N--CA 1.434 -1.252 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.006 -179.117 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.4 tppt? -63.75 -48.57 76.47 Favored 'General case' 0 N--CA 1.436 -1.126 0 CA-C-O 121.089 0.471 . . . . 0.0 110.37 179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.627 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 2.1 mp . . . . . 0 CA--C 1.486 -1.493 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.044 -178.345 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 14.0 t . . . . . 0 CA--C 1.518 -0.284 0 N-CA-C 111.769 0.285 . . . . 0.0 111.769 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -84.42 -37.08 21.89 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -72.3 -44.34 62.88 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.173 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.97 -43.8 98.69 Favored Glycine 0 C--N 1.31 -0.899 0 C-N-CA 119.527 -1.32 . . . . 0.0 110.018 -179.366 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.5 -39.93 73.86 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.891 -0.324 . . . . 0.0 111.205 179.533 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 44.8 t -64.3 -41.93 96.62 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.542 -0.463 . . . . 0.0 111.288 -178.763 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.73 -38.92 79.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.205 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 3.3 pttp -59.49 -40.86 88.38 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 -178.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.07 -36.63 90.89 Favored Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 178.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -71.63 -49.71 37.46 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 121.04 0.448 . . . . 0.0 109.962 -179.472 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 53.4 mttp -63.12 -38.57 91.71 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.471 178.528 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 12.5 ttmm -61.33 -36.99 81.69 Favored 'General case' 0 C--N 1.319 -0.748 0 C-N-CA 119.935 -0.706 . . . . 0.0 110.187 -179.613 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.324 -0.52 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.274 179.851 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.2 mm . . . . . 0 N--CA 1.444 -0.76 0 CA-C-O 121.546 0.689 . . . . 0.0 110.636 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 11.7 t-105 -62.82 -38.07 89.28 Favored 'General case' 0 N--CA 1.438 -1.059 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.725 178.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 28.6 mm-40 -64.84 -40.29 94.93 Favored 'General case' 0 CA--C 1.509 -0.61 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 178.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 72.0 mt -61.4 -37.64 84.17 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.006 178.212 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.4 mt -62.12 -42.88 99.67 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.2 -176.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 6.4 mt -67.89 -45.67 83.57 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 C-N-CA 120.25 -0.58 . . . . 0.0 110.011 177.48 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.1 mp -65.49 -44.7 94.09 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.997 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.404 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -64.46 -36.69 85.0 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.605 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.562 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 48.8 t -66.75 -45.73 87.3 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.039 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.305 -179.167 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 16.2 pt -65.97 -42.49 91.9 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-N 118.023 0.374 . . . . 0.0 110.929 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -63.47 -38.37 82.04 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.134 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.601 -178.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.404 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 90.7 t -65.69 -44.34 93.42 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.803 0 C-N-CA 118.382 -1.327 . . . . 0.0 111.713 -178.648 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.562 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 23.5 mt -61.62 -46.46 89.7 Favored 'General case' 0 C--N 1.322 -0.623 0 C-N-CA 119.907 -0.717 . . . . 0.0 111.909 -179.037 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.467 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 4.7 pp -68.09 -38.41 82.32 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 -179.607 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.467 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 2.0 m-85 -67.64 -37.7 82.8 Favored 'General case' 0 CA--C 1.517 -0.324 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -177.77 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.5 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 102.81 6.07 46.82 Favored Glycine 0 CA--C 1.499 -0.953 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 178.544 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.5 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 18.5 p 57.88 19.2 5.56 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 114.964 -0.618 . . . . 0.0 112.281 178.279 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -93.16 -19.93 20.98 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.535 -179.355 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -89.81 -60.39 1.95 Allowed 'General case' 0 C--O 1.211 -0.958 0 CA-C-O 121.178 0.513 . . . . 0.0 110.706 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.663 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 2.6 mp . . . . . 0 CA--C 1.491 -1.304 0 CA-C-O 122.495 1.141 . . . . 0.0 110.149 -179.532 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.0 p . . . . . 0 CA--C 1.521 -0.151 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -78.61 -40.97 32.93 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 179.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.3 mp -68.65 -45.92 70.52 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.551 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.51 -44.0 97.29 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.76 -40.23 76.24 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.366 -0.417 . . . . 0.0 111.364 179.196 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 43.3 m -63.63 -40.79 97.77 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.531 -0.467 . . . . 0.0 111.216 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.67 -40.93 79.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.073 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 16.2 pttt -60.24 -43.48 96.05 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.66 -36.91 92.0 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.614 -0.994 . . . . 0.0 110.614 178.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -71.67 -50.69 28.19 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-O 120.946 0.403 . . . . 0.0 110.516 -179.604 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 66.4 mmtt -63.97 -38.99 93.09 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 120.252 -0.579 . . . . 0.0 110.325 179.181 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt -61.97 -37.16 83.71 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.239 -179.663 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.32 -0.695 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.523 -179.337 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.1 mm . . . . . 0 N--CA 1.454 -0.232 0 CA-C-O 120.971 0.415 . . . . 0.0 111.872 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 9.5 t-105 -62.67 -36.61 83.44 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 21.3 mm-40 -64.47 -38.88 92.57 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 86.6 mt -63.03 -37.66 88.07 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.747 178.374 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.433 ' O ' ' CG2' ' A' ' 14' ' ' VAL . 5.2 mt -62.58 -42.89 99.84 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.13 -177.055 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.8 mt -66.95 -45.54 87.02 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.95 0 C-N-CA 119.698 -0.801 . . . . 0.0 109.51 177.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 67.1 mt -65.66 -47.56 85.71 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.806 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.327 -179.719 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -64.55 -37.34 87.21 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.4 -179.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.531 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 40.6 t -67.67 -44.25 86.17 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 C-N-CA 119.748 -0.781 . . . . 0.0 110.973 179.721 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 91.8 mt -65.27 -42.28 93.54 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.834 0 CA-C-O 120.993 0.425 . . . . 0.0 110.395 -179.087 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.417 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 0.3 OUTLIER -64.25 -38.4 82.41 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.113 0 CA-C-N 115.322 -0.854 . . . . 0.0 110.11 -178.836 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 87.1 t -64.56 -42.6 95.64 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.257 0 C-N-CA 118.389 -1.325 . . . . 0.0 111.131 -177.351 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.531 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 20.8 mt -62.08 -47.18 85.83 Favored 'General case' 0 C--N 1.316 -0.887 0 C-N-CA 119.819 -0.752 . . . . 0.0 112.566 -178.573 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.436 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.01 -38.41 82.56 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.897 -179.579 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.436 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 0.7 OUTLIER -68.07 -32.14 72.27 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -178.3 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.486 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 93.9 5.79 62.44 Favored Glycine 0 CA--C 1.504 -0.61 0 C-N-CA 120.209 -0.996 . . . . 0.0 111.044 178.523 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.486 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 14.4 p 58.39 26.93 14.71 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.161 -0.519 . . . . 0.0 112.202 178.558 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 50.2 pttt -96.97 -33.09 11.7 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.878 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 16.6 mmmt -77.45 -52.78 8.53 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.72 -0.392 . . . . 0.0 111.498 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.658 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 1.9 mp . . . . . 0 CA--C 1.489 -1.374 0 CA-C-O 122.336 1.065 . . . . 0.0 110.476 -179.32 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.1 p . . . . . 0 N--CA 1.451 -0.408 0 CA-C-O 120.816 0.341 . . . . 0.0 111.219 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 66.7 t0 -76.63 -41.04 47.38 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.289 0.566 . . . . 0.0 109.846 179.728 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.5 mp -68.68 -45.82 70.68 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.024 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.56 -43.82 98.45 Favored Glycine 0 C--N 1.308 -1.018 0 C-N-CA 119.463 -1.351 . . . . 0.0 110.031 -179.55 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.07 -40.25 75.14 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.82 0.343 . . . . 0.0 111.148 179.646 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.6 t -63.94 -42.01 97.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.132 0.491 . . . . 0.0 111.248 -178.742 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.48 -39.42 78.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.615 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 17.9 pttt -59.32 -40.35 86.0 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 -178.108 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -69.81 -37.09 75.37 Favored Glycine 0 N--CA 1.442 -0.903 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -71.61 -49.16 42.8 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-O 121.114 0.483 . . . . 0.0 109.762 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 47.5 mtpt -63.01 -38.6 91.83 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.558 178.566 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 14.2 tmtt? -61.75 -36.68 81.71 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 119.773 -0.771 . . . . 0.0 109.853 -178.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.325 -0.488 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.052 179.713 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.519 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.6 mp . . . . . 0 N--CA 1.452 -0.364 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 91.8 m95 -62.27 -41.01 98.1 Favored 'General case' 0 CA--C 1.507 -0.685 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.748 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.412 ' CG ' ' N ' ' A' ' 9' ' ' LEU . 5.6 pt20 -64.28 -39.48 94.01 Favored 'General case' 0 C--O 1.215 -0.725 0 C-N-CA 118.572 -1.251 . . . . 0.0 108.152 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.455 ' O ' ' N ' ' A' ' 13' ' ' ALA . 76.6 mt -68.59 -38.49 80.71 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.166 179.376 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 18.7 mt -63.28 -49.27 74.72 Favored 'General case' 0 C--N 1.314 -0.935 0 C-N-CA 120.076 -0.65 . . . . 0.0 111.371 -176.022 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 3.7 mp -67.19 -44.33 87.81 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 178.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.403 ' N ' ' CD1' ' A' ' 12' ' ' ILE . 1.0 OUTLIER -65.07 -44.56 95.74 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.878 -179.387 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.455 ' N ' ' O ' ' A' ' 9' ' ' LEU . . . -64.77 -36.53 84.6 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.825 -179.762 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.485 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 54.8 t -67.03 -45.03 87.87 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.826 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.442 -178.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 15.9 pt -66.23 -42.56 91.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 CA-C-O 121.05 0.452 . . . . 0.0 110.827 179.645 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -63.54 -38.12 81.38 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.905 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 -179.324 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.421 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 94.4 t -65.52 -43.72 94.25 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 C-N-CA 118.557 -1.257 . . . . 0.0 111.654 -178.303 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 21.3 mt -61.82 -47.09 86.66 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 119.566 -0.854 . . . . 0.0 111.57 -178.853 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.437 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -67.06 -38.21 85.41 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -179.221 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.437 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 1.2 m-85 -67.55 -35.83 79.81 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 -177.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.489 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 98.79 8.04 54.76 Favored Glycine 0 CA--C 1.501 -0.821 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 178.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.489 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 19.0 p 57.7 27.1 13.85 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 114.309 -0.945 . . . . 0.0 112.52 178.239 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 55.3 mtpt -100.0 -19.82 16.38 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.686 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 14.5 mmmt -88.66 -56.91 3.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.125 0.488 . . . . 0.0 110.622 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.65 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 2.3 mp . . . . . 0 CA--C 1.495 -1.173 0 CA-C-O 122.473 1.13 . . . . 0.0 110.291 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.3 t . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.628 0.251 . . . . 0.0 111.652 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 53.3 m-20 -74.15 -43.65 56.6 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.53 0.681 . . . . 0.0 109.208 179.475 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.6 mp -65.82 -44.28 86.08 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.789 -1.096 . . . . 0.0 111.553 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.52 -45.18 96.39 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 119.411 -1.376 . . . . 0.0 109.823 -179.204 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.6 -39.81 73.6 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.651 -0.274 . . . . 0.0 111.309 179.164 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 39.4 t -63.19 -41.69 99.23 Favored 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 120.528 -0.469 . . . . 0.0 110.406 -178.247 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.02 -39.27 79.47 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.715 179.027 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 24.3 tttt -59.87 -43.72 94.57 Favored 'General case' 0 C--N 1.309 -1.17 0 C-N-CA 119.287 -0.965 . . . . 0.0 108.463 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.97 -36.6 91.23 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 178.18 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -71.59 -50.77 27.81 Favored 'General case' 0 CA--C 1.52 -0.182 0 CA-C-O 120.805 0.336 . . . . 0.0 110.291 -179.621 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 53.2 mtpt -63.43 -38.52 91.46 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.37 178.646 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -61.74 -39.11 90.41 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.138 -0.625 . . . . 0.0 110.102 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.324 -0.534 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.551 -179.948 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.521 ' CG2' ' N ' ' A' ' 7' ' ' TRP . 1.5 tp . . . . . 0 N--CA 1.444 -0.755 0 CA-C-O 121.368 0.604 . . . . 0.0 111.012 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.528 ' C ' ' CD1' ' A' ' 7' ' ' TRP . 2.0 t-105 -62.15 -38.42 88.93 Favored 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -179.262 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 13.7 mm-40 -64.31 -38.75 92.16 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 179.639 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.501 ' C ' ' CD1' ' A' ' 9' ' ' LEU . 0.2 OUTLIER -70.33 -38.03 74.82 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.423 178.933 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.2 tt -62.71 -47.03 85.4 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.971 -175.607 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.444 HD13 ' N ' ' A' ' 11' ' ' ILE . 2.0 mp -65.01 -43.94 96.04 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 177.51 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 72.9 mt -63.37 -44.51 99.03 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.065 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.547 -178.671 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.443 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -64.23 -37.25 86.82 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.923 -179.241 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.469 ' O ' ' CD2' ' A' ' 18' ' ' LEU . 78.6 t -67.02 -44.05 88.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 C-N-CA 120.545 -0.462 . . . . 0.0 111.139 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.453 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 58.7 mt -66.62 -43.19 90.57 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.285 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 178.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.456 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.5 t -64.01 -42.27 95.16 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.681 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.881 -179.046 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.443 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 60.1 t -65.93 -44.92 92.29 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.118 0 C-N-CA 118.281 -1.368 . . . . 0.0 112.774 -177.376 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.469 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 1.4 pp -72.65 -42.87 63.89 Favored 'General case' 0 C--N 1.293 -1.857 0 C-N-CA 120.054 -0.659 . . . . 0.0 109.842 178.761 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.479 ' C ' ' CD1' ' A' ' 19' ' ' LEU . 2.6 tm? -64.37 -41.29 96.79 Favored 'General case' 0 N--CA 1.443 -0.806 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.617 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.456 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 5.6 m-85 -69.0 -39.47 79.31 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 118.741 -1.183 . . . . 0.0 108.749 179.17 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.51 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 105.15 11.9 28.63 Favored Glycine 0 N--CA 1.467 0.75 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 179.025 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.51 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 50.4 p 57.31 44.42 21.89 Favored 'General case' 0 CA--C 1.499 -0.983 0 CA-C-N 115.371 -0.414 . . . . 0.0 112.062 178.304 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -127.19 -18.38 4.56 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.593 -0.73 . . . . 0.0 111.551 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 9.6 tppt? -86.44 -48.38 8.47 Favored 'General case' 0 N--CA 1.447 -0.625 0 CA-C-O 121.008 0.432 . . . . 0.0 110.08 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.516 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 0.1 OUTLIER . . . . . 0 CA--C 1.505 -0.768 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.682 -178.839 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.9 t . . . . . 0 CA--C 1.519 -0.222 0 CA-C-O 120.68 0.276 . . . . 0.0 111.548 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 94.3 m-20 -76.32 -41.18 49.32 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.338 0.59 . . . . 0.0 109.614 179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -68.33 -44.43 75.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.556 179.75 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.0 -44.08 97.92 Favored Glycine 0 N--CA 1.443 -0.853 0 C-N-CA 119.363 -1.399 . . . . 0.0 109.99 -179.001 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.73 -39.87 73.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.719 0.295 . . . . 0.0 111.413 179.27 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.0 t -63.22 -41.9 99.19 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.69 -178.439 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.78 -39.17 79.78 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.009 178.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 23.9 tttt -59.69 -44.65 93.57 Favored 'General case' 0 N--CA 1.435 -1.223 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 -178.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.39 -36.61 92.88 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 178.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 38.3 t80 -71.8 -51.78 20.85 Favored 'General case' 0 CA--C 1.512 -0.495 0 CA-C-O 120.991 0.424 . . . . 0.0 110.406 -179.373 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 48.8 mtpt -62.62 -39.1 92.75 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.717 179.454 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 42.8 mtmt -61.58 -39.1 89.97 Favored 'General case' 0 C--N 1.319 -0.75 0 C-N-CA 119.043 -1.063 . . . . 0.0 109.911 -179.73 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.319 -0.759 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.322 -179.93 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.454 ' O ' ' HG ' ' A' ' 9' ' ' LEU . 16.9 mm . . . . . 0 N--CA 1.44 -0.957 0 CA-C-O 121.995 0.903 . . . . 0.0 110.88 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 22.4 t-105 -65.42 -39.39 92.07 Favored 'General case' 0 N--CA 1.432 -1.345 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.248 -179.519 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 22.0 mm-40 -65.84 -41.45 91.74 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.061 0.458 . . . . 0.0 110.8 179.58 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.454 ' HG ' ' O ' ' A' ' 6' ' ' ILE . 0.4 OUTLIER -63.41 -36.74 84.72 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.724 179.453 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.3 mt -62.03 -42.39 99.11 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.013 -177.13 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.8 mt -65.2 -44.18 95.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 177.538 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 69.7 mt -63.96 -44.37 97.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.313 -179.019 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.445 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -65.12 -37.53 87.76 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.133 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.438 ' O ' ' CD2' ' A' ' 18' ' ' LEU . 64.8 t -67.1 -44.54 87.98 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.372 0 C-N-CA 120.829 -0.348 . . . . 0.0 111.35 -178.732 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 16.1 pt -67.12 -42.86 88.77 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.11 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 178.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.457 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.7 t -63.71 -41.63 93.24 Favored 'Isoleucine or valine' 0 CA--C 1.476 -1.882 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.981 -179.213 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.445 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 61.5 t -66.49 -50.11 69.67 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.984 0 C-N-CA 117.149 -1.821 . . . . 0.0 113.11 -177.19 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.438 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 1.0 OUTLIER -66.34 -44.52 83.08 Favored 'General case' 0 C--N 1.302 -1.492 0 C-N-CA 119.209 -0.996 . . . . 0.0 112.01 179.722 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.431 ' C ' ' CD1' ' A' ' 19' ' ' LEU . 0.4 OUTLIER -65.59 -38.24 88.93 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.442 179.962 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.457 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 3.0 m-85 -68.01 -43.91 77.75 Favored 'General case' 0 CA--C 1.515 -0.381 0 C-N-CA 119.221 -0.992 . . . . 0.0 108.501 -179.487 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.51 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 111.71 11.12 17.68 Favored Glycine 0 C--N 1.316 -0.559 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 178.715 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.51 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 59.5 p 56.42 35.09 25.36 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 114.863 -0.668 . . . . 0.0 112.784 178.18 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 56.3 mtpt -116.26 -20.32 9.83 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.811 -0.632 . . . . 0.0 111.792 -179.576 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 tppt? -83.47 -52.08 6.81 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-O 121.175 0.512 . . . . 0.0 110.466 -179.741 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.531 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 0.2 OUTLIER . . . . . 0 CA--C 1.501 -0.933 0 CA-C-O 121.907 0.86 . . . . 0.0 111.285 -178.882 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 38.8 t . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.745 0.307 . . . . 0.0 111.237 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -69.94 -44.01 70.42 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.519 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -65.12 -44.4 88.85 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.149 -0.932 . . . . 0.0 111.413 179.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.31 -44.39 97.01 Favored Glycine 0 N--CA 1.438 -1.214 0 C-N-CA 119.292 -1.432 . . . . 0.0 109.986 -179.077 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.21 -40.06 71.36 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.529 -0.336 . . . . 0.0 111.414 179.076 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.8 t -63.65 -41.29 98.25 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.666 -0.413 . . . . 0.0 111.141 -178.389 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.12 -40.34 80.5 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.798 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.5 pttt -60.28 -43.19 96.44 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 -179.679 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.97 -36.68 92.37 Favored Glycine 0 CA--C 1.519 0.342 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -71.51 -52.23 19.42 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 66.0 mmtt -62.91 -38.15 89.81 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.154 178.73 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -60.94 -35.64 77.26 Favored 'General case' 0 C--N 1.312 -1.029 0 C-N-CA 119.631 -0.827 . . . . 0.0 109.909 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.323 -0.565 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.141 -179.311 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.684 ' N ' HE22 ' A' ' 8' ' ' GLN . 3.5 mm . . . . . 0 CA--C 1.535 0.402 0 CA-C-O 120.644 0.259 . . . . 0.0 110.763 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 38.5 m95 -62.0 -45.33 94.06 Favored 'General case' 0 C--O 1.22 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -178.593 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.871 HE21 ' H ' ' A' ' 9' ' ' LEU . 0.0 OUTLIER -63.8 -38.96 93.03 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 119.737 -0.785 . . . . 0.0 109.485 178.72 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.871 ' H ' HE21 ' A' ' 8' ' ' GLN . 78.8 mt -64.45 -38.21 90.24 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.264 179.727 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.403 ' O ' ' CG2' ' A' ' 14' ' ' VAL . 20.7 mt -63.3 -48.27 78.78 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.805 -176.596 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 3.8 mp -67.92 -44.58 85.03 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 C-N-CA 119.662 -0.815 . . . . 0.0 109.142 178.212 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -65.08 -47.59 87.22 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 C-N-CA 120.055 -0.658 . . . . 0.0 110.566 -179.432 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.455 ' N ' ' O ' ' A' ' 9' ' ' LEU . . . -65.85 -38.07 87.88 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 -179.545 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.42 ' O ' ' CD2' ' A' ' 18' ' ' LEU . 62.8 t -67.78 -44.29 85.73 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.625 0 C-N-CA 120.173 -0.611 . . . . 0.0 111.171 -178.824 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.47 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 0.9 OUTLIER -66.28 -44.05 91.35 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.385 0 O-C-N 123.353 0.408 . . . . 0.0 110.053 179.485 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.403 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.3 t -64.02 -41.99 94.24 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.721 0 CA-C-N 115.107 -0.951 . . . . 0.0 109.964 -178.578 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.443 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 59.6 t -66.14 -45.22 90.89 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.909 0 C-N-CA 118.03 -1.468 . . . . 0.0 112.672 -177.043 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.42 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 1.1 pp -71.23 -42.85 68.36 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.157 177.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.47 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.5 tm? -64.67 -41.49 96.04 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.908 -179.171 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.403 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 6.1 m-85 -68.97 -38.62 79.47 Favored 'General case' 0 CA--C 1.513 -0.465 0 C-N-CA 119.014 -1.074 . . . . 0.0 108.623 178.78 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.505 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 104.76 11.28 30.92 Favored Glycine 0 C--N 1.315 -0.614 0 CA-C-N 115.01 -0.995 . . . . 0.0 111.104 178.521 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.505 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 51.2 p 58.68 43.24 19.1 Favored 'General case' 0 CA--C 1.505 -0.763 0 CA-C-N 115.25 -0.475 . . . . 0.0 111.917 178.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -124.94 -20.19 5.03 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.4 -179.802 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 tppt? -84.99 -49.63 8.16 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-O 121.091 0.472 . . . . 0.0 110.496 179.826 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.529 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 0.1 OUTLIER . . . . . 0 CA--C 1.505 -0.766 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.044 -178.792 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 10.9 t . . . . . 0 CA--C 1.521 -0.148 0 CA-C-O 120.771 0.32 . . . . 0.0 111.332 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 94.9 m-20 -70.58 -43.63 69.04 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.341 0.591 . . . . 0.0 109.481 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.8 mp -65.47 -44.75 86.17 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.426 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.37 -45.07 95.85 Favored Glycine 0 N--CA 1.439 -1.157 0 C-N-CA 119.444 -1.36 . . . . 0.0 109.94 -179.118 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.39 -39.69 71.03 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.577 -0.312 . . . . 0.0 111.566 179.265 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 48.4 t -63.34 -41.79 98.9 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-O 121.125 0.488 . . . . 0.0 110.324 -178.322 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.19 -39.4 79.23 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.931 179.032 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.7 tttp -60.09 -44.08 95.05 Favored 'General case' 0 C--N 1.309 -1.152 0 C-N-CA 119.343 -0.943 . . . . 0.0 108.614 -179.043 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.68 -36.54 91.44 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 178.389 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.2 t80 -71.65 -51.83 21.1 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-O 120.76 0.314 . . . . 0.0 110.462 -179.564 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 23.7 mtpp -62.7 -38.05 88.9 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.375 179.135 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -61.02 -36.73 80.29 Favored 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 120.098 -0.641 . . . . 0.0 110.226 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.322 -0.605 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.37 -179.591 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.5 mm . . . . . 0 CA--C 1.538 0.491 0 CA-C-O 120.511 0.196 . . . . 0.0 110.915 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 55.2 m95 -62.54 -48.97 77.16 Favored 'General case' 0 C--O 1.221 -0.423 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 -179.588 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . 0.488 ' N ' ' OE1' ' A' ' 8' ' ' GLN . 0.5 OUTLIER -64.13 -38.43 91.05 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.608 179.847 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.507 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 3.2 mm? -62.8 -39.08 93.16 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.874 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.9 mt -63.76 -51.77 63.39 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.6 -178.335 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 3.5 mp -65.62 -44.49 93.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 178.372 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 70.8 mt -63.72 -45.3 97.73 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 C-N-CA 120.479 -0.488 . . . . 0.0 111.337 -179.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.437 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -64.95 -38.79 92.12 Favored 'General case' 0 C--N 1.32 -0.713 0 O-C-N 123.381 0.425 . . . . 0.0 110.975 -179.323 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.432 ' O ' ' CD2' ' A' ' 18' ' ' LEU . 70.7 t -67.54 -43.15 87.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 C-N-CA 120.566 -0.453 . . . . 0.0 110.562 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.452 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 96.7 mt -66.25 -43.35 91.78 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.322 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.453 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.48 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.4 t -63.72 -42.2 95.18 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.684 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.319 -178.68 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.437 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 61.4 t -66.02 -45.11 91.62 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.883 0 C-N-CA 118.253 -1.379 . . . . 0.0 112.672 -176.764 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.432 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 1.3 pp -72.39 -43.16 64.32 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 119.702 -0.799 . . . . 0.0 109.949 178.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.452 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.6 tm? -64.4 -41.44 96.64 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.923 -1.035 . . . . 0.0 110.313 -179.63 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.48 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 5.0 m-85 -69.02 -35.98 77.25 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 118.879 -1.129 . . . . 0.0 108.957 179.019 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.482 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 97.44 11.96 49.76 Favored Glycine 0 N--CA 1.465 0.593 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.703 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.482 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 42.8 p 55.72 69.49 0.73 Allowed 'General case' 0 CA--C 1.506 -0.713 0 CA-C-N 114.604 -0.798 . . . . 0.0 112.445 178.364 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 49.6 mtpt -139.87 -25.53 0.81 Allowed 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.873 179.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 11.2 mmmt -85.8 -53.03 5.38 Favored 'General case' 0 C--O 1.221 -0.444 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.728 179.676 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.496 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 0.1 OUTLIER . . . . . 0 CA--C 1.505 -0.784 0 CA-C-O 121.817 0.818 . . . . 0.0 110.642 -178.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.3 t . . . . . 0 CA--C 1.521 -0.145 0 CA-C-O 120.689 0.281 . . . . 0.0 111.657 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -76.43 -41.0 49.13 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.347 0.594 . . . . 0.0 109.64 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.6 mp -68.4 -46.61 69.51 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.062 -0.972 . . . . 0.0 111.575 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.93 -44.0 98.43 Favored Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -179.16 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.12 -40.39 71.45 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.825 179.057 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.4 m -64.0 -40.8 97.18 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.898 -179.342 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.492 ' N ' HD13 ' A' ' 36' ' ' ILE . 1.6 mp -68.19 -41.57 84.12 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.485 -179.433 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 16.6 pttt -60.08 -43.35 95.56 Favored 'General case' 0 C--N 1.308 -1.203 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 -179.144 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -69.7 -36.78 75.93 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 110.599 -1.001 . . . . 0.0 110.599 178.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -71.64 -49.26 41.66 Favored 'General case' 0 CA--C 1.514 -0.432 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.845 -178.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.405 ' N ' ' CD ' ' A' ' 40' ' ' LYS . 9.8 mptt -67.06 -39.07 86.82 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.484 178.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -61.65 -36.65 81.41 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 119.72 -0.792 . . . . 0.0 109.865 179.814 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.323 -0.562 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.502 179.758 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.436 ' SD ' ' N ' ' A' ' 1' ' ' MET . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 . . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 85.9 22.88 47.84 Favored Glycine 0 CA--C 1.524 0.605 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.66 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 140.74 -9.43 2.84 Favored Glycine 0 N--CA 1.462 0.409 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.9 mp -101.33 118.7 48.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.085 0.469 . . . . 0.0 110.45 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 64.2 m -143.65 -89.97 0.12 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.696 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 1.5 mp -110.99 -35.23 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.506 -179.567 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 63.8 m95 -62.65 -49.54 74.73 Favored 'General case' 0 C--O 1.221 -0.432 0 CA-C-O 120.754 0.311 . . . . 0.0 110.576 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.432 ' OE1' ' N ' ' A' ' 8' ' ' GLN . 20.9 mp0 -64.17 -38.52 91.34 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.491 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 3.0 mm? -63.64 -39.33 94.07 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.646 179.284 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 9.1 mt -63.86 -51.0 66.61 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.872 -178.077 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 3.4 mp -66.08 -44.45 91.93 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.396 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 69.3 mt -63.58 -45.01 98.8 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.086 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.285 -179.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.438 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -65.01 -37.83 88.94 Favored 'General case' 0 C--N 1.317 -0.844 0 O-C-N 123.435 0.46 . . . . 0.0 111.245 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 71.4 t -67.86 -43.98 85.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.794 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.8 mt -66.33 -43.47 91.45 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.104 0 CA-C-O 121.59 0.71 . . . . 0.0 109.322 179.435 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.8 t -63.53 -42.41 96.08 Favored 'Isoleucine or valine' 0 CA--C 1.479 -1.788 0 CA-C-N 114.794 -1.094 . . . . 0.0 109.788 -178.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.438 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 60.4 t -66.5 -48.89 79.15 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.046 0 C-N-CA 117.609 -1.636 . . . . 0.0 112.787 -177.227 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -66.99 -44.38 80.55 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 118.863 -1.135 . . . . 0.0 112.042 179.667 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.431 ' C ' ' CD1' ' A' ' 19' ' ' LEU . 0.4 OUTLIER -65.95 -38.47 88.69 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.823 -179.979 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 4.7 m-85 -67.89 -41.03 83.37 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.463 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 108.62 14.58 15.45 Favored Glycine 0 C--N 1.312 -0.803 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 178.392 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.463 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 68.0 p 52.02 39.51 26.47 Favored 'General case' 0 CA--C 1.495 -1.136 0 CA-C-N 114.747 -0.726 . . . . 0.0 112.473 178.283 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 59.5 tttm -112.43 -41.29 3.9 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.935 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.92 -56.28 9.65 Favored 'General case' 0 CA--C 1.509 -0.63 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.271 -179.492 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.509 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 0.0 OUTLIER -53.63 -36.8 62.43 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-O 121.901 0.858 . . . . 0.0 109.989 -177.972 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.34 -25.8 69.73 Favored Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.735 -178.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 67.2 m -94.21 -38.32 11.11 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 -179.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.7 pt -94.83 -36.83 7.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.995 0.426 . . . . 0.0 109.961 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.481 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -61.84 -23.25 63.17 Favored Glycine 0 CA--C 1.518 0.235 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 -179.681 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 38.7 t -64.66 -39.2 93.28 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 120.764 -0.374 . . . . 0.0 111.699 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.9 m-20 -94.24 -35.51 12.43 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 179.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -74.32 -49.35 23.31 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.408 -1.269 . . . . 0.0 111.412 -178.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.481 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -61.57 -42.97 99.86 Favored Glycine 0 CA--C 1.518 0.246 0 N-CA-C 109.304 -1.519 . . . . 0.0 109.304 179.594 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.59 -39.28 93.45 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.783 -0.709 . . . . 0.0 110.939 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 75.3 m -62.88 -41.31 99.35 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.137 -0.625 . . . . 0.0 110.709 -178.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.3 mp -68.65 -40.01 81.13 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.861 179.048 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.6 ptmt -59.79 -41.81 91.98 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 -178.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.17 -36.47 90.16 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 177.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 23.0 t80 -71.75 -52.44 17.68 Favored 'General case' 0 CA--C 1.514 -0.428 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.227 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.498 ' O ' ' OG ' ' A' ' 44' ' ' SER . 62.2 mttm -62.81 -40.18 96.56 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.43 179.075 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 38.9 ttpt -63.43 -38.36 90.84 Favored 'General case' 0 C--N 1.317 -0.846 0 C-N-CA 119.95 -0.7 . . . . 0.0 111.212 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -67.08 -37.94 84.84 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.818 -178.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 2.4 ppp? -94.22 -17.73 22.4 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.25 -179.146 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.498 ' OG ' ' O ' ' A' ' 40' ' ' LYS . 18.3 m -58.21 -40.82 82.61 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.068 0.461 . . . . 0.0 109.842 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 45.3 t0 -76.72 164.66 25.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.422 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.409 ' OD1' ' O ' ' A' ' 46' ' ' ASP . 51.4 t0 59.47 40.44 20.65 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.803 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 -148.48 150.52 34.19 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.366 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo . . . . . 0 N--CA 1.496 1.653 0 C-N-CA 122.472 2.114 . . . . 0.0 111.824 179.755 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.426 ' C ' ' H ' ' A' ' 3' ' ' GLY . 69.4 mmm . . . . . 0 N--CA 1.493 1.677 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 71.34 -5.24 10.19 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.426 ' H ' ' C ' ' A' ' 1' ' ' MET . . . -141.32 10.22 2.73 Favored Glycine 0 N--CA 1.465 0.604 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.462 ' O ' ' OG ' ' A' ' 5' ' ' SER . 3.3 mp -44.55 -85.92 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 CA-C-O 120.626 0.25 . . . . 0.0 110.968 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.462 ' OG ' ' O ' ' A' ' 4' ' ' ILE . 59.4 m -172.27 -164.4 0.28 Allowed 'General case' 0 N--CA 1.439 -0.981 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.406 ' CG2' ' N ' ' A' ' 7' ' ' TRP . 3.4 tp -84.08 -35.7 11.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-N 115.255 -0.884 . . . . 0.0 111.907 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.427 ' CD1' ' C ' ' A' ' 7' ' ' TRP . 5.6 t-105 -61.91 -39.34 91.67 Favored 'General case' 0 N--CA 1.421 -1.884 0 CA-C-N 114.88 -1.054 . . . . 0.0 108.748 -178.321 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -64.74 -38.85 92.4 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 178.158 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.507 ' O ' ' N ' ' A' ' 13' ' ' ALA . 73.7 mt -62.74 -38.09 89.14 Favored 'General case' 0 CA--C 1.503 -0.851 0 CA-C-N 114.925 -1.034 . . . . 0.0 110.479 178.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.7 mt -62.63 -47.62 82.94 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.235 -177.274 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.457 HD11 ' N ' ' A' ' 11' ' ' ILE . 3.2 mp -69.13 -44.58 80.82 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 178.21 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 77.3 mt -64.02 -44.48 97.82 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.307 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.507 ' N ' ' O ' ' A' ' 9' ' ' LEU . . . -64.9 -36.63 84.97 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.945 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.43 ' O ' ' CD2' ' A' ' 18' ' ' LEU . 48.8 t -67.28 -44.29 87.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.307 -179.026 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 14.1 pt -67.24 -43.9 87.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.831 179.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -64.79 -39.3 85.19 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.07 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.323 -179.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 75.8 t -66.25 -46.99 85.89 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 C-N-CA 118.683 -1.207 . . . . 0.0 112.743 -178.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.43 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 0.8 OUTLIER -68.88 -42.39 77.04 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.419 0.628 . . . . 0.0 110.031 179.046 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.444 ' C ' ' CD1' ' A' ' 19' ' ' LEU . 2.2 tm? -63.88 -39.84 95.14 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.623 -1.171 . . . . 0.0 109.875 -179.306 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -69.17 -37.22 78.09 Favored 'General case' 0 CA--C 1.513 -0.454 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 177.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.509 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 102.3 9.59 41.24 Favored Glycine 0 N--CA 1.462 0.405 0 CA-C-N 115.086 -0.961 . . . . 0.0 110.916 179.135 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.509 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 51.6 p 58.56 22.22 9.5 Favored 'General case' 0 C--N 1.32 -0.713 0 O-C-N 123.935 0.433 . . . . 0.0 111.99 178.774 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -100.96 -15.82 17.38 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.103 -0.499 . . . . 0.0 112.06 -179.599 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.494 ' O ' ' N ' ' A' ' 27' ' ' SER . 15.2 mmmt -92.29 -57.82 2.58 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.178 0.513 . . . . 0.0 110.718 -179.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.654 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 1.7 mp -45.78 -39.93 8.95 Favored 'General case' 0 CA--C 1.496 -1.124 0 CA-C-O 122.272 1.034 . . . . 0.0 110.417 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.0 -25.15 72.15 Favored Glycine 0 N--CA 1.427 -1.961 0 CA-C-N 113.798 -1.546 . . . . 0.0 110.607 -177.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.494 ' N ' ' O ' ' A' ' 24' ' ' LYS . 5.7 t -96.18 -35.97 11.11 Favored 'General case' 0 CA--C 1.518 -0.285 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 8.0 pt -92.12 -38.36 10.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.332 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -59.94 -28.83 66.68 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 -179.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.7 m -64.29 -40.46 96.0 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.869 -0.332 . . . . 0.0 111.214 -179.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -70.09 -43.83 70.3 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 179.302 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -65.08 -44.1 90.01 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.064 -0.971 . . . . 0.0 111.249 179.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.6 -45.49 94.51 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 119.208 -1.472 . . . . 0.0 109.863 -179.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.11 -39.65 71.94 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.56 -0.32 . . . . 0.0 111.738 179.22 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 14.5 t -63.03 -42.14 99.7 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.341 -177.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.71 -39.64 80.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.744 178.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 34.5 tttm -59.91 -43.36 94.9 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 -178.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.81 -36.79 91.67 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 177.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 13.7 t80 -71.64 -50.23 32.56 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-O 120.897 0.379 . . . . 0.0 110.221 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.518 ' O ' ' N ' ' A' ' 44' ' ' SER . 47.8 mtpt -62.86 -38.88 92.6 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.346 178.687 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 50.5 mtpt -61.82 -38.85 89.7 Favored 'General case' 0 C--N 1.319 -0.744 0 C-N-CA 119.764 -0.774 . . . . 0.0 110.083 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -67.0 -36.07 81.34 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.778 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 76.6 mtm -88.91 -28.87 20.02 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.873 0.368 . . . . 0.0 111.064 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.518 ' N ' ' O ' ' A' ' 40' ' ' LYS . 37.7 m -53.53 -26.68 22.07 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.101 -179.282 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.445 ' C ' ' H ' ' A' ' 47' ' ' GLU . 92.6 m-20 -62.01 -39.05 90.93 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.416 179.767 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -77.09 39.69 0.24 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.534 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.445 ' H ' ' C ' ' A' ' 45' ' ' ASP . 75.7 tt0 -167.99 71.14 0.88 Allowed Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.41 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo . . . . . 0 C--N 1.308 -1.572 0 C-N-CA 122.697 2.265 . . . . 0.0 111.975 -179.675 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 38.4 mmt . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -81.08 38.18 2.39 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 139.02 3.24 1.74 Allowed Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.512 ' N ' ' CD1' ' A' ' 4' ' ' ILE . 2.5 mp -94.66 110.85 24.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.269 0.557 . . . . 0.0 110.828 -179.687 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 10.9 m -88.33 -139.38 0.11 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.506 178.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 34.4 mm -91.06 -38.15 10.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.356 179.137 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 94.1 m95 -74.32 -38.93 63.15 Favored 'General case' 0 C--N 1.321 -0.638 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.096 179.595 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.499 ' N ' ' OE1' ' A' ' 8' ' ' GLN . 0.8 OUTLIER -64.23 -38.77 92.22 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -179.686 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.429 ' C ' ' CD1' ' A' ' 9' ' ' LEU . 0.4 OUTLIER -73.31 -38.19 65.93 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.249 179.672 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 13.8 mt -63.41 -46.87 84.4 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.871 0.367 . . . . 0.0 111.278 -177.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.2 mp -67.74 -44.23 85.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.201 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 35.1 mt -65.04 -44.64 95.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.121 -179.27 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.46 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -64.74 -37.54 87.93 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 115.762 -0.653 . . . . 0.0 110.966 -178.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.437 ' O ' ' CD2' ' A' ' 18' ' ' LEU . 54.4 t -66.93 -44.99 88.36 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.426 0 C-N-CA 120.435 -0.506 . . . . 0.0 111.506 -178.764 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 16.7 pt -66.9 -42.65 89.24 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.99 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.147 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.51 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.7 t -63.82 -41.43 92.54 Favored 'Isoleucine or valine' 0 CA--C 1.482 -1.659 0 CA-C-N 115.388 -0.823 . . . . 0.0 109.795 -178.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.46 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 52.2 t -66.29 -50.43 68.15 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.93 0 C-N-CA 117.548 -1.661 . . . . 0.0 113.32 -177.269 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.437 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 1.2 pp -67.04 -44.11 81.03 Favored 'General case' 0 C--N 1.296 -1.727 0 C-N-CA 119.151 -1.02 . . . . 0.0 111.881 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.436 ' C ' ' CD1' ' A' ' 19' ' ' LEU . 0.4 OUTLIER -65.78 -38.43 89.02 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.607 -0.27 . . . . 0.0 111.028 179.8 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.51 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 3.4 m-85 -68.38 -37.13 80.11 Favored 'General case' 0 CA--C 1.515 -0.376 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.819 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.466 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 97.93 13.77 42.04 Favored Glycine 0 CA--C 1.504 -0.601 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.512 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.466 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 46.2 p 53.2 76.95 0.18 Allowed 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 114.083 -1.058 . . . . 0.0 112.121 178.504 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 18.0 ptmt -142.4 -36.46 0.4 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.939 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 11.1 mmmt -77.31 -50.75 12.14 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.39 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.474 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 0.2 OUTLIER -53.23 -37.73 62.3 Favored 'General case' 0 CA--C 1.503 -0.84 0 CA-C-O 122.12 0.962 . . . . 0.0 110.449 -178.744 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.47 -24.92 73.94 Favored Glycine 0 N--CA 1.435 -1.427 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 -178.438 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.9 t -93.46 -40.4 10.37 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.4 pt -93.53 -36.06 7.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 121.361 0.601 . . . . 0.0 109.851 -179.178 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.35 -24.97 68.02 Favored Glycine 0 CA--C 1.52 0.384 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.4 t -64.65 -41.69 95.94 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.692 0.282 . . . . 0.0 111.341 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -73.93 -42.6 60.34 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -66.83 -44.44 81.11 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 114.998 -1.001 . . . . 0.0 111.475 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.41 -44.13 97.24 Favored Glycine 0 N--CA 1.44 -1.051 0 C-N-CA 119.322 -1.418 . . . . 0.0 109.817 -179.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.73 -40.13 69.61 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.529 -0.336 . . . . 0.0 111.346 179.05 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.5 m -63.69 -40.56 97.1 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.223 -178.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.408 HD11 ' N ' ' A' ' 36' ' ' ILE . 1.2 mp -70.19 -39.52 77.04 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.677 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.5 ptmt -59.79 -41.86 92.12 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 -178.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.81 -36.9 87.92 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -71.49 -50.82 27.8 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.537 ' O ' ' N ' ' A' ' 44' ' ' SER . 53.7 mtpt -63.21 -38.6 91.82 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.506 178.655 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -61.49 -39.2 90.07 Favored 'General case' 0 C--N 1.318 -0.766 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.867 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.99 -36.83 83.04 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.705 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.444 ' O ' ' O ' ' A' ' 44' ' ' SER . 74.0 mtm -91.12 -66.75 0.9 Allowed 'General case' 0 N--CA 1.463 0.181 0 CA-C-O 120.917 0.389 . . . . 0.0 110.528 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.537 ' N ' ' O ' ' A' ' 40' ' ' LYS . 83.6 p 49.68 176.37 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.498 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 45.8 t0 -92.44 113.51 25.81 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 120.851 0.358 . . . . 0.0 110.393 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -82.55 17.73 1.7 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.768 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -154.43 78.91 5.04 Favored Pre-proline 0 C--N 1.324 -0.529 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.7 179.799 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo . . . . . 0 C--N 1.307 -1.615 0 C-N-CA 122.606 2.204 . . . . 0.0 111.955 -179.985 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.457 ' H2 ' ' H ' ' A' ' 2' ' ' GLY . 1.7 mpp? . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.457 ' H ' ' H2 ' ' A' ' 1' ' ' MET . . . -62.41 -34.46 89.41 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.29 20.84 0.34 Allowed Glycine 0 N--CA 1.45 -0.388 0 N-CA-C 109.789 -1.325 . . . . 0.0 109.789 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.2 mp -92.26 105.77 17.05 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.26 0 CA-C-O 121.367 0.604 . . . . 0.0 110.132 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 49.8 m -153.04 -128.94 0.04 OUTLIER 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 114.974 -1.012 . . . . 0.0 110.316 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.49 ' CD1' ' N ' ' A' ' 6' ' ' ILE . 1.5 mp -59.85 -37.23 70.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 120.755 0.312 . . . . 0.0 110.463 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 67.6 m95 -62.15 -46.98 86.57 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.43 -38.9 92.63 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.413 ' O ' ' CB ' ' A' ' 13' ' ' ALA . 89.2 mt -66.08 -38.73 89.0 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.306 178.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 16.7 mt -63.43 -50.28 70.41 Favored 'General case' 0 C--N 1.315 -0.919 0 C-N-CA 120.131 -0.628 . . . . 0.0 110.541 -176.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 3.4 mp -66.61 -44.73 89.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.107 178.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 75.5 mt -63.91 -46.79 93.16 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.967 0 C-N-CA 120.294 -0.562 . . . . 0.0 111.432 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.436 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -65.0 -37.68 88.47 Favored 'General case' 0 C--N 1.319 -0.745 0 O-C-N 123.213 0.321 . . . . 0.0 111.349 -179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.2 t -67.8 -43.82 86.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.613 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.448 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 96.6 mt -66.2 -43.53 91.86 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.155 0 O-C-N 123.521 0.513 . . . . 0.0 109.725 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.424 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.6 t -63.72 -42.26 95.38 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.504 0 CA-C-N 115.08 -0.964 . . . . 0.0 109.919 -178.637 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.436 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 59.9 t -66.27 -44.78 91.05 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 C-N-CA 118.217 -1.393 . . . . 0.0 112.79 -176.844 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.2 pp -71.96 -42.9 66.02 Favored 'General case' 0 C--N 1.294 -1.825 0 C-N-CA 120.046 -0.661 . . . . 0.0 109.761 178.177 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.448 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.6 tm? -64.8 -41.75 95.56 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.823 -179.175 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.424 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 6.9 m-85 -69.24 -33.47 73.33 Favored 'General case' 0 CA--C 1.511 -0.558 0 C-N-CA 119.067 -1.053 . . . . 0.0 108.831 178.716 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.475 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 93.93 12.9 56.06 Favored Glycine 0 C--N 1.318 -0.471 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 179.244 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.475 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 43.1 p 55.78 77.73 0.22 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 114.684 -0.758 . . . . 0.0 112.002 178.762 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -146.28 -26.11 0.43 Allowed 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.454 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.475 ' HZ1' ' CD1' ' A' ' 28' ' ' ILE . 0.0 OUTLIER -93.65 -39.71 10.65 Favored 'General case' 0 C--O 1.223 -0.315 0 C-N-CA 120.719 -0.393 . . . . 0.0 110.905 -179.861 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.447 ' H ' ' CD1' ' A' ' 25' ' ' LEU . 0.2 OUTLIER -59.55 -37.04 77.35 Favored 'General case' 0 CA--C 1.501 -0.931 0 CA-C-O 121.714 0.768 . . . . 0.0 110.001 179.889 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.56 -25.0 75.23 Favored Glycine 0 N--CA 1.432 -1.6 0 N-CA-C 108.628 -1.789 . . . . 0.0 108.628 -179.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 8.1 t -87.25 -43.25 12.33 Favored 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 179.688 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.475 ' CD1' ' HZ1' ' A' ' 24' ' ' LYS . 13.5 pt -93.65 -34.68 5.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.278 0.561 . . . . 0.0 110.091 -178.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.404 ' N ' ' O ' ' A' ' 25' ' ' LEU . . . -63.27 -22.78 65.68 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 -179.566 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.5 t -64.71 -43.44 93.45 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 120.763 -0.375 . . . . 0.0 111.733 -179.349 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -75.54 -42.51 52.25 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.438 0.637 . . . . 0.0 109.487 179.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.8 mp -66.89 -44.66 80.28 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.043 -0.98 . . . . 0.0 111.81 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.32 -44.12 97.4 Favored Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 119.413 -1.375 . . . . 0.0 109.832 -179.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.84 -39.79 69.49 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.66 -0.27 . . . . 0.0 111.394 179.183 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.7 m -63.24 -40.92 98.79 Favored 'General case' 0 CA--C 1.518 -0.287 0 CA-C-O 121.112 0.482 . . . . 0.0 110.477 -178.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.63 -39.36 78.15 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.757 178.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 24.2 tttt -59.97 -44.56 94.37 Favored 'General case' 0 N--CA 1.435 -1.217 0 C-N-CA 119.231 -0.988 . . . . 0.0 108.414 -179.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.97 -36.34 91.91 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 178.005 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.59 ' CD2' ' SD ' ' A' ' 43' ' ' MET . 21.0 t80 -71.38 -51.41 24.24 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-O 120.835 0.35 . . . . 0.0 110.456 -179.448 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.54 ' O ' ' N ' ' A' ' 44' ' ' SER . 54.8 mtpt -63.08 -38.56 91.66 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.38 178.538 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -61.36 -36.84 81.33 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.121 -0.632 . . . . 0.0 110.012 -179.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.63 -36.01 81.55 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.126 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.59 ' SD ' ' CD2' ' A' ' 39' ' ' PHE . 0.0 OUTLIER -93.38 -68.17 0.82 Allowed 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.964 0.411 . . . . 0.0 110.802 179.769 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.54 ' N ' ' O ' ' A' ' 40' ' ' LYS . 3.1 p 47.84 10.94 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.882 -179.503 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.576 ' C ' ' H ' ' A' ' 47' ' ' GLU . 66.7 t0 46.64 -121.09 1.1 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.266 179.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.47 ' H ' ' CG ' ' A' ' 45' ' ' ASP . 90.5 m-20 -74.77 17.24 0.22 Allowed 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.576 ' H ' ' C ' ' A' ' 45' ' ' ASP . 34.2 tt0 41.47 73.5 0.88 Allowed Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.63 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_endo . . . . . 0 C--N 1.307 -1.651 0 C-N-CA 122.757 2.304 . . . . 0.0 112.036 -179.468 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 93.0 mtp . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.1 0.22 58.65 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 111.281 -0.728 . . . . 0.0 111.281 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 96.57 17.53 33.23 Favored Glycine 0 N--CA 1.466 0.696 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.0 mt -69.5 -115.73 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.342 -0.429 . . . . 0.0 110.198 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 67.5 m -165.31 -160.08 0.46 Allowed 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 4.6 tp -100.33 -36.13 4.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-N 115.37 -0.832 . . . . 0.0 111.986 179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 8.1 t-105 -62.2 -37.12 84.12 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 115.459 -0.791 . . . . 0.0 108.91 -178.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -64.35 -38.91 92.71 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 178.318 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 84.0 mt -64.79 -37.58 88.11 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.93 178.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.4 ' O ' ' CG2' ' A' ' 14' ' ' VAL . 3.9 mt -62.47 -43.89 97.71 Favored 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.274 -177.239 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.2 mt -68.35 -45.11 83.02 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 C-N-CA 119.992 -0.683 . . . . 0.0 109.593 178.049 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 72.0 mt -65.98 -44.74 92.19 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.572 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.531 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.466 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -65.22 -37.21 86.56 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.03 -179.517 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.48 ' O ' ' CD2' ' A' ' 18' ' ' LEU . 46.0 t -66.65 -44.78 89.57 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.717 0 C-N-CA 120.599 -0.44 . . . . 0.0 111.485 -179.082 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.439 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 15.2 pt -66.61 -42.64 90.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.209 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.514 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.5 t -63.85 -41.82 93.8 Favored 'Isoleucine or valine' 0 CA--C 1.483 -1.603 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.702 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.466 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 61.5 t -65.8 -45.93 90.21 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 C-N-CA 118.361 -1.335 . . . . 0.0 112.948 -177.216 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.48 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 1.4 pp -72.11 -42.85 65.59 Favored 'General case' 0 C--N 1.288 -2.093 0 CA-C-O 121.333 0.587 . . . . 0.0 109.791 178.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.467 ' C ' ' CD1' ' A' ' 19' ' ' LEU . 2.5 tm? -64.67 -42.3 95.47 Favored 'General case' 0 N--CA 1.44 -0.956 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.164 -179.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.514 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 5.7 m-85 -68.94 -34.37 75.24 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 119.138 -1.025 . . . . 0.0 109.314 179.333 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.487 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 96.32 11.38 54.32 Favored Glycine 0 N--CA 1.466 0.635 0 N-CA-C 110.647 -0.981 . . . . 0.0 110.647 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.487 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 43.4 p 56.53 68.58 0.84 Allowed 'General case' 0 CA--C 1.502 -0.884 0 CA-C-N 115.055 -0.573 . . . . 0.0 112.271 178.199 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -139.87 -24.77 0.83 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.015 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 10.1 mmmt -87.06 -52.09 5.63 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.821 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.508 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 0.1 OUTLIER -53.3 -36.92 61.76 Favored 'General case' 0 CA--C 1.505 -0.781 0 CA-C-O 121.783 0.801 . . . . 0.0 110.266 -178.966 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.45 -25.46 72.61 Favored Glycine 0 N--CA 1.436 -1.322 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 -177.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.6 t -92.89 -40.66 10.48 Favored 'General case' 0 CA--C 1.517 -0.292 0 N-CA-C 112.244 0.461 . . . . 0.0 112.244 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.3 pt -92.64 -35.42 6.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 121.173 0.511 . . . . 0.0 109.993 -178.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.17 -25.76 71.2 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.566 -1.014 . . . . 0.0 110.566 -179.563 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.1 p -65.91 -38.86 89.82 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.922 -0.311 . . . . 0.0 111.336 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 46.2 t0 -81.36 -39.47 25.02 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.254 0.549 . . . . 0.0 109.694 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.0 mp -69.37 -45.32 69.63 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.193 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.76 -43.94 98.21 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 119.531 -1.319 . . . . 0.0 109.913 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.0 -39.99 79.0 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.538 -0.331 . . . . 0.0 111.372 179.522 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 47.1 t -63.28 -42.26 99.08 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.093 0.473 . . . . 0.0 110.718 -178.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.88 -39.42 79.92 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.154 179.205 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 7.6 ttpt -59.39 -43.65 92.92 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.242 -0.983 . . . . 0.0 108.524 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.73 -36.21 92.0 Favored Glycine 0 N--CA 1.444 -0.821 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 178.439 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -71.08 -52.54 18.84 Favored 'General case' 0 CA--C 1.512 -0.517 0 CA-C-O 120.976 0.417 . . . . 0.0 110.133 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.56 ' O ' ' N ' ' A' ' 44' ' ' SER . 44.2 mttp -63.36 -38.86 92.81 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 120.27 -0.572 . . . . 0.0 110.545 178.487 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 1.9 tmtp? -61.7 -39.15 90.44 Favored 'General case' 0 C--N 1.319 -0.76 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.106 -179.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.01 -38.6 72.64 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.953 179.572 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.473 ' N ' ' SD ' ' A' ' 43' ' ' MET . 0.2 OUTLIER -88.81 -11.06 45.93 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.732 -179.407 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.56 ' N ' ' O ' ' A' ' 40' ' ' LYS . 6.3 m -67.95 143.57 55.57 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -136.59 -33.2 0.8 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.434 -179.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -75.74 48.92 0.49 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.2 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -62.96 151.21 86.35 Favored Pre-proline 0 CA--C 1.536 0.421 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.494 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo . . . . . 0 N--CA 1.494 1.528 0 C-N-CA 122.494 2.13 . . . . 0.0 111.766 179.604 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.521 ' SD ' ' N ' ' A' ' 1' ' ' MET . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 . . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -80.48 32.23 2.36 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 111.284 -0.727 . . . . 0.0 111.284 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.411 ' O ' ' OE1' ' A' ' 8' ' ' GLN . . . 143.3 -3.99 1.73 Allowed Glycine 0 C--N 1.335 0.486 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 -179.812 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.586 ' N ' ' CD1' ' A' ' 4' ' ' ILE . 1.7 mp -92.05 118.55 37.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.223 0.535 . . . . 0.0 110.41 -179.521 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 41.8 m -136.42 -139.89 0.16 Allowed 'General case' 0 CA--C 1.518 -0.255 0 CA-C-N 115.265 -0.879 . . . . 0.0 109.357 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 3.7 tp -93.13 -36.15 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.586 0 CA-C-O 121.235 0.54 . . . . 0.0 111.578 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.445 ' CD1' ' C ' ' A' ' 7' ' ' TRP . 0.3 OUTLIER -62.21 -41.62 98.54 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-N 115.365 -0.834 . . . . 0.0 108.967 -179.185 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.411 ' OE1' ' O ' ' A' ' 3' ' ' GLY . 18.4 mt-30 -64.08 -38.38 90.87 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 178.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.514 ' O ' ' N ' ' A' ' 13' ' ' ALA . 87.5 mt -65.37 -36.98 85.63 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.326 177.439 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.8 tt -61.84 -50.95 70.19 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.888 -174.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 mp -65.35 -44.73 94.64 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 C-N-CA 119.893 -0.723 . . . . 0.0 109.533 177.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.1 mp -63.77 -44.36 98.23 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.21 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.904 179.49 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.514 ' N ' ' O ' ' A' ' 9' ' ' LEU . . . -64.56 -37.35 87.27 Favored 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 121.086 -0.246 . . . . 0.0 110.836 -179.411 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.451 ' O ' ' CD2' ' A' ' 18' ' ' LEU . 53.0 t -66.93 -45.01 88.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 C-N-CA 120.544 -0.462 . . . . 0.0 111.465 -179.191 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 13.5 pt -66.87 -42.76 89.47 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.989 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 178.59 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.553 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.4 t -63.14 -41.54 93.21 Favored 'Isoleucine or valine' 0 CA--C 1.478 -1.799 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.883 -178.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.461 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 51.7 t -66.14 -51.23 62.11 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.033 0 C-N-CA 117.857 -1.537 . . . . 0.0 113.652 -177.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.451 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 1.4 pp -66.89 -44.36 81.08 Favored 'General case' 0 C--N 1.293 -1.869 0 C-N-CA 119.487 -0.885 . . . . 0.0 111.782 179.764 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.432 ' C ' ' CD1' ' A' ' 19' ' ' LEU . 0.4 OUTLIER -65.77 -38.87 90.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.704 -0.225 . . . . 0.0 110.638 -179.943 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.553 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 3.0 m-85 -68.5 -36.54 79.05 Favored 'General case' 0 CA--C 1.513 -0.476 0 C-N-CA 119.607 -0.837 . . . . 0.0 109.317 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.472 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 96.98 12.01 51.11 Favored Glycine 0 CA--C 1.506 -0.501 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 -179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.472 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 43.3 p 54.74 74.74 0.33 Allowed 'General case' 0 CA--C 1.5 -0.963 0 CA-C-N 114.196 -1.002 . . . . 0.0 112.677 178.055 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 62.1 mttp -139.04 -31.57 0.7 Allowed 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.784 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.43 ' O ' ' N ' ' A' ' 27' ' ' SER . 6.7 mmpt? -81.6 -54.35 5.48 Favored 'General case' 0 CA--C 1.501 -0.914 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.612 -179.736 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.467 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 0.0 OUTLIER -48.97 -39.29 25.96 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 122.371 1.081 . . . . 0.0 110.701 -176.662 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.74 -24.85 73.48 Favored Glycine 0 N--CA 1.429 -1.817 0 CA-C-N 114.011 -1.449 . . . . 0.0 110.289 -178.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.43 ' N ' ' O ' ' A' ' 24' ' ' LYS . 24.6 m -95.86 -40.78 9.15 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.415 0.524 . . . . 0.0 112.415 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.2 pt -91.32 -36.78 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 CA-C-O 121.054 0.454 . . . . 0.0 109.909 -179.148 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.45 -26.62 68.34 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -179.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.2 p -64.64 -38.57 91.45 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.702 0.287 . . . . 0.0 110.944 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -72.96 -43.28 62.48 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.54 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.5 mp -64.97 -44.37 89.58 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.185 179.578 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -64.02 -45.1 94.81 Favored Glycine 0 N--CA 1.44 -1.093 0 C-N-CA 119.251 -1.452 . . . . 0.0 109.765 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.65 -39.71 73.46 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.513 -0.344 . . . . 0.0 111.664 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.9 t -62.89 -41.91 99.59 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.407 -177.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.412 ' CG2' ' HZ3' ' A' ' 40' ' ' LYS . 1.2 mp -69.72 -39.77 78.44 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.145 178.613 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 36.6 tttm -60.07 -41.45 92.42 Favored 'General case' 0 N--CA 1.426 -1.644 0 N-CA-C 108.056 -1.091 . . . . 0.0 108.056 -178.529 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.12 -36.49 90.44 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 109.882 -1.287 . . . . 0.0 109.882 177.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -71.6 -51.92 20.78 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.188 -179.308 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.52 ' O ' ' N ' ' A' ' 44' ' ' SER . 54.5 mttp -63.72 -39.65 94.81 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.517 178.322 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 61.6 tttm -61.79 -38.79 89.38 Favored 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 120.054 -0.658 . . . . 0.0 110.458 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.79 -35.98 81.33 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.701 -179.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.493 ' O ' ' N ' ' A' ' 45' ' ' ASP . 73.1 mtm -91.49 -64.96 1.05 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.772 0.32 . . . . 0.0 110.273 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.52 ' N ' ' O ' ' A' ' 40' ' ' LYS . 89.0 p 38.67 -91.98 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.839 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.493 ' N ' ' O ' ' A' ' 43' ' ' MET . 97.9 m-20 53.82 33.03 16.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.754 0.311 . . . . 0.0 110.787 179.087 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -97.91 36.62 1.52 Allowed 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.42 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.521 ' N ' ' CD ' ' A' ' 48' ' ' PRO . 11.6 mt-10 53.22 50.37 7.5 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.644 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.521 ' CD ' ' N ' ' A' ' 47' ' ' GLU . 38.4 Cg_endo . . . . . 0 C--N 1.304 -1.775 0 C-N-CA 122.861 2.374 . . . . 0.0 111.742 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.583 ' SD ' ' N ' ' A' ' 1' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.609 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 . . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -121.92 -15.37 4.35 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.333 -0.707 . . . . 0.0 111.333 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -106.2 -1.04 38.41 Favored Glycine 0 N--CA 1.465 0.579 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 36.8 mt -42.18 -85.45 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.658 -0.271 . . . . 0.0 110.696 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.6 m -156.25 -165.78 2.0 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 40.8 mm -91.7 -40.66 12.57 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.06 179.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 82.9 m95 -71.68 -40.69 69.42 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 120.279 -0.568 . . . . 0.0 110.207 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.488 ' N ' ' OE1' ' A' ' 8' ' ' GLN . 1.7 mp0 -64.41 -38.8 92.31 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.055 0.455 . . . . 0.0 110.311 -179.227 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.455 ' C ' ' CD1' ' A' ' 9' ' ' LEU . 0.3 OUTLIER -72.31 -38.0 68.81 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.97 179.7 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 15.8 mt -63.28 -48.78 76.68 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.73 -176.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.2 mp -66.13 -44.33 91.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 178.394 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 69.3 mt -64.06 -44.48 97.74 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.642 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.391 -179.366 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.451 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -64.91 -37.09 86.5 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.867 -179.067 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.496 ' O ' ' CD2' ' A' ' 18' ' ' LEU . 50.2 t -66.93 -45.6 86.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 C-N-CA 120.425 -0.51 . . . . 0.0 111.574 -178.809 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 15.9 pt -66.41 -42.34 90.27 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.916 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.736 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.7 t -63.19 -42.36 96.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.35 -179.626 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.451 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 61.3 t -65.63 -48.96 80.69 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.887 0 C-N-CA 117.245 -1.782 . . . . 0.0 113.69 -176.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.496 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 1.6 pp -68.49 -44.0 75.66 Favored 'General case' 0 C--N 1.289 -2.063 0 C-N-CA 120.094 -0.642 . . . . 0.0 112.156 -179.377 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.448 ' C ' ' CD1' ' A' ' 19' ' ' LEU . 0.4 OUTLIER -66.3 -39.19 89.15 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.99 -179.604 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.736 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 1.8 m-85 -68.45 -37.62 80.37 Favored 'General case' 0 CA--C 1.506 -0.726 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.641 -178.395 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.49 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 101.2 9.53 44.56 Favored Glycine 0 C--N 1.308 -0.974 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.046 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.49 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 44.6 p 55.15 66.66 1.17 Allowed 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 178.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -139.6 -22.57 0.89 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.054 179.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 9.9 mmmt -87.13 -51.41 6.01 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.646 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.484 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 0.0 OUTLIER -54.45 -37.11 64.8 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 122.067 0.937 . . . . 0.0 110.556 -178.85 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.48 -25.07 73.55 Favored Glycine 0 C--N 1.304 -1.215 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.587 -177.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 7.5 t -92.54 -42.89 9.44 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 111.977 0.362 . . . . 0.0 111.977 -179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 4.6 pt -91.29 -36.1 7.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 121.233 0.54 . . . . 0.0 109.917 -179.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.57 -24.12 69.24 Favored Glycine 0 CA--C 1.518 0.257 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -179.126 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.2 p -65.22 -41.18 94.71 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 120.771 -0.372 . . . . 0.0 111.058 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -76.02 -39.88 54.71 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.078 0.466 . . . . 0.0 109.874 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.7 mp -70.21 -45.59 66.27 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.129 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.55 -43.57 98.83 Favored Glycine 0 N--CA 1.441 -1.007 0 C-N-CA 119.545 -1.312 . . . . 0.0 110.473 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.02 -40.04 71.99 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 120.898 0.38 . . . . 0.0 111.06 179.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 12.4 t -63.99 -41.93 97.36 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 120.559 -0.456 . . . . 0.0 110.98 -178.558 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.44 -39.87 79.2 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.71 -179.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 18.7 pttt -59.58 -40.51 87.62 Favored 'General case' 0 C--N 1.309 -1.195 0 C-N-CA 118.591 -1.243 . . . . 0.0 107.843 -178.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -69.46 -36.82 78.07 Favored Glycine 0 N--CA 1.442 -0.92 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 179.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.425 ' CE1' ' CE ' ' A' ' 43' ' ' MET . 46.0 t80 -71.52 -50.71 28.67 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.552 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.563 ' O ' ' N ' ' A' ' 44' ' ' SER . 52.7 mtpt -63.65 -38.85 92.66 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.597 178.797 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -62.04 -37.97 86.94 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 119.981 -0.687 . . . . 0.0 110.09 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.68 -36.87 83.53 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.495 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.592 ' N ' ' SD ' ' A' ' 43' ' ' MET . 0.2 OUTLIER -94.74 -10.55 31.26 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.689 -179.615 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.563 ' N ' ' O ' ' A' ' 40' ' ' LYS . 11.7 t -58.16 -44.44 87.92 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.935 0.398 . . . . 0.0 110.126 -179.32 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.495 ' CG ' ' H ' ' A' ' 46' ' ' ASP . 44.8 t0 -85.4 -179.46 6.95 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.423 179.727 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.495 ' H ' ' CG ' ' A' ' 45' ' ' ASP . 96.7 m-20 56.15 38.11 29.52 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.279 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 -70.76 152.08 95.2 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.571 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo . . . . . 0 N--CA 1.495 1.562 0 C-N-CA 122.69 2.26 . . . . 0.0 111.71 179.563 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.522 ' C ' ' H ' ' A' ' 3' ' ' GLY . 94.9 mtp . . . . . 0 N--CA 1.492 1.629 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -78.15 29.13 1.91 Allowed Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.522 ' H ' ' C ' ' A' ' 1' ' ' MET . . . -152.54 34.66 0.82 Allowed Glycine 0 N--CA 1.451 -0.341 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 179.59 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.8 mt -53.11 130.75 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.673 0 CA-C-O 122.019 0.914 . . . . 0.0 110.265 -178.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 53.3 m -106.14 -132.33 0.31 Allowed 'General case' 0 C--N 1.315 -0.891 0 CA-C-N 113.791 -1.549 . . . . 0.0 110.275 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.422 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.4 mp -104.68 -31.03 2.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.277 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 70.9 m95 -62.76 -46.97 85.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.692 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 59.1 mm-40 -64.35 -39.05 93.11 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.423 ' O ' ' N ' ' A' ' 13' ' ' ALA . 84.4 mt -65.08 -39.1 92.72 Favored 'General case' 0 CA--C 1.508 -0.649 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.146 178.626 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.0 mt -63.38 -49.16 74.91 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.521 -176.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.486 ' O ' HG12 ' A' ' 15' ' ' ILE . 3.3 mp -67.67 -44.97 85.66 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.775 0 C-N-CA 119.508 -0.877 . . . . 0.0 109.093 178.07 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 77.1 mt -63.36 -44.36 98.98 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.526 -179.165 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.423 ' N ' ' O ' ' A' ' 9' ' ' LEU . . . -63.79 -36.46 83.96 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.203 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.405 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 65.8 t -67.1 -43.06 88.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 C-N-CA 119.779 -0.769 . . . . 0.0 110.457 179.672 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.486 HG12 ' O ' ' A' ' 11' ' ' ILE . 33.5 mm -66.08 -43.04 92.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.127 0.489 . . . . 0.0 110.28 179.26 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -63.75 -38.04 81.27 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.558 -178.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.407 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 95.0 t -65.66 -43.02 93.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 C-N-CA 118.409 -1.316 . . . . 0.0 111.868 -178.308 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.405 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 16.1 mt -62.0 -45.03 95.42 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 118.631 -1.227 . . . . 0.0 111.833 -179.106 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.449 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.78 -38.37 79.97 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -178.528 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.449 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 1.3 m-85 -67.57 -32.44 73.2 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -177.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.472 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 94.45 8.88 59.46 Favored Glycine 0 CA--C 1.5 -0.887 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 178.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.472 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 18.0 p 56.95 27.95 13.94 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 114.27 -0.965 . . . . 0.0 112.502 178.034 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -100.57 -12.84 18.92 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.776 179.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.5 ' O ' ' N ' ' A' ' 27' ' ' SER . 15.4 mmmt -96.06 -58.43 2.09 Favored 'General case' 0 C--O 1.221 -0.438 0 CA-C-O 121.053 0.454 . . . . 0.0 110.281 179.511 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.684 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 2.0 mp -44.12 -42.0 6.01 Favored 'General case' 0 CA--C 1.495 -1.144 0 CA-C-O 122.459 1.123 . . . . 0.0 110.468 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.94 -25.42 71.6 Favored Glycine 0 N--CA 1.424 -2.134 0 CA-C-N 113.49 -1.686 . . . . 0.0 110.601 -177.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.5 ' N ' ' O ' ' A' ' 24' ' ' LYS . 5.4 m -95.28 -35.06 11.95 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -179.484 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 9.2 pt -93.53 -38.17 9.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.2 -24.01 49.62 Favored Glycine 0 CA--C 1.521 0.417 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 61.9 p -66.38 -57.28 7.78 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.946 -0.302 . . . . 0.0 111.761 -179.353 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.412 ' O ' ' OG ' ' A' ' 35' ' ' SER . 29.5 t70 -67.81 -39.87 83.91 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.411 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -65.46 -44.99 85.51 Favored 'General case' 0 CA--C 1.507 -0.694 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.159 179.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.43 -43.43 99.34 Favored Glycine 0 N--CA 1.433 -1.54 0 N-CA-C 108.475 -1.85 . . . . 0.0 108.475 -178.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.97 -40.0 75.63 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.073 -0.564 . . . . 0.0 111.159 178.429 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.412 ' OG ' ' O ' ' A' ' 31' ' ' ASP . 51.6 m -63.53 -43.37 97.33 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 120.408 -0.517 . . . . 0.0 110.87 -178.452 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -67.28 -39.71 83.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.64 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.0 pttt -60.02 -42.08 93.56 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 -179.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.68 -36.83 88.37 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 178.23 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.592 ' CE2' ' SD ' ' A' ' 43' ' ' MET . 14.8 t80 -71.94 -50.41 29.27 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 120.956 0.408 . . . . 0.0 110.642 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.564 ' O ' ' N ' ' A' ' 44' ' ' SER . 21.8 mtpp -62.74 -38.55 90.99 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.269 179.066 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -61.76 -38.3 87.49 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.475 -179.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.92 -35.8 80.82 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.194 0.521 . . . . 0.0 109.626 179.189 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.592 ' SD ' ' CE2' ' A' ' 39' ' ' PHE . 33.6 mtp -88.64 -16.87 31.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.06 -179.686 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.564 ' N ' ' O ' ' A' ' 40' ' ' LYS . 47.7 t -60.56 152.85 25.01 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.185 -179.346 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.507 ' C ' ' H ' ' A' ' 47' ' ' GLU . 99.3 m-20 56.56 94.88 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.9 0.381 . . . . 0.0 110.383 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -74.82 34.98 0.1 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.639 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.507 ' H ' ' C ' ' A' ' 45' ' ' ASP . 48.1 mt-10 50.07 65.26 7.13 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.677 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 77.7 Cg_endo . . . . . 0 C--N 1.306 -1.69 0 C-N-CA 122.925 2.417 . . . . 0.0 112.045 -179.834 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 92.5 mtp . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -99.09 18.32 56.87 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.86 22.39 1.79 Allowed Glycine 0 C--N 1.328 0.138 0 N-CA-C 109.116 -1.594 . . . . 0.0 109.116 179.498 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.1 mt -43.4 122.56 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.512 -0.504 0 CA-C-O 121.823 0.821 . . . . 0.0 110.463 -179.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -96.64 -162.42 0.95 Allowed 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 114.352 -1.295 . . . . 0.0 109.128 178.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.578 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.4 mp -68.48 -44.19 83.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 114.647 -1.16 . . . . 0.0 110.403 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -70.92 -39.71 72.53 Favored 'General case' 0 C--N 1.316 -0.884 0 C-N-CA 120.068 -0.653 . . . . 0.0 109.773 179.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 94.2 mm-40 -64.66 -39.15 93.19 Favored 'General case' 0 N--CA 1.442 -0.85 0 C-N-CA 120.315 -0.554 . . . . 0.0 109.617 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.443 ' O ' ' N ' ' A' ' 13' ' ' ALA . 0.4 OUTLIER -73.05 -38.36 66.51 Favored 'General case' 0 C--O 1.226 -0.176 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.014 179.027 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 15.3 mt -63.31 -47.82 80.66 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.945 -0.302 . . . . 0.0 111.22 -177.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.407 HD13 ' N ' ' A' ' 11' ' ' ILE . 2.1 mp -66.94 -44.48 88.64 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.851 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 53.3 mt -64.42 -44.72 97.09 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.076 0 CA-C-N 115.639 -0.709 . . . . 0.0 111.271 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.443 ' N ' ' O ' ' A' ' 9' ' ' LEU . . . -64.84 -37.39 87.47 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.719 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.47 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 55.3 t -67.67 -45.72 84.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 C-N-CA 119.624 -0.831 . . . . 0.0 110.697 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.5 mt -65.85 -43.88 92.97 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.717 0 CA-C-O 121.172 0.51 . . . . 0.0 111.189 -179.023 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -64.46 -38.74 83.36 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.344 0 CA-C-N 115.284 -0.871 . . . . 0.0 109.616 -178.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.412 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 61.0 t -65.75 -42.79 93.19 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.158 0 C-N-CA 118.571 -1.252 . . . . 0.0 111.389 -177.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.47 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 66.0 mt -61.77 -44.96 95.86 Favored 'General case' 0 C--N 1.312 -1.031 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.751 -179.02 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.434 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.55 -38.29 80.65 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 113.067 0.765 . . . . 0.0 113.067 -178.74 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.434 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 1.2 m-85 -67.61 -31.74 71.97 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -178.224 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.442 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 90.74 2.79 71.84 Favored Glycine 0 C--N 1.318 -0.47 0 N-CA-C 109.211 -1.556 . . . . 0.0 109.211 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.442 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 5.5 p 57.19 9.09 0.63 Allowed 'General case' 0 CA--C 1.511 -0.544 0 CA-C-N 114.727 -0.737 . . . . 0.0 112.178 178.03 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 24.7 mtpp -71.76 -42.26 67.42 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.256 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.57 -25.17 25.14 Favored 'General case' 0 C--O 1.221 -0.41 0 CA-C-N 116.16 -0.473 . . . . 0.0 112.017 -178.705 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.528 ' O ' ' N ' ' A' ' 29' ' ' GLY . 9.7 mp -59.05 -43.45 91.68 Favored 'General case' 0 CA--C 1.49 -1.328 0 CA-C-O 121.852 0.834 . . . . 0.0 109.353 -179.669 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.82 -25.34 72.08 Favored Glycine 0 N--CA 1.424 -2.111 0 N-CA-C 108.704 -1.758 . . . . 0.0 108.704 -178.235 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.7 t -76.66 -42.26 42.55 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.216 -0.492 . . . . 0.0 111.355 179.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 21.8 pt -91.47 -33.02 5.44 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 CA-C-O 121.404 0.621 . . . . 0.0 109.579 -179.67 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 25' ' ' LEU . . . -59.46 -24.02 58.83 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 7.3 t -64.6 -42.4 95.59 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.44 -0.504 . . . . 0.0 112.148 -179.342 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -86.53 -36.19 19.1 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.4 mp -73.03 -46.34 52.48 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.129 -0.942 . . . . 0.0 111.725 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -61.78 -43.66 98.94 Favored Glycine 0 C--N 1.308 -1.003 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.0 -40.32 75.34 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.486 -0.357 . . . . 0.0 111.479 179.57 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.5 t -63.61 -42.84 98.17 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.195 0.521 . . . . 0.0 110.857 -178.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.417 ' N ' HD12 ' A' ' 36' ' ' ILE . 1.1 mp -67.09 -39.76 83.92 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.753 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.1 pttp -59.81 -42.71 94.08 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 118.809 -1.156 . . . . 0.0 108.301 -178.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.87 -36.88 87.57 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.495 -1.042 . . . . 0.0 110.495 178.549 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.612 ' CE1' ' SD ' ' A' ' 43' ' ' MET . 51.6 t80 -71.91 -53.34 13.45 Favored 'General case' 0 CA--C 1.513 -0.445 0 CA-C-O 120.684 0.278 . . . . 0.0 111.597 -179.355 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 9.9 pttm -62.75 -38.37 90.3 Favored 'General case' 0 C--N 1.318 -0.773 0 C-N-CA 120.069 -0.652 . . . . 0.0 109.994 -179.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.432 ' O ' ' OG ' ' A' ' 44' ' ' SER . 52.9 tttp -61.47 -37.52 83.91 Favored 'General case' 0 N--CA 1.446 -0.654 0 C-N-CA 120.153 -0.619 . . . . 0.0 110.057 -179.523 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.86 -36.01 81.35 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.53 179.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.612 ' SD ' ' CE1' ' A' ' 39' ' ' PHE . 0.0 OUTLIER -88.48 -10.94 47.34 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.214 179.852 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.432 ' OG ' ' O ' ' A' ' 41' ' ' LYS . 65.7 p -66.22 151.84 46.13 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.854 0.359 . . . . 0.0 110.527 -179.763 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -134.53 131.87 38.49 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.555 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.415 ' N ' ' OD1' ' A' ' 46' ' ' ASP . 36.0 p-10 -93.41 13.41 21.68 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.445 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 70.3 tt0 56.16 74.11 0.74 Allowed Pre-proline 0 C--N 1.32 -0.69 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.448 -179.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo . . . . . 0 C--N 1.307 -1.617 0 C-N-CA 122.691 2.261 . . . . 0.0 111.915 -179.716 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.414 ' C ' ' H ' ' A' ' 3' ' ' GLY . 73.3 mmm . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -80.01 31.31 2.29 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.414 ' H ' ' C ' ' A' ' 1' ' ' MET . . . 134.26 20.37 0.82 Allowed Glycine 0 CA--C 1.522 0.479 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.547 ' N ' ' CD1' ' A' ' 4' ' ' ILE . 2.5 mp -101.38 101.08 11.6 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 CA-C-O 121.174 0.511 . . . . 0.0 110.656 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.546 ' H ' ' CD ' ' A' ' 8' ' ' GLN . 66.9 m -103.86 -163.04 0.94 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.593 179.191 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 26.1 mm -61.79 -45.78 97.94 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.315 -178.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -62.74 -42.0 99.46 Favored 'General case' 0 N--CA 1.434 -1.242 0 CA-C-N 115.219 -0.901 . . . . 0.0 108.756 179.338 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.546 ' CD ' ' H ' ' A' ' 5' ' ' SER . 5.9 mp0 -64.74 -38.73 91.97 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.127 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 32.7 mt -60.03 -37.28 79.3 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.789 178.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.8 mt -61.94 -44.32 97.01 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.077 -176.671 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 4.4 mp -66.65 -45.33 88.62 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.508 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.329 177.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.403 ' N ' ' CD1' ' A' ' 12' ' ' ILE . 1.1 mp -64.96 -44.79 96.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.448 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -64.18 -37.0 85.89 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.971 0.415 . . . . 0.0 110.395 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.578 ' O ' ' CD2' ' A' ' 18' ' ' LEU . 56.0 t -67.4 -43.77 87.43 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.39 0 C-N-CA 119.811 -0.756 . . . . 0.0 110.792 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 4.4 mm -65.53 -43.39 94.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.26 0.552 . . . . 0.0 110.98 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -63.54 -38.16 81.48 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.401 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.536 -178.31 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 73.5 t -64.61 -43.67 96.72 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.381 0 C-N-CA 118.429 -1.309 . . . . 0.0 109.751 -178.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.578 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 0.1 OUTLIER -63.72 -43.63 95.98 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 178.168 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.06 -43.75 94.55 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-N 114.006 -1.452 . . . . 0.0 111.605 -176.519 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -68.92 -33.1 73.19 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.51 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 97.35 14.21 42.37 Favored Glycine 0 CA--C 1.502 -0.733 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 178.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.51 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 70.3 p 57.38 14.51 2.22 Favored 'General case' 0 CA--C 1.508 -0.664 0 CA-C-N 114.57 -0.815 . . . . 0.0 112.408 179.051 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -97.51 -31.35 12.38 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.375 -178.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 13.8 tppt? -70.96 -47.36 59.36 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 121.399 0.618 . . . . 0.0 111.477 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.656 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 1.8 mp -61.0 -37.48 82.66 Favored 'General case' 0 CA--C 1.489 -1.402 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.232 -179.086 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.49 -24.79 75.66 Favored Glycine 0 N--CA 1.425 -2.053 0 CA-C-N 114.277 -1.329 . . . . 0.0 109.889 -177.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 75.7 m -84.81 -39.99 17.72 Favored 'General case' 0 CA--C 1.514 -0.408 0 C-N-CA 121.028 -0.269 . . . . 0.0 111.444 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 11.0 pt -93.95 -34.51 5.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.316 0.579 . . . . 0.0 109.759 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 25' ' ' LEU . . . -61.8 -24.79 64.93 Favored Glycine 0 C--O 1.226 -0.402 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.2 p -64.96 -38.94 92.62 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.686 -0.406 . . . . 0.0 111.606 -179.15 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 45.5 m-20 -87.28 -36.74 17.73 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -73.6 -46.03 49.6 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.456 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -61.92 -44.46 97.8 Favored Glycine 0 C--N 1.311 -0.854 0 C-N-CA 119.399 -1.382 . . . . 0.0 109.856 -179.105 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.68 -40.17 76.52 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.718 -0.241 . . . . 0.0 111.432 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.9 t -63.1 -42.35 99.56 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.565 -0.454 . . . . 0.0 110.528 -178.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.2 -39.41 81.14 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.042 178.712 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.469 ' CG ' ' HZ3' ' A' ' 40' ' ' LYS . 7.7 ttpt -59.51 -45.56 91.39 Favored 'General case' 0 N--CA 1.435 -1.175 0 C-N-CA 119.252 -0.979 . . . . 0.0 109.043 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.79 -37.11 88.3 Favored Glycine 0 CA--C 1.529 0.946 0 C-N-CA 120.05 -1.071 . . . . 0.0 110.461 178.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -71.6 -51.82 21.32 Favored 'General case' 0 CA--C 1.511 -0.528 0 CA-C-O 120.574 0.226 . . . . 0.0 111.537 -179.478 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.469 ' HZ3' ' CG ' ' A' ' 37' ' ' LYS . 8.9 pttm -62.78 -37.71 87.77 Favored 'General case' 0 C--N 1.318 -0.792 0 C-N-CA 120.207 -0.597 . . . . 0.0 110.144 -179.455 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -61.64 -36.15 79.95 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.25 -178.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.8 -35.97 82.19 Favored 'General case' 0 C--N 1.319 -0.727 0 C-N-CA 120.686 -0.405 . . . . 0.0 109.921 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.447 ' O ' ' O ' ' A' ' 44' ' ' SER . 10.3 mmt -88.81 -65.85 0.98 Allowed 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.626 -0.261 . . . . 0.0 110.418 179.624 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.453 ' N ' ' O ' ' A' ' 40' ' ' LYS . 28.1 t 53.86 164.8 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.377 -179.676 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -143.03 -49.61 0.33 Allowed 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.759 0.314 . . . . 0.0 110.72 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 41.7 p-10 -88.23 13.38 11.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.062 0.458 . . . . 0.0 110.204 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 40.56 76.02 0.54 Allowed Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.645 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_exo . . . . . 0 C--N 1.306 -1.671 0 C-N-CA 122.872 2.381 . . . . 0.0 112.155 -179.615 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 93.4 mtp . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -117.73 3.12 17.53 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.129 -0.788 . . . . 0.0 111.129 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -137.04 23.53 3.18 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 110.88 -0.888 . . . . 0.0 110.88 179.763 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 9.1 mt -63.13 -49.4 83.46 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.458 0 CA-C-O 120.925 0.393 . . . . 0.0 110.739 -179.647 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.1 m -176.72 172.71 2.07 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 122.073 0.94 . . . . 0.0 109.96 179.043 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.9 mm -62.27 -49.65 83.12 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 CA-C-N 113.78 -1.555 . . . . 0.0 111.35 -179.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 10.8 t-105 -62.6 -38.59 90.76 Favored 'General case' 0 N--CA 1.44 -0.944 0 CA-C-N 115.421 -0.808 . . . . 0.0 109.008 179.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 25.7 mm-40 -64.94 -39.25 93.22 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 29.3 mt -61.39 -38.1 85.8 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.434 178.662 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.41 ' O ' ' CG2' ' A' ' 14' ' ' VAL . 5.6 mt -62.09 -43.3 99.13 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.066 -176.809 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 5.9 mt -66.3 -45.33 89.99 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 C-N-CA 119.928 -0.709 . . . . 0.0 109.588 177.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.1 mp -65.8 -47.39 85.92 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.806 -179.268 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.4 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -64.75 -37.36 87.34 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.543 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.561 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 45.8 t -67.38 -44.28 87.18 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.052 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.709 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 97.0 mt -65.61 -43.13 94.08 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.761 0 CA-C-O 121.33 0.586 . . . . 0.0 110.685 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -63.99 -38.17 81.72 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.589 -178.082 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.4 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 83.2 t -65.61 -42.83 93.73 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.93 0 C-N-CA 118.449 -1.3 . . . . 0.0 111.474 -178.156 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.561 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 19.2 mt -62.49 -45.72 91.73 Favored 'General case' 0 C--N 1.319 -0.76 0 C-N-CA 119.66 -0.816 . . . . 0.0 112.075 -178.469 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.456 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.92 -38.24 79.41 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -179.315 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.456 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 2.0 m-85 -67.79 -36.87 81.21 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 108.804 -0.814 . . . . 0.0 108.804 -178.215 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.479 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 101.65 7.41 48.27 Favored Glycine 0 CA--C 1.501 -0.837 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 178.374 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.479 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 18.0 p 56.41 19.74 4.26 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.77 -0.715 . . . . 0.0 112.135 178.588 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 17.0 mtmt -92.09 -25.13 18.9 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.63 -0.428 . . . . 0.0 111.006 -179.081 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.605 ' O ' ' N ' ' A' ' 27' ' ' SER . 0.9 OUTLIER -85.12 -59.85 2.21 Favored 'General case' 0 C--O 1.213 -0.856 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.828 -179.514 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.635 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 2.6 mp -42.63 -39.06 2.22 Favored 'General case' 0 CA--C 1.492 -1.272 0 CA-C-O 122.503 1.145 . . . . 0.0 110.221 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.65 -25.2 70.52 Favored Glycine 0 N--CA 1.428 -1.872 0 CA-C-N 113.361 -1.745 . . . . 0.0 111.066 -178.173 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.605 ' N ' ' O ' ' A' ' 24' ' ' LYS . 8.5 t -99.23 -36.61 9.59 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -179.147 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 13.1 pt -92.75 -36.58 7.72 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 CA-C-O 121.296 0.57 . . . . 0.0 109.498 -179.03 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.24 -26.23 67.51 Favored Glycine 0 CA--C 1.521 0.415 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.0 p -64.7 -40.12 94.82 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.628 -179.469 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -76.4 -42.48 44.16 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 179.361 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -66.89 -44.18 81.51 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.587 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.13 -44.31 97.39 Favored Glycine 0 N--CA 1.44 -1.063 0 C-N-CA 119.51 -1.328 . . . . 0.0 109.884 -179.097 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -72.1 -39.92 68.58 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.671 -0.265 . . . . 0.0 111.289 178.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 67.0 m -63.31 -40.7 98.06 Favored 'General case' 0 CA--C 1.515 -0.392 0 C-N-CA 120.528 -0.469 . . . . 0.0 110.551 -178.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.48 -39.15 78.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.007 179.048 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.407 ' O ' ' CB ' ' A' ' 41' ' ' LYS . 20.8 tttt -59.49 -44.98 92.93 Favored 'General case' 0 N--CA 1.432 -1.344 0 C-N-CA 119.358 -0.937 . . . . 0.0 108.598 -178.416 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.04 -36.48 93.08 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 178.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 87.1 t80 -71.35 -54.31 11.2 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 111.66 0.244 . . . . 0.0 111.66 -179.172 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.411 ' CG ' ' N ' ' A' ' 41' ' ' LYS . 18.9 ptmt -64.8 -39.83 94.23 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.974 179.889 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.437 ' O ' ' OG ' ' A' ' 44' ' ' SER . 88.6 tttt -62.87 -36.84 84.63 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.729 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.62 -36.1 81.78 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.421 179.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 33.4 mtm -90.23 -10.71 43.31 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.843 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.437 ' OG ' ' O ' ' A' ' 41' ' ' LYS . 96.3 p -60.98 -35.14 76.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.924 0.392 . . . . 0.0 110.298 -179.686 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.526 ' C ' ' H ' ' A' ' 47' ' ' GLU . 54.1 t0 55.06 75.1 0.33 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.423 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.451 ' O ' ' O ' ' A' ' 47' ' ' GLU . 66.7 t0 -71.44 40.62 0.07 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.334 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.526 ' H ' ' C ' ' A' ' 45' ' ' ASP . 3.6 mp0 57.21 151.18 0.06 OUTLIER Pre-proline 0 CA--C 1.533 0.326 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.708 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_exo . . . . . 0 C--N 1.316 -1.166 0 C-N-CA 122.597 2.198 . . . . 0.0 112.181 179.689 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.515 ' C ' ' H ' ' A' ' 3' ' ' GLY . 69.6 mmm . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 68.53 -10.2 1.52 Allowed Glycine 0 CA--C 1.523 0.58 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.515 ' H ' ' C ' ' A' ' 1' ' ' MET . . . -138.34 28.34 2.69 Favored Glycine 0 N--CA 1.465 0.59 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.7 mt -63.71 -44.12 98.26 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.486 0 CA-C-O 121.148 0.499 . . . . 0.0 110.179 -179.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.8 m -179.84 169.02 1.31 Allowed 'General case' 0 N--CA 1.44 -0.974 0 CA-C-O 121.748 0.785 . . . . 0.0 110.592 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.497 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.5 mp -63.86 -44.49 98.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 113.765 -1.561 . . . . 0.0 109.503 177.877 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 29.0 m95 -62.69 -46.88 86.09 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 120.086 -0.645 . . . . 0.0 110.027 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.522 ' N ' ' OE1' ' A' ' 8' ' ' GLN . 0.7 OUTLIER -64.22 -39.04 93.15 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 -179.385 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.475 ' C ' ' CD1' ' A' ' 9' ' ' LEU . 0.2 OUTLIER -70.37 -37.92 74.66 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.319 178.654 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 19.2 mt -62.82 -46.55 87.41 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.899 -177.467 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 6.2 mt -65.84 -44.31 92.87 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.247 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 56.2 mt -63.44 -44.35 98.83 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.157 -178.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.403 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -64.15 -37.13 86.34 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.454 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.461 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 73.5 t -67.53 -44.31 86.62 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 C-N-CA 119.795 -0.762 . . . . 0.0 110.489 179.58 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 4.5 mm -65.99 -43.43 92.66 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.698 0 CA-C-O 121.129 0.49 . . . . 0.0 111.133 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -63.96 -38.39 82.27 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.072 0 CA-C-N 115.362 -0.835 . . . . 0.0 109.371 -178.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.403 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 79.0 t -65.4 -42.81 94.4 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.024 0 C-N-CA 118.478 -1.289 . . . . 0.0 111.64 -177.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.461 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 29.4 mt -62.42 -45.2 94.17 Favored 'General case' 0 C--N 1.317 -0.821 0 C-N-CA 118.984 -1.086 . . . . 0.0 111.721 -179.159 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.428 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -67.48 -38.46 84.42 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.818 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.428 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 1.4 m-85 -67.73 -31.25 71.04 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -178.819 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.447 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 89.62 8.77 67.35 Favored Glycine 0 CA--C 1.505 -0.541 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.12 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.447 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 14.8 p 56.65 15.6 2.22 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 114.48 -0.86 . . . . 0.0 112.279 178.139 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 13.4 ptpt -82.66 -44.38 15.79 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.296 0.569 . . . . 0.0 109.68 178.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 2.0 mmmm -67.95 -43.97 77.84 Favored 'General case' 0 C--O 1.21 -1.012 0 CA-C-N 115.218 -0.901 . . . . 0.0 112.069 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.532 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 6.7 mp -56.73 -36.87 70.22 Favored 'General case' 0 CA--C 1.49 -1.331 0 CA-C-O 121.876 0.846 . . . . 0.0 110.568 -178.889 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.28 -24.92 74.39 Favored Glycine 0 N--CA 1.422 -2.24 0 CA-C-N 114.61 -1.177 . . . . 0.0 110.669 -176.816 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 8.9 m -101.1 -33.92 9.93 Favored 'General case' 0 CA--C 1.503 -0.839 0 CA-C-O 121.166 0.508 . . . . 0.0 111.931 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -91.66 -40.99 12.86 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.137 -178.772 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -53.22 -33.68 46.13 Favored Glycine 0 C--N 1.314 -0.667 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.466 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 41.8 t -64.99 -44.27 89.85 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.442 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -76.28 -44.79 35.54 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.371 0.605 . . . . 0.0 109.485 179.651 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 10.6 mp -67.48 -43.87 79.94 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 114.795 -1.093 . . . . 0.0 111.816 -179.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.33 -43.77 98.61 Favored Glycine 0 C--N 1.308 -0.985 0 C-N-CA 119.247 -1.454 . . . . 0.0 109.789 -179.682 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.27 -40.32 71.03 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.461 -0.369 . . . . 0.0 111.25 179.407 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 40.1 t -63.49 -41.98 98.56 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.223 0.535 . . . . 0.0 111.125 -178.71 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.53 -40.12 79.3 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.665 -179.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.2 pttt -60.07 -42.84 95.41 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -179.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.03 -36.59 92.18 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 178.578 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -71.65 -51.89 20.75 Favored 'General case' 0 CA--C 1.516 -0.365 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.18 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.548 ' O ' ' N ' ' A' ' 44' ' ' SER . 42.7 mmtm -64.0 -38.97 93.01 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.37 178.783 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -61.63 -36.83 81.89 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.092 -0.643 . . . . 0.0 110.14 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.69 -36.3 82.19 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.794 -179.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.458 ' O ' ' O ' ' A' ' 44' ' ' SER . 67.2 mtm -99.92 -66.86 0.88 Allowed 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.962 0.41 . . . . 0.0 110.741 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.548 ' N ' ' O ' ' A' ' 40' ' ' LYS . 25.8 t 40.24 -166.58 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.707 -179.429 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.547 ' N ' ' OG ' ' A' ' 44' ' ' SER . 98.7 m-20 53.81 33.07 16.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.57 -0.287 . . . . 0.0 110.648 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -100.59 41.74 1.16 Allowed 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.819 0.343 . . . . 0.0 110.513 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 55.3 tt0 -162.42 73.84 2.18 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.493 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_exo . . . . . 0 C--N 1.307 -1.635 0 C-N-CA 122.874 2.383 . . . . 0.0 112.089 -179.915 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 38.9 mmt . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 84.06 26.59 40.27 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.356 -0.697 . . . . 0.0 111.356 179.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 139.17 -11.63 3.31 Favored Glycine 0 N--CA 1.463 0.49 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.8 mp -102.04 117.04 46.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.094 0.473 . . . . 0.0 110.608 -179.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 60.5 m -146.37 -88.15 0.1 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.733 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 1.6 mp -110.23 -34.57 2.5 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-O 120.768 0.318 . . . . 0.0 110.548 -179.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 58.6 m95 -62.56 -49.02 76.95 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 -179.456 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.415 ' H ' ' NE2' ' A' ' 8' ' ' GLN . 3.0 mp0 -64.53 -38.94 92.74 Favored 'General case' 0 C--N 1.312 -1.045 0 C-N-CA 120.186 -0.606 . . . . 0.0 109.577 179.625 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.504 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 3.3 mm? -63.82 -39.25 93.8 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.953 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 9.5 mt -63.4 -52.4 61.78 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.894 -178.415 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 3.5 mp -64.86 -44.58 96.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 178.495 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 71.9 mt -63.56 -45.73 96.9 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.101 0 C-N-CA 120.107 -0.637 . . . . 0.0 111.177 -179.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -64.73 -37.37 87.38 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.968 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.544 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 51.6 t -67.54 -43.84 86.89 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 C-N-CA 119.823 -0.751 . . . . 0.0 110.872 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.3 mt -65.4 -42.79 94.34 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.658 0 CA-C-O 121.1 0.476 . . . . 0.0 110.225 -179.009 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -64.5 -38.43 82.59 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.345 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.917 -178.459 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 75.1 t -63.88 -43.07 97.7 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.367 0 C-N-CA 118.544 -1.262 . . . . 0.0 111.002 -177.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.544 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 14.4 mt -60.8 -47.08 87.98 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 120.078 -0.649 . . . . 0.0 112.473 -178.789 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.436 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.95 -37.96 79.17 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -179.515 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.436 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 0.8 OUTLIER -67.45 -35.99 80.28 Favored 'General case' 0 CA--C 1.519 -0.217 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -177.946 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.618 ' C ' ' H ' ' A' ' 23' ' ' LYS . . . 102.69 10.8 36.94 Favored Glycine 0 CA--C 1.501 -0.837 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 178.298 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.539 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 44.8 p 56.52 -1.94 0.04 OUTLIER 'General case' 0 CA--C 1.497 -1.081 0 CA-C-O 121.073 0.463 . . . . 0.0 112.138 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.618 ' H ' ' C ' ' A' ' 21' ' ' GLY . 12.6 tmtt? -84.41 -36.22 22.55 Favored 'General case' 0 N--CA 1.434 -1.252 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.006 -179.117 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.4 tppt? -63.75 -48.57 76.47 Favored 'General case' 0 N--CA 1.436 -1.126 0 CA-C-O 121.089 0.471 . . . . 0.0 110.37 179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.627 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 2.1 mp -60.27 -38.63 84.13 Favored 'General case' 0 CA--C 1.486 -1.493 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.044 -178.345 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.19 -25.62 72.78 Favored Glycine 0 N--CA 1.424 -2.124 0 CA-C-N 114.708 -1.133 . . . . 0.0 110.443 -177.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 8.1 t -81.81 -42.62 19.44 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 120.775 0.321 . . . . 0.0 111.311 179.389 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 11.3 pt -91.77 -34.53 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 CA-C-O 121.189 0.518 . . . . 0.0 109.706 -179.435 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 25' ' ' LEU . . . -62.1 -22.95 63.38 Favored Glycine 0 CA--C 1.518 0.253 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 14.0 t -64.8 -43.0 94.59 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.452 -0.499 . . . . 0.0 111.769 -179.325 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -84.42 -37.08 21.89 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -72.3 -44.34 62.88 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.173 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.4 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -61.97 -43.8 98.69 Favored Glycine 0 C--N 1.31 -0.899 0 C-N-CA 119.527 -1.32 . . . . 0.0 110.018 -179.366 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.5 -39.93 73.86 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.891 -0.324 . . . . 0.0 111.205 179.533 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 44.8 t -64.3 -41.93 96.62 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.542 -0.463 . . . . 0.0 111.288 -178.763 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.73 -38.92 79.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.205 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 3.3 pttp -59.49 -40.86 88.38 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 -178.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.07 -36.63 90.89 Favored Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 178.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -71.63 -49.71 37.46 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 121.04 0.448 . . . . 0.0 109.962 -179.472 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.545 ' O ' ' N ' ' A' ' 44' ' ' SER . 53.4 mttp -63.12 -38.57 91.71 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.471 178.528 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 12.5 ttmm -61.33 -36.99 81.69 Favored 'General case' 0 C--N 1.319 -0.748 0 C-N-CA 119.935 -0.706 . . . . 0.0 110.187 -179.613 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -67.03 -36.08 81.32 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.274 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.428 ' O ' ' OD1' ' A' ' 46' ' ' ASP . 75.2 mtm -93.62 -10.29 35.13 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.746 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.545 ' N ' ' O ' ' A' ' 40' ' ' LYS . 11.6 t -56.06 -41.04 74.45 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.944 0.402 . . . . 0.0 110.093 -179.199 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.412 ' O ' ' OD1' ' A' ' 45' ' ' ASP . 53.2 p-10 -75.08 78.61 2.24 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.36 179.706 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 43' ' ' MET . 99.0 m-20 -101.57 38.38 1.62 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.557 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -149.37 61.0 4.97 Favored Pre-proline 0 N--CA 1.464 0.235 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.559 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo . . . . . 0 C--N 1.306 -1.705 0 C-N-CA 122.845 2.363 . . . . 0.0 111.836 179.808 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.2 ppp? . . . . . 0 N--CA 1.493 1.688 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -115.19 -16.59 7.13 Favored Glycine 0 N--CA 1.468 0.778 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -111.18 -44.68 0.91 Allowed Glycine 0 N--CA 1.463 0.483 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.508 ' N ' ' CD1' ' A' ' 4' ' ' ILE . 2.4 mp 55.13 96.9 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 CA-C-O 120.899 0.381 . . . . 0.0 111.133 179.056 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 34.9 m -92.33 -169.59 2.27 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.392 0.615 . . . . 0.0 109.574 178.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.2 mm -61.23 -46.74 96.02 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.636 -178.641 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 11.7 t-105 -62.82 -38.07 89.28 Favored 'General case' 0 N--CA 1.438 -1.059 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.725 178.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 28.6 mm-40 -64.84 -40.29 94.93 Favored 'General case' 0 CA--C 1.509 -0.61 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 178.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 72.0 mt -61.4 -37.64 84.17 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.006 178.212 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.4 mt -62.12 -42.88 99.67 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.2 -176.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 6.4 mt -67.89 -45.67 83.57 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 C-N-CA 120.25 -0.58 . . . . 0.0 110.011 177.48 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.1 mp -65.49 -44.7 94.09 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.997 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.404 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -64.46 -36.69 85.0 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.605 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.562 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 48.8 t -66.75 -45.73 87.3 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.039 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.305 -179.167 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 16.2 pt -65.97 -42.49 91.9 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-N 118.023 0.374 . . . . 0.0 110.929 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -63.47 -38.37 82.04 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.134 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.601 -178.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.404 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 90.7 t -65.69 -44.34 93.42 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.803 0 C-N-CA 118.382 -1.327 . . . . 0.0 111.713 -178.648 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.562 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 23.5 mt -61.62 -46.46 89.7 Favored 'General case' 0 C--N 1.322 -0.623 0 C-N-CA 119.907 -0.717 . . . . 0.0 111.909 -179.037 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.467 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 4.7 pp -68.09 -38.41 82.32 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 -179.607 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.467 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 2.0 m-85 -67.64 -37.7 82.8 Favored 'General case' 0 CA--C 1.517 -0.324 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -177.77 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.5 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 102.81 6.07 46.82 Favored Glycine 0 CA--C 1.499 -0.953 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 178.544 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.5 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 18.5 p 57.88 19.2 5.56 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 114.964 -0.618 . . . . 0.0 112.281 178.279 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -93.16 -19.93 20.98 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.535 -179.355 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.602 ' O ' ' N ' ' A' ' 27' ' ' SER . 1.0 OUTLIER -89.81 -60.39 1.95 Allowed 'General case' 0 C--O 1.211 -0.958 0 CA-C-O 121.178 0.513 . . . . 0.0 110.706 -179.775 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.663 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 2.6 mp -42.26 -39.43 2.09 Favored 'General case' 0 CA--C 1.491 -1.304 0 CA-C-O 122.495 1.141 . . . . 0.0 110.149 -179.532 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.78 -25.83 68.67 Favored Glycine 0 N--CA 1.426 -1.988 0 CA-C-N 113.246 -1.797 . . . . 0.0 111.02 -178.18 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.602 ' N ' ' O ' ' A' ' 24' ' ' LYS . 8.3 m -99.09 -34.18 10.5 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 112.438 0.532 . . . . 0.0 112.438 -179.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 13.0 pt -94.26 -36.05 6.78 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 CA-C-O 121.483 0.658 . . . . 0.0 109.533 -179.107 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.44 -27.52 71.85 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.679 -0.968 . . . . 0.0 110.679 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.0 p -64.83 -41.27 95.88 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.848 -179.121 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -78.61 -40.97 32.93 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 179.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.3 mp -68.65 -45.92 70.52 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.551 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.51 -44.0 97.29 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.76 -40.23 76.24 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.366 -0.417 . . . . 0.0 111.364 179.196 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 43.3 m -63.63 -40.79 97.77 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.531 -0.467 . . . . 0.0 111.216 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.67 -40.93 79.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.073 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 16.2 pttt -60.24 -43.48 96.05 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.66 -36.91 92.0 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.614 -0.994 . . . . 0.0 110.614 178.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.593 ' CZ ' ' SD ' ' A' ' 43' ' ' MET . 39.9 t80 -71.67 -50.69 28.19 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-O 120.946 0.403 . . . . 0.0 110.516 -179.604 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.564 ' O ' ' N ' ' A' ' 44' ' ' SER . 66.4 mmtt -63.97 -38.99 93.09 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 120.252 -0.579 . . . . 0.0 110.325 179.181 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt -61.97 -37.16 83.71 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.239 -179.663 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.54 -35.89 81.35 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.523 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.593 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 6.0 mtp -100.7 -69.82 0.76 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.711 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.564 ' N ' ' O ' ' A' ' 40' ' ' LYS . 0.9 OUTLIER 28.35 -88.03 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.635 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.16 179.853 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.504 ' N ' ' O ' ' A' ' 43' ' ' MET . 90.2 m-20 -134.07 -175.78 3.96 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.559 178.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 47' ' ' GLU . 42.0 t0 60.54 39.18 18.39 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.602 -0.272 . . . . 0.0 110.64 -179.791 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.425 ' C ' ' O ' ' A' ' 46' ' ' ASP . 51.7 mt-10 -32.5 96.43 0.09 OUTLIER Pre-proline 0 N--CA 1.47 0.535 0 O-C-N 123.485 0.491 . . . . 0.0 111.002 179.88 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo . . . . . 0 N--CA 1.496 1.657 0 C-N-CA 122.158 1.906 . . . . 0.0 112.318 -178.948 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.427 ' HG3' ' H ' ' A' ' 3' ' ' GLY . 4.5 tpt . . . . . 0 N--CA 1.488 1.426 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 116.46 3.93 18.27 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.427 ' H ' ' HG3' ' A' ' 1' ' ' MET . . . 94.08 9.78 59.15 Favored Glycine 0 N--CA 1.464 0.535 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.525 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.474 HG22 ' N ' ' A' ' 5' ' ' SER . 30.4 mt -59.07 -113.45 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.523 -0.339 . . . . 0.0 110.545 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.474 ' N ' HG22 ' A' ' 4' ' ' ILE . 38.4 m -157.98 -164.48 1.53 Allowed 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -178.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.1 mm -96.92 -45.5 12.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.872 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 9.5 t-105 -62.67 -36.61 83.44 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 21.3 mm-40 -64.47 -38.88 92.57 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 86.6 mt -63.03 -37.66 88.07 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.747 178.374 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.433 ' O ' ' CG2' ' A' ' 14' ' ' VAL . 5.2 mt -62.58 -42.89 99.84 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.13 -177.055 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.8 mt -66.95 -45.54 87.02 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.95 0 C-N-CA 119.698 -0.801 . . . . 0.0 109.51 177.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 67.1 mt -65.66 -47.56 85.71 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.806 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.327 -179.719 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -64.55 -37.34 87.21 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.4 -179.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.531 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 40.6 t -67.67 -44.25 86.17 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 C-N-CA 119.748 -0.781 . . . . 0.0 110.973 179.721 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 91.8 mt -65.27 -42.28 93.54 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.834 0 CA-C-O 120.993 0.425 . . . . 0.0 110.395 -179.087 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.417 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 0.3 OUTLIER -64.25 -38.4 82.41 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.113 0 CA-C-N 115.322 -0.854 . . . . 0.0 110.11 -178.836 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 87.1 t -64.56 -42.6 95.64 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.257 0 C-N-CA 118.389 -1.325 . . . . 0.0 111.131 -177.351 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.531 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 20.8 mt -62.08 -47.18 85.83 Favored 'General case' 0 C--N 1.316 -0.887 0 C-N-CA 119.819 -0.752 . . . . 0.0 112.566 -178.573 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.436 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.01 -38.41 82.56 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.897 -179.579 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.436 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 0.7 OUTLIER -68.07 -32.14 72.27 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -178.3 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.486 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 93.9 5.79 62.44 Favored Glycine 0 CA--C 1.504 -0.61 0 C-N-CA 120.209 -0.996 . . . . 0.0 111.044 178.523 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.486 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 14.4 p 58.39 26.93 14.71 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.161 -0.519 . . . . 0.0 112.202 178.558 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 50.2 pttt -96.97 -33.09 11.7 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.878 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 16.6 mmmt -77.45 -52.78 8.53 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.72 -0.392 . . . . 0.0 111.498 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.658 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 1.9 mp -48.75 -39.08 23.61 Favored 'General case' 0 CA--C 1.489 -1.374 0 CA-C-O 122.336 1.065 . . . . 0.0 110.476 -179.32 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.91 -25.79 70.72 Favored Glycine 0 N--CA 1.426 -2.003 0 CA-C-N 114.092 -1.413 . . . . 0.0 111.111 -177.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 7.2 t -94.0 -39.65 10.53 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 111.915 0.339 . . . . 0.0 111.915 -179.718 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 7.5 pt -89.8 -37.47 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 CA-C-O 121.387 0.613 . . . . 0.0 109.675 -179.133 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.32 -27.05 68.64 Favored Glycine 0 C--O 1.228 -0.224 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 -179.111 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.1 p -64.91 -42.01 95.1 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 120.544 -0.462 . . . . 0.0 111.219 -179.444 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 66.7 t0 -76.63 -41.04 47.38 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.289 0.566 . . . . 0.0 109.846 179.728 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.5 mp -68.68 -45.82 70.68 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.024 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.56 -43.82 98.45 Favored Glycine 0 C--N 1.308 -1.018 0 C-N-CA 119.463 -1.351 . . . . 0.0 110.031 -179.55 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.07 -40.25 75.14 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.82 0.343 . . . . 0.0 111.148 179.646 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.6 t -63.94 -42.01 97.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.132 0.491 . . . . 0.0 111.248 -178.742 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.48 -39.42 78.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.615 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 17.9 pttt -59.32 -40.35 86.0 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 -178.108 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -69.81 -37.09 75.37 Favored Glycine 0 N--CA 1.442 -0.903 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -71.61 -49.16 42.8 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-O 121.114 0.483 . . . . 0.0 109.762 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.53 ' O ' ' N ' ' A' ' 44' ' ' SER . 47.5 mtpt -63.01 -38.6 91.83 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.558 178.566 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 14.2 tmtt? -61.75 -36.68 81.71 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 119.773 -0.771 . . . . 0.0 109.853 -178.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.89 -36.44 82.29 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.052 179.713 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 75.9 mtm -92.42 -10.92 36.25 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.488 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.53 ' N ' ' O ' ' A' ' 40' ' ' LYS . 41.4 t -61.89 148.89 42.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.275 -179.666 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.41 ' C ' ' H ' ' A' ' 47' ' ' GLU . 96.8 m-20 56.25 44.9 24.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.539 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 51.4 p30 -74.4 46.2 0.26 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.7 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.41 ' H ' ' C ' ' A' ' 45' ' ' ASP . 68.9 mt-10 52.02 71.47 1.48 Allowed Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.621 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo . . . . . 0 C--N 1.306 -1.659 0 C-N-CA 122.756 2.304 . . . . 0.0 112.054 -179.994 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.5 mtp . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -111.2 24.47 16.04 Favored Glycine 0 N--CA 1.467 0.75 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.451 ' H ' HD13 ' A' ' 4' ' ' ILE . . . -130.93 19.97 4.87 Favored Glycine 0 CA--C 1.519 0.326 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 179.517 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.494 ' CD1' ' N ' ' A' ' 4' ' ' ILE . 0.0 OUTLIER -103.23 -82.23 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.851 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.745 ' N ' HE21 ' A' ' 8' ' ' GLN . 41.2 m 67.44 -80.0 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 114.931 -1.031 . . . . 0.0 112.341 179.381 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.519 ' CD1' ' N ' ' A' ' 6' ' ' ILE . 1.6 mp -92.94 -30.85 4.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.786 -178.622 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 91.8 m95 -62.27 -41.01 98.1 Favored 'General case' 0 CA--C 1.507 -0.685 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.748 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.745 HE21 ' N ' ' A' ' 5' ' ' SER . 5.6 pt20 -64.28 -39.48 94.01 Favored 'General case' 0 C--O 1.215 -0.725 0 C-N-CA 118.572 -1.251 . . . . 0.0 108.152 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.455 ' O ' ' N ' ' A' ' 13' ' ' ALA . 76.6 mt -68.59 -38.49 80.71 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.166 179.376 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 18.7 mt -63.28 -49.27 74.72 Favored 'General case' 0 C--N 1.314 -0.935 0 C-N-CA 120.076 -0.65 . . . . 0.0 111.371 -176.022 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 3.7 mp -67.19 -44.33 87.81 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 178.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.403 ' N ' ' CD1' ' A' ' 12' ' ' ILE . 1.0 OUTLIER -65.07 -44.56 95.74 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.878 -179.387 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.455 ' N ' ' O ' ' A' ' 9' ' ' LEU . . . -64.77 -36.53 84.6 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.825 -179.762 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.485 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 54.8 t -67.03 -45.03 87.87 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.826 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.442 -178.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 15.9 pt -66.23 -42.56 91.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 CA-C-O 121.05 0.452 . . . . 0.0 110.827 179.645 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -63.54 -38.12 81.38 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.905 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 -179.324 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.421 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 94.4 t -65.52 -43.72 94.25 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 C-N-CA 118.557 -1.257 . . . . 0.0 111.654 -178.303 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 21.3 mt -61.82 -47.09 86.66 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 119.566 -0.854 . . . . 0.0 111.57 -178.853 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.437 ' CD1' ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -67.06 -38.21 85.41 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -179.221 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.437 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 1.2 m-85 -67.55 -35.83 79.81 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 -177.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.489 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 98.79 8.04 54.76 Favored Glycine 0 CA--C 1.501 -0.821 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 178.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.489 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 19.0 p 57.7 27.1 13.85 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 114.309 -0.945 . . . . 0.0 112.52 178.239 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 55.3 mtpt -100.0 -19.82 16.38 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.686 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.503 ' O ' ' N ' ' A' ' 27' ' ' SER . 14.5 mmmt -88.66 -56.91 3.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.125 0.488 . . . . 0.0 110.622 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.65 ' H ' ' CD1' ' A' ' 25' ' ' LEU . 2.3 mp -45.58 -39.83 8.07 Favored 'General case' 0 CA--C 1.495 -1.173 0 CA-C-O 122.473 1.13 . . . . 0.0 110.291 179.804 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.82 -24.84 73.3 Favored Glycine 0 N--CA 1.424 -2.105 0 CA-C-N 113.568 -1.651 . . . . 0.0 110.472 -177.397 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.503 ' N ' ' O ' ' A' ' 24' ' ' LYS . 7.1 t -97.32 -35.98 10.54 Favored 'General case' 0 CA--C 1.519 -0.235 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 -179.639 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 8.7 pt -92.22 -37.21 8.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 CA-C-O 121.358 0.599 . . . . 0.0 109.412 -179.347 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.4 -27.39 65.59 Favored Glycine 0 CA--C 1.522 0.484 0 N-CA-C 110.734 -0.947 . . . . 0.0 110.734 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.3 t -64.76 -41.13 96.12 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.931 -0.308 . . . . 0.0 111.652 -179.388 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 53.3 m-20 -74.15 -43.65 56.6 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.53 0.681 . . . . 0.0 109.208 179.475 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.6 mp -65.82 -44.28 86.08 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.789 -1.096 . . . . 0.0 111.553 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.52 -45.18 96.39 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 119.411 -1.376 . . . . 0.0 109.823 -179.204 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.6 -39.81 73.6 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.651 -0.274 . . . . 0.0 111.309 179.164 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 39.4 t -63.19 -41.69 99.23 Favored 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 120.528 -0.469 . . . . 0.0 110.406 -178.247 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.02 -39.27 79.47 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.715 179.027 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 24.3 tttt -59.87 -43.72 94.57 Favored 'General case' 0 C--N 1.309 -1.17 0 C-N-CA 119.287 -0.965 . . . . 0.0 108.463 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.97 -36.6 91.23 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 178.18 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -71.59 -50.77 27.81 Favored 'General case' 0 CA--C 1.52 -0.182 0 CA-C-O 120.805 0.336 . . . . 0.0 110.291 -179.621 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.521 ' O ' ' N ' ' A' ' 44' ' ' SER . 53.2 mtpt -63.43 -38.52 91.46 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.37 178.646 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -61.74 -39.11 90.41 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.138 -0.625 . . . . 0.0 110.102 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -67.02 -35.98 81.1 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.551 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.433 ' O ' ' O ' ' A' ' 44' ' ' SER . 76.2 mtm -90.34 -65.92 0.97 Allowed 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 121.049 0.452 . . . . 0.0 110.548 179.797 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.521 ' N ' ' O ' ' A' ' 40' ' ' LYS . 60.7 p 41.98 -167.53 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.706 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -94.69 108.47 20.46 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.818 0.342 . . . . 0.0 110.242 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -97.86 22.79 8.74 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 121.059 0.457 . . . . 0.0 110.547 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 57.5 mt-10 47.37 73.16 1.05 Allowed Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.43 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 74.6 Cg_endo . . . . . 0 C--N 1.307 -1.63 0 C-N-CA 122.856 2.371 . . . . 0.0 111.946 -179.903 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.496 ' O ' ' CD1' ' A' ' 12' ' ' ILE . 98.0 mmm . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . 0.406 ' H ' ' H1 ' ' A' ' 1' ' ' MET . . . -120.85 -9.44 7.52 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.034 -0.827 . . . . 0.0 111.034 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.34 -2.07 66.11 Favored Glycine 0 N--CA 1.463 0.441 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 26.0 mt -62.66 -47.68 91.78 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 115.335 -0.432 . . . . 0.0 110.296 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.8 m -175.41 -164.97 0.15 Allowed 'General case' 0 N--CA 1.442 -0.872 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.521 ' CG2' ' N ' ' A' ' 7' ' ' TRP . 1.5 tp -88.72 -49.07 14.47 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 114.988 -1.005 . . . . 0.0 111.012 179.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.528 ' CD1' ' C ' ' A' ' 7' ' ' TRP . 2.0 t-105 -62.15 -38.42 88.93 Favored 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -179.262 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 13.7 mm-40 -64.31 -38.75 92.16 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 179.639 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.501 ' CD1' ' C ' ' A' ' 9' ' ' LEU . 0.2 OUTLIER -70.33 -38.03 74.82 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.423 178.933 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.2 tt -62.71 -47.03 85.4 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.971 -175.607 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.444 ' N ' HD13 ' A' ' 11' ' ' ILE . 2.0 mp -65.01 -43.94 96.04 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 177.51 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.496 ' CD1' ' O ' ' A' ' 1' ' ' MET . 72.9 mt -63.37 -44.51 99.03 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.065 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.547 -178.671 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.443 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -64.23 -37.25 86.82 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.923 -179.241 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.469 ' O ' ' CD2' ' A' ' 18' ' ' LEU . 78.6 t -67.02 -44.05 88.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 C-N-CA 120.545 -0.462 . . . . 0.0 111.139 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.453 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 58.7 mt -66.62 -43.19 90.57 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.285 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 178.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.456 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.5 t -64.01 -42.27 95.16 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.681 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.881 -179.046 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.443 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 60.1 t -65.93 -44.92 92.29 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.118 0 C-N-CA 118.281 -1.368 . . . . 0.0 112.774 -177.376 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.469 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 1.4 pp -72.65 -42.87 63.89 Favored 'General case' 0 C--N 1.293 -1.857 0 C-N-CA 120.054 -0.659 . . . . 0.0 109.842 178.761 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.479 ' CD1' ' C ' ' A' ' 19' ' ' LEU . 2.6 tm? -64.37 -41.29 96.79 Favored 'General case' 0 N--CA 1.443 -0.806 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.617 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.456 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 5.6 m-85 -69.0 -39.47 79.31 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 118.741 -1.183 . . . . 0.0 108.749 179.17 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.51 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 105.15 11.9 28.63 Favored Glycine 0 N--CA 1.467 0.75 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 179.025 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.51 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 50.4 p 57.31 44.42 21.89 Favored 'General case' 0 CA--C 1.499 -0.983 0 CA-C-N 115.371 -0.414 . . . . 0.0 112.062 178.304 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -127.19 -18.38 4.56 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.593 -0.73 . . . . 0.0 111.551 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 9.6 tppt? -86.44 -48.38 8.47 Favored 'General case' 0 N--CA 1.447 -0.625 0 CA-C-O 121.008 0.432 . . . . 0.0 110.08 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.526 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.1 OUTLIER -62.43 -36.76 83.42 Favored 'General case' 0 CA--C 1.505 -0.768 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.682 -178.839 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.42 -24.64 75.96 Favored Glycine 0 N--CA 1.437 -1.24 0 N-CA-C 109.914 -1.275 . . . . 0.0 109.914 -176.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 7.6 t -84.75 -42.74 14.92 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 121.104 -0.238 . . . . 0.0 111.592 179.66 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 8.6 pt -94.08 -35.94 6.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 121.228 0.537 . . . . 0.0 110.034 -179.417 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.526 ' N ' ' O ' ' A' ' 25' ' ' LEU . . . -62.06 -22.68 62.99 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 -179.502 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.9 t -64.79 -42.54 94.99 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.703 -0.399 . . . . 0.0 111.548 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 94.3 m-20 -76.32 -41.18 49.32 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.338 0.59 . . . . 0.0 109.614 179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -68.33 -44.43 75.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.556 179.75 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.0 -44.08 97.92 Favored Glycine 0 N--CA 1.443 -0.853 0 C-N-CA 119.363 -1.399 . . . . 0.0 109.99 -179.001 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.73 -39.87 73.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.719 0.295 . . . . 0.0 111.413 179.27 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.0 t -63.22 -41.9 99.19 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.69 -178.439 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.78 -39.17 79.78 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.009 178.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 23.9 tttt -59.69 -44.65 93.57 Favored 'General case' 0 N--CA 1.435 -1.223 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 -178.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.39 -36.61 92.88 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 178.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.62 ' CE2' ' SD ' ' A' ' 43' ' ' MET . 38.3 t80 -71.8 -51.78 20.85 Favored 'General case' 0 CA--C 1.512 -0.495 0 CA-C-O 120.991 0.424 . . . . 0.0 110.406 -179.373 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.511 ' O ' ' N ' ' A' ' 44' ' ' SER . 48.8 mtpt -62.62 -39.1 92.75 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.717 179.454 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 42.8 mtmt -61.58 -39.1 89.97 Favored 'General case' 0 C--N 1.319 -0.75 0 C-N-CA 119.043 -1.063 . . . . 0.0 109.911 -179.73 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.84 -36.33 82.09 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.322 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.62 ' SD ' ' CE2' ' A' ' 39' ' ' PHE . 0.0 OUTLIER -89.07 -12.27 41.7 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.527 179.239 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.511 ' N ' ' O ' ' A' ' 40' ' ' LYS . 46.8 t -61.35 -43.79 98.27 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.051 0.453 . . . . 0.0 110.246 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -89.06 113.55 24.68 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.514 179.715 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 41.1 p-10 -95.25 14.44 22.25 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.064 0.459 . . . . 0.0 110.801 -179.71 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 -168.92 75.33 0.76 Allowed Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.663 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_exo . . . . . 0 C--N 1.307 -1.643 0 C-N-CA 122.783 2.322 . . . . 0.0 111.999 179.962 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' A' ' 1' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.451 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 . . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -143.19 87.12 0.18 Allowed Glycine 0 C--N 1.33 0.233 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.894 -179.588 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 87.92 26.95 27.65 Favored Glycine 0 CA--C 1.519 0.295 0 N-CA-C 110.499 -1.041 . . . . 0.0 110.499 179.365 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.429 ' O ' ' OG ' ' A' ' 5' ' ' SER . 12.7 mm -63.33 -48.13 88.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.328 -0.436 . . . . 0.0 110.727 -179.236 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.429 ' OG ' ' O ' ' A' ' 4' ' ' ILE . 4.5 m 177.49 177.64 0.34 Allowed 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 122.07 0.938 . . . . 0.0 109.789 178.65 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.454 ' O ' ' HG ' ' A' ' 9' ' ' LEU . 16.9 mm -69.84 -47.87 67.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 CA-C-N 113.346 -1.752 . . . . 0.0 110.88 179.364 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 22.4 t-105 -65.42 -39.39 92.07 Favored 'General case' 0 N--CA 1.432 -1.345 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.248 -179.519 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 22.0 mm-40 -65.84 -41.45 91.74 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.061 0.458 . . . . 0.0 110.8 179.58 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.454 ' HG ' ' O ' ' A' ' 6' ' ' ILE . 0.4 OUTLIER -63.41 -36.74 84.72 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.724 179.453 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.3 mt -62.03 -42.39 99.11 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.013 -177.13 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.8 mt -65.2 -44.18 95.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 177.538 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 69.7 mt -63.96 -44.37 97.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.313 -179.019 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.445 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -65.12 -37.53 87.76 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.133 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.438 ' O ' ' CD2' ' A' ' 18' ' ' LEU . 64.8 t -67.1 -44.54 87.98 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.372 0 C-N-CA 120.829 -0.348 . . . . 0.0 111.35 -178.732 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 16.1 pt -67.12 -42.86 88.77 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.11 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 178.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.457 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.7 t -63.71 -41.63 93.24 Favored 'Isoleucine or valine' 0 CA--C 1.476 -1.882 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.981 -179.213 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.445 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 61.5 t -66.49 -50.11 69.67 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.984 0 C-N-CA 117.149 -1.821 . . . . 0.0 113.11 -177.19 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.438 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 1.0 OUTLIER -66.34 -44.52 83.08 Favored 'General case' 0 C--N 1.302 -1.492 0 C-N-CA 119.209 -0.996 . . . . 0.0 112.01 179.722 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.431 ' C ' ' CD1' ' A' ' 19' ' ' LEU . 0.4 OUTLIER -65.59 -38.24 88.93 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.442 179.962 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.457 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 3.0 m-85 -68.01 -43.91 77.75 Favored 'General case' 0 CA--C 1.515 -0.381 0 C-N-CA 119.221 -0.992 . . . . 0.0 108.501 -179.487 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.51 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 111.71 11.12 17.68 Favored Glycine 0 C--N 1.316 -0.559 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 178.715 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.51 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 59.5 p 56.42 35.09 25.36 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 114.863 -0.668 . . . . 0.0 112.784 178.18 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 56.3 mtpt -116.26 -20.32 9.83 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.811 -0.632 . . . . 0.0 111.792 -179.576 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 tppt? -83.47 -52.08 6.81 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-O 121.175 0.512 . . . . 0.0 110.466 -179.741 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.531 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 0.2 OUTLIER -59.35 -36.73 76.26 Favored 'General case' 0 CA--C 1.501 -0.933 0 CA-C-O 121.907 0.86 . . . . 0.0 111.285 -178.882 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.51 -24.51 76.11 Favored Glycine 0 N--CA 1.433 -1.525 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -177.257 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 7.3 t -86.33 -42.59 13.58 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 179.446 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 13.2 pt -93.66 -36.59 7.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 C-N-CA 120.353 -0.539 . . . . 0.0 109.899 -179.456 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 25' ' ' LEU . . . -61.36 -23.99 63.07 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 -179.672 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 38.8 t -64.57 -42.47 95.62 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.745 0.307 . . . . 0.0 111.237 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -69.94 -44.01 70.42 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.519 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -65.12 -44.4 88.85 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.149 -0.932 . . . . 0.0 111.413 179.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.31 -44.39 97.01 Favored Glycine 0 N--CA 1.438 -1.214 0 C-N-CA 119.292 -1.432 . . . . 0.0 109.986 -179.077 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.21 -40.06 71.36 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.529 -0.336 . . . . 0.0 111.414 179.076 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.8 t -63.65 -41.29 98.25 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.666 -0.413 . . . . 0.0 111.141 -178.389 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.12 -40.34 80.5 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.798 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.5 pttt -60.28 -43.19 96.44 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 -179.679 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.97 -36.68 92.37 Favored Glycine 0 CA--C 1.519 0.342 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.488 ' CZ ' ' CE ' ' A' ' 43' ' ' MET . 66.6 t80 -71.51 -52.23 19.42 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.625 ' O ' ' N ' ' A' ' 44' ' ' SER . 66.0 mmtt -62.91 -38.15 89.81 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.154 178.73 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -60.94 -35.64 77.26 Favored 'General case' 0 C--N 1.312 -1.029 0 C-N-CA 119.631 -0.827 . . . . 0.0 109.909 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.06 -35.73 81.32 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.141 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.488 ' CE ' ' CZ ' ' A' ' 39' ' ' PHE . 6.3 ptp -121.6 -55.29 1.93 Allowed 'General case' 0 N--CA 1.475 0.793 0 CA-C-O 121.364 0.602 . . . . 0.0 111.293 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.625 ' N ' ' O ' ' A' ' 40' ' ' LYS . 4.8 t 62.24 134.88 0.01 OUTLIER 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.717 -179.145 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -87.54 140.13 29.83 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.699 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 44.8 p-10 -90.16 12.09 18.97 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-O 121.317 0.58 . . . . 0.0 110.375 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 49.13 75.07 0.7 Allowed Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.177 -0.919 . . . . 0.0 110.295 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo . . . . . 0 C--N 1.308 -1.581 0 C-N-CA 122.809 2.339 . . . . 0.0 112.224 -179.753 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.553 ' C ' ' H ' ' A' ' 3' ' ' GLY . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 . . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.96 22.92 0.88 Allowed Glycine 0 CA--C 1.525 0.701 0 C-N-CA 120.437 -0.887 . . . . 0.0 110.992 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.553 ' H ' ' C ' ' A' ' 1' ' ' MET . . . -150.03 26.36 1.14 Allowed Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.635 -0.986 . . . . 0.0 110.635 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.0 mt -41.44 112.82 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.022 0.439 . . . . 0.0 110.871 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.727 ' C ' HE22 ' A' ' 8' ' ' GLN . 16.6 m -154.88 -78.45 0.1 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.882 -179.699 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.684 ' N ' HE22 ' A' ' 8' ' ' GLN . 3.5 mm -109.24 -29.5 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.402 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.763 -179.484 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 38.5 m95 -62.0 -45.33 94.06 Favored 'General case' 0 C--O 1.22 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -178.593 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.871 HE21 ' H ' ' A' ' 9' ' ' LEU . 0.0 OUTLIER -63.8 -38.96 93.03 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 119.737 -0.785 . . . . 0.0 109.485 178.72 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.871 ' H ' HE21 ' A' ' 8' ' ' GLN . 78.8 mt -64.45 -38.21 90.24 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.264 179.727 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.403 ' O ' ' CG2' ' A' ' 14' ' ' VAL . 20.7 mt -63.3 -48.27 78.78 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.805 -176.596 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 3.8 mp -67.92 -44.58 85.03 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 C-N-CA 119.662 -0.815 . . . . 0.0 109.142 178.212 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -65.08 -47.59 87.22 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 C-N-CA 120.055 -0.658 . . . . 0.0 110.566 -179.432 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.455 ' N ' ' O ' ' A' ' 9' ' ' LEU . . . -65.85 -38.07 87.88 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 -179.545 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.42 ' O ' ' CD2' ' A' ' 18' ' ' LEU . 62.8 t -67.78 -44.29 85.73 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.625 0 C-N-CA 120.173 -0.611 . . . . 0.0 111.171 -178.824 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.47 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 0.9 OUTLIER -66.28 -44.05 91.35 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.385 0 O-C-N 123.353 0.408 . . . . 0.0 110.053 179.485 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.403 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.3 t -64.02 -41.99 94.24 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.721 0 CA-C-N 115.107 -0.951 . . . . 0.0 109.964 -178.578 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.443 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 59.6 t -66.14 -45.22 90.89 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.909 0 C-N-CA 118.03 -1.468 . . . . 0.0 112.672 -177.043 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.42 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 1.1 pp -71.23 -42.85 68.36 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.157 177.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.47 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.5 tm? -64.67 -41.49 96.04 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.908 -179.171 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.403 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 6.1 m-85 -68.97 -38.62 79.47 Favored 'General case' 0 CA--C 1.513 -0.465 0 C-N-CA 119.014 -1.074 . . . . 0.0 108.623 178.78 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.505 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 104.76 11.28 30.92 Favored Glycine 0 C--N 1.315 -0.614 0 CA-C-N 115.01 -0.995 . . . . 0.0 111.104 178.521 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.505 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 51.2 p 58.68 43.24 19.1 Favored 'General case' 0 CA--C 1.505 -0.763 0 CA-C-N 115.25 -0.475 . . . . 0.0 111.917 178.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -124.94 -20.19 5.03 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.4 -179.802 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 tppt? -84.99 -49.63 8.16 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-O 121.091 0.472 . . . . 0.0 110.496 179.826 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.529 ' H ' ' CD1' ' A' ' 25' ' ' LEU . 0.1 OUTLIER -61.63 -36.83 81.88 Favored 'General case' 0 CA--C 1.505 -0.766 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.044 -178.792 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.26 -24.62 76.1 Favored Glycine 0 N--CA 1.435 -1.432 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -177.343 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.4 t -84.85 -42.49 15.03 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 111.607 0.225 . . . . 0.0 111.607 179.519 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 11.4 pt -94.91 -36.69 7.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 120.272 -0.571 . . . . 0.0 110.088 -179.443 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 25' ' ' LEU . . . -63.8 -24.42 68.22 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 -179.5 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 10.9 t -64.61 -42.71 95.36 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.771 0.32 . . . . 0.0 111.332 -179.698 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 94.9 m-20 -70.58 -43.63 69.04 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.341 0.591 . . . . 0.0 109.481 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.8 mp -65.47 -44.75 86.17 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.426 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.37 -45.07 95.85 Favored Glycine 0 N--CA 1.439 -1.157 0 C-N-CA 119.444 -1.36 . . . . 0.0 109.94 -179.118 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.39 -39.69 71.03 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.577 -0.312 . . . . 0.0 111.566 179.265 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 48.4 t -63.34 -41.79 98.9 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-O 121.125 0.488 . . . . 0.0 110.324 -178.322 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.19 -39.4 79.23 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.931 179.032 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.7 tttp -60.09 -44.08 95.05 Favored 'General case' 0 C--N 1.309 -1.152 0 C-N-CA 119.343 -0.943 . . . . 0.0 108.614 -179.043 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.68 -36.54 91.44 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 178.389 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.2 t80 -71.65 -51.83 21.1 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-O 120.76 0.314 . . . . 0.0 110.462 -179.564 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.533 ' O ' ' N ' ' A' ' 44' ' ' SER . 23.7 mtpp -62.7 -38.05 88.9 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.375 179.135 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -61.02 -36.73 80.29 Favored 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 120.098 -0.641 . . . . 0.0 110.226 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.43 -36.19 82.17 Favored 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.37 -179.591 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.634 ' C ' ' H ' ' A' ' 45' ' ' ASP . 5.4 mmt -97.32 -67.25 0.86 Allowed 'General case' 0 N--CA 1.467 0.412 0 CA-C-O 120.992 0.425 . . . . 0.0 110.728 179.323 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.533 ' N ' ' O ' ' A' ' 40' ' ' LYS . 13.8 t 53.68 0.48 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.797 -179.063 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.634 ' H ' ' C ' ' A' ' 43' ' ' MET . 98.4 m-20 -64.64 -42.83 95.2 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.876 0.37 . . . . 0.0 110.706 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.4 ' OD1' ' O ' ' A' ' 46' ' ' ASP . 66.7 t0 -82.04 42.9 0.75 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.974 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -49.75 146.53 7.33 Favored Pre-proline 0 CA--C 1.536 0.404 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.428 -179.559 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 80.0 Cg_exo . . . . . 0 N--CA 1.49 1.274 0 C-N-CA 122.281 1.987 . . . . 0.0 112.098 179.85 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' A' ' 1' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 . . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -80.54 36.11 2.24 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 111.656 -0.578 . . . . 0.0 111.656 -179.608 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.526 ' O ' ' NE2' ' A' ' 8' ' ' GLN . . . 138.52 -9.19 3.45 Favored Glycine 0 N--CA 1.463 0.474 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.0 mp -99.58 117.79 45.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.051 0.453 . . . . 0.0 110.628 -179.85 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 18.1 m -144.91 -85.68 0.13 Allowed 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.664 179.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.5 mm -112.63 -33.55 2.17 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.915 -179.169 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 55.2 m95 -62.54 -48.97 77.16 Favored 'General case' 0 C--O 1.221 -0.423 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 -179.588 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . 0.526 ' NE2' ' O ' ' A' ' 3' ' ' GLY . 0.5 OUTLIER -64.13 -38.43 91.05 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.608 179.847 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.507 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 3.2 mm? -62.8 -39.08 93.16 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.874 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.9 mt -63.76 -51.77 63.39 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.6 -178.335 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 3.5 mp -65.62 -44.49 93.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 178.372 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 70.8 mt -63.72 -45.3 97.73 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 C-N-CA 120.479 -0.488 . . . . 0.0 111.337 -179.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.437 ' O ' ' CG2' ' A' ' 17' ' ' VAL . . . -64.95 -38.79 92.12 Favored 'General case' 0 C--N 1.32 -0.713 0 O-C-N 123.381 0.425 . . . . 0.0 110.975 -179.323 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.432 ' O ' ' CD2' ' A' ' 18' ' ' LEU . 70.7 t -67.54 -43.15 87.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 C-N-CA 120.566 -0.453 . . . . 0.0 110.562 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.452 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 96.7 mt -66.25 -43.35 91.78 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.322 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.453 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.48 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.4 t -63.72 -42.2 95.18 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.684 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.319 -178.68 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.437 ' CG2' ' O ' ' A' ' 13' ' ' ALA . 61.4 t -66.02 -45.11 91.62 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.883 0 C-N-CA 118.253 -1.379 . . . . 0.0 112.672 -176.764 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.432 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 1.3 pp -72.39 -43.16 64.32 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 119.702 -0.799 . . . . 0.0 109.949 178.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.452 ' CB ' ' O ' ' A' ' 15' ' ' ILE . 2.6 tm? -64.4 -41.44 96.64 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.923 -1.035 . . . . 0.0 110.313 -179.63 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.48 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 5.0 m-85 -69.02 -35.98 77.25 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 118.879 -1.129 . . . . 0.0 108.957 179.019 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.482 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 97.44 11.96 49.76 Favored Glycine 0 N--CA 1.465 0.593 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.703 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.482 ' OG1' ' O ' ' A' ' 21' ' ' GLY . 42.8 p 55.72 69.49 0.73 Allowed 'General case' 0 CA--C 1.506 -0.713 0 CA-C-N 114.604 -0.798 . . . . 0.0 112.445 178.364 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 49.6 mtpt -139.87 -25.53 0.81 Allowed 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.873 179.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 11.2 mmmt -85.8 -53.03 5.38 Favored 'General case' 0 C--O 1.221 -0.444 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.728 179.676 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.496 ' CD1' ' H ' ' A' ' 25' ' ' LEU . 0.1 OUTLIER -53.05 -37.33 61.49 Favored 'General case' 0 CA--C 1.505 -0.784 0 CA-C-O 121.817 0.818 . . . . 0.0 110.642 -178.992 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.67 -25.22 72.73 Favored Glycine 0 N--CA 1.438 -1.219 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 -178.296 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 13.8 m -93.46 -39.76 10.71 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 -179.527 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.2 pt -94.19 -34.9 5.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.193 0.521 . . . . 0.0 110.017 -179.011 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.16 -26.26 71.44 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.3 t -64.7 -43.06 94.68 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.657 -179.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -76.43 -41.0 49.13 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.347 0.594 . . . . 0.0 109.64 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.6 mp -68.4 -46.61 69.51 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.062 -0.972 . . . . 0.0 111.575 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.93 -44.0 98.43 Favored Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -179.16 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.12 -40.39 71.45 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.825 179.057 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.4 m -64.0 -40.8 97.18 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.898 -179.342 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.492 ' N ' HD13 ' A' ' 36' ' ' ILE . 1.6 mp -68.19 -41.57 84.12 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.485 -179.433 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 16.6 pttt -60.08 -43.35 95.56 Favored 'General case' 0 C--N 1.308 -1.203 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 -179.144 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -69.7 -36.78 75.93 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 110.599 -1.001 . . . . 0.0 110.599 178.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.581 ' CE2' ' SD ' ' A' ' 43' ' ' MET . 24.4 t80 -71.64 -49.26 41.66 Favored 'General case' 0 CA--C 1.514 -0.432 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.845 -178.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 44' ' ' SER . 9.8 mptt -67.06 -39.07 86.82 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.484 178.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.405 ' O ' ' OG ' ' A' ' 44' ' ' SER . 63.4 tttp -61.65 -36.65 81.41 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 119.72 -0.792 . . . . 0.0 109.865 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -68.59 -35.92 78.02 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.502 179.758 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.581 ' SD ' ' CE2' ' A' ' 39' ' ' PHE . 26.4 mtp -88.64 -19.81 25.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.856 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.514 ' N ' ' O ' ' A' ' 40' ' ' LYS . 89.6 p -50.92 135.34 24.58 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.204 -179.761 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.449 ' OD1' ' N ' ' A' ' 46' ' ' ASP . 68.1 t0 -167.73 132.37 1.84 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.901 0.381 . . . . 0.0 110.749 -179.679 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . 0.449 ' N ' ' OD1' ' A' ' 45' ' ' ASP . 56.9 t0 51.79 32.88 10.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.117 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 64.5 mt-10 -68.79 151.37 97.28 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.556 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_exo . . . . . 0 N--CA 1.488 1.189 0 C-N-CA 122.424 2.083 . . . . 0.0 112.05 179.776 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 1.5 mp . . . . . 0 N--CA 1.468 0.436 0 CA-C-O 120.576 0.227 . . . . 0.0 110.506 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 63.8 m95 -62.65 -49.54 74.73 Favored 'General case' 0 C--O 1.221 -0.432 0 CA-C-O 120.754 0.311 . . . . 0.0 110.576 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLN . . . . . 0.432 ' OE1' ' N ' ' A' ' 8' ' ' GLN . 20.9 mp0 -64.17 -38.52 91.34 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.491 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 3.0 mm? -63.64 -39.33 94.07 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.646 179.284 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.571 ' O ' HG23 ' A' ' 14' ' ' VAL . 9.1 mt -63.86 -51.0 66.61 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.872 -178.077 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.445 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.4 mp -66.08 -44.45 91.93 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.396 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 69.3 mt -63.58 -45.01 98.8 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.086 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.285 -179.436 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.852 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -65.01 -37.83 88.94 Favored 'General case' 0 C--N 1.317 -0.844 0 O-C-N 123.435 0.46 . . . . 0.0 111.245 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 10' ' ' LEU . 71.4 t -67.86 -43.98 85.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.794 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.758 HG22 HD23 ' A' ' 19' ' ' LEU . 96.8 mt -66.33 -43.47 91.45 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.104 0 CA-C-O 121.59 0.71 . . . . 0.0 109.322 179.435 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.408 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.8 t -63.53 -42.41 96.08 Favored 'Isoleucine or valine' 0 CA--C 1.479 -1.788 0 CA-C-N 114.794 -1.094 . . . . 0.0 109.788 -178.821 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.852 HG23 ' O ' ' A' ' 13' ' ' ALA . 60.4 t -66.5 -48.89 79.15 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.046 0 C-N-CA 117.609 -1.636 . . . . 0.0 112.787 -177.227 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.498 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.0 OUTLIER -66.99 -44.38 80.55 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 118.863 -1.135 . . . . 0.0 112.042 179.667 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.758 HD23 HG22 ' A' ' 15' ' ' ILE . 0.4 OUTLIER -65.95 -38.47 88.69 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.823 -179.979 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.408 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 4.7 m-85 -67.89 -41.03 83.37 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 -179.562 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.463 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 108.62 14.58 15.45 Favored Glycine 0 C--N 1.312 -0.803 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 178.392 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.709 HG22 ' CG1' ' A' ' 17' ' ' VAL . 68.0 p 52.02 39.51 26.47 Favored 'General case' 0 CA--C 1.495 -1.136 0 CA-C-N 114.747 -0.726 . . . . 0.0 112.473 178.283 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 59.5 tttm -112.43 -41.29 3.9 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.935 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.92 -56.28 9.65 Favored 'General case' 0 CA--C 1.509 -0.63 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.271 -179.492 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.654 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.311 -1.07 0 CA-C-O 121.901 0.858 . . . . 0.0 109.989 -177.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 38.7 t . . . . . 0 CA--C 1.517 -0.29 0 N-CA-C 111.699 0.259 . . . . 0.0 111.699 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.9 m-20 -94.24 -35.51 12.43 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 179.309 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.512 HD13 ' O ' ' A' ' 32' ' ' LEU . 0.2 OUTLIER -74.32 -49.35 23.31 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.408 -1.269 . . . . 0.0 111.412 -178.916 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.57 -42.97 99.86 Favored Glycine 0 CA--C 1.518 0.246 0 N-CA-C 109.304 -1.519 . . . . 0.0 109.304 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.59 -39.28 93.45 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.783 -0.709 . . . . 0.0 110.939 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 75.3 m -62.88 -41.31 99.35 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.137 -0.625 . . . . 0.0 110.709 -178.51 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.3 mp -68.65 -40.01 81.13 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.861 179.048 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.6 ptmt -59.79 -41.81 91.98 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 -178.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.17 -36.47 90.16 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 177.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 23.0 t80 -71.75 -52.44 17.68 Favored 'General case' 0 CA--C 1.514 -0.428 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.227 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 62.2 mttm -62.81 -40.18 96.56 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.43 179.075 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 38.9 ttpt -63.43 -38.36 90.84 Favored 'General case' 0 C--N 1.317 -0.846 0 C-N-CA 119.95 -0.7 . . . . 0.0 111.212 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.325 -0.488 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.818 -178.974 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.406 ' CG2' ' N ' ' A' ' 7' ' ' TRP . 3.4 tp . . . . . 0 N--CA 1.442 -0.833 0 CA-C-O 121.754 0.788 . . . . 0.0 111.907 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.427 ' CD1' ' C ' ' A' ' 7' ' ' TRP . 5.6 t-105 -61.91 -39.34 91.67 Favored 'General case' 0 N--CA 1.421 -1.884 0 CA-C-N 114.88 -1.054 . . . . 0.0 108.748 -178.321 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -64.74 -38.85 92.4 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 178.158 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.464 HD23 ' HA ' ' A' ' 9' ' ' LEU . 73.7 mt -62.74 -38.09 89.14 Favored 'General case' 0 CA--C 1.503 -0.851 0 CA-C-N 114.925 -1.034 . . . . 0.0 110.479 178.78 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.633 ' O ' HG23 ' A' ' 14' ' ' VAL . 2.7 mt -62.63 -47.62 82.94 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.235 -177.274 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.505 ' N ' HD12 ' A' ' 11' ' ' ILE . 3.2 mp -69.13 -44.58 80.82 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 178.21 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 77.3 mt -64.02 -44.48 97.82 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.307 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.684 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.9 -36.63 84.97 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.945 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.633 HG23 ' O ' ' A' ' 10' ' ' LEU . 48.8 t -67.28 -44.29 87.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.307 -179.026 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 14.1 pt -67.24 -43.9 87.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.831 179.774 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.517 HG22 ' CD2' ' A' ' 20' ' ' PHE . 0.3 OUTLIER -64.79 -39.3 85.19 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.07 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.323 -179.632 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.694 ' CG1' HG22 ' A' ' 22' ' ' THR . 75.8 t -66.25 -46.99 85.89 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 C-N-CA 118.683 -1.207 . . . . 0.0 112.743 -178.573 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.43 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 0.8 OUTLIER -68.88 -42.39 77.04 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.419 0.628 . . . . 0.0 110.031 179.046 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.71 ' C ' HD13 ' A' ' 19' ' ' LEU . 2.2 tm? -63.88 -39.84 95.14 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.623 -1.171 . . . . 0.0 109.875 -179.306 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.517 ' CD2' HG22 ' A' ' 16' ' ' VAL . 3.0 m-85 -69.17 -37.22 78.09 Favored 'General case' 0 CA--C 1.513 -0.454 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 177.605 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.507 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 102.3 9.59 41.24 Favored Glycine 0 N--CA 1.462 0.405 0 CA-C-N 115.086 -0.961 . . . . 0.0 110.916 179.135 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.694 HG22 ' CG1' ' A' ' 17' ' ' VAL . 51.6 p 58.56 22.22 9.5 Favored 'General case' 0 C--N 1.32 -0.713 0 O-C-N 123.935 0.433 . . . . 0.0 111.99 178.774 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -100.96 -15.82 17.38 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.103 -0.499 . . . . 0.0 112.06 -179.599 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 15.2 mmmt -92.29 -57.82 2.58 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.178 0.513 . . . . 0.0 110.718 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.985 ' H ' HD12 ' A' ' 25' ' ' LEU . 1.7 mp . . . . . 0 CA--C 1.496 -1.124 0 CA-C-O 122.272 1.034 . . . . 0.0 110.417 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.7 m . . . . . 0 C--O 1.232 0.177 0 CA-C-O 120.657 0.265 . . . . 0.0 111.214 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -70.09 -43.83 70.3 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 179.302 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -65.08 -44.1 90.01 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.064 -0.971 . . . . 0.0 111.249 179.648 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.6 -45.49 94.51 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 119.208 -1.472 . . . . 0.0 109.863 -179.193 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.11 -39.65 71.94 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.56 -0.32 . . . . 0.0 111.738 179.22 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 14.5 t -63.03 -42.14 99.7 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.341 -177.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.71 -39.64 80.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.744 178.775 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 34.5 tttm -59.91 -43.36 94.9 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 -178.443 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.81 -36.79 91.67 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 177.835 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 13.7 t80 -71.64 -50.23 32.56 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-O 120.897 0.379 . . . . 0.0 110.221 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 47.8 mtpt -62.86 -38.88 92.6 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.346 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 50.5 mtpt -61.82 -38.85 89.7 Favored 'General case' 0 C--N 1.319 -0.744 0 C-N-CA 119.764 -0.774 . . . . 0.0 110.083 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.324 -0.515 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.778 -179.856 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 34.4 mm . . . . . 0 N--CA 1.444 -0.768 0 CA-C-O 121.092 0.472 . . . . 0.0 110.356 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 94.1 m95 -74.32 -38.93 63.15 Favored 'General case' 0 C--N 1.321 -0.638 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.096 179.595 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLN . . . . . 0.499 ' N ' ' OE1' ' A' ' 8' ' ' GLN . 0.8 OUTLIER -64.23 -38.77 92.22 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -179.686 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.666 HD12 ' C ' ' A' ' 9' ' ' LEU . 0.4 OUTLIER -73.31 -38.19 65.93 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.249 179.672 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.651 ' O ' HG23 ' A' ' 14' ' ' VAL . 13.8 mt -63.41 -46.87 84.4 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.871 0.367 . . . . 0.0 111.278 -177.661 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.2 mp -67.74 -44.23 85.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.201 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 35.1 mt -65.04 -44.64 95.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.121 -179.27 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.88 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.74 -37.54 87.93 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 115.762 -0.653 . . . . 0.0 110.966 -178.925 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.651 HG23 ' O ' ' A' ' 10' ' ' LEU . 54.4 t -66.93 -44.99 88.36 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.426 0 C-N-CA 120.435 -0.506 . . . . 0.0 111.506 -178.764 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 16.7 pt -66.9 -42.65 89.24 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.99 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.147 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.528 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.7 t -63.82 -41.43 92.54 Favored 'Isoleucine or valine' 0 CA--C 1.482 -1.659 0 CA-C-N 115.388 -0.823 . . . . 0.0 109.795 -178.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.88 HG23 ' O ' ' A' ' 13' ' ' ALA . 52.2 t -66.29 -50.43 68.15 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.93 0 C-N-CA 117.548 -1.661 . . . . 0.0 113.32 -177.269 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.558 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.2 pp -67.04 -44.11 81.03 Favored 'General case' 0 C--N 1.296 -1.727 0 C-N-CA 119.151 -1.02 . . . . 0.0 111.881 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.658 ' C ' HD12 ' A' ' 19' ' ' LEU . 0.4 OUTLIER -65.78 -38.43 89.02 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.607 -0.27 . . . . 0.0 111.028 179.8 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.528 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 3.4 m-85 -68.38 -37.13 80.11 Favored 'General case' 0 CA--C 1.515 -0.376 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.819 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.428 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 97.93 13.77 42.04 Favored Glycine 0 CA--C 1.504 -0.601 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.512 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.682 HG22 HG13 ' A' ' 17' ' ' VAL . 46.2 p 53.2 76.95 0.18 Allowed 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 114.083 -1.058 . . . . 0.0 112.121 178.504 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 18.0 ptmt -142.4 -36.46 0.4 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.939 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 11.1 mmmt -77.31 -50.75 12.14 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.39 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.611 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.2 OUTLIER . . . . . 0 CA--C 1.503 -0.84 0 CA-C-O 122.12 0.962 . . . . 0.0 110.449 -178.744 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.4 t . . . . . 0 CA--C 1.523 -0.089 0 CA-C-O 120.692 0.282 . . . . 0.0 111.341 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -73.93 -42.6 60.34 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -66.83 -44.44 81.11 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 114.998 -1.001 . . . . 0.0 111.475 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.41 -44.13 97.24 Favored Glycine 0 N--CA 1.44 -1.051 0 C-N-CA 119.322 -1.418 . . . . 0.0 109.817 -179.203 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.73 -40.13 69.61 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.529 -0.336 . . . . 0.0 111.346 179.05 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.5 m -63.69 -40.56 97.1 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.223 -178.451 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -70.19 -39.52 77.04 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.677 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.5 ptmt -59.79 -41.86 92.12 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 -178.818 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.81 -36.9 87.92 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.557 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -71.49 -50.82 27.8 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 53.7 mtpt -63.21 -38.6 91.82 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.506 178.655 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -61.49 -39.2 90.07 Favored 'General case' 0 C--N 1.318 -0.766 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.867 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.323 -0.572 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.705 179.869 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.509 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.5 mp . . . . . 0 N--CA 1.453 -0.287 0 CA-C-O 120.755 0.312 . . . . 0.0 110.463 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 67.6 m95 -62.15 -46.98 86.57 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -64.43 -38.9 92.63 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.425 HD23 ' HA ' ' A' ' 9' ' ' LEU . 89.2 mt -66.08 -38.73 89.0 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.306 178.881 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.591 ' O ' HG23 ' A' ' 14' ' ' VAL . 16.7 mt -63.43 -50.28 70.41 Favored 'General case' 0 C--N 1.315 -0.919 0 C-N-CA 120.131 -0.628 . . . . 0.0 110.541 -176.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.435 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.4 mp -66.61 -44.73 89.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.107 178.237 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 75.5 mt -63.91 -46.79 93.16 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.967 0 C-N-CA 120.294 -0.562 . . . . 0.0 111.432 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.846 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -65.0 -37.68 88.47 Favored 'General case' 0 C--N 1.319 -0.745 0 O-C-N 123.213 0.321 . . . . 0.0 111.349 -179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.591 HG23 ' O ' ' A' ' 10' ' ' LEU . 59.2 t -67.8 -43.82 86.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.613 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.448 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 96.6 mt -66.2 -43.53 91.86 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.155 0 O-C-N 123.521 0.513 . . . . 0.0 109.725 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.433 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.6 t -63.72 -42.26 95.38 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.504 0 CA-C-N 115.08 -0.964 . . . . 0.0 109.919 -178.637 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.846 HG23 ' O ' ' A' ' 13' ' ' ALA . 59.9 t -66.27 -44.78 91.05 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 C-N-CA 118.217 -1.393 . . . . 0.0 112.79 -176.844 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.483 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.2 pp -71.96 -42.9 66.02 Favored 'General case' 0 C--N 1.294 -1.825 0 C-N-CA 120.046 -0.661 . . . . 0.0 109.761 178.177 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.661 ' C ' HD13 ' A' ' 19' ' ' LEU . 2.6 tm? -64.8 -41.75 95.56 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.823 -179.175 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.433 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 6.9 m-85 -69.24 -33.47 73.33 Favored 'General case' 0 CA--C 1.511 -0.558 0 C-N-CA 119.067 -1.053 . . . . 0.0 108.831 178.716 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.466 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 93.93 12.9 56.06 Favored Glycine 0 C--N 1.318 -0.471 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 179.244 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.655 HG22 HG13 ' A' ' 17' ' ' VAL . 43.1 p 55.78 77.73 0.22 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 114.684 -0.758 . . . . 0.0 112.002 178.762 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -146.28 -26.11 0.43 Allowed 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.454 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.65 -39.71 10.65 Favored 'General case' 0 C--O 1.223 -0.315 0 C-N-CA 120.719 -0.393 . . . . 0.0 110.905 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.704 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.2 OUTLIER . . . . . 0 CA--C 1.501 -0.931 0 CA-C-O 121.714 0.768 . . . . 0.0 110.001 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.5 t . . . . . 0 CA--C 1.52 -0.177 0 N-CA-C 111.733 0.272 . . . . 0.0 111.733 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -75.54 -42.51 52.25 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.438 0.637 . . . . 0.0 109.487 179.704 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.8 mp -66.89 -44.66 80.28 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.043 -0.98 . . . . 0.0 111.81 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.32 -44.12 97.4 Favored Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 119.413 -1.375 . . . . 0.0 109.832 -179.294 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.84 -39.79 69.49 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.66 -0.27 . . . . 0.0 111.394 179.183 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.7 m -63.24 -40.92 98.79 Favored 'General case' 0 CA--C 1.518 -0.287 0 CA-C-O 121.112 0.482 . . . . 0.0 110.477 -178.599 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.63 -39.36 78.15 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.757 178.627 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 24.2 tttt -59.97 -44.56 94.37 Favored 'General case' 0 N--CA 1.435 -1.217 0 C-N-CA 119.231 -0.988 . . . . 0.0 108.414 -179.357 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.97 -36.34 91.91 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 178.005 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 21.0 t80 -71.38 -51.41 24.24 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-O 120.835 0.35 . . . . 0.0 110.456 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -63.08 -38.56 91.66 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.38 178.538 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -61.36 -36.84 81.33 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.121 -0.632 . . . . 0.0 110.012 -179.565 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.325 -0.475 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.126 179.663 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 4.6 tp . . . . . 0 N--CA 1.448 -0.557 0 CA-C-O 121.219 0.533 . . . . 0.0 111.986 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.651 ' CE2' HD11 ' A' ' 11' ' ' ILE . 8.1 t-105 -62.2 -37.12 84.12 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 115.459 -0.791 . . . . 0.0 108.91 -178.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 6.8 mp0 -64.35 -38.91 92.71 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 178.318 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.426 HD23 ' HA ' ' A' ' 9' ' ' LEU . 84.0 mt -64.79 -37.58 88.11 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.93 178.546 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.694 ' O ' HG23 ' A' ' 14' ' ' VAL . 3.9 mt -62.47 -43.89 97.71 Favored 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.274 -177.239 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.651 HD11 ' CE2' ' A' ' 7' ' ' TRP . 7.2 mt -68.35 -45.11 83.02 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 C-N-CA 119.992 -0.683 . . . . 0.0 109.593 178.049 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 72.0 mt -65.98 -44.74 92.19 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.572 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.531 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.907 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -65.22 -37.21 86.56 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.03 -179.517 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.694 HG23 ' O ' ' A' ' 10' ' ' LEU . 46.0 t -66.65 -44.78 89.57 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.717 0 C-N-CA 120.599 -0.44 . . . . 0.0 111.485 -179.082 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.439 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 15.2 pt -66.61 -42.64 90.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.209 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.531 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.5 t -63.85 -41.82 93.8 Favored 'Isoleucine or valine' 0 CA--C 1.483 -1.603 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.702 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.907 HG23 ' O ' ' A' ' 13' ' ' ALA . 61.5 t -65.8 -45.93 90.21 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 C-N-CA 118.361 -1.335 . . . . 0.0 112.948 -177.216 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.521 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.4 pp -72.11 -42.85 65.59 Favored 'General case' 0 C--N 1.288 -2.093 0 CA-C-O 121.333 0.587 . . . . 0.0 109.791 178.73 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.705 ' C ' HD13 ' A' ' 19' ' ' LEU . 2.5 tm? -64.67 -42.3 95.47 Favored 'General case' 0 N--CA 1.44 -0.956 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.164 -179.767 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.531 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 5.7 m-85 -68.94 -34.37 75.24 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 119.138 -1.025 . . . . 0.0 109.314 179.333 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.487 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 96.32 11.38 54.32 Favored Glycine 0 N--CA 1.466 0.635 0 N-CA-C 110.647 -0.981 . . . . 0.0 110.647 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.697 HG22 ' CG1' ' A' ' 17' ' ' VAL . 43.4 p 56.53 68.58 0.84 Allowed 'General case' 0 CA--C 1.502 -0.884 0 CA-C-N 115.055 -0.573 . . . . 0.0 112.271 178.199 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -139.87 -24.77 0.83 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.015 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 10.1 mmmt -87.06 -52.09 5.63 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.821 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.63 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.1 OUTLIER . . . . . 0 CA--C 1.505 -0.781 0 CA-C-O 121.783 0.801 . . . . 0.0 110.266 -178.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.1 p . . . . . 0 CA--C 1.519 -0.217 0 CA-C-O 120.655 0.265 . . . . 0.0 111.336 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 46.2 t0 -81.36 -39.47 25.02 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.254 0.549 . . . . 0.0 109.694 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.0 mp -69.37 -45.32 69.63 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.193 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.76 -43.94 98.21 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 119.531 -1.319 . . . . 0.0 109.913 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.0 -39.99 79.0 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.538 -0.331 . . . . 0.0 111.372 179.522 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 47.1 t -63.28 -42.26 99.08 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.093 0.473 . . . . 0.0 110.718 -178.845 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.88 -39.42 79.92 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.154 179.205 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 7.6 ttpt -59.39 -43.65 92.92 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.242 -0.983 . . . . 0.0 108.524 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.73 -36.21 92.0 Favored Glycine 0 N--CA 1.444 -0.821 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 178.439 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -71.08 -52.54 18.84 Favored 'General case' 0 CA--C 1.512 -0.517 0 CA-C-O 120.976 0.417 . . . . 0.0 110.133 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.427 ' HG3' ' HZ2' ' A' ' 40' ' ' LYS . 44.2 mttp -63.36 -38.86 92.81 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 120.27 -0.572 . . . . 0.0 110.545 178.487 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 1.9 tmtp? -61.7 -39.15 90.44 Favored 'General case' 0 C--N 1.319 -0.76 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.106 -179.665 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.325 -0.478 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.953 179.572 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 3.7 tp . . . . . 0 N--CA 1.447 -0.586 0 CA-C-O 121.235 0.54 . . . . 0.0 111.578 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.769 ' O ' HD12 ' A' ' 11' ' ' ILE . 0.3 OUTLIER -62.21 -41.62 98.54 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-N 115.365 -0.834 . . . . 0.0 108.967 -179.185 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 56.4 mt-30 -64.08 -38.38 90.87 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 178.701 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.514 ' O ' ' N ' ' A' ' 13' ' ' ALA . 87.5 mt -65.37 -36.98 85.63 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.326 177.439 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.573 ' O ' HG23 ' A' ' 14' ' ' VAL . 1.8 tt -61.84 -50.95 70.19 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.888 -174.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.769 HD12 ' O ' ' A' ' 7' ' ' TRP . 2.8 mp -65.35 -44.73 94.64 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 C-N-CA 119.893 -0.723 . . . . 0.0 109.533 177.838 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.1 mp -63.77 -44.36 98.23 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.21 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.904 179.49 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.9 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.56 -37.35 87.27 Favored 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 121.086 -0.246 . . . . 0.0 110.836 -179.411 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.573 HG23 ' O ' ' A' ' 10' ' ' LEU . 53.0 t -66.93 -45.01 88.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 C-N-CA 120.544 -0.462 . . . . 0.0 111.465 -179.191 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 13.5 pt -66.87 -42.76 89.47 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.989 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 178.59 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.569 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.4 t -63.14 -41.54 93.21 Favored 'Isoleucine or valine' 0 CA--C 1.478 -1.799 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.883 -178.895 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.9 HG23 ' O ' ' A' ' 13' ' ' ALA . 51.7 t -66.14 -51.23 62.11 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.033 0 C-N-CA 117.857 -1.537 . . . . 0.0 113.652 -177.471 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.598 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.4 pp -66.89 -44.36 81.08 Favored 'General case' 0 C--N 1.293 -1.869 0 C-N-CA 119.487 -0.885 . . . . 0.0 111.782 179.764 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.659 ' C ' HD12 ' A' ' 19' ' ' LEU . 0.4 OUTLIER -65.77 -38.87 90.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.704 -0.225 . . . . 0.0 110.638 -179.943 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.569 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 3.0 m-85 -68.5 -36.54 79.05 Favored 'General case' 0 CA--C 1.513 -0.476 0 C-N-CA 119.607 -0.837 . . . . 0.0 109.317 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.472 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 96.98 12.01 51.11 Favored Glycine 0 CA--C 1.506 -0.501 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 -179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.726 HG22 HG13 ' A' ' 17' ' ' VAL . 43.3 p 54.74 74.74 0.33 Allowed 'General case' 0 CA--C 1.5 -0.963 0 CA-C-N 114.196 -1.002 . . . . 0.0 112.677 178.055 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 62.1 mttp -139.04 -31.57 0.7 Allowed 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.784 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 6.7 mmpt? -81.6 -54.35 5.48 Favored 'General case' 0 CA--C 1.501 -0.914 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.612 -179.736 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.618 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.312 -1.024 0 CA-C-O 122.371 1.081 . . . . 0.0 110.701 -176.662 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.2 p . . . . . 0 N--CA 1.456 -0.168 0 CA-C-O 120.702 0.287 . . . . 0.0 110.944 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -72.96 -43.28 62.48 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.54 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.5 mp -64.97 -44.37 89.58 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.185 179.578 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -64.02 -45.1 94.81 Favored Glycine 0 N--CA 1.44 -1.093 0 C-N-CA 119.251 -1.452 . . . . 0.0 109.765 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.65 -39.71 73.46 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.513 -0.344 . . . . 0.0 111.664 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.9 t -62.89 -41.91 99.59 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.407 -177.802 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.72 -39.77 78.44 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.145 178.613 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 36.6 tttm -60.07 -41.45 92.42 Favored 'General case' 0 N--CA 1.426 -1.644 0 N-CA-C 108.056 -1.091 . . . . 0.0 108.056 -178.529 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.12 -36.49 90.44 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 109.882 -1.287 . . . . 0.0 109.882 177.625 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -71.6 -51.92 20.78 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.188 -179.308 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 54.5 mttp -63.72 -39.65 94.81 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.517 178.322 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 61.6 tttm -61.79 -38.79 89.38 Favored 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 120.054 -0.658 . . . . 0.0 110.458 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.322 -0.62 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.701 -179.637 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.456 ' HA ' HD23 ' A' ' 9' ' ' LEU . 40.8 mm . . . . . 0 N--CA 1.45 -0.464 0 CA-C-O 120.848 0.356 . . . . 0.0 111.06 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 82.9 m95 -71.68 -40.69 69.42 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 120.279 -0.568 . . . . 0.0 110.207 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLN . . . . . 0.488 ' N ' ' OE1' ' A' ' 8' ' ' GLN . 1.7 mp0 -64.41 -38.8 92.31 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.055 0.455 . . . . 0.0 110.311 -179.227 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.666 HD12 ' C ' ' A' ' 9' ' ' LEU . 0.3 OUTLIER -72.31 -38.0 68.81 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.97 179.7 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.589 ' O ' HG23 ' A' ' 14' ' ' VAL . 15.8 mt -63.28 -48.78 76.68 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.73 -176.386 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.2 mp -66.13 -44.33 91.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 178.394 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 69.3 mt -64.06 -44.48 97.74 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.642 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.391 -179.366 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.89 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.91 -37.09 86.5 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.867 -179.067 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.589 HG23 ' O ' ' A' ' 10' ' ' LEU . 50.2 t -66.93 -45.6 86.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 C-N-CA 120.425 -0.51 . . . . 0.0 111.574 -178.809 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 15.9 pt -66.41 -42.34 90.27 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.916 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.345 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.759 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.7 t -63.19 -42.36 96.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.35 -179.626 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.89 HG23 ' O ' ' A' ' 13' ' ' ALA . 61.3 t -65.63 -48.96 80.69 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.887 0 C-N-CA 117.245 -1.782 . . . . 0.0 113.69 -176.73 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.634 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.6 pp -68.49 -44.0 75.66 Favored 'General case' 0 C--N 1.289 -2.063 0 C-N-CA 120.094 -0.642 . . . . 0.0 112.156 -179.377 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.669 ' C ' HD12 ' A' ' 19' ' ' LEU . 0.4 OUTLIER -66.3 -39.19 89.15 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.99 -179.604 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.759 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 1.8 m-85 -68.45 -37.62 80.37 Favored 'General case' 0 CA--C 1.506 -0.726 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.641 -178.395 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.483 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 101.2 9.53 44.56 Favored Glycine 0 C--N 1.308 -0.974 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.046 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.697 HG22 ' CG1' ' A' ' 17' ' ' VAL . 44.6 p 55.15 66.66 1.17 Allowed 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 178.698 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -139.6 -22.57 0.89 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.054 179.452 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 9.9 mmmt -87.13 -51.41 6.01 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.646 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.634 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.316 -0.866 0 CA-C-O 122.067 0.937 . . . . 0.0 110.556 -178.85 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.2 p . . . . . 0 N--CA 1.454 -0.259 0 CA-C-O 120.796 0.332 . . . . 0.0 111.058 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -76.02 -39.88 54.71 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.078 0.466 . . . . 0.0 109.874 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.7 mp -70.21 -45.59 66.27 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.129 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.55 -43.57 98.83 Favored Glycine 0 N--CA 1.441 -1.007 0 C-N-CA 119.545 -1.312 . . . . 0.0 110.473 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.02 -40.04 71.99 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 120.898 0.38 . . . . 0.0 111.06 179.433 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 12.4 t -63.99 -41.93 97.36 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 120.559 -0.456 . . . . 0.0 110.98 -178.558 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.44 -39.87 79.2 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.71 -179.528 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 18.7 pttt -59.58 -40.51 87.62 Favored 'General case' 0 C--N 1.309 -1.195 0 C-N-CA 118.591 -1.243 . . . . 0.0 107.843 -178.277 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -69.46 -36.82 78.07 Favored Glycine 0 N--CA 1.442 -0.92 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 179.657 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -71.52 -50.71 28.67 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.552 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 52.7 mtpt -63.65 -38.85 92.66 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.597 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -62.04 -37.97 86.94 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 119.981 -0.687 . . . . 0.0 110.09 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.325 -0.471 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.495 -179.939 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.422 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.4 mp . . . . . 0 CA--C 1.534 0.334 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 70.9 m95 -62.76 -46.97 85.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.692 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 59.1 mm-40 -64.35 -39.05 93.11 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.424 HD23 ' HA ' ' A' ' 9' ' ' LEU . 84.4 mt -65.08 -39.1 92.72 Favored 'General case' 0 CA--C 1.508 -0.649 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.146 178.626 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.598 ' O ' HG23 ' A' ' 14' ' ' VAL . 8.0 mt -63.38 -49.16 74.91 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.521 -176.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.516 ' O ' HG12 ' A' ' 15' ' ' ILE . 3.3 mp -67.67 -44.97 85.66 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.775 0 C-N-CA 119.508 -0.877 . . . . 0.0 109.093 178.07 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 77.1 mt -63.36 -44.36 98.98 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.526 -179.165 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.818 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -63.79 -36.46 83.96 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.203 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.598 HG23 ' O ' ' A' ' 10' ' ' LEU . 65.8 t -67.1 -43.06 88.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 C-N-CA 119.779 -0.769 . . . . 0.0 110.457 179.672 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.516 HG12 ' O ' ' A' ' 11' ' ' ILE . 33.5 mm -66.08 -43.04 92.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.127 0.489 . . . . 0.0 110.28 179.26 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.505 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -63.75 -38.04 81.27 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.558 -178.72 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.818 HG23 ' O ' ' A' ' 13' ' ' ALA . 95.0 t -65.66 -43.02 93.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 C-N-CA 118.409 -1.316 . . . . 0.0 111.868 -178.308 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.434 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 16.1 mt -62.0 -45.03 95.42 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 118.631 -1.227 . . . . 0.0 111.833 -179.106 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.889 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.78 -38.37 79.97 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -178.528 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.889 ' N ' HD12 ' A' ' 19' ' ' LEU . 1.3 m-85 -67.57 -32.44 73.2 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -177.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 94.45 8.88 59.46 Favored Glycine 0 CA--C 1.5 -0.887 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 178.901 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.721 HG22 HG13 ' A' ' 17' ' ' VAL . 18.0 p 56.95 27.95 13.94 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 114.27 -0.965 . . . . 0.0 112.502 178.034 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -100.57 -12.84 18.92 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.776 179.774 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 15.4 mmmt -96.06 -58.43 2.09 Favored 'General case' 0 C--O 1.221 -0.438 0 CA-C-O 121.053 0.454 . . . . 0.0 110.281 179.511 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 1.086 ' H ' HD12 ' A' ' 25' ' ' LEU . 2.0 mp . . . . . 0 CA--C 1.495 -1.144 0 CA-C-O 122.459 1.123 . . . . 0.0 110.468 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 61.9 p . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.731 0.301 . . . . 0.0 111.761 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -67.81 -39.87 83.91 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.411 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -65.46 -44.99 85.51 Favored 'General case' 0 CA--C 1.507 -0.694 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.159 179.653 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.43 -43.43 99.34 Favored Glycine 0 N--CA 1.433 -1.54 0 N-CA-C 108.475 -1.85 . . . . 0.0 108.475 -178.474 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.97 -40.0 75.63 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.073 -0.564 . . . . 0.0 111.159 178.429 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 51.6 m -63.53 -43.37 97.33 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 120.408 -0.517 . . . . 0.0 110.87 -178.452 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -67.28 -39.71 83.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.64 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.0 pttt -60.02 -42.08 93.56 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 -179.209 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.68 -36.83 88.37 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 178.23 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 14.8 t80 -71.94 -50.41 29.27 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 120.956 0.408 . . . . 0.0 110.642 -179.673 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 21.8 mtpp -62.74 -38.55 90.99 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.269 179.066 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -61.76 -38.3 87.49 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.475 -179.364 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.327 -0.405 0 CA-C-O 121.194 0.521 . . . . 0.0 109.626 179.189 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.6 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.4 mp . . . . . 0 N--CA 1.435 -1.21 0 CA-C-O 121.153 0.501 . . . . 0.0 110.403 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.403 ' O ' HD13 ' A' ' 11' ' ' ILE . 95.8 m95 -70.92 -39.71 72.53 Favored 'General case' 0 C--N 1.316 -0.884 0 C-N-CA 120.068 -0.653 . . . . 0.0 109.773 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 94.2 mm-40 -64.66 -39.15 93.19 Favored 'General case' 0 N--CA 1.442 -0.85 0 C-N-CA 120.315 -0.554 . . . . 0.0 109.617 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.658 HD12 ' C ' ' A' ' 9' ' ' LEU . 0.4 OUTLIER -73.05 -38.36 66.51 Favored 'General case' 0 C--O 1.226 -0.176 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.014 179.027 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.566 ' O ' HG23 ' A' ' 14' ' ' VAL . 15.3 mt -63.31 -47.82 80.66 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.945 -0.302 . . . . 0.0 111.22 -177.613 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.403 HD13 ' O ' ' A' ' 7' ' ' TRP . 2.1 mp -66.94 -44.48 88.64 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.851 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 53.3 mt -64.42 -44.72 97.09 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.076 0 CA-C-N 115.639 -0.709 . . . . 0.0 111.271 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.694 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.84 -37.39 87.47 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.719 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.566 HG23 ' O ' ' A' ' 10' ' ' LEU . 55.3 t -67.67 -45.72 84.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 C-N-CA 119.624 -0.831 . . . . 0.0 110.697 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.5 mt -65.85 -43.88 92.97 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.717 0 CA-C-O 121.172 0.51 . . . . 0.0 111.189 -179.023 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.579 HG22 ' CD2' ' A' ' 20' ' ' PHE . 0.5 OUTLIER -64.46 -38.74 83.36 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.344 0 CA-C-N 115.284 -0.871 . . . . 0.0 109.616 -178.932 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.782 HG13 HG22 ' A' ' 22' ' ' THR . 61.0 t -65.75 -42.79 93.19 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.158 0 C-N-CA 118.571 -1.252 . . . . 0.0 111.389 -177.882 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 66.0 mt -61.77 -44.96 95.86 Favored 'General case' 0 C--N 1.312 -1.031 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.751 -179.02 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.875 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.55 -38.29 80.65 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 113.067 0.765 . . . . 0.0 113.067 -178.74 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.875 ' N ' HD12 ' A' ' 19' ' ' LEU . 1.2 m-85 -67.61 -31.74 71.97 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -178.224 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 90.74 2.79 71.84 Favored Glycine 0 C--N 1.318 -0.47 0 N-CA-C 109.211 -1.556 . . . . 0.0 109.211 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.782 HG22 HG13 ' A' ' 17' ' ' VAL . 5.5 p 57.19 9.09 0.63 Allowed 'General case' 0 CA--C 1.511 -0.544 0 CA-C-N 114.727 -0.737 . . . . 0.0 112.178 178.03 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 24.7 mtpp -71.76 -42.26 67.42 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.256 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' LYS . . . . . 0.592 ' HG3' HD12 ' A' ' 25' ' ' LEU . 0.0 OUTLIER -86.57 -25.17 25.14 Favored 'General case' 0 C--O 1.221 -0.41 0 CA-C-N 116.16 -0.473 . . . . 0.0 112.017 -178.705 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.68 HD13 ' HA ' ' A' ' 22' ' ' THR . 9.7 mp . . . . . 0 CA--C 1.49 -1.328 0 CA-C-O 121.852 0.834 . . . . 0.0 109.353 -179.669 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 7.3 t . . . . . 0 C--O 1.232 0.149 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -86.53 -36.19 19.1 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.4 mp -73.03 -46.34 52.48 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.129 -0.942 . . . . 0.0 111.725 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.78 -43.66 98.94 Favored Glycine 0 C--N 1.308 -1.003 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.579 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.0 -40.32 75.34 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.486 -0.357 . . . . 0.0 111.479 179.57 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.5 t -63.61 -42.84 98.17 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.195 0.521 . . . . 0.0 110.857 -178.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.1 mp -67.09 -39.76 83.92 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.753 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.487 ' HA ' ' HZ2' ' A' ' 40' ' ' LYS . 2.1 pttp -59.81 -42.71 94.08 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 118.809 -1.156 . . . . 0.0 108.301 -178.717 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.87 -36.88 87.57 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.495 -1.042 . . . . 0.0 110.495 178.549 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 51.6 t80 -71.91 -53.34 13.45 Favored 'General case' 0 CA--C 1.513 -0.445 0 CA-C-O 120.684 0.278 . . . . 0.0 111.597 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.487 ' HZ2' ' HA ' ' A' ' 37' ' ' LYS . 9.9 pttm -62.75 -38.37 90.3 Favored 'General case' 0 C--N 1.318 -0.773 0 C-N-CA 120.069 -0.652 . . . . 0.0 109.994 -179.423 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 52.9 tttp -61.47 -37.52 83.91 Favored 'General case' 0 N--CA 1.446 -0.654 0 C-N-CA 120.153 -0.619 . . . . 0.0 110.057 -179.523 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.324 -0.508 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.53 179.389 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 26.1 mm . . . . . 0 N--CA 1.443 -0.777 0 CA-C-O 121.523 0.678 . . . . 0.0 111.315 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.768 ' CZ2' HD11 ' A' ' 11' ' ' ILE . 6.5 t-105 -62.74 -42.0 99.46 Favored 'General case' 0 N--CA 1.434 -1.242 0 CA-C-N 115.219 -0.901 . . . . 0.0 108.756 179.338 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLN . . . . . 0.539 ' OE1' ' N ' ' A' ' 8' ' ' GLN . 5.9 mp0 -64.74 -38.73 91.97 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.127 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.439 HD23 ' HA ' ' A' ' 9' ' ' LEU . 32.7 mt -60.03 -37.28 79.3 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.789 178.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.598 ' O ' HG23 ' A' ' 14' ' ' VAL . 4.8 mt -61.94 -44.32 97.01 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.077 -176.671 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.768 HD11 ' CZ2' ' A' ' 7' ' ' TRP . 4.4 mp -66.65 -45.33 88.62 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.508 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.329 177.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.403 ' N ' ' CD1' ' A' ' 12' ' ' ILE . 1.1 mp -64.96 -44.79 96.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.448 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.776 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.18 -37.0 85.89 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.971 0.415 . . . . 0.0 110.395 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.598 HG23 ' O ' ' A' ' 10' ' ' LEU . 56.0 t -67.4 -43.77 87.43 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.39 0 C-N-CA 119.811 -0.756 . . . . 0.0 110.792 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.402 HG12 ' O ' ' A' ' 11' ' ' ILE . 4.4 mm -65.53 -43.39 94.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.26 0.552 . . . . 0.0 110.98 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.463 HG22 ' CD2' ' A' ' 20' ' ' PHE . 0.3 OUTLIER -63.54 -38.16 81.48 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.401 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.536 -178.31 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.776 HG23 ' O ' ' A' ' 13' ' ' ALA . 73.5 t -64.61 -43.67 96.72 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.381 0 C-N-CA 118.429 -1.309 . . . . 0.0 109.751 -178.404 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.588 HD21 ' O ' ' A' ' 14' ' ' VAL . 0.1 OUTLIER -63.72 -43.63 95.98 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 178.168 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.06 -43.75 94.55 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-N 114.006 -1.452 . . . . 0.0 111.605 -176.519 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.463 ' CD2' HG22 ' A' ' 16' ' ' VAL . 2.9 m-85 -68.92 -33.1 73.19 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.509 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 97.35 14.21 42.37 Favored Glycine 0 CA--C 1.502 -0.733 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 178.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.773 HG22 ' CG1' ' A' ' 17' ' ' VAL . 70.3 p 57.38 14.51 2.22 Favored 'General case' 0 CA--C 1.508 -0.664 0 CA-C-N 114.57 -0.815 . . . . 0.0 112.408 179.051 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -97.51 -31.35 12.38 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.375 -178.897 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 13.8 tppt? -70.96 -47.36 59.36 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 121.399 0.618 . . . . 0.0 111.477 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 1.092 ' H ' HD12 ' A' ' 25' ' ' LEU . 1.8 mp . . . . . 0 CA--C 1.489 -1.402 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.232 -179.086 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.2 p . . . . . 0 CA--C 1.521 -0.173 0 CA-C-O 120.575 0.226 . . . . 0.0 111.606 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 45.5 m-20 -87.28 -36.74 17.73 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -73.6 -46.03 49.6 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.456 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.92 -44.46 97.8 Favored Glycine 0 C--N 1.311 -0.854 0 C-N-CA 119.399 -1.382 . . . . 0.0 109.856 -179.105 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.68 -40.17 76.52 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.718 -0.241 . . . . 0.0 111.432 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.9 t -63.1 -42.35 99.56 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.565 -0.454 . . . . 0.0 110.528 -178.404 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.2 -39.41 81.14 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.042 178.712 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.601 ' HA ' ' HZ2' ' A' ' 40' ' ' LYS . 7.7 ttpt -59.51 -45.56 91.39 Favored 'General case' 0 N--CA 1.435 -1.175 0 C-N-CA 119.252 -0.979 . . . . 0.0 109.043 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.79 -37.11 88.3 Favored Glycine 0 CA--C 1.529 0.946 0 C-N-CA 120.05 -1.071 . . . . 0.0 110.461 178.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -71.6 -51.82 21.32 Favored 'General case' 0 CA--C 1.511 -0.528 0 CA-C-O 120.574 0.226 . . . . 0.0 111.537 -179.478 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.601 ' HZ2' ' HA ' ' A' ' 37' ' ' LYS . 8.9 pttm -62.78 -37.71 87.77 Favored 'General case' 0 C--N 1.318 -0.792 0 C-N-CA 120.207 -0.597 . . . . 0.0 110.144 -179.455 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -61.64 -36.15 79.95 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.25 -178.845 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.319 -0.727 0 C-N-CA 120.686 -0.405 . . . . 0.0 109.921 179.496 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.9 mm . . . . . 0 N--CA 1.447 -0.583 0 CA-C-O 121.585 0.707 . . . . 0.0 111.35 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.516 ' CE2' HD11 ' A' ' 11' ' ' ILE . 10.8 t-105 -62.6 -38.59 90.76 Favored 'General case' 0 N--CA 1.44 -0.944 0 CA-C-N 115.421 -0.808 . . . . 0.0 109.008 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 25.7 mm-40 -64.94 -39.25 93.22 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.716 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 29.3 mt -61.39 -38.1 85.8 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.434 178.662 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.618 ' O ' HG23 ' A' ' 14' ' ' VAL . 5.6 mt -62.09 -43.3 99.13 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.066 -176.809 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.516 HD11 ' CE2' ' A' ' 7' ' ' TRP . 5.9 mt -66.3 -45.33 89.99 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 C-N-CA 119.928 -0.709 . . . . 0.0 109.588 177.903 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.1 mp -65.8 -47.39 85.92 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.806 -179.268 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.813 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.75 -37.36 87.34 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.543 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.618 HG23 ' O ' ' A' ' 10' ' ' LEU . 45.8 t -67.38 -44.28 87.18 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.052 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.709 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 97.0 mt -65.61 -43.13 94.08 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.761 0 CA-C-O 121.33 0.586 . . . . 0.0 110.685 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.496 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -63.99 -38.17 81.72 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.589 -178.082 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.813 HG23 ' O ' ' A' ' 13' ' ' ALA . 83.2 t -65.61 -42.83 93.73 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.93 0 C-N-CA 118.449 -1.3 . . . . 0.0 111.474 -178.156 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.595 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 19.2 mt -62.49 -45.72 91.73 Favored 'General case' 0 C--N 1.319 -0.76 0 C-N-CA 119.66 -0.816 . . . . 0.0 112.075 -178.469 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.886 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.92 -38.24 79.41 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -179.315 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.886 ' N ' HD12 ' A' ' 19' ' ' LEU . 2.0 m-85 -67.79 -36.87 81.21 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 108.804 -0.814 . . . . 0.0 108.804 -178.215 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 101.65 7.41 48.27 Favored Glycine 0 CA--C 1.501 -0.837 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 178.374 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.765 ' HA ' HD13 ' A' ' 25' ' ' LEU . 18.0 p 56.41 19.74 4.26 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.77 -0.715 . . . . 0.0 112.135 178.588 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 17.0 mtmt -92.09 -25.13 18.9 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.63 -0.428 . . . . 0.0 111.006 -179.081 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -85.12 -59.85 2.21 Favored 'General case' 0 C--O 1.213 -0.856 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.828 -179.514 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 1.068 ' H ' HD12 ' A' ' 25' ' ' LEU . 2.6 mp . . . . . 0 CA--C 1.492 -1.272 0 CA-C-O 122.503 1.145 . . . . 0.0 110.221 -179.308 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.0 p . . . . . 0 C--O 1.232 0.171 0 CA-C-O 120.692 0.282 . . . . 0.0 111.628 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -76.4 -42.48 44.16 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 179.361 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -66.89 -44.18 81.51 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.587 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.13 -44.31 97.39 Favored Glycine 0 N--CA 1.44 -1.063 0 C-N-CA 119.51 -1.328 . . . . 0.0 109.884 -179.097 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -72.1 -39.92 68.58 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.671 -0.265 . . . . 0.0 111.289 178.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 67.0 m -63.31 -40.7 98.06 Favored 'General case' 0 CA--C 1.515 -0.392 0 C-N-CA 120.528 -0.469 . . . . 0.0 110.551 -178.485 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.48 -39.15 78.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.007 179.048 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.407 ' O ' ' CB ' ' A' ' 41' ' ' LYS . 20.8 tttt -59.49 -44.98 92.93 Favored 'General case' 0 N--CA 1.432 -1.344 0 C-N-CA 119.358 -0.937 . . . . 0.0 108.598 -178.416 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.04 -36.48 93.08 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 178.62 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 87.1 t80 -71.35 -54.31 11.2 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 111.66 0.244 . . . . 0.0 111.66 -179.172 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.411 ' CG ' ' N ' ' A' ' 41' ' ' LYS . 18.9 ptmt -64.8 -39.83 94.23 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.974 179.889 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.411 ' N ' ' CG ' ' A' ' 40' ' ' LYS . 88.6 tttt -62.87 -36.84 84.63 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.729 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.325 -0.478 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.421 179.743 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.54 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.5 mp . . . . . 0 N--CA 1.441 -0.877 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.493 ' O ' HD12 ' A' ' 11' ' ' ILE . 29.0 m95 -62.69 -46.88 86.09 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 120.086 -0.645 . . . . 0.0 110.027 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLN . . . . . 0.522 ' OE1' ' N ' ' A' ' 8' ' ' GLN . 0.7 OUTLIER -64.22 -39.04 93.15 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 -179.385 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.688 ' C ' HD12 ' A' ' 9' ' ' LEU . 0.2 OUTLIER -70.37 -37.92 74.66 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.319 178.654 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.559 ' O ' HG23 ' A' ' 14' ' ' VAL . 19.2 mt -62.82 -46.55 87.41 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.899 -177.467 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.493 HD12 ' O ' ' A' ' 7' ' ' TRP . 6.2 mt -65.84 -44.31 92.87 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.247 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 56.2 mt -63.44 -44.35 98.83 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.157 -178.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.778 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.15 -37.13 86.34 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.454 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.559 HG23 ' O ' ' A' ' 10' ' ' LEU . 73.5 t -67.53 -44.31 86.62 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 C-N-CA 119.795 -0.762 . . . . 0.0 110.489 179.58 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.427 HG12 ' O ' ' A' ' 11' ' ' ILE . 4.5 mm -65.99 -43.43 92.66 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.698 0 CA-C-O 121.129 0.49 . . . . 0.0 111.133 -179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.566 HG22 ' CD2' ' A' ' 20' ' ' PHE . 0.3 OUTLIER -63.96 -38.39 82.27 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.072 0 CA-C-N 115.362 -0.835 . . . . 0.0 109.371 -178.984 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.778 HG23 ' O ' ' A' ' 13' ' ' ALA . 79.0 t -65.4 -42.81 94.4 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.024 0 C-N-CA 118.478 -1.289 . . . . 0.0 111.64 -177.938 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.494 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 29.4 mt -62.42 -45.2 94.17 Favored 'General case' 0 C--N 1.317 -0.821 0 C-N-CA 118.984 -1.086 . . . . 0.0 111.721 -179.159 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.85 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -67.48 -38.46 84.42 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.818 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.85 ' N ' HD12 ' A' ' 19' ' ' LEU . 1.4 m-85 -67.73 -31.25 71.04 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -178.819 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 89.62 8.77 67.35 Favored Glycine 0 CA--C 1.505 -0.541 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.732 HG22 HG13 ' A' ' 17' ' ' VAL . 14.8 p 56.65 15.6 2.22 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 114.48 -0.86 . . . . 0.0 112.279 178.139 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 13.4 ptpt -82.66 -44.38 15.79 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.296 0.569 . . . . 0.0 109.68 178.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 2.0 mmmm -67.95 -43.97 77.84 Favored 'General case' 0 C--O 1.21 -1.012 0 CA-C-N 115.218 -0.901 . . . . 0.0 112.069 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.666 ' N ' HD12 ' A' ' 25' ' ' LEU . 6.7 mp . . . . . 0 CA--C 1.49 -1.331 0 CA-C-O 121.876 0.846 . . . . 0.0 110.568 -178.889 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 41.8 t . . . . . 0 N--CA 1.453 -0.306 0 CA-C-O 120.884 0.373 . . . . 0.0 111.442 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -76.28 -44.79 35.54 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.371 0.605 . . . . 0.0 109.485 179.651 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 10.6 mp -67.48 -43.87 79.94 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 114.795 -1.093 . . . . 0.0 111.816 -179.458 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.33 -43.77 98.61 Favored Glycine 0 C--N 1.308 -0.985 0 C-N-CA 119.247 -1.454 . . . . 0.0 109.789 -179.682 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.27 -40.32 71.03 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.461 -0.369 . . . . 0.0 111.25 179.407 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 40.1 t -63.49 -41.98 98.56 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.223 0.535 . . . . 0.0 111.125 -178.71 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.53 -40.12 79.3 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.665 -179.727 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.2 pttt -60.07 -42.84 95.41 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -179.745 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.03 -36.59 92.18 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 178.578 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -71.65 -51.89 20.75 Favored 'General case' 0 CA--C 1.516 -0.365 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.18 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 42.7 mmtm -64.0 -38.97 93.01 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.37 178.783 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -61.63 -36.83 81.89 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.092 -0.643 . . . . 0.0 110.14 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.326 -0.438 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.794 -179.686 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 1.6 mp . . . . . 0 CA--C 1.538 0.483 0 CA-C-O 120.768 0.318 . . . . 0.0 110.548 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 58.6 m95 -62.56 -49.02 76.95 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 -179.456 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 11.7 mp0 -64.53 -38.94 92.74 Favored 'General case' 0 C--N 1.312 -1.045 0 C-N-CA 120.186 -0.606 . . . . 0.0 109.577 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.504 ' N ' ' CD2' ' A' ' 9' ' ' LEU . 3.3 mm? -63.82 -39.25 93.8 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.953 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.569 ' O ' HG23 ' A' ' 14' ' ' VAL . 9.5 mt -63.4 -52.4 61.78 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.894 -178.415 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.469 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.5 mp -64.86 -44.58 96.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 178.495 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 71.9 mt -63.56 -45.73 96.9 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.101 0 C-N-CA 120.107 -0.637 . . . . 0.0 111.177 -179.6 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.799 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.73 -37.37 87.38 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.968 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.582 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 51.6 t -67.54 -43.84 86.89 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 C-N-CA 119.823 -0.751 . . . . 0.0 110.872 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.3 mt -65.4 -42.79 94.34 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.658 0 CA-C-O 121.1 0.476 . . . . 0.0 110.225 -179.009 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.476 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -64.5 -38.43 82.59 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.345 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.917 -178.459 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.804 ' CG1' HG22 ' A' ' 22' ' ' THR . 75.1 t -63.88 -43.07 97.7 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.367 0 C-N-CA 118.544 -1.262 . . . . 0.0 111.002 -177.775 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.582 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 14.4 mt -60.8 -47.08 87.98 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 120.078 -0.649 . . . . 0.0 112.473 -178.789 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.857 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.95 -37.96 79.17 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -179.515 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.857 ' N ' HD12 ' A' ' 19' ' ' LEU . 0.8 OUTLIER -67.45 -35.99 80.28 Favored 'General case' 0 CA--C 1.519 -0.217 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -177.946 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.598 ' C ' ' H ' ' A' ' 23' ' ' LYS . . . 102.69 10.8 36.94 Favored Glycine 0 CA--C 1.501 -0.837 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 178.298 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.804 HG22 ' CG1' ' A' ' 17' ' ' VAL . 44.8 p 56.52 -1.94 0.04 OUTLIER 'General case' 0 CA--C 1.497 -1.081 0 CA-C-O 121.073 0.463 . . . . 0.0 112.138 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.598 ' H ' ' C ' ' A' ' 21' ' ' GLY . 12.6 tmtt? -84.41 -36.22 22.55 Favored 'General case' 0 N--CA 1.434 -1.252 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.006 -179.117 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.4 tppt? -63.75 -48.57 76.47 Favored 'General case' 0 N--CA 1.436 -1.126 0 CA-C-O 121.089 0.471 . . . . 0.0 110.37 179.889 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 1.063 ' H ' HD12 ' A' ' 25' ' ' LEU . 2.1 mp . . . . . 0 CA--C 1.486 -1.493 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.044 -178.345 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 14.0 t . . . . . 0 CA--C 1.518 -0.284 0 N-CA-C 111.769 0.285 . . . . 0.0 111.769 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -84.42 -37.08 21.89 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -72.3 -44.34 62.88 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.173 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.97 -43.8 98.69 Favored Glycine 0 C--N 1.31 -0.899 0 C-N-CA 119.527 -1.32 . . . . 0.0 110.018 -179.366 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.5 -39.93 73.86 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.891 -0.324 . . . . 0.0 111.205 179.533 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 44.8 t -64.3 -41.93 96.62 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.542 -0.463 . . . . 0.0 111.288 -178.763 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.422 HG23 ' HZ2' ' A' ' 40' ' ' LYS . 1.2 mp -68.73 -38.92 79.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.205 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 3.3 pttp -59.49 -40.86 88.38 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 -178.746 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.07 -36.63 90.89 Favored Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 178.88 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -71.63 -49.71 37.46 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 121.04 0.448 . . . . 0.0 109.962 -179.472 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.422 ' HZ2' HG23 ' A' ' 36' ' ' ILE . 53.4 mttp -63.12 -38.57 91.71 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.471 178.528 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 12.5 ttmm -61.33 -36.99 81.69 Favored 'General case' 0 C--N 1.319 -0.748 0 C-N-CA 119.935 -0.706 . . . . 0.0 110.187 -179.613 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.324 -0.52 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.274 179.851 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.2 mm . . . . . 0 N--CA 1.444 -0.76 0 CA-C-O 121.546 0.689 . . . . 0.0 110.636 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.621 ' CE2' HD11 ' A' ' 11' ' ' ILE . 11.7 t-105 -62.82 -38.07 89.28 Favored 'General case' 0 N--CA 1.438 -1.059 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.725 178.82 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 28.6 mm-40 -64.84 -40.29 94.93 Favored 'General case' 0 CA--C 1.509 -0.61 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 178.656 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 72.0 mt -61.4 -37.64 84.17 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.006 178.212 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.719 ' O ' HG23 ' A' ' 14' ' ' VAL . 5.4 mt -62.12 -42.88 99.67 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.2 -176.44 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.621 HD11 ' CE2' ' A' ' 7' ' ' TRP . 6.4 mt -67.89 -45.67 83.57 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 C-N-CA 120.25 -0.58 . . . . 0.0 110.011 177.48 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.1 mp -65.49 -44.7 94.09 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.997 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.814 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.46 -36.69 85.0 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.605 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 10' ' ' LEU . 48.8 t -66.75 -45.73 87.3 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.039 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.305 -179.167 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 16.2 pt -65.97 -42.49 91.9 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-N 118.023 0.374 . . . . 0.0 110.929 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.492 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -63.47 -38.37 82.04 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.134 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.601 -178.96 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.814 HG23 ' O ' ' A' ' 13' ' ' ALA . 90.7 t -65.69 -44.34 93.42 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.803 0 C-N-CA 118.382 -1.327 . . . . 0.0 111.713 -178.648 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.595 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 23.5 mt -61.62 -46.46 89.7 Favored 'General case' 0 C--N 1.322 -0.623 0 C-N-CA 119.907 -0.717 . . . . 0.0 111.909 -179.037 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.869 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.7 pp -68.09 -38.41 82.32 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 -179.607 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.869 ' N ' HD12 ' A' ' 19' ' ' LEU . 2.0 m-85 -67.64 -37.7 82.8 Favored 'General case' 0 CA--C 1.517 -0.324 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -177.77 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.408 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 102.81 6.07 46.82 Favored Glycine 0 CA--C 1.499 -0.953 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 178.544 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.751 ' HA ' HD13 ' A' ' 25' ' ' LEU . 18.5 p 57.88 19.2 5.56 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 114.964 -0.618 . . . . 0.0 112.281 178.279 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -93.16 -19.93 20.98 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.535 -179.355 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -89.81 -60.39 1.95 Allowed 'General case' 0 C--O 1.211 -0.958 0 CA-C-O 121.178 0.513 . . . . 0.0 110.706 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 1.047 ' H ' HD12 ' A' ' 25' ' ' LEU . 2.6 mp . . . . . 0 CA--C 1.491 -1.304 0 CA-C-O 122.495 1.141 . . . . 0.0 110.149 -179.532 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.0 p . . . . . 0 CA--C 1.521 -0.151 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -78.61 -40.97 32.93 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 179.689 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.3 mp -68.65 -45.92 70.52 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.551 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.51 -44.0 97.29 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.76 -40.23 76.24 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.366 -0.417 . . . . 0.0 111.364 179.196 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 43.3 m -63.63 -40.79 97.77 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.531 -0.467 . . . . 0.0 111.216 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.67 -40.93 79.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.073 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 16.2 pttt -60.24 -43.48 96.05 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.66 -36.91 92.0 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.614 -0.994 . . . . 0.0 110.614 178.761 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -71.67 -50.69 28.19 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-O 120.946 0.403 . . . . 0.0 110.516 -179.604 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 66.4 mmtt -63.97 -38.99 93.09 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 120.252 -0.579 . . . . 0.0 110.325 179.181 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt -61.97 -37.16 83.71 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.239 -179.663 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.32 -0.695 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.523 -179.337 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.1 mm . . . . . 0 N--CA 1.454 -0.232 0 CA-C-O 120.971 0.415 . . . . 0.0 111.872 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.725 ' CE2' HD11 ' A' ' 11' ' ' ILE . 9.5 t-105 -62.67 -36.61 83.44 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.617 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 21.3 mm-40 -64.47 -38.88 92.57 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 86.6 mt -63.03 -37.66 88.07 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.747 178.374 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.612 ' O ' HG23 ' A' ' 14' ' ' VAL . 5.2 mt -62.58 -42.89 99.84 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.13 -177.055 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.725 HD11 ' CE2' ' A' ' 7' ' ' TRP . 7.8 mt -66.95 -45.54 87.02 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.95 0 C-N-CA 119.698 -0.801 . . . . 0.0 109.51 177.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 67.1 mt -65.66 -47.56 85.71 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.806 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.327 -179.719 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.837 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.55 -37.34 87.21 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.4 -179.764 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.612 HG23 ' O ' ' A' ' 10' ' ' LEU . 40.6 t -67.67 -44.25 86.17 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 C-N-CA 119.748 -0.781 . . . . 0.0 110.973 179.721 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 91.8 mt -65.27 -42.28 93.54 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.834 0 CA-C-O 120.993 0.425 . . . . 0.0 110.395 -179.087 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.502 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -64.25 -38.4 82.41 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.113 0 CA-C-N 115.322 -0.854 . . . . 0.0 110.11 -178.836 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.837 HG23 ' O ' ' A' ' 13' ' ' ALA . 87.1 t -64.56 -42.6 95.64 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.257 0 C-N-CA 118.389 -1.325 . . . . 0.0 111.131 -177.351 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.565 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 20.8 mt -62.08 -47.18 85.83 Favored 'General case' 0 C--N 1.316 -0.887 0 C-N-CA 119.819 -0.752 . . . . 0.0 112.566 -178.573 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.849 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.01 -38.41 82.56 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.897 -179.579 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.849 ' N ' HD12 ' A' ' 19' ' ' LEU . 0.7 OUTLIER -68.07 -32.14 72.27 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -178.3 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 93.9 5.79 62.44 Favored Glycine 0 CA--C 1.504 -0.61 0 C-N-CA 120.209 -0.996 . . . . 0.0 111.044 178.523 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.776 HG22 ' CG1' ' A' ' 17' ' ' VAL . 14.4 p 58.39 26.93 14.71 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.161 -0.519 . . . . 0.0 112.202 178.558 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 50.2 pttt -96.97 -33.09 11.7 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.878 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 16.6 mmmt -77.45 -52.78 8.53 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.72 -0.392 . . . . 0.0 111.498 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 1.071 ' H ' HD12 ' A' ' 25' ' ' LEU . 1.9 mp . . . . . 0 CA--C 1.489 -1.374 0 CA-C-O 122.336 1.065 . . . . 0.0 110.476 -179.32 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.1 p . . . . . 0 N--CA 1.451 -0.408 0 CA-C-O 120.816 0.341 . . . . 0.0 111.219 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 66.7 t0 -76.63 -41.04 47.38 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.289 0.566 . . . . 0.0 109.846 179.728 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.5 mp -68.68 -45.82 70.68 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.024 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.56 -43.82 98.45 Favored Glycine 0 C--N 1.308 -1.018 0 C-N-CA 119.463 -1.351 . . . . 0.0 110.031 -179.55 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.07 -40.25 75.14 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.82 0.343 . . . . 0.0 111.148 179.646 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.6 t -63.94 -42.01 97.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.132 0.491 . . . . 0.0 111.248 -178.742 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.48 -39.42 78.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.615 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 17.9 pttt -59.32 -40.35 86.0 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 -178.108 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -69.81 -37.09 75.37 Favored Glycine 0 N--CA 1.442 -0.903 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -71.61 -49.16 42.8 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-O 121.114 0.483 . . . . 0.0 109.762 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 47.5 mtpt -63.01 -38.6 91.83 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.558 178.566 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 14.2 tmtt? -61.75 -36.68 81.71 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 119.773 -0.771 . . . . 0.0 109.853 -178.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.325 -0.488 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.052 179.713 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.609 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.6 mp . . . . . 0 N--CA 1.452 -0.364 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 91.8 m95 -62.27 -41.01 98.1 Favored 'General case' 0 CA--C 1.507 -0.685 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.748 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLN . . . . . 0.424 ' O ' HD13 ' A' ' 12' ' ' ILE . 5.6 pt20 -64.28 -39.48 94.01 Favored 'General case' 0 C--O 1.215 -0.725 0 C-N-CA 118.572 -1.251 . . . . 0.0 108.152 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.425 ' O ' ' CB ' ' A' ' 13' ' ' ALA . 76.6 mt -68.59 -38.49 80.71 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.166 179.376 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.648 ' O ' HG23 ' A' ' 14' ' ' VAL . 18.7 mt -63.28 -49.27 74.72 Favored 'General case' 0 C--N 1.314 -0.935 0 C-N-CA 120.076 -0.65 . . . . 0.0 111.371 -176.022 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.462 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.7 mp -67.19 -44.33 87.81 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 178.914 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.424 HD13 ' O ' ' A' ' 8' ' ' GLN . 1.0 OUTLIER -65.07 -44.56 95.74 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.878 -179.387 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.846 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.77 -36.53 84.6 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.825 -179.762 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.648 HG23 ' O ' ' A' ' 10' ' ' LEU . 54.8 t -67.03 -45.03 87.87 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.826 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.442 -178.817 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 15.9 pt -66.23 -42.56 91.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 CA-C-O 121.05 0.452 . . . . 0.0 110.827 179.645 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.502 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -63.54 -38.12 81.38 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.905 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 -179.324 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.846 HG23 ' O ' ' A' ' 13' ' ' ALA . 94.4 t -65.52 -43.72 94.25 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 C-N-CA 118.557 -1.257 . . . . 0.0 111.654 -178.303 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.518 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 21.3 mt -61.82 -47.09 86.66 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 119.566 -0.854 . . . . 0.0 111.57 -178.853 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.851 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -67.06 -38.21 85.41 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -179.221 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.851 ' N ' HD12 ' A' ' 19' ' ' LEU . 1.2 m-85 -67.55 -35.83 79.81 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 -177.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.425 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 98.79 8.04 54.76 Favored Glycine 0 CA--C 1.501 -0.821 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 178.964 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.736 HG22 ' CG1' ' A' ' 17' ' ' VAL . 19.0 p 57.7 27.1 13.85 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 114.309 -0.945 . . . . 0.0 112.52 178.239 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 55.3 mtpt -100.0 -19.82 16.38 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.686 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 14.5 mmmt -88.66 -56.91 3.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.125 0.488 . . . . 0.0 110.622 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 1.064 ' H ' HD12 ' A' ' 25' ' ' LEU . 2.3 mp . . . . . 0 CA--C 1.495 -1.173 0 CA-C-O 122.473 1.13 . . . . 0.0 110.291 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.3 t . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.628 0.251 . . . . 0.0 111.652 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 53.3 m-20 -74.15 -43.65 56.6 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.53 0.681 . . . . 0.0 109.208 179.475 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.6 mp -65.82 -44.28 86.08 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.789 -1.096 . . . . 0.0 111.553 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.52 -45.18 96.39 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 119.411 -1.376 . . . . 0.0 109.823 -179.204 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.6 -39.81 73.6 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.651 -0.274 . . . . 0.0 111.309 179.164 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 39.4 t -63.19 -41.69 99.23 Favored 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 120.528 -0.469 . . . . 0.0 110.406 -178.247 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.02 -39.27 79.47 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.715 179.027 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 24.3 tttt -59.87 -43.72 94.57 Favored 'General case' 0 C--N 1.309 -1.17 0 C-N-CA 119.287 -0.965 . . . . 0.0 108.463 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.97 -36.6 91.23 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 178.18 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -71.59 -50.77 27.81 Favored 'General case' 0 CA--C 1.52 -0.182 0 CA-C-O 120.805 0.336 . . . . 0.0 110.291 -179.621 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 53.2 mtpt -63.43 -38.52 91.46 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.37 178.646 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -61.74 -39.11 90.41 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.138 -0.625 . . . . 0.0 110.102 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.324 -0.534 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.551 -179.948 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.521 ' CG2' ' N ' ' A' ' 7' ' ' TRP . 1.5 tp . . . . . 0 N--CA 1.444 -0.755 0 CA-C-O 121.368 0.604 . . . . 0.0 111.012 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.528 ' CD1' ' C ' ' A' ' 7' ' ' TRP . 2.0 t-105 -62.15 -38.42 88.93 Favored 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -179.262 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 13.7 mm-40 -64.31 -38.75 92.16 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 179.639 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.826 ' O ' HD12 ' A' ' 9' ' ' LEU . 0.2 OUTLIER -70.33 -38.03 74.82 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.423 178.933 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.558 ' O ' HG23 ' A' ' 14' ' ' VAL . 1.2 tt -62.71 -47.03 85.4 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.971 -175.607 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.45 HD11 ' CE2' ' A' ' 7' ' ' TRP . 2.0 mp -65.01 -43.94 96.04 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 177.51 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 72.9 mt -63.37 -44.51 99.03 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.065 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.547 -178.671 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.873 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.23 -37.25 86.82 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.923 -179.241 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.558 HG23 ' O ' ' A' ' 10' ' ' LEU . 78.6 t -67.02 -44.05 88.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 C-N-CA 120.545 -0.462 . . . . 0.0 111.139 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.453 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 58.7 mt -66.62 -43.19 90.57 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.285 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 178.837 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.471 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.5 t -64.01 -42.27 95.16 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.681 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.881 -179.046 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.873 HG23 ' O ' ' A' ' 13' ' ' ALA . 60.1 t -65.93 -44.92 92.29 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.118 0 C-N-CA 118.281 -1.368 . . . . 0.0 112.774 -177.376 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.518 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.4 pp -72.65 -42.87 63.89 Favored 'General case' 0 C--N 1.293 -1.857 0 C-N-CA 120.054 -0.659 . . . . 0.0 109.842 178.761 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.733 HD13 ' C ' ' A' ' 19' ' ' LEU . 2.6 tm? -64.37 -41.29 96.79 Favored 'General case' 0 N--CA 1.443 -0.806 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.617 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.471 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 5.6 m-85 -69.0 -39.47 79.31 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 118.741 -1.183 . . . . 0.0 108.749 179.17 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.478 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 105.15 11.9 28.63 Favored Glycine 0 N--CA 1.467 0.75 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 179.025 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.73 HG22 ' CG1' ' A' ' 17' ' ' VAL . 50.4 p 57.31 44.42 21.89 Favored 'General case' 0 CA--C 1.499 -0.983 0 CA-C-N 115.371 -0.414 . . . . 0.0 112.062 178.304 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -127.19 -18.38 4.56 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.593 -0.73 . . . . 0.0 111.551 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 9.6 tppt? -86.44 -48.38 8.47 Favored 'General case' 0 N--CA 1.447 -0.625 0 CA-C-O 121.008 0.432 . . . . 0.0 110.08 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.711 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.1 OUTLIER . . . . . 0 CA--C 1.505 -0.768 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.682 -178.839 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.9 t . . . . . 0 CA--C 1.519 -0.222 0 CA-C-O 120.68 0.276 . . . . 0.0 111.548 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 94.3 m-20 -76.32 -41.18 49.32 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.338 0.59 . . . . 0.0 109.614 179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -68.33 -44.43 75.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.556 179.75 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.0 -44.08 97.92 Favored Glycine 0 N--CA 1.443 -0.853 0 C-N-CA 119.363 -1.399 . . . . 0.0 109.99 -179.001 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.73 -39.87 73.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.719 0.295 . . . . 0.0 111.413 179.27 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.0 t -63.22 -41.9 99.19 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.69 -178.439 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.78 -39.17 79.78 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.009 178.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 23.9 tttt -59.69 -44.65 93.57 Favored 'General case' 0 N--CA 1.435 -1.223 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 -178.923 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.39 -36.61 92.88 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 178.06 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 38.3 t80 -71.8 -51.78 20.85 Favored 'General case' 0 CA--C 1.512 -0.495 0 CA-C-O 120.991 0.424 . . . . 0.0 110.406 -179.373 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 48.8 mtpt -62.62 -39.1 92.75 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.717 179.454 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 42.8 mtmt -61.58 -39.1 89.97 Favored 'General case' 0 C--N 1.319 -0.75 0 C-N-CA 119.043 -1.063 . . . . 0.0 109.911 -179.73 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.319 -0.759 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.322 -179.93 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.524 ' HA ' HD23 ' A' ' 9' ' ' LEU . 16.9 mm . . . . . 0 N--CA 1.44 -0.957 0 CA-C-O 121.995 0.903 . . . . 0.0 110.88 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.588 ' CE2' HD11 ' A' ' 11' ' ' ILE . 22.4 t-105 -65.42 -39.39 92.07 Favored 'General case' 0 N--CA 1.432 -1.345 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.248 -179.519 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 22.0 mm-40 -65.84 -41.45 91.74 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.061 0.458 . . . . 0.0 110.8 179.58 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.683 HD12 ' C ' ' A' ' 9' ' ' LEU . 0.4 OUTLIER -63.41 -36.74 84.72 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.724 179.453 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.628 ' O ' HG23 ' A' ' 14' ' ' VAL . 6.3 mt -62.03 -42.39 99.11 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.013 -177.13 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.588 HD11 ' CE2' ' A' ' 7' ' ' TRP . 7.8 mt -65.2 -44.18 95.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 177.538 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 69.7 mt -63.96 -44.37 97.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.313 -179.019 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.868 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -65.12 -37.53 87.76 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.133 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.628 HG23 ' O ' ' A' ' 10' ' ' LEU . 64.8 t -67.1 -44.54 87.98 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.372 0 C-N-CA 120.829 -0.348 . . . . 0.0 111.35 -178.732 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 16.1 pt -67.12 -42.86 88.77 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.11 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 178.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.473 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.7 t -63.71 -41.63 93.24 Favored 'Isoleucine or valine' 0 CA--C 1.476 -1.882 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.981 -179.213 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.868 HG23 ' O ' ' A' ' 13' ' ' ALA . 61.5 t -66.49 -50.11 69.67 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.984 0 C-N-CA 117.149 -1.821 . . . . 0.0 113.11 -177.19 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.497 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.0 OUTLIER -66.34 -44.52 83.08 Favored 'General case' 0 C--N 1.302 -1.492 0 C-N-CA 119.209 -0.996 . . . . 0.0 112.01 179.722 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.651 ' C ' HD12 ' A' ' 19' ' ' LEU . 0.4 OUTLIER -65.59 -38.24 88.93 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.442 179.962 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.473 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 3.0 m-85 -68.01 -43.91 77.75 Favored 'General case' 0 CA--C 1.515 -0.381 0 C-N-CA 119.221 -0.992 . . . . 0.0 108.501 -179.487 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.504 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 111.71 11.12 17.68 Favored Glycine 0 C--N 1.316 -0.559 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 178.715 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.739 HG22 ' CG1' ' A' ' 17' ' ' VAL . 59.5 p 56.42 35.09 25.36 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 114.863 -0.668 . . . . 0.0 112.784 178.18 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 56.3 mtpt -116.26 -20.32 9.83 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.811 -0.632 . . . . 0.0 111.792 -179.576 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 tppt? -83.47 -52.08 6.81 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-O 121.175 0.512 . . . . 0.0 110.466 -179.741 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.748 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.2 OUTLIER . . . . . 0 CA--C 1.501 -0.933 0 CA-C-O 121.907 0.86 . . . . 0.0 111.285 -178.882 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 38.8 t . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.745 0.307 . . . . 0.0 111.237 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -69.94 -44.01 70.42 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.519 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.406 ' N ' HD12 ' A' ' 32' ' ' LEU . 8.1 mp -65.12 -44.4 88.85 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.149 -0.932 . . . . 0.0 111.413 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.31 -44.39 97.01 Favored Glycine 0 N--CA 1.438 -1.214 0 C-N-CA 119.292 -1.432 . . . . 0.0 109.986 -179.077 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.21 -40.06 71.36 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.529 -0.336 . . . . 0.0 111.414 179.076 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.8 t -63.65 -41.29 98.25 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.666 -0.413 . . . . 0.0 111.141 -178.389 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.12 -40.34 80.5 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.798 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.5 pttt -60.28 -43.19 96.44 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 -179.679 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.97 -36.68 92.37 Favored Glycine 0 CA--C 1.519 0.342 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -71.51 -52.23 19.42 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 66.0 mmtt -62.91 -38.15 89.81 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.154 178.73 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -60.94 -35.64 77.26 Favored 'General case' 0 C--N 1.312 -1.029 0 C-N-CA 119.631 -0.827 . . . . 0.0 109.909 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.323 -0.565 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.141 -179.311 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 3.5 mm . . . . . 0 CA--C 1.535 0.402 0 CA-C-O 120.644 0.259 . . . . 0.0 110.763 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 38.5 m95 -62.0 -45.33 94.06 Favored 'General case' 0 C--O 1.22 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -178.593 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLN . . . . . 0.584 ' OE1' ' N ' ' A' ' 8' ' ' GLN . 3.2 pm0 -63.8 -38.96 93.03 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 119.737 -0.785 . . . . 0.0 109.485 178.72 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.421 ' O ' ' CB ' ' A' ' 13' ' ' ALA . 78.8 mt -64.45 -38.21 90.24 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.264 179.727 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.642 ' O ' HG23 ' A' ' 14' ' ' VAL . 20.7 mt -63.3 -48.27 78.78 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.805 -176.596 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.501 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.8 mp -67.92 -44.58 85.03 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 C-N-CA 119.662 -0.815 . . . . 0.0 109.142 178.212 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -65.08 -47.59 87.22 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 C-N-CA 120.055 -0.658 . . . . 0.0 110.566 -179.432 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.857 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -65.85 -38.07 87.88 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 -179.545 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.642 HG23 ' O ' ' A' ' 10' ' ' LEU . 62.8 t -67.78 -44.29 85.73 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.625 0 C-N-CA 120.173 -0.611 . . . . 0.0 111.171 -178.824 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.47 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 0.9 OUTLIER -66.28 -44.05 91.35 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.385 0 O-C-N 123.353 0.408 . . . . 0.0 110.053 179.485 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.414 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.3 t -64.02 -41.99 94.24 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.721 0 CA-C-N 115.107 -0.951 . . . . 0.0 109.964 -178.578 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.857 HG23 ' O ' ' A' ' 13' ' ' ALA . 59.6 t -66.14 -45.22 90.89 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.909 0 C-N-CA 118.03 -1.468 . . . . 0.0 112.672 -177.043 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.431 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.1 pp -71.23 -42.85 68.36 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.157 177.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.677 HD13 ' C ' ' A' ' 19' ' ' LEU . 2.5 tm? -64.67 -41.49 96.04 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.908 -179.171 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.414 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 6.1 m-85 -68.97 -38.62 79.47 Favored 'General case' 0 CA--C 1.513 -0.465 0 C-N-CA 119.014 -1.074 . . . . 0.0 108.623 178.78 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.499 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 104.76 11.28 30.92 Favored Glycine 0 C--N 1.315 -0.614 0 CA-C-N 115.01 -0.995 . . . . 0.0 111.104 178.521 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.725 HG22 ' CG1' ' A' ' 17' ' ' VAL . 51.2 p 58.68 43.24 19.1 Favored 'General case' 0 CA--C 1.505 -0.763 0 CA-C-N 115.25 -0.475 . . . . 0.0 111.917 178.872 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -124.94 -20.19 5.03 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.4 -179.802 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 tppt? -84.99 -49.63 8.16 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-O 121.091 0.472 . . . . 0.0 110.496 179.826 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.767 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.1 OUTLIER . . . . . 0 CA--C 1.505 -0.766 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.044 -178.792 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 10.9 t . . . . . 0 CA--C 1.521 -0.148 0 CA-C-O 120.771 0.32 . . . . 0.0 111.332 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 94.9 m-20 -70.58 -43.63 69.04 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.341 0.591 . . . . 0.0 109.481 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.8 mp -65.47 -44.75 86.17 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.426 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.37 -45.07 95.85 Favored Glycine 0 N--CA 1.439 -1.157 0 C-N-CA 119.444 -1.36 . . . . 0.0 109.94 -179.118 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.39 -39.69 71.03 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.577 -0.312 . . . . 0.0 111.566 179.265 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 48.4 t -63.34 -41.79 98.9 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-O 121.125 0.488 . . . . 0.0 110.324 -178.322 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.19 -39.4 79.23 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.931 179.032 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.7 tttp -60.09 -44.08 95.05 Favored 'General case' 0 C--N 1.309 -1.152 0 C-N-CA 119.343 -0.943 . . . . 0.0 108.614 -179.043 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.68 -36.54 91.44 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 178.389 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.2 t80 -71.65 -51.83 21.1 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-O 120.76 0.314 . . . . 0.0 110.462 -179.564 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 23.7 mtpp -62.7 -38.05 88.9 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.375 179.135 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -61.02 -36.73 80.29 Favored 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 120.098 -0.641 . . . . 0.0 110.226 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.322 -0.605 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.37 -179.591 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.5 mm . . . . . 0 CA--C 1.538 0.491 0 CA-C-O 120.511 0.196 . . . . 0.0 110.915 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 55.2 m95 -62.54 -48.97 77.16 Favored 'General case' 0 C--O 1.221 -0.423 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 -179.588 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLN . . . . . 0.488 ' OE1' ' N ' ' A' ' 8' ' ' GLN . 0.5 OUTLIER -64.13 -38.43 91.05 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.608 179.847 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.507 ' N ' ' CD2' ' A' ' 9' ' ' LEU . 3.2 mm? -62.8 -39.08 93.16 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.874 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.544 ' O ' HG23 ' A' ' 14' ' ' VAL . 8.9 mt -63.76 -51.77 63.39 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.6 -178.335 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.485 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.5 mp -65.62 -44.49 93.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 178.372 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 70.8 mt -63.72 -45.3 97.73 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 C-N-CA 120.479 -0.488 . . . . 0.0 111.337 -179.667 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.865 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.95 -38.79 92.12 Favored 'General case' 0 C--N 1.32 -0.713 0 O-C-N 123.381 0.425 . . . . 0.0 110.975 -179.323 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.544 HG23 ' O ' ' A' ' 10' ' ' LEU . 70.7 t -67.54 -43.15 87.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 C-N-CA 120.566 -0.453 . . . . 0.0 110.562 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.452 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 96.7 mt -66.25 -43.35 91.78 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.322 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.453 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.5 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.4 t -63.72 -42.2 95.18 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.684 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.319 -178.68 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.865 HG23 ' O ' ' A' ' 13' ' ' ALA . 61.4 t -66.02 -45.11 91.62 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.883 0 C-N-CA 118.253 -1.379 . . . . 0.0 112.672 -176.764 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.527 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.3 pp -72.39 -43.16 64.32 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 119.702 -0.799 . . . . 0.0 109.949 178.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.698 HD13 ' C ' ' A' ' 19' ' ' LEU . 2.6 tm? -64.4 -41.44 96.64 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.923 -1.035 . . . . 0.0 110.313 -179.63 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.5 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 5.0 m-85 -69.02 -35.98 77.25 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 118.879 -1.129 . . . . 0.0 108.957 179.019 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.482 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 97.44 11.96 49.76 Favored Glycine 0 N--CA 1.465 0.593 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.703 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.701 HG22 ' CG1' ' A' ' 17' ' ' VAL . 42.8 p 55.72 69.49 0.73 Allowed 'General case' 0 CA--C 1.506 -0.713 0 CA-C-N 114.604 -0.798 . . . . 0.0 112.445 178.364 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 49.6 mtpt -139.87 -25.53 0.81 Allowed 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.873 179.664 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 11.2 mmmt -85.8 -53.03 5.38 Favored 'General case' 0 C--O 1.221 -0.444 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.728 179.676 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.623 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.1 OUTLIER . . . . . 0 CA--C 1.505 -0.784 0 CA-C-O 121.817 0.818 . . . . 0.0 110.642 -178.992 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.3 t . . . . . 0 CA--C 1.521 -0.145 0 CA-C-O 120.689 0.281 . . . . 0.0 111.657 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -76.43 -41.0 49.13 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.347 0.594 . . . . 0.0 109.64 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.678 ' O ' HD13 ' A' ' 36' ' ' ILE . 7.6 mp -68.4 -46.61 69.51 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.062 -0.972 . . . . 0.0 111.575 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.93 -44.0 98.43 Favored Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -179.16 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.12 -40.39 71.45 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.825 179.057 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.4 m -64.0 -40.8 97.18 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.898 -179.342 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.678 HD13 ' O ' ' A' ' 32' ' ' LEU . 1.6 mp -68.19 -41.57 84.12 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.485 -179.433 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.4 ' HG2' ' N ' ' A' ' 38' ' ' GLY . 16.6 pttt -60.08 -43.35 95.56 Favored 'General case' 0 C--N 1.308 -1.203 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 -179.144 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.4 ' N ' ' HG2' ' A' ' 37' ' ' LYS . . . -69.7 -36.78 75.93 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 110.599 -1.001 . . . . 0.0 110.599 178.891 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -71.64 -49.26 41.66 Favored 'General case' 0 CA--C 1.514 -0.432 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.845 -178.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.405 ' N ' ' CD ' ' A' ' 40' ' ' LYS . 9.8 mptt -67.06 -39.07 86.82 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.484 178.86 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -61.65 -36.65 81.41 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 119.72 -0.792 . . . . 0.0 109.865 179.814 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.323 -0.562 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.502 179.758 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 85.9 22.88 47.84 Favored Glycine 0 CA--C 1.524 0.605 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.66 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 140.74 -9.43 2.84 Favored Glycine 0 N--CA 1.462 0.409 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.517 HG23 ' HB2' ' A' ' 8' ' ' GLN . 3.9 mp -101.33 118.7 48.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.085 0.469 . . . . 0.0 110.45 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.492 ' C ' HD12 ' A' ' 6' ' ' ILE . 64.2 m -143.65 -89.97 0.12 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.696 179.378 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.492 HD12 ' C ' ' A' ' 5' ' ' SER . 1.5 mp -110.99 -35.23 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.506 -179.567 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 63.8 m95 -62.65 -49.54 74.73 Favored 'General case' 0 C--O 1.221 -0.432 0 CA-C-O 120.754 0.311 . . . . 0.0 110.576 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.517 ' HB2' HG23 ' A' ' 4' ' ' ILE . 20.9 mp0 -64.17 -38.52 91.34 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.491 ' N ' ' CD2' ' A' ' 9' ' ' LEU . 3.0 mm? -63.64 -39.33 94.07 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.646 179.284 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.571 ' O ' HG23 ' A' ' 14' ' ' VAL . 9.1 mt -63.86 -51.0 66.61 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.872 -178.077 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.445 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.4 mp -66.08 -44.45 91.93 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.396 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 69.3 mt -63.58 -45.01 98.8 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.086 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.285 -179.436 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.852 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -65.01 -37.83 88.94 Favored 'General case' 0 C--N 1.317 -0.844 0 O-C-N 123.435 0.46 . . . . 0.0 111.245 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 10' ' ' LEU . 71.4 t -67.86 -43.98 85.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.794 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.758 HG22 HD23 ' A' ' 19' ' ' LEU . 96.8 mt -66.33 -43.47 91.45 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.104 0 CA-C-O 121.59 0.71 . . . . 0.0 109.322 179.435 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.408 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.8 t -63.53 -42.41 96.08 Favored 'Isoleucine or valine' 0 CA--C 1.479 -1.788 0 CA-C-N 114.794 -1.094 . . . . 0.0 109.788 -178.821 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.852 HG23 ' O ' ' A' ' 13' ' ' ALA . 60.4 t -66.5 -48.89 79.15 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.046 0 C-N-CA 117.609 -1.636 . . . . 0.0 112.787 -177.227 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.498 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.0 OUTLIER -66.99 -44.38 80.55 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 118.863 -1.135 . . . . 0.0 112.042 179.667 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.758 HD23 HG22 ' A' ' 15' ' ' ILE . 0.4 OUTLIER -65.95 -38.47 88.69 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.823 -179.979 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.408 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 4.7 m-85 -67.89 -41.03 83.37 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 -179.562 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.463 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 108.62 14.58 15.45 Favored Glycine 0 C--N 1.312 -0.803 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 178.392 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.709 HG22 ' CG1' ' A' ' 17' ' ' VAL . 68.0 p 52.02 39.51 26.47 Favored 'General case' 0 CA--C 1.495 -1.136 0 CA-C-N 114.747 -0.726 . . . . 0.0 112.473 178.283 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 59.5 tttm -112.43 -41.29 3.9 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.935 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.92 -56.28 9.65 Favored 'General case' 0 CA--C 1.509 -0.63 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.271 -179.492 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.654 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.0 OUTLIER -53.63 -36.8 62.43 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-O 121.901 0.858 . . . . 0.0 109.989 -177.972 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.34 -25.8 69.73 Favored Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.735 -178.784 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 67.2 m -94.21 -38.32 11.11 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 -179.169 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.7 pt -94.83 -36.83 7.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.995 0.426 . . . . 0.0 109.961 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.481 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -61.84 -23.25 63.17 Favored Glycine 0 CA--C 1.518 0.235 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 -179.681 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 38.7 t -64.66 -39.2 93.28 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 120.764 -0.374 . . . . 0.0 111.699 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.9 m-20 -94.24 -35.51 12.43 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 179.309 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.512 HD13 ' O ' ' A' ' 32' ' ' LEU . 0.2 OUTLIER -74.32 -49.35 23.31 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.408 -1.269 . . . . 0.0 111.412 -178.916 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.481 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -61.57 -42.97 99.86 Favored Glycine 0 CA--C 1.518 0.246 0 N-CA-C 109.304 -1.519 . . . . 0.0 109.304 179.594 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.59 -39.28 93.45 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.783 -0.709 . . . . 0.0 110.939 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 75.3 m -62.88 -41.31 99.35 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.137 -0.625 . . . . 0.0 110.709 -178.51 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.3 mp -68.65 -40.01 81.13 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.861 179.048 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.6 ptmt -59.79 -41.81 91.98 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 -178.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.17 -36.47 90.16 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 177.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 23.0 t80 -71.75 -52.44 17.68 Favored 'General case' 0 CA--C 1.514 -0.428 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.227 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.47 ' O ' ' N ' ' A' ' 44' ' ' SER . 62.2 mttm -62.81 -40.18 96.56 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.43 179.075 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 38.9 ttpt -63.43 -38.36 90.84 Favored 'General case' 0 C--N 1.317 -0.846 0 C-N-CA 119.95 -0.7 . . . . 0.0 111.212 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -67.08 -37.94 84.84 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.818 -178.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.442 ' H ' ' HG3' ' A' ' 43' ' ' MET . 2.4 ppp? -94.22 -17.73 22.4 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.25 -179.146 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.47 ' N ' ' O ' ' A' ' 40' ' ' LYS . 18.3 m -58.21 -40.82 82.61 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.068 0.461 . . . . 0.0 109.842 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 45.3 t0 -76.72 164.66 25.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.422 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.409 ' OD1' ' O ' ' A' ' 46' ' ' ASP . 51.4 t0 59.47 40.44 20.65 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.803 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 -148.48 150.52 34.19 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.366 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo . . . . . 0 N--CA 1.496 1.653 0 C-N-CA 122.472 2.114 . . . . 0.0 111.824 179.755 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.4 mmm . . . . . 0 N--CA 1.493 1.677 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 71.34 -5.24 10.19 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -141.32 10.22 2.73 Favored Glycine 0 N--CA 1.465 0.604 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.419 ' H ' HD12 ' A' ' 4' ' ' ILE . 3.3 mp -44.55 -85.92 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 CA-C-O 120.626 0.25 . . . . 0.0 110.968 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 59.4 m -172.27 -164.4 0.28 Allowed 'General case' 0 N--CA 1.439 -0.981 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.406 ' CG2' ' N ' ' A' ' 7' ' ' TRP . 3.4 tp -84.08 -35.7 11.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-N 115.255 -0.884 . . . . 0.0 111.907 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.427 ' CD1' ' C ' ' A' ' 7' ' ' TRP . 5.6 t-105 -61.91 -39.34 91.67 Favored 'General case' 0 N--CA 1.421 -1.884 0 CA-C-N 114.88 -1.054 . . . . 0.0 108.748 -178.321 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 17.0 tp60 -64.74 -38.85 92.4 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 178.158 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.464 ' HA ' HD23 ' A' ' 9' ' ' LEU . 73.7 mt -62.74 -38.09 89.14 Favored 'General case' 0 CA--C 1.503 -0.851 0 CA-C-N 114.925 -1.034 . . . . 0.0 110.479 178.78 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.633 ' O ' HG23 ' A' ' 14' ' ' VAL . 2.7 mt -62.63 -47.62 82.94 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.235 -177.274 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.505 HD12 ' N ' ' A' ' 11' ' ' ILE . 3.2 mp -69.13 -44.58 80.82 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 178.21 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 77.3 mt -64.02 -44.48 97.82 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.307 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.684 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.9 -36.63 84.97 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.945 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.633 HG23 ' O ' ' A' ' 10' ' ' LEU . 48.8 t -67.28 -44.29 87.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.307 -179.026 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 14.1 pt -67.24 -43.9 87.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.831 179.774 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.517 HG22 ' CD2' ' A' ' 20' ' ' PHE . 0.3 OUTLIER -64.79 -39.3 85.19 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.07 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.323 -179.632 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.694 ' CG1' HG22 ' A' ' 22' ' ' THR . 75.8 t -66.25 -46.99 85.89 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 C-N-CA 118.683 -1.207 . . . . 0.0 112.743 -178.573 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.43 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 0.8 OUTLIER -68.88 -42.39 77.04 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.419 0.628 . . . . 0.0 110.031 179.046 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.71 HD13 ' C ' ' A' ' 19' ' ' LEU . 2.2 tm? -63.88 -39.84 95.14 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.623 -1.171 . . . . 0.0 109.875 -179.306 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.517 ' CD2' HG22 ' A' ' 16' ' ' VAL . 3.0 m-85 -69.17 -37.22 78.09 Favored 'General case' 0 CA--C 1.513 -0.454 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 177.605 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.507 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 102.3 9.59 41.24 Favored Glycine 0 N--CA 1.462 0.405 0 CA-C-N 115.086 -0.961 . . . . 0.0 110.916 179.135 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.694 HG22 ' CG1' ' A' ' 17' ' ' VAL . 51.6 p 58.56 22.22 9.5 Favored 'General case' 0 C--N 1.32 -0.713 0 O-C-N 123.935 0.433 . . . . 0.0 111.99 178.774 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -100.96 -15.82 17.38 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.103 -0.499 . . . . 0.0 112.06 -179.599 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.494 ' O ' ' N ' ' A' ' 27' ' ' SER . 15.2 mmmt -92.29 -57.82 2.58 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.178 0.513 . . . . 0.0 110.718 -179.78 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.985 ' H ' HD12 ' A' ' 25' ' ' LEU . 1.7 mp -45.78 -39.93 8.95 Favored 'General case' 0 CA--C 1.496 -1.124 0 CA-C-O 122.272 1.034 . . . . 0.0 110.417 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.0 -25.15 72.15 Favored Glycine 0 N--CA 1.427 -1.961 0 CA-C-N 113.798 -1.546 . . . . 0.0 110.607 -177.682 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.494 ' N ' ' O ' ' A' ' 24' ' ' LYS . 5.7 t -96.18 -35.97 11.11 Favored 'General case' 0 CA--C 1.518 -0.285 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 8.0 pt -92.12 -38.36 10.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.332 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -59.94 -28.83 66.68 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 -179.604 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.7 m -64.29 -40.46 96.0 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.869 -0.332 . . . . 0.0 111.214 -179.708 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -70.09 -43.83 70.3 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 179.302 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -65.08 -44.1 90.01 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.064 -0.971 . . . . 0.0 111.249 179.648 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.6 -45.49 94.51 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 119.208 -1.472 . . . . 0.0 109.863 -179.193 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.11 -39.65 71.94 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.56 -0.32 . . . . 0.0 111.738 179.22 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 14.5 t -63.03 -42.14 99.7 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.341 -177.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.71 -39.64 80.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.744 178.775 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 34.5 tttm -59.91 -43.36 94.9 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 -178.443 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.81 -36.79 91.67 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 177.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 13.7 t80 -71.64 -50.23 32.56 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-O 120.897 0.379 . . . . 0.0 110.221 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.518 ' O ' ' N ' ' A' ' 44' ' ' SER . 47.8 mtpt -62.86 -38.88 92.6 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.346 178.687 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 50.5 mtpt -61.82 -38.85 89.7 Favored 'General case' 0 C--N 1.319 -0.744 0 C-N-CA 119.764 -0.774 . . . . 0.0 110.083 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -67.0 -36.07 81.34 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.778 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 76.6 mtm -88.91 -28.87 20.02 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.873 0.368 . . . . 0.0 111.064 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.518 ' N ' ' O ' ' A' ' 40' ' ' LYS . 37.7 m -53.53 -26.68 22.07 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.101 -179.282 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.415 ' C ' ' H ' ' A' ' 47' ' ' GLU . 92.6 m-20 -62.01 -39.05 90.93 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.416 179.767 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -77.09 39.69 0.24 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.534 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.415 ' H ' ' C ' ' A' ' 45' ' ' ASP . 75.7 tt0 -167.99 71.14 0.88 Allowed Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.41 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo . . . . . 0 C--N 1.308 -1.572 0 C-N-CA 122.697 2.265 . . . . 0.0 111.975 -179.675 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.454 ' H2 ' HD13 ' A' ' 4' ' ' ILE . 38.4 mmt . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -81.08 38.18 2.39 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 139.02 3.24 1.74 Allowed Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.739 ' N ' HD12 ' A' ' 4' ' ' ILE . 2.5 mp -94.66 110.85 24.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.269 0.557 . . . . 0.0 110.828 -179.687 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 10.9 m -88.33 -139.38 0.11 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.506 178.613 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 34.4 mm -91.06 -38.15 10.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.356 179.137 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 94.1 m95 -74.32 -38.93 63.15 Favored 'General case' 0 C--N 1.321 -0.638 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.096 179.595 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.499 ' N ' ' OE1' ' A' ' 8' ' ' GLN . 0.8 OUTLIER -64.23 -38.77 92.22 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -179.686 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.666 HD12 ' C ' ' A' ' 9' ' ' LEU . 0.4 OUTLIER -73.31 -38.19 65.93 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.249 179.672 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.651 ' O ' HG23 ' A' ' 14' ' ' VAL . 13.8 mt -63.41 -46.87 84.4 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.871 0.367 . . . . 0.0 111.278 -177.661 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.2 mp -67.74 -44.23 85.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.201 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 35.1 mt -65.04 -44.64 95.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.121 -179.27 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.88 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.74 -37.54 87.93 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 115.762 -0.653 . . . . 0.0 110.966 -178.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.651 HG23 ' O ' ' A' ' 10' ' ' LEU . 54.4 t -66.93 -44.99 88.36 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.426 0 C-N-CA 120.435 -0.506 . . . . 0.0 111.506 -178.764 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 16.7 pt -66.9 -42.65 89.24 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.99 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.147 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.528 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.7 t -63.82 -41.43 92.54 Favored 'Isoleucine or valine' 0 CA--C 1.482 -1.659 0 CA-C-N 115.388 -0.823 . . . . 0.0 109.795 -178.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.88 HG23 ' O ' ' A' ' 13' ' ' ALA . 52.2 t -66.29 -50.43 68.15 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.93 0 C-N-CA 117.548 -1.661 . . . . 0.0 113.32 -177.269 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.558 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.2 pp -67.04 -44.11 81.03 Favored 'General case' 0 C--N 1.296 -1.727 0 C-N-CA 119.151 -1.02 . . . . 0.0 111.881 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.658 ' C ' HD12 ' A' ' 19' ' ' LEU . 0.4 OUTLIER -65.78 -38.43 89.02 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.607 -0.27 . . . . 0.0 111.028 179.8 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.528 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 3.4 m-85 -68.38 -37.13 80.11 Favored 'General case' 0 CA--C 1.515 -0.376 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.819 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.428 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 97.93 13.77 42.04 Favored Glycine 0 CA--C 1.504 -0.601 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.512 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.682 HG22 HG13 ' A' ' 17' ' ' VAL . 46.2 p 53.2 76.95 0.18 Allowed 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 114.083 -1.058 . . . . 0.0 112.121 178.504 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 18.0 ptmt -142.4 -36.46 0.4 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.939 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 11.1 mmmt -77.31 -50.75 12.14 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.39 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.611 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.2 OUTLIER -53.23 -37.73 62.3 Favored 'General case' 0 CA--C 1.503 -0.84 0 CA-C-O 122.12 0.962 . . . . 0.0 110.449 -178.744 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.47 -24.92 73.94 Favored Glycine 0 N--CA 1.435 -1.427 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 -178.438 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.9 t -93.46 -40.4 10.37 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.4 pt -93.53 -36.06 7.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 121.361 0.601 . . . . 0.0 109.851 -179.178 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.35 -24.97 68.02 Favored Glycine 0 CA--C 1.52 0.384 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.4 t -64.65 -41.69 95.94 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.692 0.282 . . . . 0.0 111.341 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -73.93 -42.6 60.34 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -66.83 -44.44 81.11 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 114.998 -1.001 . . . . 0.0 111.475 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.41 -44.13 97.24 Favored Glycine 0 N--CA 1.44 -1.051 0 C-N-CA 119.322 -1.418 . . . . 0.0 109.817 -179.203 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.73 -40.13 69.61 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.529 -0.336 . . . . 0.0 111.346 179.05 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.5 m -63.69 -40.56 97.1 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.223 -178.451 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -70.19 -39.52 77.04 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.677 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.5 ptmt -59.79 -41.86 92.12 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 -178.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.81 -36.9 87.92 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.557 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -71.49 -50.82 27.8 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.537 ' O ' ' N ' ' A' ' 44' ' ' SER . 53.7 mtpt -63.21 -38.6 91.82 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.506 178.655 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -61.49 -39.2 90.07 Favored 'General case' 0 C--N 1.318 -0.766 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.867 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.99 -36.83 83.04 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.705 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.444 ' O ' ' O ' ' A' ' 44' ' ' SER . 74.0 mtm -91.12 -66.75 0.9 Allowed 'General case' 0 N--CA 1.463 0.181 0 CA-C-O 120.917 0.389 . . . . 0.0 110.528 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.537 ' N ' ' O ' ' A' ' 40' ' ' LYS . 83.6 p 49.68 176.37 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.498 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 45.8 t0 -92.44 113.51 25.81 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 120.851 0.358 . . . . 0.0 110.393 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -82.55 17.73 1.7 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.768 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -154.43 78.91 5.04 Favored Pre-proline 0 C--N 1.324 -0.529 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.7 179.799 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo . . . . . 0 C--N 1.307 -1.615 0 C-N-CA 122.606 2.204 . . . . 0.0 111.955 -179.985 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.471 ' H2 ' HD13 ' A' ' 4' ' ' ILE . 1.7 mpp? . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -62.41 -34.46 89.41 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.29 20.84 0.34 Allowed Glycine 0 N--CA 1.45 -0.388 0 N-CA-C 109.789 -1.325 . . . . 0.0 109.789 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.471 HD13 ' H2 ' ' A' ' 1' ' ' MET . 4.2 mp -92.26 105.77 17.05 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.26 0 CA-C-O 121.367 0.604 . . . . 0.0 110.132 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 49.8 m -153.04 -128.94 0.04 OUTLIER 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 114.974 -1.012 . . . . 0.0 110.316 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.509 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.5 mp -59.85 -37.23 70.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 120.755 0.312 . . . . 0.0 110.463 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 67.6 m95 -62.15 -46.98 86.57 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -64.43 -38.9 92.63 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.425 HD23 ' HA ' ' A' ' 9' ' ' LEU . 89.2 mt -66.08 -38.73 89.0 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.306 178.881 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.591 ' O ' HG23 ' A' ' 14' ' ' VAL . 16.7 mt -63.43 -50.28 70.41 Favored 'General case' 0 C--N 1.315 -0.919 0 C-N-CA 120.131 -0.628 . . . . 0.0 110.541 -176.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.435 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.4 mp -66.61 -44.73 89.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.107 178.237 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 75.5 mt -63.91 -46.79 93.16 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.967 0 C-N-CA 120.294 -0.562 . . . . 0.0 111.432 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.846 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -65.0 -37.68 88.47 Favored 'General case' 0 C--N 1.319 -0.745 0 O-C-N 123.213 0.321 . . . . 0.0 111.349 -179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.591 HG23 ' O ' ' A' ' 10' ' ' LEU . 59.2 t -67.8 -43.82 86.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.613 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.448 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 96.6 mt -66.2 -43.53 91.86 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.155 0 O-C-N 123.521 0.513 . . . . 0.0 109.725 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.433 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.6 t -63.72 -42.26 95.38 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.504 0 CA-C-N 115.08 -0.964 . . . . 0.0 109.919 -178.637 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.846 HG23 ' O ' ' A' ' 13' ' ' ALA . 59.9 t -66.27 -44.78 91.05 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 C-N-CA 118.217 -1.393 . . . . 0.0 112.79 -176.844 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.483 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.2 pp -71.96 -42.9 66.02 Favored 'General case' 0 C--N 1.294 -1.825 0 C-N-CA 120.046 -0.661 . . . . 0.0 109.761 178.177 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.661 HD13 ' C ' ' A' ' 19' ' ' LEU . 2.6 tm? -64.8 -41.75 95.56 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.823 -179.175 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.433 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 6.9 m-85 -69.24 -33.47 73.33 Favored 'General case' 0 CA--C 1.511 -0.558 0 C-N-CA 119.067 -1.053 . . . . 0.0 108.831 178.716 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.466 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 93.93 12.9 56.06 Favored Glycine 0 C--N 1.318 -0.471 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 179.244 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.655 HG22 HG13 ' A' ' 17' ' ' VAL . 43.1 p 55.78 77.73 0.22 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 114.684 -0.758 . . . . 0.0 112.002 178.762 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -146.28 -26.11 0.43 Allowed 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.454 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.407 ' HZ2' HD11 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -93.65 -39.71 10.65 Favored 'General case' 0 C--O 1.223 -0.315 0 C-N-CA 120.719 -0.393 . . . . 0.0 110.905 -179.861 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.704 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.2 OUTLIER -59.55 -37.04 77.35 Favored 'General case' 0 CA--C 1.501 -0.931 0 CA-C-O 121.714 0.768 . . . . 0.0 110.001 179.889 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.56 -25.0 75.23 Favored Glycine 0 N--CA 1.432 -1.6 0 N-CA-C 108.628 -1.789 . . . . 0.0 108.628 -179.243 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 8.1 t -87.25 -43.25 12.33 Favored 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 179.688 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.407 HD11 ' HZ2' ' A' ' 24' ' ' LYS . 13.5 pt -93.65 -34.68 5.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.278 0.561 . . . . 0.0 110.091 -178.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.27 -22.78 65.68 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 -179.566 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.5 t -64.71 -43.44 93.45 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 120.763 -0.375 . . . . 0.0 111.733 -179.349 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -75.54 -42.51 52.25 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.438 0.637 . . . . 0.0 109.487 179.704 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.8 mp -66.89 -44.66 80.28 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.043 -0.98 . . . . 0.0 111.81 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.32 -44.12 97.4 Favored Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 119.413 -1.375 . . . . 0.0 109.832 -179.294 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.84 -39.79 69.49 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.66 -0.27 . . . . 0.0 111.394 179.183 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.7 m -63.24 -40.92 98.79 Favored 'General case' 0 CA--C 1.518 -0.287 0 CA-C-O 121.112 0.482 . . . . 0.0 110.477 -178.599 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.63 -39.36 78.15 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.757 178.627 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 24.2 tttt -59.97 -44.56 94.37 Favored 'General case' 0 N--CA 1.435 -1.217 0 C-N-CA 119.231 -0.988 . . . . 0.0 108.414 -179.357 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.97 -36.34 91.91 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 178.005 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.59 ' CD2' ' SD ' ' A' ' 43' ' ' MET . 21.0 t80 -71.38 -51.41 24.24 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-O 120.835 0.35 . . . . 0.0 110.456 -179.448 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.54 ' O ' ' N ' ' A' ' 44' ' ' SER . 54.8 mtpt -63.08 -38.56 91.66 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.38 178.538 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -61.36 -36.84 81.33 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.121 -0.632 . . . . 0.0 110.012 -179.565 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.63 -36.01 81.55 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.126 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.59 ' SD ' ' CD2' ' A' ' 39' ' ' PHE . 0.0 OUTLIER -93.38 -68.17 0.82 Allowed 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.964 0.411 . . . . 0.0 110.802 179.769 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.54 ' N ' ' O ' ' A' ' 40' ' ' LYS . 3.1 p 47.84 10.94 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.882 -179.503 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.525 ' C ' ' H ' ' A' ' 47' ' ' GLU . 66.7 t0 46.64 -121.09 1.1 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.266 179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.441 ' H ' ' CG ' ' A' ' 45' ' ' ASP . 90.5 m-20 -74.77 17.24 0.22 Allowed 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.525 ' H ' ' C ' ' A' ' 45' ' ' ASP . 34.2 tt0 41.47 73.5 0.88 Allowed Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.63 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_endo . . . . . 0 C--N 1.307 -1.651 0 C-N-CA 122.757 2.304 . . . . 0.0 112.036 -179.468 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 93.0 mtp . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.1 0.22 58.65 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 111.281 -0.728 . . . . 0.0 111.281 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 96.57 17.53 33.23 Favored Glycine 0 N--CA 1.466 0.696 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.411 HG22 ' N ' ' A' ' 5' ' ' SER . 29.0 mt -69.5 -115.73 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.342 -0.429 . . . . 0.0 110.198 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.411 ' N ' HG22 ' A' ' 4' ' ' ILE . 67.5 m -165.31 -160.08 0.46 Allowed 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 -179.771 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 4.6 tp -100.33 -36.13 4.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-N 115.37 -0.832 . . . . 0.0 111.986 179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.651 ' CE2' HD11 ' A' ' 11' ' ' ILE . 8.1 t-105 -62.2 -37.12 84.12 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 115.459 -0.791 . . . . 0.0 108.91 -178.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 6.8 mp0 -64.35 -38.91 92.71 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 178.318 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.426 HD23 ' HA ' ' A' ' 9' ' ' LEU . 84.0 mt -64.79 -37.58 88.11 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.93 178.546 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.694 ' O ' HG23 ' A' ' 14' ' ' VAL . 3.9 mt -62.47 -43.89 97.71 Favored 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.274 -177.239 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.651 HD11 ' CE2' ' A' ' 7' ' ' TRP . 7.2 mt -68.35 -45.11 83.02 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 C-N-CA 119.992 -0.683 . . . . 0.0 109.593 178.049 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 72.0 mt -65.98 -44.74 92.19 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.572 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.531 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.907 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -65.22 -37.21 86.56 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.03 -179.517 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.694 HG23 ' O ' ' A' ' 10' ' ' LEU . 46.0 t -66.65 -44.78 89.57 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.717 0 C-N-CA 120.599 -0.44 . . . . 0.0 111.485 -179.082 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.439 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 15.2 pt -66.61 -42.64 90.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.209 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.531 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.5 t -63.85 -41.82 93.8 Favored 'Isoleucine or valine' 0 CA--C 1.483 -1.603 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.702 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.907 HG23 ' O ' ' A' ' 13' ' ' ALA . 61.5 t -65.8 -45.93 90.21 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 C-N-CA 118.361 -1.335 . . . . 0.0 112.948 -177.216 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.521 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.4 pp -72.11 -42.85 65.59 Favored 'General case' 0 C--N 1.288 -2.093 0 CA-C-O 121.333 0.587 . . . . 0.0 109.791 178.73 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.705 HD13 ' C ' ' A' ' 19' ' ' LEU . 2.5 tm? -64.67 -42.3 95.47 Favored 'General case' 0 N--CA 1.44 -0.956 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.164 -179.767 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.531 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 5.7 m-85 -68.94 -34.37 75.24 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 119.138 -1.025 . . . . 0.0 109.314 179.333 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.487 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 96.32 11.38 54.32 Favored Glycine 0 N--CA 1.466 0.635 0 N-CA-C 110.647 -0.981 . . . . 0.0 110.647 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.697 HG22 ' CG1' ' A' ' 17' ' ' VAL . 43.4 p 56.53 68.58 0.84 Allowed 'General case' 0 CA--C 1.502 -0.884 0 CA-C-N 115.055 -0.573 . . . . 0.0 112.271 178.199 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -139.87 -24.77 0.83 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.015 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 10.1 mmmt -87.06 -52.09 5.63 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.821 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.63 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.1 OUTLIER -53.3 -36.92 61.76 Favored 'General case' 0 CA--C 1.505 -0.781 0 CA-C-O 121.783 0.801 . . . . 0.0 110.266 -178.966 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.45 -25.46 72.61 Favored Glycine 0 N--CA 1.436 -1.322 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 -177.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.6 t -92.89 -40.66 10.48 Favored 'General case' 0 CA--C 1.517 -0.292 0 N-CA-C 112.244 0.461 . . . . 0.0 112.244 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.3 pt -92.64 -35.42 6.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 121.173 0.511 . . . . 0.0 109.993 -178.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.17 -25.76 71.2 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.566 -1.014 . . . . 0.0 110.566 -179.563 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.1 p -65.91 -38.86 89.82 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.922 -0.311 . . . . 0.0 111.336 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 46.2 t0 -81.36 -39.47 25.02 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.254 0.549 . . . . 0.0 109.694 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.0 mp -69.37 -45.32 69.63 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.193 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.76 -43.94 98.21 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 119.531 -1.319 . . . . 0.0 109.913 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.0 -39.99 79.0 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.538 -0.331 . . . . 0.0 111.372 179.522 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 47.1 t -63.28 -42.26 99.08 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.093 0.473 . . . . 0.0 110.718 -178.845 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.88 -39.42 79.92 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.154 179.205 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 7.6 ttpt -59.39 -43.65 92.92 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.242 -0.983 . . . . 0.0 108.524 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.73 -36.21 92.0 Favored Glycine 0 N--CA 1.444 -0.821 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 178.439 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -71.08 -52.54 18.84 Favored 'General case' 0 CA--C 1.512 -0.517 0 CA-C-O 120.976 0.417 . . . . 0.0 110.133 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.56 ' O ' ' N ' ' A' ' 44' ' ' SER . 44.2 mttp -63.36 -38.86 92.81 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 120.27 -0.572 . . . . 0.0 110.545 178.487 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 1.9 tmtp? -61.7 -39.15 90.44 Favored 'General case' 0 C--N 1.319 -0.76 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.106 -179.665 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.01 -38.6 72.64 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.953 179.572 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.473 ' SD ' ' N ' ' A' ' 43' ' ' MET . 0.2 OUTLIER -88.81 -11.06 45.93 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.732 -179.407 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.56 ' N ' ' O ' ' A' ' 40' ' ' LYS . 6.3 m -67.95 143.57 55.57 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -136.59 -33.2 0.8 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.434 -179.793 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -75.74 48.92 0.49 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.2 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -62.96 151.21 86.35 Favored Pre-proline 0 CA--C 1.536 0.421 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.494 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo . . . . . 0 N--CA 1.494 1.528 0 C-N-CA 122.494 2.13 . . . . 0.0 111.766 179.604 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -80.48 32.23 2.36 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 111.284 -0.727 . . . . 0.0 111.284 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.562 ' O ' ' NE2' ' A' ' 8' ' ' GLN . . . 143.3 -3.99 1.73 Allowed Glycine 0 C--N 1.335 0.486 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 -179.812 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.787 ' N ' HD12 ' A' ' 4' ' ' ILE . 1.7 mp -92.05 118.55 37.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.223 0.535 . . . . 0.0 110.41 -179.521 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 41.8 m -136.42 -139.89 0.16 Allowed 'General case' 0 CA--C 1.518 -0.255 0 CA-C-N 115.265 -0.879 . . . . 0.0 109.357 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 3.7 tp -93.13 -36.15 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.586 0 CA-C-O 121.235 0.54 . . . . 0.0 111.578 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.769 ' O ' HD12 ' A' ' 11' ' ' ILE . 0.3 OUTLIER -62.21 -41.62 98.54 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-N 115.365 -0.834 . . . . 0.0 108.967 -179.185 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.562 ' NE2' ' O ' ' A' ' 3' ' ' GLY . 56.4 mt-30 -64.08 -38.38 90.87 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 178.701 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.514 ' O ' ' N ' ' A' ' 13' ' ' ALA . 87.5 mt -65.37 -36.98 85.63 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.326 177.439 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.573 ' O ' HG23 ' A' ' 14' ' ' VAL . 1.8 tt -61.84 -50.95 70.19 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.888 -174.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.769 HD12 ' O ' ' A' ' 7' ' ' TRP . 2.8 mp -65.35 -44.73 94.64 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 C-N-CA 119.893 -0.723 . . . . 0.0 109.533 177.838 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.1 mp -63.77 -44.36 98.23 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.21 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.904 179.49 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.9 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.56 -37.35 87.27 Favored 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 121.086 -0.246 . . . . 0.0 110.836 -179.411 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.573 HG23 ' O ' ' A' ' 10' ' ' LEU . 53.0 t -66.93 -45.01 88.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 C-N-CA 120.544 -0.462 . . . . 0.0 111.465 -179.191 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 13.5 pt -66.87 -42.76 89.47 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.989 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 178.59 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.569 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.4 t -63.14 -41.54 93.21 Favored 'Isoleucine or valine' 0 CA--C 1.478 -1.799 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.883 -178.895 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.9 HG23 ' O ' ' A' ' 13' ' ' ALA . 51.7 t -66.14 -51.23 62.11 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.033 0 C-N-CA 117.857 -1.537 . . . . 0.0 113.652 -177.471 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.598 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.4 pp -66.89 -44.36 81.08 Favored 'General case' 0 C--N 1.293 -1.869 0 C-N-CA 119.487 -0.885 . . . . 0.0 111.782 179.764 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.659 ' C ' HD12 ' A' ' 19' ' ' LEU . 0.4 OUTLIER -65.77 -38.87 90.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.704 -0.225 . . . . 0.0 110.638 -179.943 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.569 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 3.0 m-85 -68.5 -36.54 79.05 Favored 'General case' 0 CA--C 1.513 -0.476 0 C-N-CA 119.607 -0.837 . . . . 0.0 109.317 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.472 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 96.98 12.01 51.11 Favored Glycine 0 CA--C 1.506 -0.501 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 -179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.726 HG22 HG13 ' A' ' 17' ' ' VAL . 43.3 p 54.74 74.74 0.33 Allowed 'General case' 0 CA--C 1.5 -0.963 0 CA-C-N 114.196 -1.002 . . . . 0.0 112.677 178.055 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 62.1 mttp -139.04 -31.57 0.7 Allowed 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.784 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.43 ' O ' ' N ' ' A' ' 27' ' ' SER . 6.7 mmpt? -81.6 -54.35 5.48 Favored 'General case' 0 CA--C 1.501 -0.914 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.612 -179.736 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.618 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.0 OUTLIER -48.97 -39.29 25.96 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 122.371 1.081 . . . . 0.0 110.701 -176.662 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.74 -24.85 73.48 Favored Glycine 0 N--CA 1.429 -1.817 0 CA-C-N 114.011 -1.449 . . . . 0.0 110.289 -178.776 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.43 ' N ' ' O ' ' A' ' 24' ' ' LYS . 24.6 m -95.86 -40.78 9.15 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.415 0.524 . . . . 0.0 112.415 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.2 pt -91.32 -36.78 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 CA-C-O 121.054 0.454 . . . . 0.0 109.909 -179.148 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.45 -26.62 68.34 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -179.425 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.2 p -64.64 -38.57 91.45 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.702 0.287 . . . . 0.0 110.944 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -72.96 -43.28 62.48 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.54 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.5 mp -64.97 -44.37 89.58 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.185 179.578 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -64.02 -45.1 94.81 Favored Glycine 0 N--CA 1.44 -1.093 0 C-N-CA 119.251 -1.452 . . . . 0.0 109.765 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.65 -39.71 73.46 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.513 -0.344 . . . . 0.0 111.664 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.9 t -62.89 -41.91 99.59 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.407 -177.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.72 -39.77 78.44 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.145 178.613 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 36.6 tttm -60.07 -41.45 92.42 Favored 'General case' 0 N--CA 1.426 -1.644 0 N-CA-C 108.056 -1.091 . . . . 0.0 108.056 -178.529 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.12 -36.49 90.44 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 109.882 -1.287 . . . . 0.0 109.882 177.625 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -71.6 -51.92 20.78 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.188 -179.308 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.52 ' O ' ' N ' ' A' ' 44' ' ' SER . 54.5 mttp -63.72 -39.65 94.81 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.517 178.322 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 61.6 tttm -61.79 -38.79 89.38 Favored 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 120.054 -0.658 . . . . 0.0 110.458 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.79 -35.98 81.33 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.701 -179.637 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.493 ' O ' ' N ' ' A' ' 45' ' ' ASP . 73.1 mtm -91.49 -64.96 1.05 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.772 0.32 . . . . 0.0 110.273 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.52 ' N ' ' O ' ' A' ' 40' ' ' LYS . 89.0 p 38.67 -91.98 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.839 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.493 ' N ' ' O ' ' A' ' 43' ' ' MET . 97.9 m-20 53.82 33.03 16.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.754 0.311 . . . . 0.0 110.787 179.087 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -97.91 36.62 1.52 Allowed 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.42 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.521 ' N ' ' CD ' ' A' ' 48' ' ' PRO . 11.6 mt-10 53.22 50.37 7.5 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.644 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.521 ' CD ' ' N ' ' A' ' 47' ' ' GLU . 38.4 Cg_endo . . . . . 0 C--N 1.304 -1.775 0 C-N-CA 122.861 2.374 . . . . 0.0 111.742 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.568 ' N ' ' SD ' ' A' ' 1' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.609 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 . . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -121.92 -15.37 4.35 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.333 -0.707 . . . . 0.0 111.333 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -106.2 -1.04 38.41 Favored Glycine 0 N--CA 1.465 0.579 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.699 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 36.8 mt -42.18 -85.45 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.658 -0.271 . . . . 0.0 110.696 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.6 m -156.25 -165.78 2.0 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.456 ' HA ' HD23 ' A' ' 9' ' ' LEU . 40.8 mm -91.7 -40.66 12.57 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.06 179.139 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 82.9 m95 -71.68 -40.69 69.42 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 120.279 -0.568 . . . . 0.0 110.207 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.488 ' OE1' ' N ' ' A' ' 8' ' ' GLN . 1.7 mp0 -64.41 -38.8 92.31 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.055 0.455 . . . . 0.0 110.311 -179.227 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.666 ' C ' HD12 ' A' ' 9' ' ' LEU . 0.3 OUTLIER -72.31 -38.0 68.81 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.97 179.7 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.589 ' O ' HG23 ' A' ' 14' ' ' VAL . 15.8 mt -63.28 -48.78 76.68 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.73 -176.386 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.2 mp -66.13 -44.33 91.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 178.394 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 69.3 mt -64.06 -44.48 97.74 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.642 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.391 -179.366 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.89 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.91 -37.09 86.5 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.867 -179.067 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.589 HG23 ' O ' ' A' ' 10' ' ' LEU . 50.2 t -66.93 -45.6 86.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 C-N-CA 120.425 -0.51 . . . . 0.0 111.574 -178.809 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 15.9 pt -66.41 -42.34 90.27 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.916 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.345 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.759 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.7 t -63.19 -42.36 96.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.35 -179.626 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.89 HG23 ' O ' ' A' ' 13' ' ' ALA . 61.3 t -65.63 -48.96 80.69 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.887 0 C-N-CA 117.245 -1.782 . . . . 0.0 113.69 -176.73 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.634 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.6 pp -68.49 -44.0 75.66 Favored 'General case' 0 C--N 1.289 -2.063 0 C-N-CA 120.094 -0.642 . . . . 0.0 112.156 -179.377 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.669 ' C ' HD12 ' A' ' 19' ' ' LEU . 0.4 OUTLIER -66.3 -39.19 89.15 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.99 -179.604 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.759 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 1.8 m-85 -68.45 -37.62 80.37 Favored 'General case' 0 CA--C 1.506 -0.726 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.641 -178.395 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.483 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 101.2 9.53 44.56 Favored Glycine 0 C--N 1.308 -0.974 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.046 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.697 HG22 ' CG1' ' A' ' 17' ' ' VAL . 44.6 p 55.15 66.66 1.17 Allowed 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 178.698 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -139.6 -22.57 0.89 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.054 179.452 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 9.9 mmmt -87.13 -51.41 6.01 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.646 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.634 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.0 OUTLIER -54.45 -37.11 64.8 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 122.067 0.937 . . . . 0.0 110.556 -178.85 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.48 -25.07 73.55 Favored Glycine 0 C--N 1.304 -1.215 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.587 -177.685 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 7.5 t -92.54 -42.89 9.44 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 111.977 0.362 . . . . 0.0 111.977 -179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 4.6 pt -91.29 -36.1 7.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 121.233 0.54 . . . . 0.0 109.917 -179.033 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.57 -24.12 69.24 Favored Glycine 0 CA--C 1.518 0.257 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -179.126 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.2 p -65.22 -41.18 94.71 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 120.771 -0.372 . . . . 0.0 111.058 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -76.02 -39.88 54.71 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.078 0.466 . . . . 0.0 109.874 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.7 mp -70.21 -45.59 66.27 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.129 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.55 -43.57 98.83 Favored Glycine 0 N--CA 1.441 -1.007 0 C-N-CA 119.545 -1.312 . . . . 0.0 110.473 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.02 -40.04 71.99 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 120.898 0.38 . . . . 0.0 111.06 179.433 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 12.4 t -63.99 -41.93 97.36 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 120.559 -0.456 . . . . 0.0 110.98 -178.558 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.44 -39.87 79.2 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.71 -179.528 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 18.7 pttt -59.58 -40.51 87.62 Favored 'General case' 0 C--N 1.309 -1.195 0 C-N-CA 118.591 -1.243 . . . . 0.0 107.843 -178.277 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -69.46 -36.82 78.07 Favored Glycine 0 N--CA 1.442 -0.92 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 179.657 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.425 ' CE1' ' CE ' ' A' ' 43' ' ' MET . 46.0 t80 -71.52 -50.71 28.67 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.552 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.563 ' O ' ' N ' ' A' ' 44' ' ' SER . 52.7 mtpt -63.65 -38.85 92.66 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.597 178.797 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -62.04 -37.97 86.94 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 119.981 -0.687 . . . . 0.0 110.09 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.68 -36.87 83.53 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.495 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.592 ' SD ' ' N ' ' A' ' 43' ' ' MET . 0.2 OUTLIER -94.74 -10.55 31.26 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.689 -179.615 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.563 ' N ' ' O ' ' A' ' 40' ' ' LYS . 11.7 t -58.16 -44.44 87.92 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.935 0.398 . . . . 0.0 110.126 -179.32 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.467 ' CG ' ' H ' ' A' ' 46' ' ' ASP . 44.8 t0 -85.4 -179.46 6.95 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.423 179.727 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.467 ' H ' ' CG ' ' A' ' 45' ' ' ASP . 96.7 m-20 56.15 38.11 29.52 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.279 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 -70.76 152.08 95.2 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.571 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo . . . . . 0 N--CA 1.495 1.562 0 C-N-CA 122.69 2.26 . . . . 0.0 111.71 179.563 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.49 ' C ' ' H ' ' A' ' 3' ' ' GLY . 94.9 mtp . . . . . 0 N--CA 1.492 1.629 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -78.15 29.13 1.91 Allowed Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.49 ' H ' ' C ' ' A' ' 1' ' ' MET . . . -152.54 34.66 0.82 Allowed Glycine 0 N--CA 1.451 -0.341 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 179.59 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.8 mt -53.11 130.75 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.673 0 CA-C-O 122.019 0.914 . . . . 0.0 110.265 -178.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.494 ' C ' HD12 ' A' ' 6' ' ' ILE . 53.3 m -106.14 -132.33 0.31 Allowed 'General case' 0 C--N 1.315 -0.891 0 CA-C-N 113.791 -1.549 . . . . 0.0 110.275 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.494 HD12 ' C ' ' A' ' 5' ' ' SER . 1.4 mp -104.68 -31.03 2.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.277 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 70.9 m95 -62.76 -46.97 85.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.692 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 59.1 mm-40 -64.35 -39.05 93.11 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.424 HD23 ' HA ' ' A' ' 9' ' ' LEU . 84.4 mt -65.08 -39.1 92.72 Favored 'General case' 0 CA--C 1.508 -0.649 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.146 178.626 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.598 ' O ' HG23 ' A' ' 14' ' ' VAL . 8.0 mt -63.38 -49.16 74.91 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.521 -176.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.516 ' O ' HG12 ' A' ' 15' ' ' ILE . 3.3 mp -67.67 -44.97 85.66 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.775 0 C-N-CA 119.508 -0.877 . . . . 0.0 109.093 178.07 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 77.1 mt -63.36 -44.36 98.98 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.526 -179.165 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.818 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -63.79 -36.46 83.96 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.203 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.598 HG23 ' O ' ' A' ' 10' ' ' LEU . 65.8 t -67.1 -43.06 88.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 C-N-CA 119.779 -0.769 . . . . 0.0 110.457 179.672 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.516 HG12 ' O ' ' A' ' 11' ' ' ILE . 33.5 mm -66.08 -43.04 92.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.127 0.489 . . . . 0.0 110.28 179.26 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.505 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -63.75 -38.04 81.27 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.558 -178.72 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.818 HG23 ' O ' ' A' ' 13' ' ' ALA . 95.0 t -65.66 -43.02 93.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 C-N-CA 118.409 -1.316 . . . . 0.0 111.868 -178.308 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.434 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 16.1 mt -62.0 -45.03 95.42 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 118.631 -1.227 . . . . 0.0 111.833 -179.106 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.889 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.78 -38.37 79.97 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -178.528 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.889 ' N ' HD12 ' A' ' 19' ' ' LEU . 1.3 m-85 -67.57 -32.44 73.2 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -177.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 94.45 8.88 59.46 Favored Glycine 0 CA--C 1.5 -0.887 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 178.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.721 HG22 HG13 ' A' ' 17' ' ' VAL . 18.0 p 56.95 27.95 13.94 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 114.27 -0.965 . . . . 0.0 112.502 178.034 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -100.57 -12.84 18.92 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.776 179.774 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.5 ' O ' ' N ' ' A' ' 27' ' ' SER . 15.4 mmmt -96.06 -58.43 2.09 Favored 'General case' 0 C--O 1.221 -0.438 0 CA-C-O 121.053 0.454 . . . . 0.0 110.281 179.511 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 1.086 ' H ' HD12 ' A' ' 25' ' ' LEU . 2.0 mp -44.12 -42.0 6.01 Favored 'General case' 0 CA--C 1.495 -1.144 0 CA-C-O 122.459 1.123 . . . . 0.0 110.468 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.94 -25.42 71.6 Favored Glycine 0 N--CA 1.424 -2.134 0 CA-C-N 113.49 -1.686 . . . . 0.0 110.601 -177.536 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.5 ' N ' ' O ' ' A' ' 24' ' ' LYS . 5.4 m -95.28 -35.06 11.95 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -179.484 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.472 ' N ' ' O ' ' A' ' 24' ' ' LYS . 9.2 pt -93.53 -38.17 9.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -179.578 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.2 -24.01 49.62 Favored Glycine 0 CA--C 1.521 0.417 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 61.9 p -66.38 -57.28 7.78 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.946 -0.302 . . . . 0.0 111.761 -179.353 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -67.81 -39.87 83.91 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.411 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -65.46 -44.99 85.51 Favored 'General case' 0 CA--C 1.507 -0.694 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.159 179.653 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.43 -43.43 99.34 Favored Glycine 0 N--CA 1.433 -1.54 0 N-CA-C 108.475 -1.85 . . . . 0.0 108.475 -178.474 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.97 -40.0 75.63 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.073 -0.564 . . . . 0.0 111.159 178.429 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 51.6 m -63.53 -43.37 97.33 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 120.408 -0.517 . . . . 0.0 110.87 -178.452 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -67.28 -39.71 83.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.64 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.0 pttt -60.02 -42.08 93.56 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 -179.209 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.68 -36.83 88.37 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 178.23 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.592 ' CE2' ' SD ' ' A' ' 43' ' ' MET . 14.8 t80 -71.94 -50.41 29.27 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 120.956 0.408 . . . . 0.0 110.642 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.564 ' O ' ' N ' ' A' ' 44' ' ' SER . 21.8 mtpp -62.74 -38.55 90.99 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.269 179.066 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -61.76 -38.3 87.49 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.475 -179.364 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.92 -35.8 80.82 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.194 0.521 . . . . 0.0 109.626 179.189 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.592 ' SD ' ' CE2' ' A' ' 39' ' ' PHE . 33.6 mtp -88.64 -16.87 31.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.06 -179.686 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.564 ' N ' ' O ' ' A' ' 40' ' ' LYS . 47.7 t -60.56 152.85 25.01 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.185 -179.346 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.472 ' C ' ' H ' ' A' ' 47' ' ' GLU . 99.3 m-20 56.56 94.88 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.9 0.381 . . . . 0.0 110.383 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -74.82 34.98 0.1 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.639 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.472 ' H ' ' C ' ' A' ' 45' ' ' ASP . 48.1 mt-10 50.07 65.26 7.13 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.677 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 77.7 Cg_endo . . . . . 0 C--N 1.306 -1.69 0 C-N-CA 122.925 2.417 . . . . 0.0 112.045 -179.834 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 92.5 mtp . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -99.09 18.32 56.87 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.86 22.39 1.79 Allowed Glycine 0 C--N 1.328 0.138 0 N-CA-C 109.116 -1.594 . . . . 0.0 109.116 179.498 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.452 HG23 ' CB ' ' A' ' 8' ' ' GLN . 22.1 mt -43.4 122.56 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.512 -0.504 0 CA-C-O 121.823 0.821 . . . . 0.0 110.463 -179.31 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -96.64 -162.42 0.95 Allowed 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 114.352 -1.295 . . . . 0.0 109.128 178.825 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.6 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.4 mp -68.48 -44.19 83.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 114.647 -1.16 . . . . 0.0 110.403 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.403 ' O ' HD13 ' A' ' 11' ' ' ILE . 95.8 m95 -70.92 -39.71 72.53 Favored 'General case' 0 C--N 1.316 -0.884 0 C-N-CA 120.068 -0.653 . . . . 0.0 109.773 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.452 ' CB ' HG23 ' A' ' 4' ' ' ILE . 94.2 mm-40 -64.66 -39.15 93.19 Favored 'General case' 0 N--CA 1.442 -0.85 0 C-N-CA 120.315 -0.554 . . . . 0.0 109.617 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.658 ' C ' HD12 ' A' ' 9' ' ' LEU . 0.4 OUTLIER -73.05 -38.36 66.51 Favored 'General case' 0 C--O 1.226 -0.176 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.014 179.027 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.566 ' O ' HG23 ' A' ' 14' ' ' VAL . 15.3 mt -63.31 -47.82 80.66 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.945 -0.302 . . . . 0.0 111.22 -177.613 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.403 HD13 ' O ' ' A' ' 7' ' ' TRP . 2.1 mp -66.94 -44.48 88.64 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.851 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 53.3 mt -64.42 -44.72 97.09 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.076 0 CA-C-N 115.639 -0.709 . . . . 0.0 111.271 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.694 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.84 -37.39 87.47 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.719 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.566 HG23 ' O ' ' A' ' 10' ' ' LEU . 55.3 t -67.67 -45.72 84.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 C-N-CA 119.624 -0.831 . . . . 0.0 110.697 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.5 mt -65.85 -43.88 92.97 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.717 0 CA-C-O 121.172 0.51 . . . . 0.0 111.189 -179.023 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.579 HG22 ' CD2' ' A' ' 20' ' ' PHE . 0.5 OUTLIER -64.46 -38.74 83.36 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.344 0 CA-C-N 115.284 -0.871 . . . . 0.0 109.616 -178.932 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.782 HG13 HG22 ' A' ' 22' ' ' THR . 61.0 t -65.75 -42.79 93.19 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.158 0 C-N-CA 118.571 -1.252 . . . . 0.0 111.389 -177.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 66.0 mt -61.77 -44.96 95.86 Favored 'General case' 0 C--N 1.312 -1.031 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.751 -179.02 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.875 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.55 -38.29 80.65 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 113.067 0.765 . . . . 0.0 113.067 -178.74 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.875 ' N ' HD12 ' A' ' 19' ' ' LEU . 1.2 m-85 -67.61 -31.74 71.97 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -178.224 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 90.74 2.79 71.84 Favored Glycine 0 C--N 1.318 -0.47 0 N-CA-C 109.211 -1.556 . . . . 0.0 109.211 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.782 HG22 HG13 ' A' ' 17' ' ' VAL . 5.5 p 57.19 9.09 0.63 Allowed 'General case' 0 CA--C 1.511 -0.544 0 CA-C-N 114.727 -0.737 . . . . 0.0 112.178 178.03 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 24.7 mtpp -71.76 -42.26 67.42 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.256 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.592 ' HG3' HD12 ' A' ' 25' ' ' LEU . 0.0 OUTLIER -86.57 -25.17 25.14 Favored 'General case' 0 C--O 1.221 -0.41 0 CA-C-N 116.16 -0.473 . . . . 0.0 112.017 -178.705 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.68 HD13 ' HA ' ' A' ' 22' ' ' THR . 9.7 mp -59.05 -43.45 91.68 Favored 'General case' 0 CA--C 1.49 -1.328 0 CA-C-O 121.852 0.834 . . . . 0.0 109.353 -179.669 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.82 -25.34 72.08 Favored Glycine 0 N--CA 1.424 -2.111 0 N-CA-C 108.704 -1.758 . . . . 0.0 108.704 -178.235 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.7 t -76.66 -42.26 42.55 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.216 -0.492 . . . . 0.0 111.355 179.122 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.434 HD13 ' NZ ' ' A' ' 24' ' ' LYS . 21.8 pt -91.47 -33.02 5.44 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 CA-C-O 121.404 0.621 . . . . 0.0 109.579 -179.67 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.488 ' N ' ' O ' ' A' ' 25' ' ' LEU . . . -59.46 -24.02 58.83 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 7.3 t -64.6 -42.4 95.59 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.44 -0.504 . . . . 0.0 112.148 -179.342 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -86.53 -36.19 19.1 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.4 mp -73.03 -46.34 52.48 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.129 -0.942 . . . . 0.0 111.725 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.78 -43.66 98.94 Favored Glycine 0 C--N 1.308 -1.003 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.579 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.0 -40.32 75.34 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.486 -0.357 . . . . 0.0 111.479 179.57 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.5 t -63.61 -42.84 98.17 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.195 0.521 . . . . 0.0 110.857 -178.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.1 mp -67.09 -39.76 83.92 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.753 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.487 ' HA ' ' HZ2' ' A' ' 40' ' ' LYS . 2.1 pttp -59.81 -42.71 94.08 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 118.809 -1.156 . . . . 0.0 108.301 -178.717 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.87 -36.88 87.57 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.495 -1.042 . . . . 0.0 110.495 178.549 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.612 ' CE1' ' SD ' ' A' ' 43' ' ' MET . 51.6 t80 -71.91 -53.34 13.45 Favored 'General case' 0 CA--C 1.513 -0.445 0 CA-C-O 120.684 0.278 . . . . 0.0 111.597 -179.355 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.487 ' HZ2' ' HA ' ' A' ' 37' ' ' LYS . 9.9 pttm -62.75 -38.37 90.3 Favored 'General case' 0 C--N 1.318 -0.773 0 C-N-CA 120.069 -0.652 . . . . 0.0 109.994 -179.423 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 52.9 tttp -61.47 -37.52 83.91 Favored 'General case' 0 N--CA 1.446 -0.654 0 C-N-CA 120.153 -0.619 . . . . 0.0 110.057 -179.523 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.86 -36.01 81.35 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.53 179.389 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.612 ' SD ' ' CE1' ' A' ' 39' ' ' PHE . 0.0 OUTLIER -88.48 -10.94 47.34 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.214 179.852 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 65.7 p -66.22 151.84 46.13 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.854 0.359 . . . . 0.0 110.527 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -134.53 131.87 38.49 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.555 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 36.0 p-10 -93.41 13.41 21.68 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.445 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 70.3 tt0 56.16 74.11 0.74 Allowed Pre-proline 0 C--N 1.32 -0.69 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.448 -179.846 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo . . . . . 0 C--N 1.307 -1.617 0 C-N-CA 122.691 2.261 . . . . 0.0 111.915 -179.716 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 73.3 mmm . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -80.01 31.31 2.29 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.448 ' C ' HD12 ' A' ' 4' ' ' ILE . . . 134.26 20.37 0.82 Allowed Glycine 0 CA--C 1.522 0.479 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.781 ' N ' HD12 ' A' ' 4' ' ' ILE . 2.5 mp -101.38 101.08 11.6 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 CA-C-O 121.174 0.511 . . . . 0.0 110.656 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.614 ' H ' ' CD ' ' A' ' 8' ' ' GLN . 66.9 m -103.86 -163.04 0.94 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.593 179.191 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 26.1 mm -61.79 -45.78 97.94 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.315 -178.808 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.768 ' CZ2' HD11 ' A' ' 11' ' ' ILE . 6.5 t-105 -62.74 -42.0 99.46 Favored 'General case' 0 N--CA 1.434 -1.242 0 CA-C-N 115.219 -0.901 . . . . 0.0 108.756 179.338 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.614 ' CD ' ' H ' ' A' ' 5' ' ' SER . 5.9 mp0 -64.74 -38.73 91.97 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.127 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.439 HD23 ' HA ' ' A' ' 9' ' ' LEU . 32.7 mt -60.03 -37.28 79.3 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.789 178.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.598 ' O ' HG23 ' A' ' 14' ' ' VAL . 4.8 mt -61.94 -44.32 97.01 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.077 -176.671 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.768 HD11 ' CZ2' ' A' ' 7' ' ' TRP . 4.4 mp -66.65 -45.33 88.62 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.508 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.329 177.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.403 ' N ' ' CD1' ' A' ' 12' ' ' ILE . 1.1 mp -64.96 -44.79 96.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.448 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.776 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.18 -37.0 85.89 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.971 0.415 . . . . 0.0 110.395 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.598 HG23 ' O ' ' A' ' 10' ' ' LEU . 56.0 t -67.4 -43.77 87.43 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.39 0 C-N-CA 119.811 -0.756 . . . . 0.0 110.792 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.402 HG12 ' O ' ' A' ' 11' ' ' ILE . 4.4 mm -65.53 -43.39 94.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.26 0.552 . . . . 0.0 110.98 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.463 HG22 ' CD2' ' A' ' 20' ' ' PHE . 0.3 OUTLIER -63.54 -38.16 81.48 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.401 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.536 -178.31 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.776 HG23 ' O ' ' A' ' 13' ' ' ALA . 73.5 t -64.61 -43.67 96.72 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.381 0 C-N-CA 118.429 -1.309 . . . . 0.0 109.751 -178.404 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.588 HD21 ' O ' ' A' ' 14' ' ' VAL . 0.1 OUTLIER -63.72 -43.63 95.98 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 178.168 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.06 -43.75 94.55 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-N 114.006 -1.452 . . . . 0.0 111.605 -176.519 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.463 ' CD2' HG22 ' A' ' 16' ' ' VAL . 2.9 m-85 -68.92 -33.1 73.19 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.509 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 97.35 14.21 42.37 Favored Glycine 0 CA--C 1.502 -0.733 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 178.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.773 HG22 ' CG1' ' A' ' 17' ' ' VAL . 70.3 p 57.38 14.51 2.22 Favored 'General case' 0 CA--C 1.508 -0.664 0 CA-C-N 114.57 -0.815 . . . . 0.0 112.408 179.051 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -97.51 -31.35 12.38 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.375 -178.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 13.8 tppt? -70.96 -47.36 59.36 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 121.399 0.618 . . . . 0.0 111.477 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 1.092 ' H ' HD12 ' A' ' 25' ' ' LEU . 1.8 mp -61.0 -37.48 82.66 Favored 'General case' 0 CA--C 1.489 -1.402 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.232 -179.086 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.49 -24.79 75.66 Favored Glycine 0 N--CA 1.425 -2.053 0 CA-C-N 114.277 -1.329 . . . . 0.0 109.889 -177.451 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 75.7 m -84.81 -39.99 17.72 Favored 'General case' 0 CA--C 1.514 -0.408 0 C-N-CA 121.028 -0.269 . . . . 0.0 111.444 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 11.0 pt -93.95 -34.51 5.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.316 0.579 . . . . 0.0 109.759 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 25' ' ' LEU . . . -61.8 -24.79 64.93 Favored Glycine 0 C--O 1.226 -0.402 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.2 p -64.96 -38.94 92.62 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.686 -0.406 . . . . 0.0 111.606 -179.15 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 45.5 m-20 -87.28 -36.74 17.73 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -73.6 -46.03 49.6 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.456 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.404 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -61.92 -44.46 97.8 Favored Glycine 0 C--N 1.311 -0.854 0 C-N-CA 119.399 -1.382 . . . . 0.0 109.856 -179.105 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.68 -40.17 76.52 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.718 -0.241 . . . . 0.0 111.432 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.9 t -63.1 -42.35 99.56 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.565 -0.454 . . . . 0.0 110.528 -178.404 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.2 -39.41 81.14 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.042 178.712 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.601 ' HA ' ' HZ2' ' A' ' 40' ' ' LYS . 7.7 ttpt -59.51 -45.56 91.39 Favored 'General case' 0 N--CA 1.435 -1.175 0 C-N-CA 119.252 -0.979 . . . . 0.0 109.043 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.79 -37.11 88.3 Favored Glycine 0 CA--C 1.529 0.946 0 C-N-CA 120.05 -1.071 . . . . 0.0 110.461 178.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -71.6 -51.82 21.32 Favored 'General case' 0 CA--C 1.511 -0.528 0 CA-C-O 120.574 0.226 . . . . 0.0 111.537 -179.478 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.601 ' HZ2' ' HA ' ' A' ' 37' ' ' LYS . 8.9 pttm -62.78 -37.71 87.77 Favored 'General case' 0 C--N 1.318 -0.792 0 C-N-CA 120.207 -0.597 . . . . 0.0 110.144 -179.455 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -61.64 -36.15 79.95 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.25 -178.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.8 -35.97 82.19 Favored 'General case' 0 C--N 1.319 -0.727 0 C-N-CA 120.686 -0.405 . . . . 0.0 109.921 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.447 ' O ' ' O ' ' A' ' 44' ' ' SER . 10.3 mmt -88.81 -65.85 0.98 Allowed 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.626 -0.261 . . . . 0.0 110.418 179.624 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.453 ' N ' ' O ' ' A' ' 40' ' ' LYS . 28.1 t 53.86 164.8 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.377 -179.676 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -143.03 -49.61 0.33 Allowed 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.759 0.314 . . . . 0.0 110.72 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 41.7 p-10 -88.23 13.38 11.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.062 0.458 . . . . 0.0 110.204 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 40.56 76.02 0.54 Allowed Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.645 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_exo . . . . . 0 C--N 1.306 -1.671 0 C-N-CA 122.872 2.381 . . . . 0.0 112.155 -179.615 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 93.4 mtp . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.651 ' O ' HD21 ' A' ' 9' ' ' LEU . . . -117.73 3.12 17.53 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.129 -0.788 . . . . 0.0 111.129 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -137.04 23.53 3.18 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 110.88 -0.888 . . . . 0.0 110.88 179.763 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 9.1 mt -63.13 -49.4 83.46 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.458 0 CA-C-O 120.925 0.393 . . . . 0.0 110.739 -179.647 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.1 m -176.72 172.71 2.07 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 122.073 0.94 . . . . 0.0 109.96 179.043 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.9 mm -62.27 -49.65 83.12 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 CA-C-N 113.78 -1.555 . . . . 0.0 111.35 -179.809 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.516 ' CE2' HD11 ' A' ' 11' ' ' ILE . 10.8 t-105 -62.6 -38.59 90.76 Favored 'General case' 0 N--CA 1.44 -0.944 0 CA-C-N 115.421 -0.808 . . . . 0.0 109.008 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 25.7 mm-40 -64.94 -39.25 93.22 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.716 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.651 HD21 ' O ' ' A' ' 2' ' ' GLY . 29.3 mt -61.39 -38.1 85.8 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.434 178.662 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.618 ' O ' HG23 ' A' ' 14' ' ' VAL . 5.6 mt -62.09 -43.3 99.13 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.066 -176.809 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.516 HD11 ' CE2' ' A' ' 7' ' ' TRP . 5.9 mt -66.3 -45.33 89.99 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 C-N-CA 119.928 -0.709 . . . . 0.0 109.588 177.903 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.1 mp -65.8 -47.39 85.92 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.806 -179.268 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.813 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.75 -37.36 87.34 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.543 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.618 HG23 ' O ' ' A' ' 10' ' ' LEU . 45.8 t -67.38 -44.28 87.18 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.052 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.709 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 97.0 mt -65.61 -43.13 94.08 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.761 0 CA-C-O 121.33 0.586 . . . . 0.0 110.685 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.496 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -63.99 -38.17 81.72 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.589 -178.082 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.813 HG23 ' O ' ' A' ' 13' ' ' ALA . 83.2 t -65.61 -42.83 93.73 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.93 0 C-N-CA 118.449 -1.3 . . . . 0.0 111.474 -178.156 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.595 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 19.2 mt -62.49 -45.72 91.73 Favored 'General case' 0 C--N 1.319 -0.76 0 C-N-CA 119.66 -0.816 . . . . 0.0 112.075 -178.469 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.886 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.92 -38.24 79.41 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -179.315 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.886 ' N ' HD12 ' A' ' 19' ' ' LEU . 2.0 m-85 -67.79 -36.87 81.21 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 108.804 -0.814 . . . . 0.0 108.804 -178.215 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 101.65 7.41 48.27 Favored Glycine 0 CA--C 1.501 -0.837 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 178.374 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.765 ' HA ' HD13 ' A' ' 25' ' ' LEU . 18.0 p 56.41 19.74 4.26 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.77 -0.715 . . . . 0.0 112.135 178.588 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 17.0 mtmt -92.09 -25.13 18.9 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.63 -0.428 . . . . 0.0 111.006 -179.081 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.605 ' O ' ' N ' ' A' ' 27' ' ' SER . 0.9 OUTLIER -85.12 -59.85 2.21 Favored 'General case' 0 C--O 1.213 -0.856 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.828 -179.514 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 1.068 ' H ' HD12 ' A' ' 25' ' ' LEU . 2.6 mp -42.63 -39.06 2.22 Favored 'General case' 0 CA--C 1.492 -1.272 0 CA-C-O 122.503 1.145 . . . . 0.0 110.221 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.65 -25.2 70.52 Favored Glycine 0 N--CA 1.428 -1.872 0 CA-C-N 113.361 -1.745 . . . . 0.0 111.066 -178.173 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.605 ' N ' ' O ' ' A' ' 24' ' ' LYS . 8.5 t -99.23 -36.61 9.59 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -179.147 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.429 ' N ' ' O ' ' A' ' 24' ' ' LYS . 13.1 pt -92.75 -36.58 7.72 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 CA-C-O 121.296 0.57 . . . . 0.0 109.498 -179.03 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.24 -26.23 67.51 Favored Glycine 0 CA--C 1.521 0.415 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.0 p -64.7 -40.12 94.82 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.628 -179.469 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -76.4 -42.48 44.16 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 179.361 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -66.89 -44.18 81.51 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.587 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.13 -44.31 97.39 Favored Glycine 0 N--CA 1.44 -1.063 0 C-N-CA 119.51 -1.328 . . . . 0.0 109.884 -179.097 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -72.1 -39.92 68.58 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.671 -0.265 . . . . 0.0 111.289 178.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 67.0 m -63.31 -40.7 98.06 Favored 'General case' 0 CA--C 1.515 -0.392 0 C-N-CA 120.528 -0.469 . . . . 0.0 110.551 -178.485 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.48 -39.15 78.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.007 179.048 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.407 ' O ' ' CB ' ' A' ' 41' ' ' LYS . 20.8 tttt -59.49 -44.98 92.93 Favored 'General case' 0 N--CA 1.432 -1.344 0 C-N-CA 119.358 -0.937 . . . . 0.0 108.598 -178.416 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.04 -36.48 93.08 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 178.62 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 87.1 t80 -71.35 -54.31 11.2 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 111.66 0.244 . . . . 0.0 111.66 -179.172 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.411 ' CG ' ' N ' ' A' ' 41' ' ' LYS . 18.9 ptmt -64.8 -39.83 94.23 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.974 179.889 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.411 ' N ' ' CG ' ' A' ' 40' ' ' LYS . 88.6 tttt -62.87 -36.84 84.63 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.729 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.62 -36.1 81.78 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.421 179.743 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 33.4 mtm -90.23 -10.71 43.31 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.843 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 96.3 p -60.98 -35.14 76.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.924 0.392 . . . . 0.0 110.298 -179.686 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.485 ' C ' ' H ' ' A' ' 47' ' ' GLU . 54.1 t0 55.06 75.1 0.33 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.423 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.451 ' O ' ' O ' ' A' ' 47' ' ' GLU . 66.7 t0 -71.44 40.62 0.07 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.334 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.485 ' H ' ' C ' ' A' ' 45' ' ' ASP . 3.6 mp0 57.21 151.18 0.06 OUTLIER Pre-proline 0 CA--C 1.533 0.326 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.708 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_exo . . . . . 0 C--N 1.316 -1.166 0 C-N-CA 122.597 2.198 . . . . 0.0 112.181 179.689 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.477 ' C ' ' H ' ' A' ' 3' ' ' GLY . 69.6 mmm . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 68.53 -10.2 1.52 Allowed Glycine 0 CA--C 1.523 0.58 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.477 ' H ' ' C ' ' A' ' 1' ' ' MET . . . -138.34 28.34 2.69 Favored Glycine 0 N--CA 1.465 0.59 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.7 mt -63.71 -44.12 98.26 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.486 0 CA-C-O 121.148 0.499 . . . . 0.0 110.179 -179.802 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.8 m -179.84 169.02 1.31 Allowed 'General case' 0 N--CA 1.44 -0.974 0 CA-C-O 121.748 0.785 . . . . 0.0 110.592 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.54 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.5 mp -63.86 -44.49 98.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 113.765 -1.561 . . . . 0.0 109.503 177.877 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.493 ' O ' HD12 ' A' ' 11' ' ' ILE . 29.0 m95 -62.69 -46.88 86.09 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 120.086 -0.645 . . . . 0.0 110.027 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.522 ' OE1' ' N ' ' A' ' 8' ' ' GLN . 0.7 OUTLIER -64.22 -39.04 93.15 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 -179.385 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.688 ' C ' HD12 ' A' ' 9' ' ' LEU . 0.2 OUTLIER -70.37 -37.92 74.66 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.319 178.654 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.559 ' O ' HG23 ' A' ' 14' ' ' VAL . 19.2 mt -62.82 -46.55 87.41 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.899 -177.467 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.493 HD12 ' O ' ' A' ' 7' ' ' TRP . 6.2 mt -65.84 -44.31 92.87 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.247 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 56.2 mt -63.44 -44.35 98.83 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.157 -178.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.778 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.15 -37.13 86.34 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.454 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.559 HG23 ' O ' ' A' ' 10' ' ' LEU . 73.5 t -67.53 -44.31 86.62 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 C-N-CA 119.795 -0.762 . . . . 0.0 110.489 179.58 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.427 HG12 ' O ' ' A' ' 11' ' ' ILE . 4.5 mm -65.99 -43.43 92.66 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.698 0 CA-C-O 121.129 0.49 . . . . 0.0 111.133 -179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.566 HG22 ' CD2' ' A' ' 20' ' ' PHE . 0.3 OUTLIER -63.96 -38.39 82.27 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.072 0 CA-C-N 115.362 -0.835 . . . . 0.0 109.371 -178.984 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.778 HG23 ' O ' ' A' ' 13' ' ' ALA . 79.0 t -65.4 -42.81 94.4 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.024 0 C-N-CA 118.478 -1.289 . . . . 0.0 111.64 -177.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.494 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 29.4 mt -62.42 -45.2 94.17 Favored 'General case' 0 C--N 1.317 -0.821 0 C-N-CA 118.984 -1.086 . . . . 0.0 111.721 -179.159 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.85 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -67.48 -38.46 84.42 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.818 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.85 ' N ' HD12 ' A' ' 19' ' ' LEU . 1.4 m-85 -67.73 -31.25 71.04 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -178.819 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 89.62 8.77 67.35 Favored Glycine 0 CA--C 1.505 -0.541 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.732 HG22 HG13 ' A' ' 17' ' ' VAL . 14.8 p 56.65 15.6 2.22 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 114.48 -0.86 . . . . 0.0 112.279 178.139 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 13.4 ptpt -82.66 -44.38 15.79 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.296 0.569 . . . . 0.0 109.68 178.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.443 ' O ' ' N ' ' A' ' 28' ' ' ILE . 2.0 mmmm -67.95 -43.97 77.84 Favored 'General case' 0 C--O 1.21 -1.012 0 CA-C-N 115.218 -0.901 . . . . 0.0 112.069 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.666 ' N ' HD12 ' A' ' 25' ' ' LEU . 6.7 mp -56.73 -36.87 70.22 Favored 'General case' 0 CA--C 1.49 -1.331 0 CA-C-O 121.876 0.846 . . . . 0.0 110.568 -178.889 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.28 -24.92 74.39 Favored Glycine 0 N--CA 1.422 -2.24 0 CA-C-N 114.61 -1.177 . . . . 0.0 110.669 -176.816 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 8.9 m -101.1 -33.92 9.93 Favored 'General case' 0 CA--C 1.503 -0.839 0 CA-C-O 121.166 0.508 . . . . 0.0 111.931 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.688 HG23 HD22 ' A' ' 32' ' ' LEU . 0.2 OUTLIER -91.66 -40.99 12.86 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.137 -178.772 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -53.22 -33.68 46.13 Favored Glycine 0 C--N 1.314 -0.667 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.466 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 41.8 t -64.99 -44.27 89.85 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.442 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -76.28 -44.79 35.54 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.371 0.605 . . . . 0.0 109.485 179.651 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.688 HD22 HG23 ' A' ' 28' ' ' ILE . 10.6 mp -67.48 -43.87 79.94 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 114.795 -1.093 . . . . 0.0 111.816 -179.458 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.33 -43.77 98.61 Favored Glycine 0 C--N 1.308 -0.985 0 C-N-CA 119.247 -1.454 . . . . 0.0 109.789 -179.682 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.27 -40.32 71.03 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.461 -0.369 . . . . 0.0 111.25 179.407 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 40.1 t -63.49 -41.98 98.56 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.223 0.535 . . . . 0.0 111.125 -178.71 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.53 -40.12 79.3 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.665 -179.727 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.2 pttt -60.07 -42.84 95.41 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -179.745 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.03 -36.59 92.18 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 178.578 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -71.65 -51.89 20.75 Favored 'General case' 0 CA--C 1.516 -0.365 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.18 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.548 ' O ' ' N ' ' A' ' 44' ' ' SER . 42.7 mmtm -64.0 -38.97 93.01 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.37 178.783 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -61.63 -36.83 81.89 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.092 -0.643 . . . . 0.0 110.14 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.69 -36.3 82.19 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.794 -179.686 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.458 ' O ' ' O ' ' A' ' 44' ' ' SER . 67.2 mtm -99.92 -66.86 0.88 Allowed 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.962 0.41 . . . . 0.0 110.741 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.548 ' N ' ' O ' ' A' ' 40' ' ' LYS . 25.8 t 40.24 -166.58 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.707 -179.429 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.547 ' N ' ' OG ' ' A' ' 44' ' ' SER . 98.7 m-20 53.81 33.07 16.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.57 -0.287 . . . . 0.0 110.648 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -100.59 41.74 1.16 Allowed 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.819 0.343 . . . . 0.0 110.513 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 55.3 tt0 -162.42 73.84 2.18 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.493 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_exo . . . . . 0 C--N 1.307 -1.635 0 C-N-CA 122.874 2.383 . . . . 0.0 112.089 -179.915 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 38.9 mmt . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 84.06 26.59 40.27 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.356 -0.697 . . . . 0.0 111.356 179.799 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 139.17 -11.63 3.31 Favored Glycine 0 N--CA 1.463 0.49 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.468 HG23 ' CB ' ' A' ' 8' ' ' GLN . 3.8 mp -102.04 117.04 46.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.094 0.473 . . . . 0.0 110.608 -179.773 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.484 ' C ' HD12 ' A' ' 6' ' ' ILE . 60.5 m -146.37 -88.15 0.1 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.733 179.427 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.484 HD12 ' C ' ' A' ' 5' ' ' SER . 1.6 mp -110.23 -34.57 2.5 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-O 120.768 0.318 . . . . 0.0 110.548 -179.755 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 58.6 m95 -62.56 -49.02 76.95 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 -179.456 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.468 ' CB ' HG23 ' A' ' 4' ' ' ILE . 11.7 mp0 -64.53 -38.94 92.74 Favored 'General case' 0 C--N 1.312 -1.045 0 C-N-CA 120.186 -0.606 . . . . 0.0 109.577 179.625 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.504 ' N ' ' CD2' ' A' ' 9' ' ' LEU . 3.3 mm? -63.82 -39.25 93.8 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.953 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.569 ' O ' HG23 ' A' ' 14' ' ' VAL . 9.5 mt -63.4 -52.4 61.78 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.894 -178.415 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.469 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.5 mp -64.86 -44.58 96.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 178.495 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 71.9 mt -63.56 -45.73 96.9 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.101 0 C-N-CA 120.107 -0.637 . . . . 0.0 111.177 -179.6 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.799 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.73 -37.37 87.38 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.968 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.582 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 51.6 t -67.54 -43.84 86.89 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 C-N-CA 119.823 -0.751 . . . . 0.0 110.872 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.3 mt -65.4 -42.79 94.34 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.658 0 CA-C-O 121.1 0.476 . . . . 0.0 110.225 -179.009 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.476 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -64.5 -38.43 82.59 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.345 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.917 -178.459 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.804 ' CG1' HG22 ' A' ' 22' ' ' THR . 75.1 t -63.88 -43.07 97.7 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.367 0 C-N-CA 118.544 -1.262 . . . . 0.0 111.002 -177.775 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.582 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 14.4 mt -60.8 -47.08 87.98 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 120.078 -0.649 . . . . 0.0 112.473 -178.789 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.857 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.95 -37.96 79.17 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -179.515 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.857 ' N ' HD12 ' A' ' 19' ' ' LEU . 0.8 OUTLIER -67.45 -35.99 80.28 Favored 'General case' 0 CA--C 1.519 -0.217 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -177.946 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.598 ' C ' ' H ' ' A' ' 23' ' ' LYS . . . 102.69 10.8 36.94 Favored Glycine 0 CA--C 1.501 -0.837 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 178.298 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.804 HG22 ' CG1' ' A' ' 17' ' ' VAL . 44.8 p 56.52 -1.94 0.04 OUTLIER 'General case' 0 CA--C 1.497 -1.081 0 CA-C-O 121.073 0.463 . . . . 0.0 112.138 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.598 ' H ' ' C ' ' A' ' 21' ' ' GLY . 12.6 tmtt? -84.41 -36.22 22.55 Favored 'General case' 0 N--CA 1.434 -1.252 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.006 -179.117 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.4 tppt? -63.75 -48.57 76.47 Favored 'General case' 0 N--CA 1.436 -1.126 0 CA-C-O 121.089 0.471 . . . . 0.0 110.37 179.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 1.063 ' H ' HD12 ' A' ' 25' ' ' LEU . 2.1 mp -60.27 -38.63 84.13 Favored 'General case' 0 CA--C 1.486 -1.493 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.044 -178.345 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.19 -25.62 72.78 Favored Glycine 0 N--CA 1.424 -2.124 0 CA-C-N 114.708 -1.133 . . . . 0.0 110.443 -177.541 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 8.1 t -81.81 -42.62 19.44 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 120.775 0.321 . . . . 0.0 111.311 179.389 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 11.3 pt -91.77 -34.53 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 CA-C-O 121.189 0.518 . . . . 0.0 109.706 -179.435 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 25' ' ' LEU . . . -62.1 -22.95 63.38 Favored Glycine 0 CA--C 1.518 0.253 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 14.0 t -64.8 -43.0 94.59 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.452 -0.499 . . . . 0.0 111.769 -179.325 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -84.42 -37.08 21.89 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -72.3 -44.34 62.88 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.173 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.4 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -61.97 -43.8 98.69 Favored Glycine 0 C--N 1.31 -0.899 0 C-N-CA 119.527 -1.32 . . . . 0.0 110.018 -179.366 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.5 -39.93 73.86 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.891 -0.324 . . . . 0.0 111.205 179.533 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 44.8 t -64.3 -41.93 96.62 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.542 -0.463 . . . . 0.0 111.288 -178.763 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.422 HG23 ' HZ2' ' A' ' 40' ' ' LYS . 1.2 mp -68.73 -38.92 79.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.205 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 3.3 pttp -59.49 -40.86 88.38 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 -178.746 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.07 -36.63 90.89 Favored Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 178.88 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -71.63 -49.71 37.46 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 121.04 0.448 . . . . 0.0 109.962 -179.472 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.545 ' O ' ' N ' ' A' ' 44' ' ' SER . 53.4 mttp -63.12 -38.57 91.71 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.471 178.528 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 12.5 ttmm -61.33 -36.99 81.69 Favored 'General case' 0 C--N 1.319 -0.748 0 C-N-CA 119.935 -0.706 . . . . 0.0 110.187 -179.613 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -67.03 -36.08 81.32 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.274 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.428 ' O ' ' OD1' ' A' ' 46' ' ' ASP . 75.2 mtm -93.62 -10.29 35.13 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.746 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.545 ' N ' ' O ' ' A' ' 40' ' ' LYS . 11.6 t -56.06 -41.04 74.45 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.944 0.402 . . . . 0.0 110.093 -179.199 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.412 ' O ' ' OD1' ' A' ' 45' ' ' ASP . 53.2 p-10 -75.08 78.61 2.24 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.36 179.706 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 43' ' ' MET . 99.0 m-20 -101.57 38.38 1.62 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.557 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -149.37 61.0 4.97 Favored Pre-proline 0 N--CA 1.464 0.235 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.559 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo . . . . . 0 C--N 1.306 -1.705 0 C-N-CA 122.845 2.363 . . . . 0.0 111.836 179.808 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.452 ' C ' HD11 ' A' ' 4' ' ' ILE . 1.2 ppp? . . . . . 0 N--CA 1.493 1.688 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -115.19 -16.59 7.13 Favored Glycine 0 N--CA 1.468 0.778 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -111.18 -44.68 0.91 Allowed Glycine 0 N--CA 1.463 0.483 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.719 ' N ' HD12 ' A' ' 4' ' ' ILE . 2.4 mp 55.13 96.9 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 CA-C-O 120.899 0.381 . . . . 0.0 111.133 179.056 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 34.9 m -92.33 -169.59 2.27 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.392 0.615 . . . . 0.0 109.574 178.82 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.2 mm -61.23 -46.74 96.02 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.636 -178.641 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.621 ' CE2' HD11 ' A' ' 11' ' ' ILE . 11.7 t-105 -62.82 -38.07 89.28 Favored 'General case' 0 N--CA 1.438 -1.059 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.725 178.82 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 28.6 mm-40 -64.84 -40.29 94.93 Favored 'General case' 0 CA--C 1.509 -0.61 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 178.656 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 72.0 mt -61.4 -37.64 84.17 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.006 178.212 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.719 ' O ' HG23 ' A' ' 14' ' ' VAL . 5.4 mt -62.12 -42.88 99.67 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.2 -176.44 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.621 HD11 ' CE2' ' A' ' 7' ' ' TRP . 6.4 mt -67.89 -45.67 83.57 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 C-N-CA 120.25 -0.58 . . . . 0.0 110.011 177.48 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.1 mp -65.49 -44.7 94.09 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.997 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.814 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.46 -36.69 85.0 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.605 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 10' ' ' LEU . 48.8 t -66.75 -45.73 87.3 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.039 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.305 -179.167 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 16.2 pt -65.97 -42.49 91.9 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-N 118.023 0.374 . . . . 0.0 110.929 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.492 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -63.47 -38.37 82.04 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.134 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.601 -178.96 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.814 HG23 ' O ' ' A' ' 13' ' ' ALA . 90.7 t -65.69 -44.34 93.42 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.803 0 C-N-CA 118.382 -1.327 . . . . 0.0 111.713 -178.648 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.595 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 23.5 mt -61.62 -46.46 89.7 Favored 'General case' 0 C--N 1.322 -0.623 0 C-N-CA 119.907 -0.717 . . . . 0.0 111.909 -179.037 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.869 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.7 pp -68.09 -38.41 82.32 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 -179.607 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.869 ' N ' HD12 ' A' ' 19' ' ' LEU . 2.0 m-85 -67.64 -37.7 82.8 Favored 'General case' 0 CA--C 1.517 -0.324 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -177.77 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.408 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 102.81 6.07 46.82 Favored Glycine 0 CA--C 1.499 -0.953 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 178.544 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.751 ' HA ' HD13 ' A' ' 25' ' ' LEU . 18.5 p 57.88 19.2 5.56 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 114.964 -0.618 . . . . 0.0 112.281 178.279 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -93.16 -19.93 20.98 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.535 -179.355 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.602 ' O ' ' N ' ' A' ' 27' ' ' SER . 1.0 OUTLIER -89.81 -60.39 1.95 Allowed 'General case' 0 C--O 1.211 -0.958 0 CA-C-O 121.178 0.513 . . . . 0.0 110.706 -179.775 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 1.047 ' H ' HD12 ' A' ' 25' ' ' LEU . 2.6 mp -42.26 -39.43 2.09 Favored 'General case' 0 CA--C 1.491 -1.304 0 CA-C-O 122.495 1.141 . . . . 0.0 110.149 -179.532 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.78 -25.83 68.67 Favored Glycine 0 N--CA 1.426 -1.988 0 CA-C-N 113.246 -1.797 . . . . 0.0 111.02 -178.18 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.602 ' N ' ' O ' ' A' ' 24' ' ' LYS . 8.3 m -99.09 -34.18 10.5 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 112.438 0.532 . . . . 0.0 112.438 -179.28 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.467 ' N ' ' O ' ' A' ' 24' ' ' LYS . 13.0 pt -94.26 -36.05 6.78 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 CA-C-O 121.483 0.658 . . . . 0.0 109.533 -179.107 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.44 -27.52 71.85 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.679 -0.968 . . . . 0.0 110.679 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.0 p -64.83 -41.27 95.88 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.848 -179.121 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -78.61 -40.97 32.93 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 179.689 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.3 mp -68.65 -45.92 70.52 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.551 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.51 -44.0 97.29 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.76 -40.23 76.24 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.366 -0.417 . . . . 0.0 111.364 179.196 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 43.3 m -63.63 -40.79 97.77 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.531 -0.467 . . . . 0.0 111.216 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.67 -40.93 79.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.073 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 16.2 pttt -60.24 -43.48 96.05 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.66 -36.91 92.0 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.614 -0.994 . . . . 0.0 110.614 178.761 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.593 ' CZ ' ' SD ' ' A' ' 43' ' ' MET . 39.9 t80 -71.67 -50.69 28.19 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-O 120.946 0.403 . . . . 0.0 110.516 -179.604 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.564 ' O ' ' N ' ' A' ' 44' ' ' SER . 66.4 mmtt -63.97 -38.99 93.09 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 120.252 -0.579 . . . . 0.0 110.325 179.181 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt -61.97 -37.16 83.71 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.239 -179.663 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.54 -35.89 81.35 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.523 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.593 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 6.0 mtp -100.7 -69.82 0.76 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.711 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.564 ' N ' ' O ' ' A' ' 40' ' ' LYS . 0.9 OUTLIER 28.35 -88.03 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.635 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.16 179.853 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.504 ' N ' ' O ' ' A' ' 43' ' ' MET . 90.2 m-20 -134.07 -175.78 3.96 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.559 178.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 47' ' ' GLU . 42.0 t0 60.54 39.18 18.39 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.602 -0.272 . . . . 0.0 110.64 -179.791 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.425 ' C ' ' O ' ' A' ' 46' ' ' ASP . 51.7 mt-10 -32.5 96.43 0.09 OUTLIER Pre-proline 0 N--CA 1.47 0.535 0 O-C-N 123.485 0.491 . . . . 0.0 111.002 179.88 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo . . . . . 0 N--CA 1.496 1.657 0 C-N-CA 122.158 1.906 . . . . 0.0 112.318 -178.948 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.482 ' HG3' ' H ' ' A' ' 3' ' ' GLY . 4.5 tpt . . . . . 0 N--CA 1.488 1.426 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 116.46 3.93 18.27 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.482 ' H ' ' HG3' ' A' ' 1' ' ' MET . . . 94.08 9.78 59.15 Favored Glycine 0 N--CA 1.464 0.535 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.525 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.481 HG22 ' N ' ' A' ' 5' ' ' SER . 30.4 mt -59.07 -113.45 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.523 -0.339 . . . . 0.0 110.545 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.481 ' N ' HG22 ' A' ' 4' ' ' ILE . 38.4 m -157.98 -164.48 1.53 Allowed 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -178.928 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.1 mm -96.92 -45.5 12.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.872 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.725 ' CE2' HD11 ' A' ' 11' ' ' ILE . 9.5 t-105 -62.67 -36.61 83.44 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.617 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 21.3 mm-40 -64.47 -38.88 92.57 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 86.6 mt -63.03 -37.66 88.07 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.747 178.374 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.612 ' O ' HG23 ' A' ' 14' ' ' VAL . 5.2 mt -62.58 -42.89 99.84 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.13 -177.055 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.725 HD11 ' CE2' ' A' ' 7' ' ' TRP . 7.8 mt -66.95 -45.54 87.02 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.95 0 C-N-CA 119.698 -0.801 . . . . 0.0 109.51 177.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 67.1 mt -65.66 -47.56 85.71 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.806 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.327 -179.719 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.837 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.55 -37.34 87.21 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.4 -179.764 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.612 HG23 ' O ' ' A' ' 10' ' ' LEU . 40.6 t -67.67 -44.25 86.17 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 C-N-CA 119.748 -0.781 . . . . 0.0 110.973 179.721 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 91.8 mt -65.27 -42.28 93.54 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.834 0 CA-C-O 120.993 0.425 . . . . 0.0 110.395 -179.087 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.502 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -64.25 -38.4 82.41 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.113 0 CA-C-N 115.322 -0.854 . . . . 0.0 110.11 -178.836 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.837 HG23 ' O ' ' A' ' 13' ' ' ALA . 87.1 t -64.56 -42.6 95.64 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.257 0 C-N-CA 118.389 -1.325 . . . . 0.0 111.131 -177.351 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.565 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 20.8 mt -62.08 -47.18 85.83 Favored 'General case' 0 C--N 1.316 -0.887 0 C-N-CA 119.819 -0.752 . . . . 0.0 112.566 -178.573 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.849 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.01 -38.41 82.56 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.897 -179.579 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.849 ' N ' HD12 ' A' ' 19' ' ' LEU . 0.7 OUTLIER -68.07 -32.14 72.27 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -178.3 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 93.9 5.79 62.44 Favored Glycine 0 CA--C 1.504 -0.61 0 C-N-CA 120.209 -0.996 . . . . 0.0 111.044 178.523 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.776 HG22 ' CG1' ' A' ' 17' ' ' VAL . 14.4 p 58.39 26.93 14.71 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.161 -0.519 . . . . 0.0 112.202 178.558 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 50.2 pttt -96.97 -33.09 11.7 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.878 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 16.6 mmmt -77.45 -52.78 8.53 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.72 -0.392 . . . . 0.0 111.498 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 1.071 ' H ' HD12 ' A' ' 25' ' ' LEU . 1.9 mp -48.75 -39.08 23.61 Favored 'General case' 0 CA--C 1.489 -1.374 0 CA-C-O 122.336 1.065 . . . . 0.0 110.476 -179.32 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.91 -25.79 70.72 Favored Glycine 0 N--CA 1.426 -2.003 0 CA-C-N 114.092 -1.413 . . . . 0.0 111.111 -177.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 7.2 t -94.0 -39.65 10.53 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 111.915 0.339 . . . . 0.0 111.915 -179.718 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 7.5 pt -89.8 -37.47 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 CA-C-O 121.387 0.613 . . . . 0.0 109.675 -179.133 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.32 -27.05 68.64 Favored Glycine 0 C--O 1.228 -0.224 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 -179.111 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.1 p -64.91 -42.01 95.1 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 120.544 -0.462 . . . . 0.0 111.219 -179.444 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 66.7 t0 -76.63 -41.04 47.38 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.289 0.566 . . . . 0.0 109.846 179.728 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.5 mp -68.68 -45.82 70.68 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.024 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.56 -43.82 98.45 Favored Glycine 0 C--N 1.308 -1.018 0 C-N-CA 119.463 -1.351 . . . . 0.0 110.031 -179.55 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.07 -40.25 75.14 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.82 0.343 . . . . 0.0 111.148 179.646 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.6 t -63.94 -42.01 97.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.132 0.491 . . . . 0.0 111.248 -178.742 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.48 -39.42 78.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.615 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 17.9 pttt -59.32 -40.35 86.0 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 -178.108 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -69.81 -37.09 75.37 Favored Glycine 0 N--CA 1.442 -0.903 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -71.61 -49.16 42.8 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-O 121.114 0.483 . . . . 0.0 109.762 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.53 ' O ' ' N ' ' A' ' 44' ' ' SER . 47.5 mtpt -63.01 -38.6 91.83 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.558 178.566 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 14.2 tmtt? -61.75 -36.68 81.71 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 119.773 -0.771 . . . . 0.0 109.853 -178.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.89 -36.44 82.29 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.052 179.713 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 75.9 mtm -92.42 -10.92 36.25 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.488 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.53 ' N ' ' O ' ' A' ' 40' ' ' LYS . 41.4 t -61.89 148.89 42.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.275 -179.666 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 56.25 44.9 24.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.539 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 51.4 p30 -74.4 46.2 0.26 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.7 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 68.9 mt-10 52.02 71.47 1.48 Allowed Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.621 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo . . . . . 0 C--N 1.306 -1.659 0 C-N-CA 122.756 2.304 . . . . 0.0 112.054 -179.994 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.647 ' HA ' HD11 ' A' ' 4' ' ' ILE . 91.5 mtp . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -111.2 24.47 16.04 Favored Glycine 0 N--CA 1.467 0.75 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.49 ' C ' HD13 ' A' ' 4' ' ' ILE . . . -130.93 19.97 4.87 Favored Glycine 0 CA--C 1.519 0.326 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 179.517 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.685 ' N ' HD13 ' A' ' 4' ' ' ILE . 0.0 OUTLIER -103.23 -82.23 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.851 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.464 ' N ' ' OE1' ' A' ' 8' ' ' GLN . 41.2 m 67.44 -80.0 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 114.931 -1.031 . . . . 0.0 112.341 179.381 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.609 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.6 mp -92.94 -30.85 4.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.786 -178.622 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 91.8 m95 -62.27 -41.01 98.1 Favored 'General case' 0 CA--C 1.507 -0.685 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.748 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.464 ' OE1' ' N ' ' A' ' 5' ' ' SER . 9.5 pt20 -64.28 -39.48 94.01 Favored 'General case' 0 C--O 1.215 -0.725 0 C-N-CA 118.572 -1.251 . . . . 0.0 108.152 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.425 ' O ' ' CB ' ' A' ' 13' ' ' ALA . 76.6 mt -68.59 -38.49 80.71 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.166 179.376 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.648 ' O ' HG23 ' A' ' 14' ' ' VAL . 18.7 mt -63.28 -49.27 74.72 Favored 'General case' 0 C--N 1.314 -0.935 0 C-N-CA 120.076 -0.65 . . . . 0.0 111.371 -176.022 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.462 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.7 mp -67.19 -44.33 87.81 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 178.914 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.424 HD13 ' O ' ' A' ' 8' ' ' GLN . 1.0 OUTLIER -65.07 -44.56 95.74 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.878 -179.387 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.846 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.77 -36.53 84.6 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.825 -179.762 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.648 HG23 ' O ' ' A' ' 10' ' ' LEU . 54.8 t -67.03 -45.03 87.87 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.826 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.442 -178.817 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 15.9 pt -66.23 -42.56 91.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 CA-C-O 121.05 0.452 . . . . 0.0 110.827 179.645 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.502 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -63.54 -38.12 81.38 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.905 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 -179.324 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.846 HG23 ' O ' ' A' ' 13' ' ' ALA . 94.4 t -65.52 -43.72 94.25 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 C-N-CA 118.557 -1.257 . . . . 0.0 111.654 -178.303 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.518 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 21.3 mt -61.82 -47.09 86.66 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 119.566 -0.854 . . . . 0.0 111.57 -178.853 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.851 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -67.06 -38.21 85.41 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -179.221 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.851 ' N ' HD12 ' A' ' 19' ' ' LEU . 1.2 m-85 -67.55 -35.83 79.81 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 -177.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.425 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 98.79 8.04 54.76 Favored Glycine 0 CA--C 1.501 -0.821 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 178.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.736 HG22 ' CG1' ' A' ' 17' ' ' VAL . 19.0 p 57.7 27.1 13.85 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 114.309 -0.945 . . . . 0.0 112.52 178.239 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 55.3 mtpt -100.0 -19.82 16.38 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.686 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.503 ' O ' ' N ' ' A' ' 27' ' ' SER . 14.5 mmmt -88.66 -56.91 3.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.125 0.488 . . . . 0.0 110.622 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 1.064 ' H ' HD12 ' A' ' 25' ' ' LEU . 2.3 mp -45.58 -39.83 8.07 Favored 'General case' 0 CA--C 1.495 -1.173 0 CA-C-O 122.473 1.13 . . . . 0.0 110.291 179.804 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.82 -24.84 73.3 Favored Glycine 0 N--CA 1.424 -2.105 0 CA-C-N 113.568 -1.651 . . . . 0.0 110.472 -177.397 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.503 ' N ' ' O ' ' A' ' 24' ' ' LYS . 7.1 t -97.32 -35.98 10.54 Favored 'General case' 0 CA--C 1.519 -0.235 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 -179.639 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 8.7 pt -92.22 -37.21 8.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 CA-C-O 121.358 0.599 . . . . 0.0 109.412 -179.347 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.4 -27.39 65.59 Favored Glycine 0 CA--C 1.522 0.484 0 N-CA-C 110.734 -0.947 . . . . 0.0 110.734 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.3 t -64.76 -41.13 96.12 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.931 -0.308 . . . . 0.0 111.652 -179.388 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 53.3 m-20 -74.15 -43.65 56.6 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.53 0.681 . . . . 0.0 109.208 179.475 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.6 mp -65.82 -44.28 86.08 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.789 -1.096 . . . . 0.0 111.553 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.52 -45.18 96.39 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 119.411 -1.376 . . . . 0.0 109.823 -179.204 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.6 -39.81 73.6 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.651 -0.274 . . . . 0.0 111.309 179.164 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 39.4 t -63.19 -41.69 99.23 Favored 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 120.528 -0.469 . . . . 0.0 110.406 -178.247 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.02 -39.27 79.47 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.715 179.027 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 24.3 tttt -59.87 -43.72 94.57 Favored 'General case' 0 C--N 1.309 -1.17 0 C-N-CA 119.287 -0.965 . . . . 0.0 108.463 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.97 -36.6 91.23 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 178.18 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -71.59 -50.77 27.81 Favored 'General case' 0 CA--C 1.52 -0.182 0 CA-C-O 120.805 0.336 . . . . 0.0 110.291 -179.621 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.521 ' O ' ' N ' ' A' ' 44' ' ' SER . 53.2 mtpt -63.43 -38.52 91.46 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.37 178.646 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -61.74 -39.11 90.41 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.138 -0.625 . . . . 0.0 110.102 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -67.02 -35.98 81.1 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.551 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.433 ' O ' ' O ' ' A' ' 44' ' ' SER . 76.2 mtm -90.34 -65.92 0.97 Allowed 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 121.049 0.452 . . . . 0.0 110.548 179.797 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.521 ' N ' ' O ' ' A' ' 40' ' ' LYS . 60.7 p 41.98 -167.53 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.706 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -94.69 108.47 20.46 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.818 0.342 . . . . 0.0 110.242 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -97.86 22.79 8.74 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 121.059 0.457 . . . . 0.0 110.547 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 57.5 mt-10 47.37 73.16 1.05 Allowed Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.43 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 74.6 Cg_endo . . . . . 0 C--N 1.307 -1.63 0 C-N-CA 122.856 2.371 . . . . 0.0 111.946 -179.903 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.496 ' O ' ' CD1' ' A' ' 12' ' ' ILE . 98.0 mmm . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -120.85 -9.44 7.52 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.034 -0.827 . . . . 0.0 111.034 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.34 -2.07 66.11 Favored Glycine 0 N--CA 1.463 0.441 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 26.0 mt -62.66 -47.68 91.78 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 115.335 -0.432 . . . . 0.0 110.296 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.8 m -175.41 -164.97 0.15 Allowed 'General case' 0 N--CA 1.442 -0.872 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.521 ' CG2' ' N ' ' A' ' 7' ' ' TRP . 1.5 tp -88.72 -49.07 14.47 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 114.988 -1.005 . . . . 0.0 111.012 179.0 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.528 ' CD1' ' C ' ' A' ' 7' ' ' TRP . 2.0 t-105 -62.15 -38.42 88.93 Favored 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -179.262 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 13.7 mm-40 -64.31 -38.75 92.16 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 179.639 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.826 ' O ' HD12 ' A' ' 9' ' ' LEU . 0.2 OUTLIER -70.33 -38.03 74.82 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.423 178.933 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.558 ' O ' HG23 ' A' ' 14' ' ' VAL . 1.2 tt -62.71 -47.03 85.4 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.971 -175.607 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.45 HD11 ' CE2' ' A' ' 7' ' ' TRP . 2.0 mp -65.01 -43.94 96.04 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 177.51 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.496 ' CD1' ' O ' ' A' ' 1' ' ' MET . 72.9 mt -63.37 -44.51 99.03 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.065 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.547 -178.671 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.873 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.23 -37.25 86.82 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.923 -179.241 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.558 HG23 ' O ' ' A' ' 10' ' ' LEU . 78.6 t -67.02 -44.05 88.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 C-N-CA 120.545 -0.462 . . . . 0.0 111.139 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.453 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 58.7 mt -66.62 -43.19 90.57 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.285 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 178.837 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.471 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.5 t -64.01 -42.27 95.16 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.681 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.881 -179.046 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.873 HG23 ' O ' ' A' ' 13' ' ' ALA . 60.1 t -65.93 -44.92 92.29 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.118 0 C-N-CA 118.281 -1.368 . . . . 0.0 112.774 -177.376 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.518 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.4 pp -72.65 -42.87 63.89 Favored 'General case' 0 C--N 1.293 -1.857 0 C-N-CA 120.054 -0.659 . . . . 0.0 109.842 178.761 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.733 HD13 ' C ' ' A' ' 19' ' ' LEU . 2.6 tm? -64.37 -41.29 96.79 Favored 'General case' 0 N--CA 1.443 -0.806 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.617 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.471 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 5.6 m-85 -69.0 -39.47 79.31 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 118.741 -1.183 . . . . 0.0 108.749 179.17 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.478 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 105.15 11.9 28.63 Favored Glycine 0 N--CA 1.467 0.75 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 179.025 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.73 HG22 ' CG1' ' A' ' 17' ' ' VAL . 50.4 p 57.31 44.42 21.89 Favored 'General case' 0 CA--C 1.499 -0.983 0 CA-C-N 115.371 -0.414 . . . . 0.0 112.062 178.304 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -127.19 -18.38 4.56 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.593 -0.73 . . . . 0.0 111.551 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 9.6 tppt? -86.44 -48.38 8.47 Favored 'General case' 0 N--CA 1.447 -0.625 0 CA-C-O 121.008 0.432 . . . . 0.0 110.08 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.711 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.1 OUTLIER -62.43 -36.76 83.42 Favored 'General case' 0 CA--C 1.505 -0.768 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.682 -178.839 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.42 -24.64 75.96 Favored Glycine 0 N--CA 1.437 -1.24 0 N-CA-C 109.914 -1.275 . . . . 0.0 109.914 -176.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 7.6 t -84.75 -42.74 14.92 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 121.104 -0.238 . . . . 0.0 111.592 179.66 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.416 HD13 HG21 ' A' ' 28' ' ' ILE . 8.6 pt -94.08 -35.94 6.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 121.228 0.537 . . . . 0.0 110.034 -179.417 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.526 ' N ' ' O ' ' A' ' 25' ' ' LEU . . . -62.06 -22.68 62.99 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 -179.502 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.9 t -64.79 -42.54 94.99 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.703 -0.399 . . . . 0.0 111.548 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 94.3 m-20 -76.32 -41.18 49.32 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.338 0.59 . . . . 0.0 109.614 179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -68.33 -44.43 75.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.556 179.75 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.0 -44.08 97.92 Favored Glycine 0 N--CA 1.443 -0.853 0 C-N-CA 119.363 -1.399 . . . . 0.0 109.99 -179.001 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.73 -39.87 73.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.719 0.295 . . . . 0.0 111.413 179.27 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.0 t -63.22 -41.9 99.19 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.69 -178.439 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.78 -39.17 79.78 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.009 178.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 23.9 tttt -59.69 -44.65 93.57 Favored 'General case' 0 N--CA 1.435 -1.223 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 -178.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.39 -36.61 92.88 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 178.06 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.62 ' CE2' ' SD ' ' A' ' 43' ' ' MET . 38.3 t80 -71.8 -51.78 20.85 Favored 'General case' 0 CA--C 1.512 -0.495 0 CA-C-O 120.991 0.424 . . . . 0.0 110.406 -179.373 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.511 ' O ' ' N ' ' A' ' 44' ' ' SER . 48.8 mtpt -62.62 -39.1 92.75 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.717 179.454 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 42.8 mtmt -61.58 -39.1 89.97 Favored 'General case' 0 C--N 1.319 -0.75 0 C-N-CA 119.043 -1.063 . . . . 0.0 109.911 -179.73 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.84 -36.33 82.09 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.322 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.62 ' SD ' ' CE2' ' A' ' 39' ' ' PHE . 0.0 OUTLIER -89.07 -12.27 41.7 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.527 179.239 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.511 ' N ' ' O ' ' A' ' 40' ' ' LYS . 46.8 t -61.35 -43.79 98.27 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.051 0.453 . . . . 0.0 110.246 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -89.06 113.55 24.68 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.514 179.715 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 41.1 p-10 -95.25 14.44 22.25 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.064 0.459 . . . . 0.0 110.801 -179.71 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 -168.92 75.33 0.76 Allowed Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.663 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_exo . . . . . 0 C--N 1.307 -1.643 0 C-N-CA 122.783 2.322 . . . . 0.0 111.999 179.962 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.499 ' SD ' ' N ' ' A' ' 1' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.451 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 . . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -143.19 87.12 0.18 Allowed Glycine 0 C--N 1.33 0.233 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.894 -179.588 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 87.92 26.95 27.65 Favored Glycine 0 CA--C 1.519 0.295 0 N-CA-C 110.499 -1.041 . . . . 0.0 110.499 179.365 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 12.7 mm -63.33 -48.13 88.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.328 -0.436 . . . . 0.0 110.727 -179.236 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.5 m 177.49 177.64 0.34 Allowed 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 122.07 0.938 . . . . 0.0 109.789 178.65 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.524 ' HA ' HD23 ' A' ' 9' ' ' LEU . 16.9 mm -69.84 -47.87 67.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 CA-C-N 113.346 -1.752 . . . . 0.0 110.88 179.364 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.588 ' CE2' HD11 ' A' ' 11' ' ' ILE . 22.4 t-105 -65.42 -39.39 92.07 Favored 'General case' 0 N--CA 1.432 -1.345 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.248 -179.519 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 22.0 mm-40 -65.84 -41.45 91.74 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.061 0.458 . . . . 0.0 110.8 179.58 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.683 ' C ' HD12 ' A' ' 9' ' ' LEU . 0.4 OUTLIER -63.41 -36.74 84.72 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.724 179.453 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.628 ' O ' HG23 ' A' ' 14' ' ' VAL . 6.3 mt -62.03 -42.39 99.11 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.013 -177.13 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.588 HD11 ' CE2' ' A' ' 7' ' ' TRP . 7.8 mt -65.2 -44.18 95.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 177.538 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 69.7 mt -63.96 -44.37 97.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.313 -179.019 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.868 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -65.12 -37.53 87.76 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.133 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.628 HG23 ' O ' ' A' ' 10' ' ' LEU . 64.8 t -67.1 -44.54 87.98 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.372 0 C-N-CA 120.829 -0.348 . . . . 0.0 111.35 -178.732 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 16.1 pt -67.12 -42.86 88.77 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.11 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 178.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.473 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.7 t -63.71 -41.63 93.24 Favored 'Isoleucine or valine' 0 CA--C 1.476 -1.882 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.981 -179.213 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.868 HG23 ' O ' ' A' ' 13' ' ' ALA . 61.5 t -66.49 -50.11 69.67 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.984 0 C-N-CA 117.149 -1.821 . . . . 0.0 113.11 -177.19 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.497 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.0 OUTLIER -66.34 -44.52 83.08 Favored 'General case' 0 C--N 1.302 -1.492 0 C-N-CA 119.209 -0.996 . . . . 0.0 112.01 179.722 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.651 ' C ' HD12 ' A' ' 19' ' ' LEU . 0.4 OUTLIER -65.59 -38.24 88.93 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.442 179.962 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.473 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 3.0 m-85 -68.01 -43.91 77.75 Favored 'General case' 0 CA--C 1.515 -0.381 0 C-N-CA 119.221 -0.992 . . . . 0.0 108.501 -179.487 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.504 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 111.71 11.12 17.68 Favored Glycine 0 C--N 1.316 -0.559 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 178.715 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.739 HG22 ' CG1' ' A' ' 17' ' ' VAL . 59.5 p 56.42 35.09 25.36 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 114.863 -0.668 . . . . 0.0 112.784 178.18 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 56.3 mtpt -116.26 -20.32 9.83 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.811 -0.632 . . . . 0.0 111.792 -179.576 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 tppt? -83.47 -52.08 6.81 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-O 121.175 0.512 . . . . 0.0 110.466 -179.741 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.748 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.2 OUTLIER -59.35 -36.73 76.26 Favored 'General case' 0 CA--C 1.501 -0.933 0 CA-C-O 121.907 0.86 . . . . 0.0 111.285 -178.882 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.51 -24.51 76.11 Favored Glycine 0 N--CA 1.433 -1.525 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -177.257 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 7.3 t -86.33 -42.59 13.58 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 179.446 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 13.2 pt -93.66 -36.59 7.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 C-N-CA 120.353 -0.539 . . . . 0.0 109.899 -179.456 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 25' ' ' LEU . . . -61.36 -23.99 63.07 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 -179.672 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 38.8 t -64.57 -42.47 95.62 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.745 0.307 . . . . 0.0 111.237 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -69.94 -44.01 70.42 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.519 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.406 ' N ' HD12 ' A' ' 32' ' ' LEU . 8.1 mp -65.12 -44.4 88.85 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.149 -0.932 . . . . 0.0 111.413 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.31 -44.39 97.01 Favored Glycine 0 N--CA 1.438 -1.214 0 C-N-CA 119.292 -1.432 . . . . 0.0 109.986 -179.077 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.21 -40.06 71.36 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.529 -0.336 . . . . 0.0 111.414 179.076 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.8 t -63.65 -41.29 98.25 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.666 -0.413 . . . . 0.0 111.141 -178.389 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.12 -40.34 80.5 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.798 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.5 pttt -60.28 -43.19 96.44 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 -179.679 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.97 -36.68 92.37 Favored Glycine 0 CA--C 1.519 0.342 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.488 ' CZ ' ' CE ' ' A' ' 43' ' ' MET . 66.6 t80 -71.51 -52.23 19.42 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.625 ' O ' ' N ' ' A' ' 44' ' ' SER . 66.0 mmtt -62.91 -38.15 89.81 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.154 178.73 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -60.94 -35.64 77.26 Favored 'General case' 0 C--N 1.312 -1.029 0 C-N-CA 119.631 -0.827 . . . . 0.0 109.909 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.06 -35.73 81.32 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.141 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.488 ' CE ' ' CZ ' ' A' ' 39' ' ' PHE . 6.3 ptp -121.6 -55.29 1.93 Allowed 'General case' 0 N--CA 1.475 0.793 0 CA-C-O 121.364 0.602 . . . . 0.0 111.293 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.625 ' N ' ' O ' ' A' ' 40' ' ' LYS . 4.8 t 62.24 134.88 0.01 OUTLIER 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.717 -179.145 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -87.54 140.13 29.83 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.699 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 44.8 p-10 -90.16 12.09 18.97 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-O 121.317 0.58 . . . . 0.0 110.375 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 49.13 75.07 0.7 Allowed Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.177 -0.919 . . . . 0.0 110.295 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo . . . . . 0 C--N 1.308 -1.581 0 C-N-CA 122.809 2.339 . . . . 0.0 112.224 -179.753 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.519 ' C ' ' H ' ' A' ' 3' ' ' GLY . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 . . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.96 22.92 0.88 Allowed Glycine 0 CA--C 1.525 0.701 0 C-N-CA 120.437 -0.887 . . . . 0.0 110.992 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.519 ' H ' ' C ' ' A' ' 1' ' ' MET . . . -150.03 26.36 1.14 Allowed Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.635 -0.986 . . . . 0.0 110.635 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.409 ' CG2' HE21 ' A' ' 8' ' ' GLN . 5.0 mt -41.44 112.82 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.022 0.439 . . . . 0.0 110.871 -179.872 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.979 ' CA ' HE22 ' A' ' 8' ' ' GLN . 16.6 m -154.88 -78.45 0.1 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.882 -179.699 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 3.5 mm -109.24 -29.5 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.402 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.763 -179.484 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 38.5 m95 -62.0 -45.33 94.06 Favored 'General case' 0 C--O 1.22 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -178.593 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.979 HE22 ' CA ' ' A' ' 5' ' ' SER . 3.2 pm0 -63.8 -38.96 93.03 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 119.737 -0.785 . . . . 0.0 109.485 178.72 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.421 ' O ' ' CB ' ' A' ' 13' ' ' ALA . 78.8 mt -64.45 -38.21 90.24 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.264 179.727 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.642 ' O ' HG23 ' A' ' 14' ' ' VAL . 20.7 mt -63.3 -48.27 78.78 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.805 -176.596 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.501 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.8 mp -67.92 -44.58 85.03 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 C-N-CA 119.662 -0.815 . . . . 0.0 109.142 178.212 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -65.08 -47.59 87.22 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 C-N-CA 120.055 -0.658 . . . . 0.0 110.566 -179.432 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.857 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -65.85 -38.07 87.88 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 -179.545 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.642 HG23 ' O ' ' A' ' 10' ' ' LEU . 62.8 t -67.78 -44.29 85.73 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.625 0 C-N-CA 120.173 -0.611 . . . . 0.0 111.171 -178.824 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.47 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 0.9 OUTLIER -66.28 -44.05 91.35 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.385 0 O-C-N 123.353 0.408 . . . . 0.0 110.053 179.485 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.414 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.3 t -64.02 -41.99 94.24 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.721 0 CA-C-N 115.107 -0.951 . . . . 0.0 109.964 -178.578 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.857 HG23 ' O ' ' A' ' 13' ' ' ALA . 59.6 t -66.14 -45.22 90.89 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.909 0 C-N-CA 118.03 -1.468 . . . . 0.0 112.672 -177.043 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.431 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.1 pp -71.23 -42.85 68.36 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.157 177.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.677 HD13 ' C ' ' A' ' 19' ' ' LEU . 2.5 tm? -64.67 -41.49 96.04 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.908 -179.171 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.414 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 6.1 m-85 -68.97 -38.62 79.47 Favored 'General case' 0 CA--C 1.513 -0.465 0 C-N-CA 119.014 -1.074 . . . . 0.0 108.623 178.78 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.499 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 104.76 11.28 30.92 Favored Glycine 0 C--N 1.315 -0.614 0 CA-C-N 115.01 -0.995 . . . . 0.0 111.104 178.521 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.725 HG22 ' CG1' ' A' ' 17' ' ' VAL . 51.2 p 58.68 43.24 19.1 Favored 'General case' 0 CA--C 1.505 -0.763 0 CA-C-N 115.25 -0.475 . . . . 0.0 111.917 178.872 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -124.94 -20.19 5.03 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.4 -179.802 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 tppt? -84.99 -49.63 8.16 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-O 121.091 0.472 . . . . 0.0 110.496 179.826 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.767 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.1 OUTLIER -61.63 -36.83 81.88 Favored 'General case' 0 CA--C 1.505 -0.766 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.044 -178.792 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.26 -24.62 76.1 Favored Glycine 0 N--CA 1.435 -1.432 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -177.343 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.4 t -84.85 -42.49 15.03 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 111.607 0.225 . . . . 0.0 111.607 179.519 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 11.4 pt -94.91 -36.69 7.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 120.272 -0.571 . . . . 0.0 110.088 -179.443 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 25' ' ' LEU . . . -63.8 -24.42 68.22 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 -179.5 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 10.9 t -64.61 -42.71 95.36 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.771 0.32 . . . . 0.0 111.332 -179.698 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 94.9 m-20 -70.58 -43.63 69.04 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.341 0.591 . . . . 0.0 109.481 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.8 mp -65.47 -44.75 86.17 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.426 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.37 -45.07 95.85 Favored Glycine 0 N--CA 1.439 -1.157 0 C-N-CA 119.444 -1.36 . . . . 0.0 109.94 -179.118 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.39 -39.69 71.03 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.577 -0.312 . . . . 0.0 111.566 179.265 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 48.4 t -63.34 -41.79 98.9 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-O 121.125 0.488 . . . . 0.0 110.324 -178.322 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.19 -39.4 79.23 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.931 179.032 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.7 tttp -60.09 -44.08 95.05 Favored 'General case' 0 C--N 1.309 -1.152 0 C-N-CA 119.343 -0.943 . . . . 0.0 108.614 -179.043 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.68 -36.54 91.44 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 178.389 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.2 t80 -71.65 -51.83 21.1 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-O 120.76 0.314 . . . . 0.0 110.462 -179.564 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.533 ' O ' ' N ' ' A' ' 44' ' ' SER . 23.7 mtpp -62.7 -38.05 88.9 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.375 179.135 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -61.02 -36.73 80.29 Favored 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 120.098 -0.641 . . . . 0.0 110.226 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.43 -36.19 82.17 Favored 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.37 -179.591 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.605 ' C ' ' H ' ' A' ' 45' ' ' ASP . 5.4 mmt -97.32 -67.25 0.86 Allowed 'General case' 0 N--CA 1.467 0.412 0 CA-C-O 120.992 0.425 . . . . 0.0 110.728 179.323 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.533 ' N ' ' O ' ' A' ' 40' ' ' LYS . 13.8 t 53.68 0.48 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.797 -179.063 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.605 ' H ' ' C ' ' A' ' 43' ' ' MET . 98.4 m-20 -64.64 -42.83 95.2 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.876 0.37 . . . . 0.0 110.706 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.4 ' OD1' ' O ' ' A' ' 46' ' ' ASP . 66.7 t0 -82.04 42.9 0.75 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.974 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -49.75 146.53 7.33 Favored Pre-proline 0 CA--C 1.536 0.404 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.428 -179.559 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 80.0 Cg_exo . . . . . 0 N--CA 1.49 1.274 0 C-N-CA 122.281 1.987 . . . . 0.0 112.098 179.85 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.427 ' SD ' ' N ' ' A' ' 1' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 . . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -80.54 36.11 2.24 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 111.656 -0.578 . . . . 0.0 111.656 -179.608 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.526 ' O ' ' NE2' ' A' ' 8' ' ' GLN . . . 138.52 -9.19 3.45 Favored Glycine 0 N--CA 1.463 0.474 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.536 HG23 ' CB ' ' A' ' 8' ' ' GLN . 4.0 mp -99.58 117.79 45.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.051 0.453 . . . . 0.0 110.628 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.425 ' O ' HD23 ' A' ' 9' ' ' LEU . 18.1 m -144.91 -85.68 0.13 Allowed 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.664 179.409 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.5 mm -112.63 -33.55 2.17 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.915 -179.169 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 55.2 m95 -62.54 -48.97 77.16 Favored 'General case' 0 C--O 1.221 -0.423 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 -179.588 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLN . . . . . 0.536 ' CB ' HG23 ' A' ' 4' ' ' ILE . 0.5 OUTLIER -64.13 -38.43 91.05 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.608 179.847 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.507 ' N ' ' CD2' ' A' ' 9' ' ' LEU . 3.2 mm? -62.8 -39.08 93.16 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.874 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.544 ' O ' HG23 ' A' ' 14' ' ' VAL . 8.9 mt -63.76 -51.77 63.39 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.6 -178.335 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.485 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.5 mp -65.62 -44.49 93.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 178.372 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 70.8 mt -63.72 -45.3 97.73 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 C-N-CA 120.479 -0.488 . . . . 0.0 111.337 -179.667 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.865 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.95 -38.79 92.12 Favored 'General case' 0 C--N 1.32 -0.713 0 O-C-N 123.381 0.425 . . . . 0.0 110.975 -179.323 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.544 HG23 ' O ' ' A' ' 10' ' ' LEU . 70.7 t -67.54 -43.15 87.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 C-N-CA 120.566 -0.453 . . . . 0.0 110.562 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.452 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 96.7 mt -66.25 -43.35 91.78 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.322 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.453 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.5 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.4 t -63.72 -42.2 95.18 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.684 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.319 -178.68 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.865 HG23 ' O ' ' A' ' 13' ' ' ALA . 61.4 t -66.02 -45.11 91.62 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.883 0 C-N-CA 118.253 -1.379 . . . . 0.0 112.672 -176.764 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.527 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.3 pp -72.39 -43.16 64.32 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 119.702 -0.799 . . . . 0.0 109.949 178.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.698 HD13 ' C ' ' A' ' 19' ' ' LEU . 2.6 tm? -64.4 -41.44 96.64 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.923 -1.035 . . . . 0.0 110.313 -179.63 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.5 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 5.0 m-85 -69.02 -35.98 77.25 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 118.879 -1.129 . . . . 0.0 108.957 179.019 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.482 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 97.44 11.96 49.76 Favored Glycine 0 N--CA 1.465 0.593 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.703 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.701 HG22 ' CG1' ' A' ' 17' ' ' VAL . 42.8 p 55.72 69.49 0.73 Allowed 'General case' 0 CA--C 1.506 -0.713 0 CA-C-N 114.604 -0.798 . . . . 0.0 112.445 178.364 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 49.6 mtpt -139.87 -25.53 0.81 Allowed 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.873 179.664 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 11.2 mmmt -85.8 -53.03 5.38 Favored 'General case' 0 C--O 1.221 -0.444 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.728 179.676 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.623 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.1 OUTLIER -53.05 -37.33 61.49 Favored 'General case' 0 CA--C 1.505 -0.784 0 CA-C-O 121.817 0.818 . . . . 0.0 110.642 -178.992 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.67 -25.22 72.73 Favored Glycine 0 N--CA 1.438 -1.219 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 -178.296 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 13.8 m -93.46 -39.76 10.71 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 -179.527 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.2 pt -94.19 -34.9 5.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.193 0.521 . . . . 0.0 110.017 -179.011 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.16 -26.26 71.44 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.3 t -64.7 -43.06 94.68 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.657 -179.643 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -76.43 -41.0 49.13 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.347 0.594 . . . . 0.0 109.64 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.678 ' O ' HD13 ' A' ' 36' ' ' ILE . 7.6 mp -68.4 -46.61 69.51 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.062 -0.972 . . . . 0.0 111.575 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.93 -44.0 98.43 Favored Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -179.16 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.12 -40.39 71.45 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.825 179.057 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.4 m -64.0 -40.8 97.18 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.898 -179.342 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.678 HD13 ' O ' ' A' ' 32' ' ' LEU . 1.6 mp -68.19 -41.57 84.12 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.485 -179.433 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.4 ' HG2' ' N ' ' A' ' 38' ' ' GLY . 16.6 pttt -60.08 -43.35 95.56 Favored 'General case' 0 C--N 1.308 -1.203 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 -179.144 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.4 ' N ' ' HG2' ' A' ' 37' ' ' LYS . . . -69.7 -36.78 75.93 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 110.599 -1.001 . . . . 0.0 110.599 178.891 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.581 ' CE2' ' SD ' ' A' ' 43' ' ' MET . 24.4 t80 -71.64 -49.26 41.66 Favored 'General case' 0 CA--C 1.514 -0.432 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.845 -178.882 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 44' ' ' SER . 9.8 mptt -67.06 -39.07 86.82 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.484 178.86 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.405 ' O ' ' OG ' ' A' ' 44' ' ' SER . 63.4 tttp -61.65 -36.65 81.41 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 119.72 -0.792 . . . . 0.0 109.865 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -68.59 -35.92 78.02 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.502 179.758 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.581 ' SD ' ' CE2' ' A' ' 39' ' ' PHE . 26.4 mtp -88.64 -19.81 25.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.856 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.514 ' N ' ' O ' ' A' ' 40' ' ' LYS . 89.6 p -50.92 135.34 24.58 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.204 -179.761 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.449 ' OD1' ' N ' ' A' ' 46' ' ' ASP . 68.1 t0 -167.73 132.37 1.84 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.901 0.381 . . . . 0.0 110.749 -179.679 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.449 ' N ' ' OD1' ' A' ' 45' ' ' ASP . 56.9 t0 51.79 32.88 10.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.117 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 64.5 mt-10 -68.79 151.37 97.28 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.556 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_exo . . . . . 0 N--CA 1.488 1.189 0 C-N-CA 122.424 2.083 . . . . 0.0 112.05 179.776 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 1.5 mp . . . . . 0 N--CA 1.468 0.436 0 CA-C-O 120.576 0.227 . . . . 0.0 110.506 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 63.8 m95 -62.65 -49.54 74.73 Favored 'General case' 0 C--O 1.221 -0.432 0 CA-C-O 120.754 0.311 . . . . 0.0 110.576 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.432 ' OE1' ' N ' ' A' ' 8' ' ' GLN . 20.9 mp0 -64.17 -38.52 91.34 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.491 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 3.0 mm? -63.64 -39.33 94.07 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.646 179.284 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.571 ' O ' HG23 ' A' ' 14' ' ' VAL . 9.1 mt -63.86 -51.0 66.61 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.872 -178.077 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.445 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.4 mp -66.08 -44.45 91.93 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.396 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 69.3 mt -63.58 -45.01 98.8 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.086 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.285 -179.436 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.852 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -65.01 -37.83 88.94 Favored 'General case' 0 C--N 1.317 -0.844 0 O-C-N 123.435 0.46 . . . . 0.0 111.245 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 10' ' ' LEU . 71.4 t -67.86 -43.98 85.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.794 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.758 HG22 HD23 ' A' ' 19' ' ' LEU . 96.8 mt -66.33 -43.47 91.45 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.104 0 CA-C-O 121.59 0.71 . . . . 0.0 109.322 179.435 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.408 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.8 t -63.53 -42.41 96.08 Favored 'Isoleucine or valine' 0 CA--C 1.479 -1.788 0 CA-C-N 114.794 -1.094 . . . . 0.0 109.788 -178.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.852 HG23 ' O ' ' A' ' 13' ' ' ALA . 60.4 t -66.5 -48.89 79.15 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.046 0 C-N-CA 117.609 -1.636 . . . . 0.0 112.787 -177.227 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.498 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.0 OUTLIER -66.99 -44.38 80.55 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 118.863 -1.135 . . . . 0.0 112.042 179.667 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.758 HD23 HG22 ' A' ' 15' ' ' ILE . 0.4 OUTLIER -65.95 -38.47 88.69 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.823 -179.979 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.408 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 4.7 m-85 -67.89 -41.03 83.37 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 -179.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.463 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 108.62 14.58 15.45 Favored Glycine 0 C--N 1.312 -0.803 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 178.392 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.709 HG22 ' CG1' ' A' ' 17' ' ' VAL . 68.0 p 52.02 39.51 26.47 Favored 'General case' 0 CA--C 1.495 -1.136 0 CA-C-N 114.747 -0.726 . . . . 0.0 112.473 178.283 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 59.5 tttm -112.43 -41.29 3.9 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.935 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.92 -56.28 9.65 Favored 'General case' 0 CA--C 1.509 -0.63 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.271 -179.492 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.654 HD12 ' H ' ' A' ' 25' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.311 -1.07 0 CA-C-O 121.901 0.858 . . . . 0.0 109.989 -177.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 38.7 t . . . . . 0 CA--C 1.517 -0.29 0 N-CA-C 111.699 0.259 . . . . 0.0 111.699 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.9 m-20 -94.24 -35.51 12.43 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 179.309 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.512 HD13 ' O ' ' A' ' 32' ' ' LEU . 0.2 OUTLIER -74.32 -49.35 23.31 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.408 -1.269 . . . . 0.0 111.412 -178.916 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.57 -42.97 99.86 Favored Glycine 0 CA--C 1.518 0.246 0 N-CA-C 109.304 -1.519 . . . . 0.0 109.304 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.59 -39.28 93.45 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.783 -0.709 . . . . 0.0 110.939 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 75.3 m -62.88 -41.31 99.35 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.137 -0.625 . . . . 0.0 110.709 -178.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.3 mp -68.65 -40.01 81.13 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.861 179.048 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.6 ptmt -59.79 -41.81 91.98 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 -178.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.17 -36.47 90.16 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 177.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 23.0 t80 -71.75 -52.44 17.68 Favored 'General case' 0 CA--C 1.514 -0.428 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.227 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 62.2 mttm -62.81 -40.18 96.56 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.43 179.075 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 38.9 ttpt -63.43 -38.36 90.84 Favored 'General case' 0 C--N 1.317 -0.846 0 C-N-CA 119.95 -0.7 . . . . 0.0 111.212 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.325 -0.488 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.818 -178.974 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.406 ' CG2' ' N ' ' A' ' 7' ' ' TRP . 3.4 tp . . . . . 0 N--CA 1.442 -0.833 0 CA-C-O 121.754 0.788 . . . . 0.0 111.907 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.427 ' CD1' ' C ' ' A' ' 7' ' ' TRP . 5.6 t-105 -61.91 -39.34 91.67 Favored 'General case' 0 N--CA 1.421 -1.884 0 CA-C-N 114.88 -1.054 . . . . 0.0 108.748 -178.321 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -64.74 -38.85 92.4 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 178.158 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.464 HD23 ' HA ' ' A' ' 9' ' ' LEU . 73.7 mt -62.74 -38.09 89.14 Favored 'General case' 0 CA--C 1.503 -0.851 0 CA-C-N 114.925 -1.034 . . . . 0.0 110.479 178.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.633 ' O ' HG23 ' A' ' 14' ' ' VAL . 2.7 mt -62.63 -47.62 82.94 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.235 -177.274 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.505 HD12 ' N ' ' A' ' 11' ' ' ILE . 3.2 mp -69.13 -44.58 80.82 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 178.21 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 77.3 mt -64.02 -44.48 97.82 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.307 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.684 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.9 -36.63 84.97 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.945 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.633 HG23 ' O ' ' A' ' 10' ' ' LEU . 48.8 t -67.28 -44.29 87.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.307 -179.026 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 14.1 pt -67.24 -43.9 87.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.831 179.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.517 HG22 ' CD2' ' A' ' 20' ' ' PHE . 0.3 OUTLIER -64.79 -39.3 85.19 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.07 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.323 -179.632 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.694 ' CG1' HG22 ' A' ' 22' ' ' THR . 75.8 t -66.25 -46.99 85.89 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 C-N-CA 118.683 -1.207 . . . . 0.0 112.743 -178.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.43 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 0.8 OUTLIER -68.88 -42.39 77.04 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.419 0.628 . . . . 0.0 110.031 179.046 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.71 HD13 ' C ' ' A' ' 19' ' ' LEU . 2.2 tm? -63.88 -39.84 95.14 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.623 -1.171 . . . . 0.0 109.875 -179.306 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.517 ' CD2' HG22 ' A' ' 16' ' ' VAL . 3.0 m-85 -69.17 -37.22 78.09 Favored 'General case' 0 CA--C 1.513 -0.454 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 177.605 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.507 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 102.3 9.59 41.24 Favored Glycine 0 N--CA 1.462 0.405 0 CA-C-N 115.086 -0.961 . . . . 0.0 110.916 179.135 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.694 HG22 ' CG1' ' A' ' 17' ' ' VAL . 51.6 p 58.56 22.22 9.5 Favored 'General case' 0 C--N 1.32 -0.713 0 O-C-N 123.935 0.433 . . . . 0.0 111.99 178.774 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -100.96 -15.82 17.38 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.103 -0.499 . . . . 0.0 112.06 -179.599 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 15.2 mmmt -92.29 -57.82 2.58 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.178 0.513 . . . . 0.0 110.718 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.985 HD12 ' H ' ' A' ' 25' ' ' LEU . 1.7 mp . . . . . 0 CA--C 1.496 -1.124 0 CA-C-O 122.272 1.034 . . . . 0.0 110.417 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.7 m . . . . . 0 C--O 1.232 0.177 0 CA-C-O 120.657 0.265 . . . . 0.0 111.214 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -70.09 -43.83 70.3 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 179.302 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -65.08 -44.1 90.01 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.064 -0.971 . . . . 0.0 111.249 179.648 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.6 -45.49 94.51 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 119.208 -1.472 . . . . 0.0 109.863 -179.193 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.11 -39.65 71.94 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.56 -0.32 . . . . 0.0 111.738 179.22 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 14.5 t -63.03 -42.14 99.7 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.341 -177.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.71 -39.64 80.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.744 178.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 34.5 tttm -59.91 -43.36 94.9 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 -178.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.81 -36.79 91.67 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 177.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 13.7 t80 -71.64 -50.23 32.56 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-O 120.897 0.379 . . . . 0.0 110.221 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 47.8 mtpt -62.86 -38.88 92.6 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.346 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 50.5 mtpt -61.82 -38.85 89.7 Favored 'General case' 0 C--N 1.319 -0.744 0 C-N-CA 119.764 -0.774 . . . . 0.0 110.083 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.324 -0.515 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.778 -179.856 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 34.4 mm . . . . . 0 N--CA 1.444 -0.768 0 CA-C-O 121.092 0.472 . . . . 0.0 110.356 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 94.1 m95 -74.32 -38.93 63.15 Favored 'General case' 0 C--N 1.321 -0.638 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.096 179.595 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.499 ' OE1' ' N ' ' A' ' 8' ' ' GLN . 0.8 OUTLIER -64.23 -38.77 92.22 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -179.686 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.666 HD12 ' C ' ' A' ' 9' ' ' LEU . 0.4 OUTLIER -73.31 -38.19 65.93 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.249 179.672 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.651 ' O ' HG23 ' A' ' 14' ' ' VAL . 13.8 mt -63.41 -46.87 84.4 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.871 0.367 . . . . 0.0 111.278 -177.661 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.2 mp -67.74 -44.23 85.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.201 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 35.1 mt -65.04 -44.64 95.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.121 -179.27 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.88 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.74 -37.54 87.93 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 115.762 -0.653 . . . . 0.0 110.966 -178.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.651 HG23 ' O ' ' A' ' 10' ' ' LEU . 54.4 t -66.93 -44.99 88.36 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.426 0 C-N-CA 120.435 -0.506 . . . . 0.0 111.506 -178.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 16.7 pt -66.9 -42.65 89.24 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.99 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.147 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.528 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.7 t -63.82 -41.43 92.54 Favored 'Isoleucine or valine' 0 CA--C 1.482 -1.659 0 CA-C-N 115.388 -0.823 . . . . 0.0 109.795 -178.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.88 HG23 ' O ' ' A' ' 13' ' ' ALA . 52.2 t -66.29 -50.43 68.15 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.93 0 C-N-CA 117.548 -1.661 . . . . 0.0 113.32 -177.269 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.558 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.2 pp -67.04 -44.11 81.03 Favored 'General case' 0 C--N 1.296 -1.727 0 C-N-CA 119.151 -1.02 . . . . 0.0 111.881 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.658 ' C ' HD12 ' A' ' 19' ' ' LEU . 0.4 OUTLIER -65.78 -38.43 89.02 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.607 -0.27 . . . . 0.0 111.028 179.8 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.528 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 3.4 m-85 -68.38 -37.13 80.11 Favored 'General case' 0 CA--C 1.515 -0.376 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.819 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.428 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 97.93 13.77 42.04 Favored Glycine 0 CA--C 1.504 -0.601 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.512 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.682 HG22 HG13 ' A' ' 17' ' ' VAL . 46.2 p 53.2 76.95 0.18 Allowed 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 114.083 -1.058 . . . . 0.0 112.121 178.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 18.0 ptmt -142.4 -36.46 0.4 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.939 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 11.1 mmmt -77.31 -50.75 12.14 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.39 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.611 HD12 ' H ' ' A' ' 25' ' ' LEU . 0.2 OUTLIER . . . . . 0 CA--C 1.503 -0.84 0 CA-C-O 122.12 0.962 . . . . 0.0 110.449 -178.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.4 t . . . . . 0 CA--C 1.523 -0.089 0 CA-C-O 120.692 0.282 . . . . 0.0 111.341 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -73.93 -42.6 60.34 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -66.83 -44.44 81.11 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 114.998 -1.001 . . . . 0.0 111.475 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.41 -44.13 97.24 Favored Glycine 0 N--CA 1.44 -1.051 0 C-N-CA 119.322 -1.418 . . . . 0.0 109.817 -179.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.73 -40.13 69.61 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.529 -0.336 . . . . 0.0 111.346 179.05 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.5 m -63.69 -40.56 97.1 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.223 -178.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -70.19 -39.52 77.04 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.677 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.5 ptmt -59.79 -41.86 92.12 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 -178.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.81 -36.9 87.92 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.557 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -71.49 -50.82 27.8 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 53.7 mtpt -63.21 -38.6 91.82 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.506 178.655 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -61.49 -39.2 90.07 Favored 'General case' 0 C--N 1.318 -0.766 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.867 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.323 -0.572 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.705 179.869 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.509 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.5 mp . . . . . 0 N--CA 1.453 -0.287 0 CA-C-O 120.755 0.312 . . . . 0.0 110.463 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 67.6 m95 -62.15 -46.98 86.57 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.43 -38.9 92.63 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.425 HD23 ' HA ' ' A' ' 9' ' ' LEU . 89.2 mt -66.08 -38.73 89.0 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.306 178.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.591 ' O ' HG23 ' A' ' 14' ' ' VAL . 16.7 mt -63.43 -50.28 70.41 Favored 'General case' 0 C--N 1.315 -0.919 0 C-N-CA 120.131 -0.628 . . . . 0.0 110.541 -176.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.435 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.4 mp -66.61 -44.73 89.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.107 178.237 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 75.5 mt -63.91 -46.79 93.16 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.967 0 C-N-CA 120.294 -0.562 . . . . 0.0 111.432 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.846 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -65.0 -37.68 88.47 Favored 'General case' 0 C--N 1.319 -0.745 0 O-C-N 123.213 0.321 . . . . 0.0 111.349 -179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.591 HG23 ' O ' ' A' ' 10' ' ' LEU . 59.2 t -67.8 -43.82 86.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.613 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.448 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 96.6 mt -66.2 -43.53 91.86 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.155 0 O-C-N 123.521 0.513 . . . . 0.0 109.725 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.433 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.6 t -63.72 -42.26 95.38 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.504 0 CA-C-N 115.08 -0.964 . . . . 0.0 109.919 -178.637 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.846 HG23 ' O ' ' A' ' 13' ' ' ALA . 59.9 t -66.27 -44.78 91.05 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 C-N-CA 118.217 -1.393 . . . . 0.0 112.79 -176.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.483 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.2 pp -71.96 -42.9 66.02 Favored 'General case' 0 C--N 1.294 -1.825 0 C-N-CA 120.046 -0.661 . . . . 0.0 109.761 178.177 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.661 HD13 ' C ' ' A' ' 19' ' ' LEU . 2.6 tm? -64.8 -41.75 95.56 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.823 -179.175 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.433 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 6.9 m-85 -69.24 -33.47 73.33 Favored 'General case' 0 CA--C 1.511 -0.558 0 C-N-CA 119.067 -1.053 . . . . 0.0 108.831 178.716 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.466 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 93.93 12.9 56.06 Favored Glycine 0 C--N 1.318 -0.471 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 179.244 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.655 HG22 HG13 ' A' ' 17' ' ' VAL . 43.1 p 55.78 77.73 0.22 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 114.684 -0.758 . . . . 0.0 112.002 178.762 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -146.28 -26.11 0.43 Allowed 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.454 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.65 -39.71 10.65 Favored 'General case' 0 C--O 1.223 -0.315 0 C-N-CA 120.719 -0.393 . . . . 0.0 110.905 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.704 HD12 ' H ' ' A' ' 25' ' ' LEU . 0.2 OUTLIER . . . . . 0 CA--C 1.501 -0.931 0 CA-C-O 121.714 0.768 . . . . 0.0 110.001 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.5 t . . . . . 0 CA--C 1.52 -0.177 0 N-CA-C 111.733 0.272 . . . . 0.0 111.733 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -75.54 -42.51 52.25 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.438 0.637 . . . . 0.0 109.487 179.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.8 mp -66.89 -44.66 80.28 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.043 -0.98 . . . . 0.0 111.81 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.32 -44.12 97.4 Favored Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 119.413 -1.375 . . . . 0.0 109.832 -179.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.84 -39.79 69.49 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.66 -0.27 . . . . 0.0 111.394 179.183 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.7 m -63.24 -40.92 98.79 Favored 'General case' 0 CA--C 1.518 -0.287 0 CA-C-O 121.112 0.482 . . . . 0.0 110.477 -178.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.63 -39.36 78.15 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.757 178.627 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 24.2 tttt -59.97 -44.56 94.37 Favored 'General case' 0 N--CA 1.435 -1.217 0 C-N-CA 119.231 -0.988 . . . . 0.0 108.414 -179.357 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.97 -36.34 91.91 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 178.005 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 21.0 t80 -71.38 -51.41 24.24 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-O 120.835 0.35 . . . . 0.0 110.456 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -63.08 -38.56 91.66 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.38 178.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -61.36 -36.84 81.33 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.121 -0.632 . . . . 0.0 110.012 -179.565 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.325 -0.475 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.126 179.663 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 4.6 tp . . . . . 0 N--CA 1.448 -0.557 0 CA-C-O 121.219 0.533 . . . . 0.0 111.986 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.651 ' CE2' HD11 ' A' ' 11' ' ' ILE . 8.1 t-105 -62.2 -37.12 84.12 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 115.459 -0.791 . . . . 0.0 108.91 -178.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -64.35 -38.91 92.71 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 178.318 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.426 HD23 ' HA ' ' A' ' 9' ' ' LEU . 84.0 mt -64.79 -37.58 88.11 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.93 178.546 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.694 ' O ' HG23 ' A' ' 14' ' ' VAL . 3.9 mt -62.47 -43.89 97.71 Favored 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.274 -177.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.651 HD11 ' CE2' ' A' ' 7' ' ' TRP . 7.2 mt -68.35 -45.11 83.02 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 C-N-CA 119.992 -0.683 . . . . 0.0 109.593 178.049 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 72.0 mt -65.98 -44.74 92.19 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.572 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.531 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.907 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -65.22 -37.21 86.56 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.03 -179.517 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.694 HG23 ' O ' ' A' ' 10' ' ' LEU . 46.0 t -66.65 -44.78 89.57 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.717 0 C-N-CA 120.599 -0.44 . . . . 0.0 111.485 -179.082 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.439 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 15.2 pt -66.61 -42.64 90.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.209 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.531 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.5 t -63.85 -41.82 93.8 Favored 'Isoleucine or valine' 0 CA--C 1.483 -1.603 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.702 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.907 HG23 ' O ' ' A' ' 13' ' ' ALA . 61.5 t -65.8 -45.93 90.21 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 C-N-CA 118.361 -1.335 . . . . 0.0 112.948 -177.216 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.521 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.4 pp -72.11 -42.85 65.59 Favored 'General case' 0 C--N 1.288 -2.093 0 CA-C-O 121.333 0.587 . . . . 0.0 109.791 178.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.705 HD13 ' C ' ' A' ' 19' ' ' LEU . 2.5 tm? -64.67 -42.3 95.47 Favored 'General case' 0 N--CA 1.44 -0.956 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.164 -179.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.531 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 5.7 m-85 -68.94 -34.37 75.24 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 119.138 -1.025 . . . . 0.0 109.314 179.333 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.487 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 96.32 11.38 54.32 Favored Glycine 0 N--CA 1.466 0.635 0 N-CA-C 110.647 -0.981 . . . . 0.0 110.647 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.697 HG22 ' CG1' ' A' ' 17' ' ' VAL . 43.4 p 56.53 68.58 0.84 Allowed 'General case' 0 CA--C 1.502 -0.884 0 CA-C-N 115.055 -0.573 . . . . 0.0 112.271 178.199 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -139.87 -24.77 0.83 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.015 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 10.1 mmmt -87.06 -52.09 5.63 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.821 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.63 HD12 ' H ' ' A' ' 25' ' ' LEU . 0.1 OUTLIER . . . . . 0 CA--C 1.505 -0.781 0 CA-C-O 121.783 0.801 . . . . 0.0 110.266 -178.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.1 p . . . . . 0 CA--C 1.519 -0.217 0 CA-C-O 120.655 0.265 . . . . 0.0 111.336 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 46.2 t0 -81.36 -39.47 25.02 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.254 0.549 . . . . 0.0 109.694 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.0 mp -69.37 -45.32 69.63 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.193 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.76 -43.94 98.21 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 119.531 -1.319 . . . . 0.0 109.913 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.0 -39.99 79.0 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.538 -0.331 . . . . 0.0 111.372 179.522 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 47.1 t -63.28 -42.26 99.08 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.093 0.473 . . . . 0.0 110.718 -178.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.88 -39.42 79.92 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.154 179.205 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 7.6 ttpt -59.39 -43.65 92.92 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.242 -0.983 . . . . 0.0 108.524 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.73 -36.21 92.0 Favored Glycine 0 N--CA 1.444 -0.821 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 178.439 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -71.08 -52.54 18.84 Favored 'General case' 0 CA--C 1.512 -0.517 0 CA-C-O 120.976 0.417 . . . . 0.0 110.133 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.427 ' HG3' ' HZ2' ' A' ' 40' ' ' LYS . 44.2 mttp -63.36 -38.86 92.81 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 120.27 -0.572 . . . . 0.0 110.545 178.487 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 1.9 tmtp? -61.7 -39.15 90.44 Favored 'General case' 0 C--N 1.319 -0.76 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.106 -179.665 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.325 -0.478 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.953 179.572 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 3.7 tp . . . . . 0 N--CA 1.447 -0.586 0 CA-C-O 121.235 0.54 . . . . 0.0 111.578 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.769 ' O ' HD12 ' A' ' 11' ' ' ILE . 0.3 OUTLIER -62.21 -41.62 98.54 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-N 115.365 -0.834 . . . . 0.0 108.967 -179.185 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 18.4 mt-30 -64.08 -38.38 90.87 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 178.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.514 ' O ' ' N ' ' A' ' 13' ' ' ALA . 87.5 mt -65.37 -36.98 85.63 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.326 177.439 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.573 ' O ' HG23 ' A' ' 14' ' ' VAL . 1.8 tt -61.84 -50.95 70.19 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.888 -174.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.769 HD12 ' O ' ' A' ' 7' ' ' TRP . 2.8 mp -65.35 -44.73 94.64 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 C-N-CA 119.893 -0.723 . . . . 0.0 109.533 177.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.1 mp -63.77 -44.36 98.23 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.21 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.904 179.49 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.9 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.56 -37.35 87.27 Favored 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 121.086 -0.246 . . . . 0.0 110.836 -179.411 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.573 HG23 ' O ' ' A' ' 10' ' ' LEU . 53.0 t -66.93 -45.01 88.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 C-N-CA 120.544 -0.462 . . . . 0.0 111.465 -179.191 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 13.5 pt -66.87 -42.76 89.47 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.989 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 178.59 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.569 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.4 t -63.14 -41.54 93.21 Favored 'Isoleucine or valine' 0 CA--C 1.478 -1.799 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.883 -178.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.9 HG23 ' O ' ' A' ' 13' ' ' ALA . 51.7 t -66.14 -51.23 62.11 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.033 0 C-N-CA 117.857 -1.537 . . . . 0.0 113.652 -177.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.598 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.4 pp -66.89 -44.36 81.08 Favored 'General case' 0 C--N 1.293 -1.869 0 C-N-CA 119.487 -0.885 . . . . 0.0 111.782 179.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.659 ' C ' HD12 ' A' ' 19' ' ' LEU . 0.4 OUTLIER -65.77 -38.87 90.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.704 -0.225 . . . . 0.0 110.638 -179.943 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.569 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 3.0 m-85 -68.5 -36.54 79.05 Favored 'General case' 0 CA--C 1.513 -0.476 0 C-N-CA 119.607 -0.837 . . . . 0.0 109.317 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.472 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 96.98 12.01 51.11 Favored Glycine 0 CA--C 1.506 -0.501 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 -179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.726 HG22 HG13 ' A' ' 17' ' ' VAL . 43.3 p 54.74 74.74 0.33 Allowed 'General case' 0 CA--C 1.5 -0.963 0 CA-C-N 114.196 -1.002 . . . . 0.0 112.677 178.055 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 62.1 mttp -139.04 -31.57 0.7 Allowed 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.784 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 6.7 mmpt? -81.6 -54.35 5.48 Favored 'General case' 0 CA--C 1.501 -0.914 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.612 -179.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.618 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.312 -1.024 0 CA-C-O 122.371 1.081 . . . . 0.0 110.701 -176.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.2 p . . . . . 0 N--CA 1.456 -0.168 0 CA-C-O 120.702 0.287 . . . . 0.0 110.944 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -72.96 -43.28 62.48 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.54 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.5 mp -64.97 -44.37 89.58 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.185 179.578 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -64.02 -45.1 94.81 Favored Glycine 0 N--CA 1.44 -1.093 0 C-N-CA 119.251 -1.452 . . . . 0.0 109.765 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.65 -39.71 73.46 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.513 -0.344 . . . . 0.0 111.664 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.9 t -62.89 -41.91 99.59 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.407 -177.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.72 -39.77 78.44 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.145 178.613 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 36.6 tttm -60.07 -41.45 92.42 Favored 'General case' 0 N--CA 1.426 -1.644 0 N-CA-C 108.056 -1.091 . . . . 0.0 108.056 -178.529 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.12 -36.49 90.44 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 109.882 -1.287 . . . . 0.0 109.882 177.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -71.6 -51.92 20.78 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.188 -179.308 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 54.5 mttp -63.72 -39.65 94.81 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.517 178.322 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 61.6 tttm -61.79 -38.79 89.38 Favored 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 120.054 -0.658 . . . . 0.0 110.458 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.322 -0.62 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.701 -179.637 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.456 ' HA ' HD23 ' A' ' 9' ' ' LEU . 40.8 mm . . . . . 0 N--CA 1.45 -0.464 0 CA-C-O 120.848 0.356 . . . . 0.0 111.06 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 82.9 m95 -71.68 -40.69 69.42 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 120.279 -0.568 . . . . 0.0 110.207 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.488 ' OE1' ' N ' ' A' ' 8' ' ' GLN . 1.7 mp0 -64.41 -38.8 92.31 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.055 0.455 . . . . 0.0 110.311 -179.227 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.666 HD12 ' C ' ' A' ' 9' ' ' LEU . 0.3 OUTLIER -72.31 -38.0 68.81 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.97 179.7 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.589 ' O ' HG23 ' A' ' 14' ' ' VAL . 15.8 mt -63.28 -48.78 76.68 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.73 -176.386 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.2 mp -66.13 -44.33 91.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 178.394 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 69.3 mt -64.06 -44.48 97.74 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.642 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.391 -179.366 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.89 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.91 -37.09 86.5 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.867 -179.067 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.589 HG23 ' O ' ' A' ' 10' ' ' LEU . 50.2 t -66.93 -45.6 86.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 C-N-CA 120.425 -0.51 . . . . 0.0 111.574 -178.809 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 15.9 pt -66.41 -42.34 90.27 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.916 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.759 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.7 t -63.19 -42.36 96.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.35 -179.626 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.89 HG23 ' O ' ' A' ' 13' ' ' ALA . 61.3 t -65.63 -48.96 80.69 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.887 0 C-N-CA 117.245 -1.782 . . . . 0.0 113.69 -176.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.634 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.6 pp -68.49 -44.0 75.66 Favored 'General case' 0 C--N 1.289 -2.063 0 C-N-CA 120.094 -0.642 . . . . 0.0 112.156 -179.377 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.669 ' C ' HD12 ' A' ' 19' ' ' LEU . 0.4 OUTLIER -66.3 -39.19 89.15 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.99 -179.604 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.759 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 1.8 m-85 -68.45 -37.62 80.37 Favored 'General case' 0 CA--C 1.506 -0.726 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.641 -178.395 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.483 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 101.2 9.53 44.56 Favored Glycine 0 C--N 1.308 -0.974 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.046 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.697 HG22 ' CG1' ' A' ' 17' ' ' VAL . 44.6 p 55.15 66.66 1.17 Allowed 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 178.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -139.6 -22.57 0.89 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.054 179.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 9.9 mmmt -87.13 -51.41 6.01 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.646 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.634 HD12 ' H ' ' A' ' 25' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.316 -0.866 0 CA-C-O 122.067 0.937 . . . . 0.0 110.556 -178.85 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.2 p . . . . . 0 N--CA 1.454 -0.259 0 CA-C-O 120.796 0.332 . . . . 0.0 111.058 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -76.02 -39.88 54.71 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.078 0.466 . . . . 0.0 109.874 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.7 mp -70.21 -45.59 66.27 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.129 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.55 -43.57 98.83 Favored Glycine 0 N--CA 1.441 -1.007 0 C-N-CA 119.545 -1.312 . . . . 0.0 110.473 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.02 -40.04 71.99 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 120.898 0.38 . . . . 0.0 111.06 179.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 12.4 t -63.99 -41.93 97.36 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 120.559 -0.456 . . . . 0.0 110.98 -178.558 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.44 -39.87 79.2 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.71 -179.528 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 18.7 pttt -59.58 -40.51 87.62 Favored 'General case' 0 C--N 1.309 -1.195 0 C-N-CA 118.591 -1.243 . . . . 0.0 107.843 -178.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -69.46 -36.82 78.07 Favored Glycine 0 N--CA 1.442 -0.92 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 179.657 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -71.52 -50.71 28.67 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.552 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 52.7 mtpt -63.65 -38.85 92.66 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.597 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -62.04 -37.97 86.94 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 119.981 -0.687 . . . . 0.0 110.09 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.325 -0.471 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.495 -179.939 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.422 ' N ' ' CD1' ' A' ' 6' ' ' ILE . 1.4 mp . . . . . 0 CA--C 1.534 0.334 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 70.9 m95 -62.76 -46.97 85.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.692 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 59.1 mm-40 -64.35 -39.05 93.11 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.424 HD23 ' HA ' ' A' ' 9' ' ' LEU . 84.4 mt -65.08 -39.1 92.72 Favored 'General case' 0 CA--C 1.508 -0.649 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.146 178.626 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.598 ' O ' HG23 ' A' ' 14' ' ' VAL . 8.0 mt -63.38 -49.16 74.91 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.521 -176.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.516 ' O ' HG12 ' A' ' 15' ' ' ILE . 3.3 mp -67.67 -44.97 85.66 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.775 0 C-N-CA 119.508 -0.877 . . . . 0.0 109.093 178.07 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 77.1 mt -63.36 -44.36 98.98 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.526 -179.165 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.818 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -63.79 -36.46 83.96 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.203 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.598 HG23 ' O ' ' A' ' 10' ' ' LEU . 65.8 t -67.1 -43.06 88.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 C-N-CA 119.779 -0.769 . . . . 0.0 110.457 179.672 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.516 HG12 ' O ' ' A' ' 11' ' ' ILE . 33.5 mm -66.08 -43.04 92.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.127 0.489 . . . . 0.0 110.28 179.26 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.505 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -63.75 -38.04 81.27 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.558 -178.72 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.818 HG23 ' O ' ' A' ' 13' ' ' ALA . 95.0 t -65.66 -43.02 93.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 C-N-CA 118.409 -1.316 . . . . 0.0 111.868 -178.308 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.434 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 16.1 mt -62.0 -45.03 95.42 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 118.631 -1.227 . . . . 0.0 111.833 -179.106 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.889 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.78 -38.37 79.97 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -178.528 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.889 ' N ' HD12 ' A' ' 19' ' ' LEU . 1.3 m-85 -67.57 -32.44 73.2 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -177.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 94.45 8.88 59.46 Favored Glycine 0 CA--C 1.5 -0.887 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 178.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.721 HG22 HG13 ' A' ' 17' ' ' VAL . 18.0 p 56.95 27.95 13.94 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 114.27 -0.965 . . . . 0.0 112.502 178.034 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -100.57 -12.84 18.92 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.776 179.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 15.4 mmmt -96.06 -58.43 2.09 Favored 'General case' 0 C--O 1.221 -0.438 0 CA-C-O 121.053 0.454 . . . . 0.0 110.281 179.511 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 1.086 HD12 ' H ' ' A' ' 25' ' ' LEU . 2.0 mp . . . . . 0 CA--C 1.495 -1.144 0 CA-C-O 122.459 1.123 . . . . 0.0 110.468 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 61.9 p . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.731 0.301 . . . . 0.0 111.761 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -67.81 -39.87 83.91 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.411 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -65.46 -44.99 85.51 Favored 'General case' 0 CA--C 1.507 -0.694 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.159 179.653 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.43 -43.43 99.34 Favored Glycine 0 N--CA 1.433 -1.54 0 N-CA-C 108.475 -1.85 . . . . 0.0 108.475 -178.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.97 -40.0 75.63 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.073 -0.564 . . . . 0.0 111.159 178.429 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 51.6 m -63.53 -43.37 97.33 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 120.408 -0.517 . . . . 0.0 110.87 -178.452 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -67.28 -39.71 83.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.64 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.0 pttt -60.02 -42.08 93.56 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 -179.209 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.68 -36.83 88.37 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 178.23 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 14.8 t80 -71.94 -50.41 29.27 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 120.956 0.408 . . . . 0.0 110.642 -179.673 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 21.8 mtpp -62.74 -38.55 90.99 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.269 179.066 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -61.76 -38.3 87.49 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.475 -179.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.327 -0.405 0 CA-C-O 121.194 0.521 . . . . 0.0 109.626 179.189 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.6 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.4 mp . . . . . 0 N--CA 1.435 -1.21 0 CA-C-O 121.153 0.501 . . . . 0.0 110.403 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.403 ' O ' HD13 ' A' ' 11' ' ' ILE . 95.8 m95 -70.92 -39.71 72.53 Favored 'General case' 0 C--N 1.316 -0.884 0 C-N-CA 120.068 -0.653 . . . . 0.0 109.773 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 94.2 mm-40 -64.66 -39.15 93.19 Favored 'General case' 0 N--CA 1.442 -0.85 0 C-N-CA 120.315 -0.554 . . . . 0.0 109.617 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.658 HD12 ' C ' ' A' ' 9' ' ' LEU . 0.4 OUTLIER -73.05 -38.36 66.51 Favored 'General case' 0 C--O 1.226 -0.176 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.014 179.027 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.566 ' O ' HG23 ' A' ' 14' ' ' VAL . 15.3 mt -63.31 -47.82 80.66 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.945 -0.302 . . . . 0.0 111.22 -177.613 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.403 HD13 ' O ' ' A' ' 7' ' ' TRP . 2.1 mp -66.94 -44.48 88.64 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.851 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 53.3 mt -64.42 -44.72 97.09 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.076 0 CA-C-N 115.639 -0.709 . . . . 0.0 111.271 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.694 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.84 -37.39 87.47 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.719 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.566 HG23 ' O ' ' A' ' 10' ' ' LEU . 55.3 t -67.67 -45.72 84.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 C-N-CA 119.624 -0.831 . . . . 0.0 110.697 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.5 mt -65.85 -43.88 92.97 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.717 0 CA-C-O 121.172 0.51 . . . . 0.0 111.189 -179.023 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.579 HG22 ' CD2' ' A' ' 20' ' ' PHE . 0.5 OUTLIER -64.46 -38.74 83.36 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.344 0 CA-C-N 115.284 -0.871 . . . . 0.0 109.616 -178.932 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.782 HG13 HG22 ' A' ' 22' ' ' THR . 61.0 t -65.75 -42.79 93.19 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.158 0 C-N-CA 118.571 -1.252 . . . . 0.0 111.389 -177.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 66.0 mt -61.77 -44.96 95.86 Favored 'General case' 0 C--N 1.312 -1.031 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.751 -179.02 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.875 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.55 -38.29 80.65 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 113.067 0.765 . . . . 0.0 113.067 -178.74 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.875 ' N ' HD12 ' A' ' 19' ' ' LEU . 1.2 m-85 -67.61 -31.74 71.97 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -178.224 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 90.74 2.79 71.84 Favored Glycine 0 C--N 1.318 -0.47 0 N-CA-C 109.211 -1.556 . . . . 0.0 109.211 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.782 HG22 HG13 ' A' ' 17' ' ' VAL . 5.5 p 57.19 9.09 0.63 Allowed 'General case' 0 CA--C 1.511 -0.544 0 CA-C-N 114.727 -0.737 . . . . 0.0 112.178 178.03 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 24.7 mtpp -71.76 -42.26 67.42 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.256 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . 0.592 ' HG3' HD12 ' A' ' 25' ' ' LEU . 0.0 OUTLIER -86.57 -25.17 25.14 Favored 'General case' 0 C--O 1.221 -0.41 0 CA-C-N 116.16 -0.473 . . . . 0.0 112.017 -178.705 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.68 HD13 ' HA ' ' A' ' 22' ' ' THR . 9.7 mp . . . . . 0 CA--C 1.49 -1.328 0 CA-C-O 121.852 0.834 . . . . 0.0 109.353 -179.669 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 7.3 t . . . . . 0 C--O 1.232 0.149 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -86.53 -36.19 19.1 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.4 mp -73.03 -46.34 52.48 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.129 -0.942 . . . . 0.0 111.725 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.78 -43.66 98.94 Favored Glycine 0 C--N 1.308 -1.003 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.579 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.0 -40.32 75.34 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.486 -0.357 . . . . 0.0 111.479 179.57 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.5 t -63.61 -42.84 98.17 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.195 0.521 . . . . 0.0 110.857 -178.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.1 mp -67.09 -39.76 83.92 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.753 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.487 ' HA ' ' HZ2' ' A' ' 40' ' ' LYS . 2.1 pttp -59.81 -42.71 94.08 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 118.809 -1.156 . . . . 0.0 108.301 -178.717 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.87 -36.88 87.57 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.495 -1.042 . . . . 0.0 110.495 178.549 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 51.6 t80 -71.91 -53.34 13.45 Favored 'General case' 0 CA--C 1.513 -0.445 0 CA-C-O 120.684 0.278 . . . . 0.0 111.597 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.487 ' HZ2' ' HA ' ' A' ' 37' ' ' LYS . 9.9 pttm -62.75 -38.37 90.3 Favored 'General case' 0 C--N 1.318 -0.773 0 C-N-CA 120.069 -0.652 . . . . 0.0 109.994 -179.423 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 52.9 tttp -61.47 -37.52 83.91 Favored 'General case' 0 N--CA 1.446 -0.654 0 C-N-CA 120.153 -0.619 . . . . 0.0 110.057 -179.523 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.324 -0.508 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.53 179.389 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 26.1 mm . . . . . 0 N--CA 1.443 -0.777 0 CA-C-O 121.523 0.678 . . . . 0.0 111.315 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.768 ' CZ2' HD11 ' A' ' 11' ' ' ILE . 6.5 t-105 -62.74 -42.0 99.46 Favored 'General case' 0 N--CA 1.434 -1.242 0 CA-C-N 115.219 -0.901 . . . . 0.0 108.756 179.338 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.539 ' OE1' ' N ' ' A' ' 8' ' ' GLN . 5.9 mp0 -64.74 -38.73 91.97 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.127 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.439 HD23 ' HA ' ' A' ' 9' ' ' LEU . 32.7 mt -60.03 -37.28 79.3 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.789 178.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.598 ' O ' HG23 ' A' ' 14' ' ' VAL . 4.8 mt -61.94 -44.32 97.01 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.077 -176.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.768 HD11 ' CZ2' ' A' ' 7' ' ' TRP . 4.4 mp -66.65 -45.33 88.62 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.508 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.329 177.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.403 ' N ' ' CD1' ' A' ' 12' ' ' ILE . 1.1 mp -64.96 -44.79 96.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.448 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.776 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.18 -37.0 85.89 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.971 0.415 . . . . 0.0 110.395 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.598 HG23 ' O ' ' A' ' 10' ' ' LEU . 56.0 t -67.4 -43.77 87.43 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.39 0 C-N-CA 119.811 -0.756 . . . . 0.0 110.792 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.402 HG12 ' O ' ' A' ' 11' ' ' ILE . 4.4 mm -65.53 -43.39 94.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.26 0.552 . . . . 0.0 110.98 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.463 HG22 ' CD2' ' A' ' 20' ' ' PHE . 0.3 OUTLIER -63.54 -38.16 81.48 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.401 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.536 -178.31 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.776 HG23 ' O ' ' A' ' 13' ' ' ALA . 73.5 t -64.61 -43.67 96.72 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.381 0 C-N-CA 118.429 -1.309 . . . . 0.0 109.751 -178.404 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.588 HD21 ' O ' ' A' ' 14' ' ' VAL . 0.1 OUTLIER -63.72 -43.63 95.98 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 178.168 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.06 -43.75 94.55 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-N 114.006 -1.452 . . . . 0.0 111.605 -176.519 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.463 ' CD2' HG22 ' A' ' 16' ' ' VAL . 2.9 m-85 -68.92 -33.1 73.19 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.509 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 97.35 14.21 42.37 Favored Glycine 0 CA--C 1.502 -0.733 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 178.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.773 HG22 ' CG1' ' A' ' 17' ' ' VAL . 70.3 p 57.38 14.51 2.22 Favored 'General case' 0 CA--C 1.508 -0.664 0 CA-C-N 114.57 -0.815 . . . . 0.0 112.408 179.051 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -97.51 -31.35 12.38 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.375 -178.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 13.8 tppt? -70.96 -47.36 59.36 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 121.399 0.618 . . . . 0.0 111.477 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 1.092 ' H ' HD12 ' A' ' 25' ' ' LEU . 1.8 mp . . . . . 0 CA--C 1.489 -1.402 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.232 -179.086 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.2 p . . . . . 0 CA--C 1.521 -0.173 0 CA-C-O 120.575 0.226 . . . . 0.0 111.606 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 45.5 m-20 -87.28 -36.74 17.73 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -73.6 -46.03 49.6 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.456 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.92 -44.46 97.8 Favored Glycine 0 C--N 1.311 -0.854 0 C-N-CA 119.399 -1.382 . . . . 0.0 109.856 -179.105 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.68 -40.17 76.52 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.718 -0.241 . . . . 0.0 111.432 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.9 t -63.1 -42.35 99.56 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.565 -0.454 . . . . 0.0 110.528 -178.404 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.2 -39.41 81.14 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.042 178.712 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.601 ' HA ' ' HZ2' ' A' ' 40' ' ' LYS . 7.7 ttpt -59.51 -45.56 91.39 Favored 'General case' 0 N--CA 1.435 -1.175 0 C-N-CA 119.252 -0.979 . . . . 0.0 109.043 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.79 -37.11 88.3 Favored Glycine 0 CA--C 1.529 0.946 0 C-N-CA 120.05 -1.071 . . . . 0.0 110.461 178.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -71.6 -51.82 21.32 Favored 'General case' 0 CA--C 1.511 -0.528 0 CA-C-O 120.574 0.226 . . . . 0.0 111.537 -179.478 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.601 ' HZ2' ' HA ' ' A' ' 37' ' ' LYS . 8.9 pttm -62.78 -37.71 87.77 Favored 'General case' 0 C--N 1.318 -0.792 0 C-N-CA 120.207 -0.597 . . . . 0.0 110.144 -179.455 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -61.64 -36.15 79.95 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.25 -178.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.319 -0.727 0 C-N-CA 120.686 -0.405 . . . . 0.0 109.921 179.496 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.9 mm . . . . . 0 N--CA 1.447 -0.583 0 CA-C-O 121.585 0.707 . . . . 0.0 111.35 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.516 ' CE2' HD11 ' A' ' 11' ' ' ILE . 10.8 t-105 -62.6 -38.59 90.76 Favored 'General case' 0 N--CA 1.44 -0.944 0 CA-C-N 115.421 -0.808 . . . . 0.0 109.008 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 25.7 mm-40 -64.94 -39.25 93.22 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 29.3 mt -61.39 -38.1 85.8 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.434 178.662 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.618 ' O ' HG23 ' A' ' 14' ' ' VAL . 5.6 mt -62.09 -43.3 99.13 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.066 -176.809 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.516 HD11 ' CE2' ' A' ' 7' ' ' TRP . 5.9 mt -66.3 -45.33 89.99 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 C-N-CA 119.928 -0.709 . . . . 0.0 109.588 177.903 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.1 mp -65.8 -47.39 85.92 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.806 -179.268 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.813 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.75 -37.36 87.34 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.543 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.618 HG23 ' O ' ' A' ' 10' ' ' LEU . 45.8 t -67.38 -44.28 87.18 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.052 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.709 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 97.0 mt -65.61 -43.13 94.08 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.761 0 CA-C-O 121.33 0.586 . . . . 0.0 110.685 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.496 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -63.99 -38.17 81.72 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.589 -178.082 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.813 HG23 ' O ' ' A' ' 13' ' ' ALA . 83.2 t -65.61 -42.83 93.73 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.93 0 C-N-CA 118.449 -1.3 . . . . 0.0 111.474 -178.156 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.595 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 19.2 mt -62.49 -45.72 91.73 Favored 'General case' 0 C--N 1.319 -0.76 0 C-N-CA 119.66 -0.816 . . . . 0.0 112.075 -178.469 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.886 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.92 -38.24 79.41 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -179.315 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.886 ' N ' HD12 ' A' ' 19' ' ' LEU . 2.0 m-85 -67.79 -36.87 81.21 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 108.804 -0.814 . . . . 0.0 108.804 -178.215 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 101.65 7.41 48.27 Favored Glycine 0 CA--C 1.501 -0.837 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 178.374 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.765 ' HA ' HD13 ' A' ' 25' ' ' LEU . 18.0 p 56.41 19.74 4.26 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.77 -0.715 . . . . 0.0 112.135 178.588 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 17.0 mtmt -92.09 -25.13 18.9 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.63 -0.428 . . . . 0.0 111.006 -179.081 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -85.12 -59.85 2.21 Favored 'General case' 0 C--O 1.213 -0.856 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.828 -179.514 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 1.068 HD12 ' H ' ' A' ' 25' ' ' LEU . 2.6 mp . . . . . 0 CA--C 1.492 -1.272 0 CA-C-O 122.503 1.145 . . . . 0.0 110.221 -179.308 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.0 p . . . . . 0 C--O 1.232 0.171 0 CA-C-O 120.692 0.282 . . . . 0.0 111.628 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -76.4 -42.48 44.16 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 179.361 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -66.89 -44.18 81.51 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.587 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.13 -44.31 97.39 Favored Glycine 0 N--CA 1.44 -1.063 0 C-N-CA 119.51 -1.328 . . . . 0.0 109.884 -179.097 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -72.1 -39.92 68.58 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.671 -0.265 . . . . 0.0 111.289 178.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 67.0 m -63.31 -40.7 98.06 Favored 'General case' 0 CA--C 1.515 -0.392 0 C-N-CA 120.528 -0.469 . . . . 0.0 110.551 -178.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.48 -39.15 78.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.007 179.048 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.407 ' O ' ' CB ' ' A' ' 41' ' ' LYS . 20.8 tttt -59.49 -44.98 92.93 Favored 'General case' 0 N--CA 1.432 -1.344 0 C-N-CA 119.358 -0.937 . . . . 0.0 108.598 -178.416 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.04 -36.48 93.08 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 178.62 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 87.1 t80 -71.35 -54.31 11.2 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 111.66 0.244 . . . . 0.0 111.66 -179.172 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.411 ' CG ' ' N ' ' A' ' 41' ' ' LYS . 18.9 ptmt -64.8 -39.83 94.23 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.974 179.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.411 ' N ' ' CG ' ' A' ' 40' ' ' LYS . 88.6 tttt -62.87 -36.84 84.63 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.729 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.325 -0.478 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.421 179.743 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.54 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.5 mp . . . . . 0 N--CA 1.441 -0.877 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.493 ' O ' HD12 ' A' ' 11' ' ' ILE . 29.0 m95 -62.69 -46.88 86.09 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 120.086 -0.645 . . . . 0.0 110.027 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.522 ' OE1' ' N ' ' A' ' 8' ' ' GLN . 0.7 OUTLIER -64.22 -39.04 93.15 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 -179.385 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.688 ' C ' HD12 ' A' ' 9' ' ' LEU . 0.2 OUTLIER -70.37 -37.92 74.66 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.319 178.654 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.559 ' O ' HG23 ' A' ' 14' ' ' VAL . 19.2 mt -62.82 -46.55 87.41 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.899 -177.467 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.493 HD12 ' O ' ' A' ' 7' ' ' TRP . 6.2 mt -65.84 -44.31 92.87 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.247 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 56.2 mt -63.44 -44.35 98.83 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.157 -178.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.778 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.15 -37.13 86.34 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.454 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.559 HG23 ' O ' ' A' ' 10' ' ' LEU . 73.5 t -67.53 -44.31 86.62 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 C-N-CA 119.795 -0.762 . . . . 0.0 110.489 179.58 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.427 HG12 ' O ' ' A' ' 11' ' ' ILE . 4.5 mm -65.99 -43.43 92.66 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.698 0 CA-C-O 121.129 0.49 . . . . 0.0 111.133 -179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.566 HG22 ' CD2' ' A' ' 20' ' ' PHE . 0.3 OUTLIER -63.96 -38.39 82.27 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.072 0 CA-C-N 115.362 -0.835 . . . . 0.0 109.371 -178.984 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.778 HG23 ' O ' ' A' ' 13' ' ' ALA . 79.0 t -65.4 -42.81 94.4 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.024 0 C-N-CA 118.478 -1.289 . . . . 0.0 111.64 -177.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.494 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 29.4 mt -62.42 -45.2 94.17 Favored 'General case' 0 C--N 1.317 -0.821 0 C-N-CA 118.984 -1.086 . . . . 0.0 111.721 -179.159 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.85 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -67.48 -38.46 84.42 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.818 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.85 ' N ' HD12 ' A' ' 19' ' ' LEU . 1.4 m-85 -67.73 -31.25 71.04 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -178.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 89.62 8.77 67.35 Favored Glycine 0 CA--C 1.505 -0.541 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.732 HG22 HG13 ' A' ' 17' ' ' VAL . 14.8 p 56.65 15.6 2.22 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 114.48 -0.86 . . . . 0.0 112.279 178.139 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 13.4 ptpt -82.66 -44.38 15.79 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.296 0.569 . . . . 0.0 109.68 178.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 2.0 mmmm -67.95 -43.97 77.84 Favored 'General case' 0 C--O 1.21 -1.012 0 CA-C-N 115.218 -0.901 . . . . 0.0 112.069 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.666 ' N ' HD12 ' A' ' 25' ' ' LEU . 6.7 mp . . . . . 0 CA--C 1.49 -1.331 0 CA-C-O 121.876 0.846 . . . . 0.0 110.568 -178.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 41.8 t . . . . . 0 N--CA 1.453 -0.306 0 CA-C-O 120.884 0.373 . . . . 0.0 111.442 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -76.28 -44.79 35.54 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.371 0.605 . . . . 0.0 109.485 179.651 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 10.6 mp -67.48 -43.87 79.94 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 114.795 -1.093 . . . . 0.0 111.816 -179.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.33 -43.77 98.61 Favored Glycine 0 C--N 1.308 -0.985 0 C-N-CA 119.247 -1.454 . . . . 0.0 109.789 -179.682 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.27 -40.32 71.03 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.461 -0.369 . . . . 0.0 111.25 179.407 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 40.1 t -63.49 -41.98 98.56 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.223 0.535 . . . . 0.0 111.125 -178.71 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.53 -40.12 79.3 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.665 -179.727 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.2 pttt -60.07 -42.84 95.41 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -179.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.03 -36.59 92.18 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 178.578 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -71.65 -51.89 20.75 Favored 'General case' 0 CA--C 1.516 -0.365 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.18 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 42.7 mmtm -64.0 -38.97 93.01 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.37 178.783 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -61.63 -36.83 81.89 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.092 -0.643 . . . . 0.0 110.14 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.326 -0.438 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.794 -179.686 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 1.6 mp . . . . . 0 CA--C 1.538 0.483 0 CA-C-O 120.768 0.318 . . . . 0.0 110.548 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 58.6 m95 -62.56 -49.02 76.95 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 -179.456 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.461 ' H ' ' NE2' ' A' ' 8' ' ' GLN . 3.0 mp0 -64.53 -38.94 92.74 Favored 'General case' 0 C--N 1.312 -1.045 0 C-N-CA 120.186 -0.606 . . . . 0.0 109.577 179.625 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.504 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 3.3 mm? -63.82 -39.25 93.8 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.953 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.569 ' O ' HG23 ' A' ' 14' ' ' VAL . 9.5 mt -63.4 -52.4 61.78 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.894 -178.415 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.469 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.5 mp -64.86 -44.58 96.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 178.495 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 71.9 mt -63.56 -45.73 96.9 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.101 0 C-N-CA 120.107 -0.637 . . . . 0.0 111.177 -179.6 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.799 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.73 -37.37 87.38 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.968 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.582 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 51.6 t -67.54 -43.84 86.89 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 C-N-CA 119.823 -0.751 . . . . 0.0 110.872 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.3 mt -65.4 -42.79 94.34 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.658 0 CA-C-O 121.1 0.476 . . . . 0.0 110.225 -179.009 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.476 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -64.5 -38.43 82.59 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.345 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.917 -178.459 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.804 ' CG1' HG22 ' A' ' 22' ' ' THR . 75.1 t -63.88 -43.07 97.7 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.367 0 C-N-CA 118.544 -1.262 . . . . 0.0 111.002 -177.775 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.582 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 14.4 mt -60.8 -47.08 87.98 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 120.078 -0.649 . . . . 0.0 112.473 -178.789 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.857 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.95 -37.96 79.17 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -179.515 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.857 ' N ' HD12 ' A' ' 19' ' ' LEU . 0.8 OUTLIER -67.45 -35.99 80.28 Favored 'General case' 0 CA--C 1.519 -0.217 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -177.946 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.598 ' C ' ' H ' ' A' ' 23' ' ' LYS . . . 102.69 10.8 36.94 Favored Glycine 0 CA--C 1.501 -0.837 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 178.298 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.804 HG22 ' CG1' ' A' ' 17' ' ' VAL . 44.8 p 56.52 -1.94 0.04 OUTLIER 'General case' 0 CA--C 1.497 -1.081 0 CA-C-O 121.073 0.463 . . . . 0.0 112.138 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.598 ' H ' ' C ' ' A' ' 21' ' ' GLY . 12.6 tmtt? -84.41 -36.22 22.55 Favored 'General case' 0 N--CA 1.434 -1.252 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.006 -179.117 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.4 tppt? -63.75 -48.57 76.47 Favored 'General case' 0 N--CA 1.436 -1.126 0 CA-C-O 121.089 0.471 . . . . 0.0 110.37 179.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 1.063 ' H ' HD12 ' A' ' 25' ' ' LEU . 2.1 mp . . . . . 0 CA--C 1.486 -1.493 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.044 -178.345 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 14.0 t . . . . . 0 CA--C 1.518 -0.284 0 N-CA-C 111.769 0.285 . . . . 0.0 111.769 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -84.42 -37.08 21.89 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -72.3 -44.34 62.88 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.173 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.97 -43.8 98.69 Favored Glycine 0 C--N 1.31 -0.899 0 C-N-CA 119.527 -1.32 . . . . 0.0 110.018 -179.366 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.5 -39.93 73.86 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.891 -0.324 . . . . 0.0 111.205 179.533 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 44.8 t -64.3 -41.93 96.62 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.542 -0.463 . . . . 0.0 111.288 -178.763 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.422 HG23 ' HZ2' ' A' ' 40' ' ' LYS . 1.2 mp -68.73 -38.92 79.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.205 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 3.3 pttp -59.49 -40.86 88.38 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 -178.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.07 -36.63 90.89 Favored Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 178.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -71.63 -49.71 37.46 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 121.04 0.448 . . . . 0.0 109.962 -179.472 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.422 ' HZ2' HG23 ' A' ' 36' ' ' ILE . 53.4 mttp -63.12 -38.57 91.71 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.471 178.528 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 12.5 ttmm -61.33 -36.99 81.69 Favored 'General case' 0 C--N 1.319 -0.748 0 C-N-CA 119.935 -0.706 . . . . 0.0 110.187 -179.613 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.324 -0.52 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.274 179.851 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.2 mm . . . . . 0 N--CA 1.444 -0.76 0 CA-C-O 121.546 0.689 . . . . 0.0 110.636 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.621 ' CE2' HD11 ' A' ' 11' ' ' ILE . 11.7 t-105 -62.82 -38.07 89.28 Favored 'General case' 0 N--CA 1.438 -1.059 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.725 178.82 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 28.6 mm-40 -64.84 -40.29 94.93 Favored 'General case' 0 CA--C 1.509 -0.61 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 178.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 72.0 mt -61.4 -37.64 84.17 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.006 178.212 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.719 ' O ' HG23 ' A' ' 14' ' ' VAL . 5.4 mt -62.12 -42.88 99.67 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.2 -176.44 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.621 HD11 ' CE2' ' A' ' 7' ' ' TRP . 6.4 mt -67.89 -45.67 83.57 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 C-N-CA 120.25 -0.58 . . . . 0.0 110.011 177.48 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.1 mp -65.49 -44.7 94.09 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.997 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.814 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.46 -36.69 85.0 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.605 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 10' ' ' LEU . 48.8 t -66.75 -45.73 87.3 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.039 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.305 -179.167 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 16.2 pt -65.97 -42.49 91.9 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-N 118.023 0.374 . . . . 0.0 110.929 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.492 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -63.47 -38.37 82.04 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.134 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.601 -178.96 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.814 HG23 ' O ' ' A' ' 13' ' ' ALA . 90.7 t -65.69 -44.34 93.42 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.803 0 C-N-CA 118.382 -1.327 . . . . 0.0 111.713 -178.648 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.595 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 23.5 mt -61.62 -46.46 89.7 Favored 'General case' 0 C--N 1.322 -0.623 0 C-N-CA 119.907 -0.717 . . . . 0.0 111.909 -179.037 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.869 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.7 pp -68.09 -38.41 82.32 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 -179.607 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.869 ' N ' HD12 ' A' ' 19' ' ' LEU . 2.0 m-85 -67.64 -37.7 82.8 Favored 'General case' 0 CA--C 1.517 -0.324 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -177.77 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.408 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 102.81 6.07 46.82 Favored Glycine 0 CA--C 1.499 -0.953 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 178.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.751 ' HA ' HD13 ' A' ' 25' ' ' LEU . 18.5 p 57.88 19.2 5.56 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 114.964 -0.618 . . . . 0.0 112.281 178.279 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -93.16 -19.93 20.98 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.535 -179.355 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -89.81 -60.39 1.95 Allowed 'General case' 0 C--O 1.211 -0.958 0 CA-C-O 121.178 0.513 . . . . 0.0 110.706 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 1.047 HD12 ' H ' ' A' ' 25' ' ' LEU . 2.6 mp . . . . . 0 CA--C 1.491 -1.304 0 CA-C-O 122.495 1.141 . . . . 0.0 110.149 -179.532 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.0 p . . . . . 0 CA--C 1.521 -0.151 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -78.61 -40.97 32.93 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 179.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.3 mp -68.65 -45.92 70.52 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.551 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.51 -44.0 97.29 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.76 -40.23 76.24 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.366 -0.417 . . . . 0.0 111.364 179.196 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 43.3 m -63.63 -40.79 97.77 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.531 -0.467 . . . . 0.0 111.216 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.67 -40.93 79.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.073 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 16.2 pttt -60.24 -43.48 96.05 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.66 -36.91 92.0 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.614 -0.994 . . . . 0.0 110.614 178.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -71.67 -50.69 28.19 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-O 120.946 0.403 . . . . 0.0 110.516 -179.604 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 66.4 mmtt -63.97 -38.99 93.09 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 120.252 -0.579 . . . . 0.0 110.325 179.181 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt -61.97 -37.16 83.71 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.239 -179.663 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.32 -0.695 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.523 -179.337 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.1 mm . . . . . 0 N--CA 1.454 -0.232 0 CA-C-O 120.971 0.415 . . . . 0.0 111.872 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.725 ' CE2' HD11 ' A' ' 11' ' ' ILE . 9.5 t-105 -62.67 -36.61 83.44 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.617 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 21.3 mm-40 -64.47 -38.88 92.57 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 86.6 mt -63.03 -37.66 88.07 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.747 178.374 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.612 ' O ' HG23 ' A' ' 14' ' ' VAL . 5.2 mt -62.58 -42.89 99.84 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.13 -177.055 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.725 HD11 ' CE2' ' A' ' 7' ' ' TRP . 7.8 mt -66.95 -45.54 87.02 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.95 0 C-N-CA 119.698 -0.801 . . . . 0.0 109.51 177.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 67.1 mt -65.66 -47.56 85.71 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.806 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.327 -179.719 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.837 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.55 -37.34 87.21 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.4 -179.764 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.612 HG23 ' O ' ' A' ' 10' ' ' LEU . 40.6 t -67.67 -44.25 86.17 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 C-N-CA 119.748 -0.781 . . . . 0.0 110.973 179.721 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 91.8 mt -65.27 -42.28 93.54 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.834 0 CA-C-O 120.993 0.425 . . . . 0.0 110.395 -179.087 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.502 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -64.25 -38.4 82.41 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.113 0 CA-C-N 115.322 -0.854 . . . . 0.0 110.11 -178.836 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.837 HG23 ' O ' ' A' ' 13' ' ' ALA . 87.1 t -64.56 -42.6 95.64 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.257 0 C-N-CA 118.389 -1.325 . . . . 0.0 111.131 -177.351 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.565 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 20.8 mt -62.08 -47.18 85.83 Favored 'General case' 0 C--N 1.316 -0.887 0 C-N-CA 119.819 -0.752 . . . . 0.0 112.566 -178.573 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.849 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.01 -38.41 82.56 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.897 -179.579 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.849 ' N ' HD12 ' A' ' 19' ' ' LEU . 0.7 OUTLIER -68.07 -32.14 72.27 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -178.3 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 93.9 5.79 62.44 Favored Glycine 0 CA--C 1.504 -0.61 0 C-N-CA 120.209 -0.996 . . . . 0.0 111.044 178.523 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.776 HG22 ' CG1' ' A' ' 17' ' ' VAL . 14.4 p 58.39 26.93 14.71 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.161 -0.519 . . . . 0.0 112.202 178.558 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 50.2 pttt -96.97 -33.09 11.7 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.878 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 16.6 mmmt -77.45 -52.78 8.53 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.72 -0.392 . . . . 0.0 111.498 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 1.071 HD12 ' H ' ' A' ' 25' ' ' LEU . 1.9 mp . . . . . 0 CA--C 1.489 -1.374 0 CA-C-O 122.336 1.065 . . . . 0.0 110.476 -179.32 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.1 p . . . . . 0 N--CA 1.451 -0.408 0 CA-C-O 120.816 0.341 . . . . 0.0 111.219 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 66.7 t0 -76.63 -41.04 47.38 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.289 0.566 . . . . 0.0 109.846 179.728 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.5 mp -68.68 -45.82 70.68 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.024 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.56 -43.82 98.45 Favored Glycine 0 C--N 1.308 -1.018 0 C-N-CA 119.463 -1.351 . . . . 0.0 110.031 -179.55 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.07 -40.25 75.14 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.82 0.343 . . . . 0.0 111.148 179.646 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.6 t -63.94 -42.01 97.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.132 0.491 . . . . 0.0 111.248 -178.742 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.48 -39.42 78.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.615 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 17.9 pttt -59.32 -40.35 86.0 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 -178.108 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -69.81 -37.09 75.37 Favored Glycine 0 N--CA 1.442 -0.903 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -71.61 -49.16 42.8 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-O 121.114 0.483 . . . . 0.0 109.762 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 47.5 mtpt -63.01 -38.6 91.83 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.558 178.566 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 14.2 tmtt? -61.75 -36.68 81.71 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 119.773 -0.771 . . . . 0.0 109.853 -178.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.325 -0.488 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.052 179.713 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.609 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.6 mp . . . . . 0 N--CA 1.452 -0.364 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 91.8 m95 -62.27 -41.01 98.1 Favored 'General case' 0 CA--C 1.507 -0.685 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.748 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.424 ' O ' HD13 ' A' ' 12' ' ' ILE . 5.6 pt20 -64.28 -39.48 94.01 Favored 'General case' 0 C--O 1.215 -0.725 0 C-N-CA 118.572 -1.251 . . . . 0.0 108.152 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.425 ' O ' ' CB ' ' A' ' 13' ' ' ALA . 76.6 mt -68.59 -38.49 80.71 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.166 179.376 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.648 ' O ' HG23 ' A' ' 14' ' ' VAL . 18.7 mt -63.28 -49.27 74.72 Favored 'General case' 0 C--N 1.314 -0.935 0 C-N-CA 120.076 -0.65 . . . . 0.0 111.371 -176.022 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.462 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.7 mp -67.19 -44.33 87.81 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 178.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.424 HD13 ' O ' ' A' ' 8' ' ' GLN . 1.0 OUTLIER -65.07 -44.56 95.74 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.878 -179.387 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.846 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.77 -36.53 84.6 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.825 -179.762 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.648 HG23 ' O ' ' A' ' 10' ' ' LEU . 54.8 t -67.03 -45.03 87.87 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.826 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.442 -178.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 15.9 pt -66.23 -42.56 91.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 CA-C-O 121.05 0.452 . . . . 0.0 110.827 179.645 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.502 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -63.54 -38.12 81.38 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.905 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 -179.324 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.846 HG23 ' O ' ' A' ' 13' ' ' ALA . 94.4 t -65.52 -43.72 94.25 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 C-N-CA 118.557 -1.257 . . . . 0.0 111.654 -178.303 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.518 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 21.3 mt -61.82 -47.09 86.66 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 119.566 -0.854 . . . . 0.0 111.57 -178.853 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.851 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -67.06 -38.21 85.41 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -179.221 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.851 ' N ' HD12 ' A' ' 19' ' ' LEU . 1.2 m-85 -67.55 -35.83 79.81 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 -177.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.425 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 98.79 8.04 54.76 Favored Glycine 0 CA--C 1.501 -0.821 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 178.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.736 HG22 ' CG1' ' A' ' 17' ' ' VAL . 19.0 p 57.7 27.1 13.85 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 114.309 -0.945 . . . . 0.0 112.52 178.239 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 55.3 mtpt -100.0 -19.82 16.38 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.686 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 14.5 mmmt -88.66 -56.91 3.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.125 0.488 . . . . 0.0 110.622 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 1.064 ' H ' HD12 ' A' ' 25' ' ' LEU . 2.3 mp . . . . . 0 CA--C 1.495 -1.173 0 CA-C-O 122.473 1.13 . . . . 0.0 110.291 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.3 t . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.628 0.251 . . . . 0.0 111.652 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 53.3 m-20 -74.15 -43.65 56.6 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.53 0.681 . . . . 0.0 109.208 179.475 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.6 mp -65.82 -44.28 86.08 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.789 -1.096 . . . . 0.0 111.553 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.52 -45.18 96.39 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 119.411 -1.376 . . . . 0.0 109.823 -179.204 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.6 -39.81 73.6 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.651 -0.274 . . . . 0.0 111.309 179.164 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 39.4 t -63.19 -41.69 99.23 Favored 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 120.528 -0.469 . . . . 0.0 110.406 -178.247 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.02 -39.27 79.47 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.715 179.027 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 24.3 tttt -59.87 -43.72 94.57 Favored 'General case' 0 C--N 1.309 -1.17 0 C-N-CA 119.287 -0.965 . . . . 0.0 108.463 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.97 -36.6 91.23 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 178.18 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -71.59 -50.77 27.81 Favored 'General case' 0 CA--C 1.52 -0.182 0 CA-C-O 120.805 0.336 . . . . 0.0 110.291 -179.621 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 53.2 mtpt -63.43 -38.52 91.46 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.37 178.646 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -61.74 -39.11 90.41 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.138 -0.625 . . . . 0.0 110.102 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.324 -0.534 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.551 -179.948 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.521 ' CG2' ' N ' ' A' ' 7' ' ' TRP . 1.5 tp . . . . . 0 N--CA 1.444 -0.755 0 CA-C-O 121.368 0.604 . . . . 0.0 111.012 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.528 ' CD1' ' C ' ' A' ' 7' ' ' TRP . 2.0 t-105 -62.15 -38.42 88.93 Favored 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -179.262 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 13.7 mm-40 -64.31 -38.75 92.16 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 179.639 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.826 ' O ' HD12 ' A' ' 9' ' ' LEU . 0.2 OUTLIER -70.33 -38.03 74.82 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.423 178.933 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.558 ' O ' HG23 ' A' ' 14' ' ' VAL . 1.2 tt -62.71 -47.03 85.4 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.971 -175.607 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.45 HD11 ' CE2' ' A' ' 7' ' ' TRP . 2.0 mp -65.01 -43.94 96.04 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 177.51 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 72.9 mt -63.37 -44.51 99.03 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.065 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.547 -178.671 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.873 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.23 -37.25 86.82 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.923 -179.241 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.558 HG23 ' O ' ' A' ' 10' ' ' LEU . 78.6 t -67.02 -44.05 88.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 C-N-CA 120.545 -0.462 . . . . 0.0 111.139 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.453 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 58.7 mt -66.62 -43.19 90.57 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.285 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 178.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.471 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.5 t -64.01 -42.27 95.16 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.681 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.881 -179.046 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.873 HG23 ' O ' ' A' ' 13' ' ' ALA . 60.1 t -65.93 -44.92 92.29 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.118 0 C-N-CA 118.281 -1.368 . . . . 0.0 112.774 -177.376 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.518 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.4 pp -72.65 -42.87 63.89 Favored 'General case' 0 C--N 1.293 -1.857 0 C-N-CA 120.054 -0.659 . . . . 0.0 109.842 178.761 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.733 ' C ' HD13 ' A' ' 19' ' ' LEU . 2.6 tm? -64.37 -41.29 96.79 Favored 'General case' 0 N--CA 1.443 -0.806 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.617 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.471 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 5.6 m-85 -69.0 -39.47 79.31 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 118.741 -1.183 . . . . 0.0 108.749 179.17 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.478 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 105.15 11.9 28.63 Favored Glycine 0 N--CA 1.467 0.75 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 179.025 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.73 HG22 ' CG1' ' A' ' 17' ' ' VAL . 50.4 p 57.31 44.42 21.89 Favored 'General case' 0 CA--C 1.499 -0.983 0 CA-C-N 115.371 -0.414 . . . . 0.0 112.062 178.304 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -127.19 -18.38 4.56 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.593 -0.73 . . . . 0.0 111.551 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 9.6 tppt? -86.44 -48.38 8.47 Favored 'General case' 0 N--CA 1.447 -0.625 0 CA-C-O 121.008 0.432 . . . . 0.0 110.08 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.711 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.1 OUTLIER . . . . . 0 CA--C 1.505 -0.768 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.682 -178.839 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.9 t . . . . . 0 CA--C 1.519 -0.222 0 CA-C-O 120.68 0.276 . . . . 0.0 111.548 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 94.3 m-20 -76.32 -41.18 49.32 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.338 0.59 . . . . 0.0 109.614 179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -68.33 -44.43 75.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.556 179.75 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.0 -44.08 97.92 Favored Glycine 0 N--CA 1.443 -0.853 0 C-N-CA 119.363 -1.399 . . . . 0.0 109.99 -179.001 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.73 -39.87 73.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.719 0.295 . . . . 0.0 111.413 179.27 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.0 t -63.22 -41.9 99.19 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.69 -178.439 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.78 -39.17 79.78 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.009 178.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 23.9 tttt -59.69 -44.65 93.57 Favored 'General case' 0 N--CA 1.435 -1.223 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 -178.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.39 -36.61 92.88 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 178.06 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 38.3 t80 -71.8 -51.78 20.85 Favored 'General case' 0 CA--C 1.512 -0.495 0 CA-C-O 120.991 0.424 . . . . 0.0 110.406 -179.373 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 48.8 mtpt -62.62 -39.1 92.75 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.717 179.454 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 42.8 mtmt -61.58 -39.1 89.97 Favored 'General case' 0 C--N 1.319 -0.75 0 C-N-CA 119.043 -1.063 . . . . 0.0 109.911 -179.73 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.319 -0.759 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.322 -179.93 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.524 ' HA ' HD23 ' A' ' 9' ' ' LEU . 16.9 mm . . . . . 0 N--CA 1.44 -0.957 0 CA-C-O 121.995 0.903 . . . . 0.0 110.88 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.588 ' CE2' HD11 ' A' ' 11' ' ' ILE . 22.4 t-105 -65.42 -39.39 92.07 Favored 'General case' 0 N--CA 1.432 -1.345 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.248 -179.519 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 22.0 mm-40 -65.84 -41.45 91.74 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.061 0.458 . . . . 0.0 110.8 179.58 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.683 HD12 ' C ' ' A' ' 9' ' ' LEU . 0.4 OUTLIER -63.41 -36.74 84.72 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.724 179.453 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.628 ' O ' HG23 ' A' ' 14' ' ' VAL . 6.3 mt -62.03 -42.39 99.11 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.013 -177.13 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.588 HD11 ' CE2' ' A' ' 7' ' ' TRP . 7.8 mt -65.2 -44.18 95.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 177.538 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 69.7 mt -63.96 -44.37 97.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.313 -179.019 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.868 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -65.12 -37.53 87.76 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.133 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.628 HG23 ' O ' ' A' ' 10' ' ' LEU . 64.8 t -67.1 -44.54 87.98 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.372 0 C-N-CA 120.829 -0.348 . . . . 0.0 111.35 -178.732 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 16.1 pt -67.12 -42.86 88.77 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.11 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 178.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.473 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.7 t -63.71 -41.63 93.24 Favored 'Isoleucine or valine' 0 CA--C 1.476 -1.882 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.981 -179.213 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.868 HG23 ' O ' ' A' ' 13' ' ' ALA . 61.5 t -66.49 -50.11 69.67 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.984 0 C-N-CA 117.149 -1.821 . . . . 0.0 113.11 -177.19 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.497 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.0 OUTLIER -66.34 -44.52 83.08 Favored 'General case' 0 C--N 1.302 -1.492 0 C-N-CA 119.209 -0.996 . . . . 0.0 112.01 179.722 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.651 ' C ' HD12 ' A' ' 19' ' ' LEU . 0.4 OUTLIER -65.59 -38.24 88.93 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.442 179.962 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.473 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 3.0 m-85 -68.01 -43.91 77.75 Favored 'General case' 0 CA--C 1.515 -0.381 0 C-N-CA 119.221 -0.992 . . . . 0.0 108.501 -179.487 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.504 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 111.71 11.12 17.68 Favored Glycine 0 C--N 1.316 -0.559 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 178.715 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.739 HG22 ' CG1' ' A' ' 17' ' ' VAL . 59.5 p 56.42 35.09 25.36 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 114.863 -0.668 . . . . 0.0 112.784 178.18 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 56.3 mtpt -116.26 -20.32 9.83 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.811 -0.632 . . . . 0.0 111.792 -179.576 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 tppt? -83.47 -52.08 6.81 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-O 121.175 0.512 . . . . 0.0 110.466 -179.741 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.748 HD12 ' H ' ' A' ' 25' ' ' LEU . 0.2 OUTLIER . . . . . 0 CA--C 1.501 -0.933 0 CA-C-O 121.907 0.86 . . . . 0.0 111.285 -178.882 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 38.8 t . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.745 0.307 . . . . 0.0 111.237 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -69.94 -44.01 70.42 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.519 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.406 ' N ' HD12 ' A' ' 32' ' ' LEU . 8.1 mp -65.12 -44.4 88.85 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.149 -0.932 . . . . 0.0 111.413 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.31 -44.39 97.01 Favored Glycine 0 N--CA 1.438 -1.214 0 C-N-CA 119.292 -1.432 . . . . 0.0 109.986 -179.077 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.21 -40.06 71.36 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.529 -0.336 . . . . 0.0 111.414 179.076 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.8 t -63.65 -41.29 98.25 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.666 -0.413 . . . . 0.0 111.141 -178.389 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.12 -40.34 80.5 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.798 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.5 pttt -60.28 -43.19 96.44 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 -179.679 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.97 -36.68 92.37 Favored Glycine 0 CA--C 1.519 0.342 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -71.51 -52.23 19.42 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 66.0 mmtt -62.91 -38.15 89.81 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.154 178.73 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -60.94 -35.64 77.26 Favored 'General case' 0 C--N 1.312 -1.029 0 C-N-CA 119.631 -0.827 . . . . 0.0 109.909 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.323 -0.565 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.141 -179.311 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.737 ' N ' HE22 ' A' ' 8' ' ' GLN . 3.5 mm . . . . . 0 CA--C 1.535 0.402 0 CA-C-O 120.644 0.259 . . . . 0.0 110.763 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 38.5 m95 -62.0 -45.33 94.06 Favored 'General case' 0 C--O 1.22 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -178.593 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.921 HE21 ' H ' ' A' ' 9' ' ' LEU . 0.0 OUTLIER -63.8 -38.96 93.03 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 119.737 -0.785 . . . . 0.0 109.485 178.72 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.921 ' H ' HE21 ' A' ' 8' ' ' GLN . 78.8 mt -64.45 -38.21 90.24 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.264 179.727 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.642 ' O ' HG23 ' A' ' 14' ' ' VAL . 20.7 mt -63.3 -48.27 78.78 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.805 -176.596 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.501 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.8 mp -67.92 -44.58 85.03 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 C-N-CA 119.662 -0.815 . . . . 0.0 109.142 178.212 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -65.08 -47.59 87.22 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 C-N-CA 120.055 -0.658 . . . . 0.0 110.566 -179.432 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.857 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -65.85 -38.07 87.88 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 -179.545 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.642 HG23 ' O ' ' A' ' 10' ' ' LEU . 62.8 t -67.78 -44.29 85.73 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.625 0 C-N-CA 120.173 -0.611 . . . . 0.0 111.171 -178.824 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.47 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 0.9 OUTLIER -66.28 -44.05 91.35 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.385 0 O-C-N 123.353 0.408 . . . . 0.0 110.053 179.485 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.414 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.3 t -64.02 -41.99 94.24 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.721 0 CA-C-N 115.107 -0.951 . . . . 0.0 109.964 -178.578 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.857 HG23 ' O ' ' A' ' 13' ' ' ALA . 59.6 t -66.14 -45.22 90.89 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.909 0 C-N-CA 118.03 -1.468 . . . . 0.0 112.672 -177.043 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.431 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.1 pp -71.23 -42.85 68.36 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.157 177.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.677 ' C ' HD13 ' A' ' 19' ' ' LEU . 2.5 tm? -64.67 -41.49 96.04 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.908 -179.171 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.414 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 6.1 m-85 -68.97 -38.62 79.47 Favored 'General case' 0 CA--C 1.513 -0.465 0 C-N-CA 119.014 -1.074 . . . . 0.0 108.623 178.78 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.499 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 104.76 11.28 30.92 Favored Glycine 0 C--N 1.315 -0.614 0 CA-C-N 115.01 -0.995 . . . . 0.0 111.104 178.521 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.725 HG22 ' CG1' ' A' ' 17' ' ' VAL . 51.2 p 58.68 43.24 19.1 Favored 'General case' 0 CA--C 1.505 -0.763 0 CA-C-N 115.25 -0.475 . . . . 0.0 111.917 178.872 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -124.94 -20.19 5.03 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.4 -179.802 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 tppt? -84.99 -49.63 8.16 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-O 121.091 0.472 . . . . 0.0 110.496 179.826 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.767 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.1 OUTLIER . . . . . 0 CA--C 1.505 -0.766 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.044 -178.792 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 10.9 t . . . . . 0 CA--C 1.521 -0.148 0 CA-C-O 120.771 0.32 . . . . 0.0 111.332 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 94.9 m-20 -70.58 -43.63 69.04 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.341 0.591 . . . . 0.0 109.481 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.8 mp -65.47 -44.75 86.17 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.426 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.37 -45.07 95.85 Favored Glycine 0 N--CA 1.439 -1.157 0 C-N-CA 119.444 -1.36 . . . . 0.0 109.94 -179.118 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.39 -39.69 71.03 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.577 -0.312 . . . . 0.0 111.566 179.265 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 48.4 t -63.34 -41.79 98.9 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-O 121.125 0.488 . . . . 0.0 110.324 -178.322 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.19 -39.4 79.23 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.931 179.032 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.7 tttp -60.09 -44.08 95.05 Favored 'General case' 0 C--N 1.309 -1.152 0 C-N-CA 119.343 -0.943 . . . . 0.0 108.614 -179.043 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.68 -36.54 91.44 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 178.389 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.2 t80 -71.65 -51.83 21.1 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-O 120.76 0.314 . . . . 0.0 110.462 -179.564 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 23.7 mtpp -62.7 -38.05 88.9 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.375 179.135 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -61.02 -36.73 80.29 Favored 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 120.098 -0.641 . . . . 0.0 110.226 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.322 -0.605 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.37 -179.591 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.5 mm . . . . . 0 CA--C 1.538 0.491 0 CA-C-O 120.511 0.196 . . . . 0.0 110.915 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 55.2 m95 -62.54 -48.97 77.16 Favored 'General case' 0 C--O 1.221 -0.423 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 -179.588 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . 0.488 ' OE1' ' N ' ' A' ' 8' ' ' GLN . 0.5 OUTLIER -64.13 -38.43 91.05 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.608 179.847 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.507 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 3.2 mm? -62.8 -39.08 93.16 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.874 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.544 ' O ' HG23 ' A' ' 14' ' ' VAL . 8.9 mt -63.76 -51.77 63.39 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.6 -178.335 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.485 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.5 mp -65.62 -44.49 93.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 178.372 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 70.8 mt -63.72 -45.3 97.73 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 C-N-CA 120.479 -0.488 . . . . 0.0 111.337 -179.667 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.865 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.95 -38.79 92.12 Favored 'General case' 0 C--N 1.32 -0.713 0 O-C-N 123.381 0.425 . . . . 0.0 110.975 -179.323 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.544 HG23 ' O ' ' A' ' 10' ' ' LEU . 70.7 t -67.54 -43.15 87.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 C-N-CA 120.566 -0.453 . . . . 0.0 110.562 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.452 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 96.7 mt -66.25 -43.35 91.78 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.322 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.453 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.5 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.4 t -63.72 -42.2 95.18 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.684 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.319 -178.68 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.865 HG23 ' O ' ' A' ' 13' ' ' ALA . 61.4 t -66.02 -45.11 91.62 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.883 0 C-N-CA 118.253 -1.379 . . . . 0.0 112.672 -176.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.527 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.3 pp -72.39 -43.16 64.32 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 119.702 -0.799 . . . . 0.0 109.949 178.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.698 ' C ' HD13 ' A' ' 19' ' ' LEU . 2.6 tm? -64.4 -41.44 96.64 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.923 -1.035 . . . . 0.0 110.313 -179.63 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.5 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 5.0 m-85 -69.02 -35.98 77.25 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 118.879 -1.129 . . . . 0.0 108.957 179.019 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.482 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 97.44 11.96 49.76 Favored Glycine 0 N--CA 1.465 0.593 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.703 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.701 HG22 ' CG1' ' A' ' 17' ' ' VAL . 42.8 p 55.72 69.49 0.73 Allowed 'General case' 0 CA--C 1.506 -0.713 0 CA-C-N 114.604 -0.798 . . . . 0.0 112.445 178.364 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 49.6 mtpt -139.87 -25.53 0.81 Allowed 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.873 179.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 11.2 mmmt -85.8 -53.03 5.38 Favored 'General case' 0 C--O 1.221 -0.444 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.728 179.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.623 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.1 OUTLIER . . . . . 0 CA--C 1.505 -0.784 0 CA-C-O 121.817 0.818 . . . . 0.0 110.642 -178.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.3 t . . . . . 0 CA--C 1.521 -0.145 0 CA-C-O 120.689 0.281 . . . . 0.0 111.657 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -76.43 -41.0 49.13 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.347 0.594 . . . . 0.0 109.64 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.678 ' O ' HD13 ' A' ' 36' ' ' ILE . 7.6 mp -68.4 -46.61 69.51 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.062 -0.972 . . . . 0.0 111.575 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.93 -44.0 98.43 Favored Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -179.16 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.12 -40.39 71.45 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.825 179.057 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.4 m -64.0 -40.8 97.18 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.898 -179.342 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.678 HD13 ' O ' ' A' ' 32' ' ' LEU . 1.6 mp -68.19 -41.57 84.12 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.485 -179.433 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.4 ' HG2' ' N ' ' A' ' 38' ' ' GLY . 16.6 pttt -60.08 -43.35 95.56 Favored 'General case' 0 C--N 1.308 -1.203 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 -179.144 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.4 ' N ' ' HG2' ' A' ' 37' ' ' LYS . . . -69.7 -36.78 75.93 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 110.599 -1.001 . . . . 0.0 110.599 178.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -71.64 -49.26 41.66 Favored 'General case' 0 CA--C 1.514 -0.432 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.845 -178.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.405 ' N ' ' CD ' ' A' ' 40' ' ' LYS . 9.8 mptt -67.06 -39.07 86.82 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.484 178.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -61.65 -36.65 81.41 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 119.72 -0.792 . . . . 0.0 109.865 179.814 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.323 -0.562 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.502 179.758 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 85.9 22.88 47.84 Favored Glycine 0 CA--C 1.524 0.605 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.66 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 140.74 -9.43 2.84 Favored Glycine 0 N--CA 1.462 0.409 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.517 HG23 ' HB2' ' A' ' 8' ' ' GLN . 3.9 mp -101.33 118.7 48.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.085 0.469 . . . . 0.0 110.45 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.492 ' C ' HD12 ' A' ' 6' ' ' ILE . 64.2 m -143.65 -89.97 0.12 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.696 179.378 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.492 HD12 ' C ' ' A' ' 5' ' ' SER . 1.5 mp -110.99 -35.23 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.506 -179.567 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 63.8 m95 -62.65 -49.54 74.73 Favored 'General case' 0 C--O 1.221 -0.432 0 CA-C-O 120.754 0.311 . . . . 0.0 110.576 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.517 ' HB2' HG23 ' A' ' 4' ' ' ILE . 20.9 mp0 -64.17 -38.52 91.34 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.491 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 3.0 mm? -63.64 -39.33 94.07 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.646 179.284 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.571 ' O ' HG23 ' A' ' 14' ' ' VAL . 9.1 mt -63.86 -51.0 66.61 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.872 -178.077 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.445 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.4 mp -66.08 -44.45 91.93 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.396 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 69.3 mt -63.58 -45.01 98.8 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.086 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.285 -179.436 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.852 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -65.01 -37.83 88.94 Favored 'General case' 0 C--N 1.317 -0.844 0 O-C-N 123.435 0.46 . . . . 0.0 111.245 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 10' ' ' LEU . 71.4 t -67.86 -43.98 85.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.794 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.758 HG22 HD23 ' A' ' 19' ' ' LEU . 96.8 mt -66.33 -43.47 91.45 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.104 0 CA-C-O 121.59 0.71 . . . . 0.0 109.322 179.435 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.408 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.8 t -63.53 -42.41 96.08 Favored 'Isoleucine or valine' 0 CA--C 1.479 -1.788 0 CA-C-N 114.794 -1.094 . . . . 0.0 109.788 -178.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.852 HG23 ' O ' ' A' ' 13' ' ' ALA . 60.4 t -66.5 -48.89 79.15 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.046 0 C-N-CA 117.609 -1.636 . . . . 0.0 112.787 -177.227 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.498 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.0 OUTLIER -66.99 -44.38 80.55 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 118.863 -1.135 . . . . 0.0 112.042 179.667 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.758 HD23 HG22 ' A' ' 15' ' ' ILE . 0.4 OUTLIER -65.95 -38.47 88.69 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.823 -179.979 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.408 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 4.7 m-85 -67.89 -41.03 83.37 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 -179.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.463 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 108.62 14.58 15.45 Favored Glycine 0 C--N 1.312 -0.803 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 178.392 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.709 HG22 ' CG1' ' A' ' 17' ' ' VAL . 68.0 p 52.02 39.51 26.47 Favored 'General case' 0 CA--C 1.495 -1.136 0 CA-C-N 114.747 -0.726 . . . . 0.0 112.473 178.283 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 59.5 tttm -112.43 -41.29 3.9 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.935 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.92 -56.28 9.65 Favored 'General case' 0 CA--C 1.509 -0.63 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.271 -179.492 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.654 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.0 OUTLIER -53.63 -36.8 62.43 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-O 121.901 0.858 . . . . 0.0 109.989 -177.972 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.34 -25.8 69.73 Favored Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.735 -178.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 67.2 m -94.21 -38.32 11.11 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 -179.169 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.7 pt -94.83 -36.83 7.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.995 0.426 . . . . 0.0 109.961 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.481 ' O ' ' N ' ' A' ' 33' ' ' GLY . . . -61.84 -23.25 63.17 Favored Glycine 0 CA--C 1.518 0.235 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 -179.681 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 38.7 t -64.66 -39.2 93.28 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 120.764 -0.374 . . . . 0.0 111.699 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.9 m-20 -94.24 -35.51 12.43 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 179.309 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.512 ' O ' HD13 ' A' ' 32' ' ' LEU . 0.2 OUTLIER -74.32 -49.35 23.31 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.408 -1.269 . . . . 0.0 111.412 -178.916 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.481 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -61.57 -42.97 99.86 Favored Glycine 0 CA--C 1.518 0.246 0 N-CA-C 109.304 -1.519 . . . . 0.0 109.304 179.594 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -64.59 -39.28 93.45 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.783 -0.709 . . . . 0.0 110.939 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 75.3 m -62.88 -41.31 99.35 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.137 -0.625 . . . . 0.0 110.709 -178.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.3 mp -68.65 -40.01 81.13 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.861 179.048 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.6 ptmt -59.79 -41.81 91.98 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 -178.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.17 -36.47 90.16 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 177.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 23.0 t80 -71.75 -52.44 17.68 Favored 'General case' 0 CA--C 1.514 -0.428 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.227 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.47 ' O ' ' N ' ' A' ' 44' ' ' SER . 62.2 mttm -62.81 -40.18 96.56 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.43 179.075 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 38.9 ttpt -63.43 -38.36 90.84 Favored 'General case' 0 C--N 1.317 -0.846 0 C-N-CA 119.95 -0.7 . . . . 0.0 111.212 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -67.08 -37.94 84.84 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.818 -178.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.442 ' H ' ' HG3' ' A' ' 43' ' ' MET . 2.4 ppp? -94.22 -17.73 22.4 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.25 -179.146 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.47 ' N ' ' O ' ' A' ' 40' ' ' LYS . 18.3 m -58.21 -40.82 82.61 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.068 0.461 . . . . 0.0 109.842 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 45.3 t0 -76.72 164.66 25.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.422 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.409 ' O ' ' OD1' ' A' ' 46' ' ' ASP . 51.4 t0 59.47 40.44 20.65 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.803 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 -148.48 150.52 34.19 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.366 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo . . . . . 0 N--CA 1.496 1.653 0 C-N-CA 122.472 2.114 . . . . 0.0 111.824 179.755 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.4 mmm . . . . . 0 N--CA 1.493 1.677 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 71.34 -5.24 10.19 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -141.32 10.22 2.73 Favored Glycine 0 N--CA 1.465 0.604 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.527 HG21 HE21 ' A' ' 8' ' ' GLN . 3.3 mp -44.55 -85.92 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 CA-C-O 120.626 0.25 . . . . 0.0 110.968 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 59.4 m -172.27 -164.4 0.28 Allowed 'General case' 0 N--CA 1.439 -0.981 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.406 ' CG2' ' N ' ' A' ' 7' ' ' TRP . 3.4 tp -84.08 -35.7 11.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-N 115.255 -0.884 . . . . 0.0 111.907 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.427 ' CD1' ' C ' ' A' ' 7' ' ' TRP . 5.6 t-105 -61.91 -39.34 91.67 Favored 'General case' 0 N--CA 1.421 -1.884 0 CA-C-N 114.88 -1.054 . . . . 0.0 108.748 -178.321 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.527 HE21 HG21 ' A' ' 4' ' ' ILE . 3.5 tp-100 -64.74 -38.85 92.4 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 178.158 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.464 HD23 ' HA ' ' A' ' 9' ' ' LEU . 73.7 mt -62.74 -38.09 89.14 Favored 'General case' 0 CA--C 1.503 -0.851 0 CA-C-N 114.925 -1.034 . . . . 0.0 110.479 178.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.633 ' O ' HG23 ' A' ' 14' ' ' VAL . 2.7 mt -62.63 -47.62 82.94 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.235 -177.274 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.505 ' N ' HD12 ' A' ' 11' ' ' ILE . 3.2 mp -69.13 -44.58 80.82 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 178.21 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 77.3 mt -64.02 -44.48 97.82 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.307 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.684 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.9 -36.63 84.97 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.945 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.633 HG23 ' O ' ' A' ' 10' ' ' LEU . 48.8 t -67.28 -44.29 87.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.307 -179.026 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 14.1 pt -67.24 -43.9 87.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.831 179.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.517 HG22 ' CD2' ' A' ' 20' ' ' PHE . 0.3 OUTLIER -64.79 -39.3 85.19 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.07 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.323 -179.632 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.694 ' CG1' HG22 ' A' ' 22' ' ' THR . 75.8 t -66.25 -46.99 85.89 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 C-N-CA 118.683 -1.207 . . . . 0.0 112.743 -178.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.43 ' CD2' ' O ' ' A' ' 14' ' ' VAL . 0.8 OUTLIER -68.88 -42.39 77.04 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.419 0.628 . . . . 0.0 110.031 179.046 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.71 ' C ' HD13 ' A' ' 19' ' ' LEU . 2.2 tm? -63.88 -39.84 95.14 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.623 -1.171 . . . . 0.0 109.875 -179.306 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.517 ' CD2' HG22 ' A' ' 16' ' ' VAL . 3.0 m-85 -69.17 -37.22 78.09 Favored 'General case' 0 CA--C 1.513 -0.454 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 177.605 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.507 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 102.3 9.59 41.24 Favored Glycine 0 N--CA 1.462 0.405 0 CA-C-N 115.086 -0.961 . . . . 0.0 110.916 179.135 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.694 HG22 ' CG1' ' A' ' 17' ' ' VAL . 51.6 p 58.56 22.22 9.5 Favored 'General case' 0 C--N 1.32 -0.713 0 O-C-N 123.935 0.433 . . . . 0.0 111.99 178.774 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -100.96 -15.82 17.38 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.103 -0.499 . . . . 0.0 112.06 -179.599 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.494 ' O ' ' N ' ' A' ' 27' ' ' SER . 15.2 mmmt -92.29 -57.82 2.58 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.178 0.513 . . . . 0.0 110.718 -179.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.985 ' H ' HD12 ' A' ' 25' ' ' LEU . 1.7 mp -45.78 -39.93 8.95 Favored 'General case' 0 CA--C 1.496 -1.124 0 CA-C-O 122.272 1.034 . . . . 0.0 110.417 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.0 -25.15 72.15 Favored Glycine 0 N--CA 1.427 -1.961 0 CA-C-N 113.798 -1.546 . . . . 0.0 110.607 -177.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.494 ' N ' ' O ' ' A' ' 24' ' ' LYS . 5.7 t -96.18 -35.97 11.11 Favored 'General case' 0 CA--C 1.518 -0.285 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 8.0 pt -92.12 -38.36 10.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.332 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -59.94 -28.83 66.68 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 -179.604 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.7 m -64.29 -40.46 96.0 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.869 -0.332 . . . . 0.0 111.214 -179.708 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -70.09 -43.83 70.3 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 179.302 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -65.08 -44.1 90.01 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.064 -0.971 . . . . 0.0 111.249 179.648 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.6 -45.49 94.51 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 119.208 -1.472 . . . . 0.0 109.863 -179.193 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.11 -39.65 71.94 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.56 -0.32 . . . . 0.0 111.738 179.22 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 14.5 t -63.03 -42.14 99.7 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.341 -177.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.71 -39.64 80.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.744 178.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 34.5 tttm -59.91 -43.36 94.9 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 -178.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.81 -36.79 91.67 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 177.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 13.7 t80 -71.64 -50.23 32.56 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-O 120.897 0.379 . . . . 0.0 110.221 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.518 ' O ' ' N ' ' A' ' 44' ' ' SER . 47.8 mtpt -62.86 -38.88 92.6 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.346 178.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 50.5 mtpt -61.82 -38.85 89.7 Favored 'General case' 0 C--N 1.319 -0.744 0 C-N-CA 119.764 -0.774 . . . . 0.0 110.083 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -67.0 -36.07 81.34 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.778 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 76.6 mtm -88.91 -28.87 20.02 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.873 0.368 . . . . 0.0 111.064 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.518 ' N ' ' O ' ' A' ' 40' ' ' LYS . 37.7 m -53.53 -26.68 22.07 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.101 -179.282 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.415 ' C ' ' H ' ' A' ' 47' ' ' GLU . 92.6 m-20 -62.01 -39.05 90.93 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.416 179.767 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -77.09 39.69 0.24 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.534 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.415 ' H ' ' C ' ' A' ' 45' ' ' ASP . 75.7 tt0 -167.99 71.14 0.88 Allowed Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.41 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo . . . . . 0 C--N 1.308 -1.572 0 C-N-CA 122.697 2.265 . . . . 0.0 111.975 -179.675 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.454 ' H2 ' HD13 ' A' ' 4' ' ' ILE . 38.4 mmt . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -81.08 38.18 2.39 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 139.02 3.24 1.74 Allowed Glycine 0 C--N 1.336 0.543 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.739 ' N ' HD12 ' A' ' 4' ' ' ILE . 2.5 mp -94.66 110.85 24.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.269 0.557 . . . . 0.0 110.828 -179.687 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 10.9 m -88.33 -139.38 0.11 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.506 178.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 34.4 mm -91.06 -38.15 10.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.356 179.137 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 94.1 m95 -74.32 -38.93 63.15 Favored 'General case' 0 C--N 1.321 -0.638 0 C-N-CA 120.397 -0.521 . . . . 0.0 110.096 179.595 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.499 ' OE1' ' N ' ' A' ' 8' ' ' GLN . 0.8 OUTLIER -64.23 -38.77 92.22 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -179.686 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.666 HD12 ' C ' ' A' ' 9' ' ' LEU . 0.4 OUTLIER -73.31 -38.19 65.93 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.249 179.672 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.651 ' O ' HG23 ' A' ' 14' ' ' VAL . 13.8 mt -63.41 -46.87 84.4 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.871 0.367 . . . . 0.0 111.278 -177.661 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.2 mp -67.74 -44.23 85.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.201 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 35.1 mt -65.04 -44.64 95.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.121 -179.27 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.88 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.74 -37.54 87.93 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 115.762 -0.653 . . . . 0.0 110.966 -178.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.651 HG23 ' O ' ' A' ' 10' ' ' LEU . 54.4 t -66.93 -44.99 88.36 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.426 0 C-N-CA 120.435 -0.506 . . . . 0.0 111.506 -178.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 16.7 pt -66.9 -42.65 89.24 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.99 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.147 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.528 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.7 t -63.82 -41.43 92.54 Favored 'Isoleucine or valine' 0 CA--C 1.482 -1.659 0 CA-C-N 115.388 -0.823 . . . . 0.0 109.795 -178.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.88 HG23 ' O ' ' A' ' 13' ' ' ALA . 52.2 t -66.29 -50.43 68.15 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.93 0 C-N-CA 117.548 -1.661 . . . . 0.0 113.32 -177.269 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.558 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.2 pp -67.04 -44.11 81.03 Favored 'General case' 0 C--N 1.296 -1.727 0 C-N-CA 119.151 -1.02 . . . . 0.0 111.881 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.658 ' C ' HD12 ' A' ' 19' ' ' LEU . 0.4 OUTLIER -65.78 -38.43 89.02 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.607 -0.27 . . . . 0.0 111.028 179.8 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.528 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 3.4 m-85 -68.38 -37.13 80.11 Favored 'General case' 0 CA--C 1.515 -0.376 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.819 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.428 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 97.93 13.77 42.04 Favored Glycine 0 CA--C 1.504 -0.601 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.512 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.682 HG22 HG13 ' A' ' 17' ' ' VAL . 46.2 p 53.2 76.95 0.18 Allowed 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 114.083 -1.058 . . . . 0.0 112.121 178.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 18.0 ptmt -142.4 -36.46 0.4 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.939 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 11.1 mmmt -77.31 -50.75 12.14 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.39 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.611 HD12 ' H ' ' A' ' 25' ' ' LEU . 0.2 OUTLIER -53.23 -37.73 62.3 Favored 'General case' 0 CA--C 1.503 -0.84 0 CA-C-O 122.12 0.962 . . . . 0.0 110.449 -178.744 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.47 -24.92 73.94 Favored Glycine 0 N--CA 1.435 -1.427 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 -178.438 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.9 t -93.46 -40.4 10.37 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.4 pt -93.53 -36.06 7.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 121.361 0.601 . . . . 0.0 109.851 -179.178 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.35 -24.97 68.02 Favored Glycine 0 CA--C 1.52 0.384 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.4 t -64.65 -41.69 95.94 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.692 0.282 . . . . 0.0 111.341 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -73.93 -42.6 60.34 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -66.83 -44.44 81.11 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 114.998 -1.001 . . . . 0.0 111.475 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.41 -44.13 97.24 Favored Glycine 0 N--CA 1.44 -1.051 0 C-N-CA 119.322 -1.418 . . . . 0.0 109.817 -179.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.73 -40.13 69.61 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.529 -0.336 . . . . 0.0 111.346 179.05 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.5 m -63.69 -40.56 97.1 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.223 -178.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -70.19 -39.52 77.04 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.677 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.5 ptmt -59.79 -41.86 92.12 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 -178.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.81 -36.9 87.92 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.557 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -71.49 -50.82 27.8 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.537 ' O ' ' N ' ' A' ' 44' ' ' SER . 53.7 mtpt -63.21 -38.6 91.82 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.506 178.655 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -61.49 -39.2 90.07 Favored 'General case' 0 C--N 1.318 -0.766 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.867 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.99 -36.83 83.04 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.705 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.444 ' O ' ' O ' ' A' ' 44' ' ' SER . 74.0 mtm -91.12 -66.75 0.9 Allowed 'General case' 0 N--CA 1.463 0.181 0 CA-C-O 120.917 0.389 . . . . 0.0 110.528 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.537 ' N ' ' O ' ' A' ' 40' ' ' LYS . 83.6 p 49.68 176.37 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.498 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 45.8 t0 -92.44 113.51 25.81 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 120.851 0.358 . . . . 0.0 110.393 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -82.55 17.73 1.7 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.768 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -154.43 78.91 5.04 Favored Pre-proline 0 C--N 1.324 -0.529 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.7 179.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo . . . . . 0 C--N 1.307 -1.615 0 C-N-CA 122.606 2.204 . . . . 0.0 111.955 -179.985 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.471 ' H2 ' HD13 ' A' ' 4' ' ' ILE . 1.7 mpp? . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -62.41 -34.46 89.41 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.29 20.84 0.34 Allowed Glycine 0 N--CA 1.45 -0.388 0 N-CA-C 109.789 -1.325 . . . . 0.0 109.789 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.471 HD13 ' H2 ' ' A' ' 1' ' ' MET . 4.2 mp -92.26 105.77 17.05 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.26 0 CA-C-O 121.367 0.604 . . . . 0.0 110.132 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 49.8 m -153.04 -128.94 0.04 OUTLIER 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 114.974 -1.012 . . . . 0.0 110.316 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.509 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.5 mp -59.85 -37.23 70.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 120.755 0.312 . . . . 0.0 110.463 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 67.6 m95 -62.15 -46.98 86.57 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.43 -38.9 92.63 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.425 HD23 ' HA ' ' A' ' 9' ' ' LEU . 89.2 mt -66.08 -38.73 89.0 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.306 178.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.591 ' O ' HG23 ' A' ' 14' ' ' VAL . 16.7 mt -63.43 -50.28 70.41 Favored 'General case' 0 C--N 1.315 -0.919 0 C-N-CA 120.131 -0.628 . . . . 0.0 110.541 -176.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.435 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.4 mp -66.61 -44.73 89.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.107 178.237 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 75.5 mt -63.91 -46.79 93.16 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.967 0 C-N-CA 120.294 -0.562 . . . . 0.0 111.432 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.846 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -65.0 -37.68 88.47 Favored 'General case' 0 C--N 1.319 -0.745 0 O-C-N 123.213 0.321 . . . . 0.0 111.349 -179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.591 HG23 ' O ' ' A' ' 10' ' ' LEU . 59.2 t -67.8 -43.82 86.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.613 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.448 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 96.6 mt -66.2 -43.53 91.86 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.155 0 O-C-N 123.521 0.513 . . . . 0.0 109.725 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.433 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.6 t -63.72 -42.26 95.38 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.504 0 CA-C-N 115.08 -0.964 . . . . 0.0 109.919 -178.637 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.846 HG23 ' O ' ' A' ' 13' ' ' ALA . 59.9 t -66.27 -44.78 91.05 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 C-N-CA 118.217 -1.393 . . . . 0.0 112.79 -176.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.483 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.2 pp -71.96 -42.9 66.02 Favored 'General case' 0 C--N 1.294 -1.825 0 C-N-CA 120.046 -0.661 . . . . 0.0 109.761 178.177 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.661 ' C ' HD13 ' A' ' 19' ' ' LEU . 2.6 tm? -64.8 -41.75 95.56 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.823 -179.175 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.433 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 6.9 m-85 -69.24 -33.47 73.33 Favored 'General case' 0 CA--C 1.511 -0.558 0 C-N-CA 119.067 -1.053 . . . . 0.0 108.831 178.716 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.466 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 93.93 12.9 56.06 Favored Glycine 0 C--N 1.318 -0.471 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 179.244 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.655 HG22 HG13 ' A' ' 17' ' ' VAL . 43.1 p 55.78 77.73 0.22 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 114.684 -0.758 . . . . 0.0 112.002 178.762 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -146.28 -26.11 0.43 Allowed 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.454 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.407 ' HZ2' HD11 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -93.65 -39.71 10.65 Favored 'General case' 0 C--O 1.223 -0.315 0 C-N-CA 120.719 -0.393 . . . . 0.0 110.905 -179.861 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.704 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.2 OUTLIER -59.55 -37.04 77.35 Favored 'General case' 0 CA--C 1.501 -0.931 0 CA-C-O 121.714 0.768 . . . . 0.0 110.001 179.889 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.56 -25.0 75.23 Favored Glycine 0 N--CA 1.432 -1.6 0 N-CA-C 108.628 -1.789 . . . . 0.0 108.628 -179.243 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 8.1 t -87.25 -43.25 12.33 Favored 'General case' 0 CA--C 1.519 -0.242 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 179.688 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.407 HD11 ' HZ2' ' A' ' 24' ' ' LYS . 13.5 pt -93.65 -34.68 5.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.278 0.561 . . . . 0.0 110.091 -178.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.27 -22.78 65.68 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 -179.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.5 t -64.71 -43.44 93.45 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 120.763 -0.375 . . . . 0.0 111.733 -179.349 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -75.54 -42.51 52.25 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.438 0.637 . . . . 0.0 109.487 179.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.8 mp -66.89 -44.66 80.28 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.043 -0.98 . . . . 0.0 111.81 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.32 -44.12 97.4 Favored Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 119.413 -1.375 . . . . 0.0 109.832 -179.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.84 -39.79 69.49 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.66 -0.27 . . . . 0.0 111.394 179.183 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.7 m -63.24 -40.92 98.79 Favored 'General case' 0 CA--C 1.518 -0.287 0 CA-C-O 121.112 0.482 . . . . 0.0 110.477 -178.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.63 -39.36 78.15 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.757 178.627 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 24.2 tttt -59.97 -44.56 94.37 Favored 'General case' 0 N--CA 1.435 -1.217 0 C-N-CA 119.231 -0.988 . . . . 0.0 108.414 -179.357 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.97 -36.34 91.91 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 178.005 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.59 ' CD2' ' SD ' ' A' ' 43' ' ' MET . 21.0 t80 -71.38 -51.41 24.24 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-O 120.835 0.35 . . . . 0.0 110.456 -179.448 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.54 ' O ' ' N ' ' A' ' 44' ' ' SER . 54.8 mtpt -63.08 -38.56 91.66 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.38 178.538 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -61.36 -36.84 81.33 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.121 -0.632 . . . . 0.0 110.012 -179.565 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.63 -36.01 81.55 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.126 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.59 ' SD ' ' CD2' ' A' ' 39' ' ' PHE . 0.0 OUTLIER -93.38 -68.17 0.82 Allowed 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.964 0.411 . . . . 0.0 110.802 179.769 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.54 ' N ' ' O ' ' A' ' 40' ' ' LYS . 3.1 p 47.84 10.94 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.882 -179.503 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.525 ' C ' ' H ' ' A' ' 47' ' ' GLU . 66.7 t0 46.64 -121.09 1.1 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.266 179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.441 ' H ' ' CG ' ' A' ' 45' ' ' ASP . 90.5 m-20 -74.77 17.24 0.22 Allowed 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.525 ' H ' ' C ' ' A' ' 45' ' ' ASP . 34.2 tt0 41.47 73.5 0.88 Allowed Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.63 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_endo . . . . . 0 C--N 1.307 -1.651 0 C-N-CA 122.757 2.304 . . . . 0.0 112.036 -179.468 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 93.0 mtp . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.1 0.22 58.65 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 111.281 -0.728 . . . . 0.0 111.281 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 96.57 17.53 33.23 Favored Glycine 0 N--CA 1.466 0.696 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.411 HG22 ' N ' ' A' ' 5' ' ' SER . 29.0 mt -69.5 -115.73 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.342 -0.429 . . . . 0.0 110.198 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.411 ' N ' HG22 ' A' ' 4' ' ' ILE . 67.5 m -165.31 -160.08 0.46 Allowed 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 -179.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 4.6 tp -100.33 -36.13 4.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-N 115.37 -0.832 . . . . 0.0 111.986 179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.651 ' CE2' HD11 ' A' ' 11' ' ' ILE . 8.1 t-105 -62.2 -37.12 84.12 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 115.459 -0.791 . . . . 0.0 108.91 -178.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -64.35 -38.91 92.71 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 178.318 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.426 HD23 ' HA ' ' A' ' 9' ' ' LEU . 84.0 mt -64.79 -37.58 88.11 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.93 178.546 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.694 ' O ' HG23 ' A' ' 14' ' ' VAL . 3.9 mt -62.47 -43.89 97.71 Favored 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.274 -177.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.651 HD11 ' CE2' ' A' ' 7' ' ' TRP . 7.2 mt -68.35 -45.11 83.02 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 C-N-CA 119.992 -0.683 . . . . 0.0 109.593 178.049 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 72.0 mt -65.98 -44.74 92.19 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.572 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.531 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.907 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -65.22 -37.21 86.56 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.03 -179.517 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.694 HG23 ' O ' ' A' ' 10' ' ' LEU . 46.0 t -66.65 -44.78 89.57 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.717 0 C-N-CA 120.599 -0.44 . . . . 0.0 111.485 -179.082 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.439 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 15.2 pt -66.61 -42.64 90.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.209 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.531 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.5 t -63.85 -41.82 93.8 Favored 'Isoleucine or valine' 0 CA--C 1.483 -1.603 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.702 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.907 HG23 ' O ' ' A' ' 13' ' ' ALA . 61.5 t -65.8 -45.93 90.21 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 C-N-CA 118.361 -1.335 . . . . 0.0 112.948 -177.216 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.521 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.4 pp -72.11 -42.85 65.59 Favored 'General case' 0 C--N 1.288 -2.093 0 CA-C-O 121.333 0.587 . . . . 0.0 109.791 178.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.705 ' C ' HD13 ' A' ' 19' ' ' LEU . 2.5 tm? -64.67 -42.3 95.47 Favored 'General case' 0 N--CA 1.44 -0.956 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.164 -179.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.531 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 5.7 m-85 -68.94 -34.37 75.24 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 119.138 -1.025 . . . . 0.0 109.314 179.333 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.487 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 96.32 11.38 54.32 Favored Glycine 0 N--CA 1.466 0.635 0 N-CA-C 110.647 -0.981 . . . . 0.0 110.647 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.697 HG22 ' CG1' ' A' ' 17' ' ' VAL . 43.4 p 56.53 68.58 0.84 Allowed 'General case' 0 CA--C 1.502 -0.884 0 CA-C-N 115.055 -0.573 . . . . 0.0 112.271 178.199 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -139.87 -24.77 0.83 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.015 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 10.1 mmmt -87.06 -52.09 5.63 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.821 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.63 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.1 OUTLIER -53.3 -36.92 61.76 Favored 'General case' 0 CA--C 1.505 -0.781 0 CA-C-O 121.783 0.801 . . . . 0.0 110.266 -178.966 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.45 -25.46 72.61 Favored Glycine 0 N--CA 1.436 -1.322 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 -177.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.6 t -92.89 -40.66 10.48 Favored 'General case' 0 CA--C 1.517 -0.292 0 N-CA-C 112.244 0.461 . . . . 0.0 112.244 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.3 pt -92.64 -35.42 6.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 121.173 0.511 . . . . 0.0 109.993 -178.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.17 -25.76 71.2 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.566 -1.014 . . . . 0.0 110.566 -179.563 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.1 p -65.91 -38.86 89.82 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 120.922 -0.311 . . . . 0.0 111.336 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 46.2 t0 -81.36 -39.47 25.02 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.254 0.549 . . . . 0.0 109.694 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.0 mp -69.37 -45.32 69.63 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.193 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.76 -43.94 98.21 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 119.531 -1.319 . . . . 0.0 109.913 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.0 -39.99 79.0 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.538 -0.331 . . . . 0.0 111.372 179.522 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 47.1 t -63.28 -42.26 99.08 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.093 0.473 . . . . 0.0 110.718 -178.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.88 -39.42 79.92 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.154 179.205 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 7.6 ttpt -59.39 -43.65 92.92 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.242 -0.983 . . . . 0.0 108.524 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.73 -36.21 92.0 Favored Glycine 0 N--CA 1.444 -0.821 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 178.439 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -71.08 -52.54 18.84 Favored 'General case' 0 CA--C 1.512 -0.517 0 CA-C-O 120.976 0.417 . . . . 0.0 110.133 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.56 ' O ' ' N ' ' A' ' 44' ' ' SER . 44.2 mttp -63.36 -38.86 92.81 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 120.27 -0.572 . . . . 0.0 110.545 178.487 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 1.9 tmtp? -61.7 -39.15 90.44 Favored 'General case' 0 C--N 1.319 -0.76 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.106 -179.665 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.01 -38.6 72.64 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.953 179.572 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.473 ' N ' ' SD ' ' A' ' 43' ' ' MET . 0.2 OUTLIER -88.81 -11.06 45.93 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.732 -179.407 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.56 ' N ' ' O ' ' A' ' 40' ' ' LYS . 6.3 m -67.95 143.57 55.57 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -136.59 -33.2 0.8 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.434 -179.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -75.74 48.92 0.49 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.2 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -62.96 151.21 86.35 Favored Pre-proline 0 CA--C 1.536 0.421 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.494 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo . . . . . 0 N--CA 1.494 1.528 0 C-N-CA 122.494 2.13 . . . . 0.0 111.766 179.604 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -80.48 32.23 2.36 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 111.284 -0.727 . . . . 0.0 111.284 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.411 ' O ' ' OE1' ' A' ' 8' ' ' GLN . . . 143.3 -3.99 1.73 Allowed Glycine 0 C--N 1.335 0.486 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 -179.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.787 ' N ' HD12 ' A' ' 4' ' ' ILE . 1.7 mp -92.05 118.55 37.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.223 0.535 . . . . 0.0 110.41 -179.521 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 41.8 m -136.42 -139.89 0.16 Allowed 'General case' 0 CA--C 1.518 -0.255 0 CA-C-N 115.265 -0.879 . . . . 0.0 109.357 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 3.7 tp -93.13 -36.15 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.586 0 CA-C-O 121.235 0.54 . . . . 0.0 111.578 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.769 ' O ' HD12 ' A' ' 11' ' ' ILE . 0.3 OUTLIER -62.21 -41.62 98.54 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-N 115.365 -0.834 . . . . 0.0 108.967 -179.185 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.411 ' OE1' ' O ' ' A' ' 3' ' ' GLY . 18.4 mt-30 -64.08 -38.38 90.87 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 178.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.514 ' O ' ' N ' ' A' ' 13' ' ' ALA . 87.5 mt -65.37 -36.98 85.63 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.326 177.439 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.573 ' O ' HG23 ' A' ' 14' ' ' VAL . 1.8 tt -61.84 -50.95 70.19 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.888 -174.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.769 HD12 ' O ' ' A' ' 7' ' ' TRP . 2.8 mp -65.35 -44.73 94.64 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 C-N-CA 119.893 -0.723 . . . . 0.0 109.533 177.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.1 mp -63.77 -44.36 98.23 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.21 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.904 179.49 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.9 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.56 -37.35 87.27 Favored 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 121.086 -0.246 . . . . 0.0 110.836 -179.411 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.573 HG23 ' O ' ' A' ' 10' ' ' LEU . 53.0 t -66.93 -45.01 88.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 C-N-CA 120.544 -0.462 . . . . 0.0 111.465 -179.191 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 13.5 pt -66.87 -42.76 89.47 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.989 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 178.59 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.569 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.4 t -63.14 -41.54 93.21 Favored 'Isoleucine or valine' 0 CA--C 1.478 -1.799 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.883 -178.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.9 HG23 ' O ' ' A' ' 13' ' ' ALA . 51.7 t -66.14 -51.23 62.11 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.033 0 C-N-CA 117.857 -1.537 . . . . 0.0 113.652 -177.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.598 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.4 pp -66.89 -44.36 81.08 Favored 'General case' 0 C--N 1.293 -1.869 0 C-N-CA 119.487 -0.885 . . . . 0.0 111.782 179.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.659 ' C ' HD12 ' A' ' 19' ' ' LEU . 0.4 OUTLIER -65.77 -38.87 90.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.704 -0.225 . . . . 0.0 110.638 -179.943 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.569 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 3.0 m-85 -68.5 -36.54 79.05 Favored 'General case' 0 CA--C 1.513 -0.476 0 C-N-CA 119.607 -0.837 . . . . 0.0 109.317 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.472 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 96.98 12.01 51.11 Favored Glycine 0 CA--C 1.506 -0.501 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 -179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.726 HG22 HG13 ' A' ' 17' ' ' VAL . 43.3 p 54.74 74.74 0.33 Allowed 'General case' 0 CA--C 1.5 -0.963 0 CA-C-N 114.196 -1.002 . . . . 0.0 112.677 178.055 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 62.1 mttp -139.04 -31.57 0.7 Allowed 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.784 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.43 ' O ' ' N ' ' A' ' 27' ' ' SER . 6.7 mmpt? -81.6 -54.35 5.48 Favored 'General case' 0 CA--C 1.501 -0.914 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.612 -179.736 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.618 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.0 OUTLIER -48.97 -39.29 25.96 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 122.371 1.081 . . . . 0.0 110.701 -176.662 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.74 -24.85 73.48 Favored Glycine 0 N--CA 1.429 -1.817 0 CA-C-N 114.011 -1.449 . . . . 0.0 110.289 -178.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.43 ' N ' ' O ' ' A' ' 24' ' ' LYS . 24.6 m -95.86 -40.78 9.15 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.415 0.524 . . . . 0.0 112.415 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.2 pt -91.32 -36.78 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 CA-C-O 121.054 0.454 . . . . 0.0 109.909 -179.148 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.45 -26.62 68.34 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -179.425 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.2 p -64.64 -38.57 91.45 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.702 0.287 . . . . 0.0 110.944 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -72.96 -43.28 62.48 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.54 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.5 mp -64.97 -44.37 89.58 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.185 179.578 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -64.02 -45.1 94.81 Favored Glycine 0 N--CA 1.44 -1.093 0 C-N-CA 119.251 -1.452 . . . . 0.0 109.765 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.65 -39.71 73.46 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.513 -0.344 . . . . 0.0 111.664 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.9 t -62.89 -41.91 99.59 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.407 -177.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.72 -39.77 78.44 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.145 178.613 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 36.6 tttm -60.07 -41.45 92.42 Favored 'General case' 0 N--CA 1.426 -1.644 0 N-CA-C 108.056 -1.091 . . . . 0.0 108.056 -178.529 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.12 -36.49 90.44 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 109.882 -1.287 . . . . 0.0 109.882 177.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -71.6 -51.92 20.78 Favored 'General case' 0 CA--C 1.518 -0.263 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.188 -179.308 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.52 ' O ' ' N ' ' A' ' 44' ' ' SER . 54.5 mttp -63.72 -39.65 94.81 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 120.143 -0.623 . . . . 0.0 110.517 178.322 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 61.6 tttm -61.79 -38.79 89.38 Favored 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 120.054 -0.658 . . . . 0.0 110.458 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.79 -35.98 81.33 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.701 -179.637 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.493 ' O ' ' N ' ' A' ' 45' ' ' ASP . 73.1 mtm -91.49 -64.96 1.05 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.772 0.32 . . . . 0.0 110.273 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.52 ' N ' ' O ' ' A' ' 40' ' ' LYS . 89.0 p 38.67 -91.98 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.839 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.493 ' N ' ' O ' ' A' ' 43' ' ' MET . 97.9 m-20 53.82 33.03 16.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.754 0.311 . . . . 0.0 110.787 179.087 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -97.91 36.62 1.52 Allowed 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.42 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.521 ' N ' ' CD ' ' A' ' 48' ' ' PRO . 11.6 mt-10 53.22 50.37 7.5 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.644 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.521 ' CD ' ' N ' ' A' ' 47' ' ' GLU . 38.4 Cg_endo . . . . . 0 C--N 1.304 -1.775 0 C-N-CA 122.861 2.374 . . . . 0.0 111.742 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.568 ' N ' ' SD ' ' A' ' 1' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.609 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -121.92 -15.37 4.35 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.333 -0.707 . . . . 0.0 111.333 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -106.2 -1.04 38.41 Favored Glycine 0 N--CA 1.465 0.579 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 36.8 mt -42.18 -85.45 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.658 -0.271 . . . . 0.0 110.696 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.6 m -156.25 -165.78 2.0 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.456 ' HA ' HD23 ' A' ' 9' ' ' LEU . 40.8 mm -91.7 -40.66 12.57 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.06 179.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 82.9 m95 -71.68 -40.69 69.42 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 120.279 -0.568 . . . . 0.0 110.207 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.488 ' OE1' ' N ' ' A' ' 8' ' ' GLN . 1.7 mp0 -64.41 -38.8 92.31 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.055 0.455 . . . . 0.0 110.311 -179.227 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.666 ' C ' HD12 ' A' ' 9' ' ' LEU . 0.3 OUTLIER -72.31 -38.0 68.81 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.97 179.7 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.589 ' O ' HG23 ' A' ' 14' ' ' VAL . 15.8 mt -63.28 -48.78 76.68 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.73 -176.386 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.2 mp -66.13 -44.33 91.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 178.394 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 69.3 mt -64.06 -44.48 97.74 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.642 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.391 -179.366 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.89 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.91 -37.09 86.5 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.867 -179.067 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.589 HG23 ' O ' ' A' ' 10' ' ' LEU . 50.2 t -66.93 -45.6 86.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 C-N-CA 120.425 -0.51 . . . . 0.0 111.574 -178.809 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 15.9 pt -66.41 -42.34 90.27 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.916 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.759 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.7 t -63.19 -42.36 96.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.35 -179.626 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.89 HG23 ' O ' ' A' ' 13' ' ' ALA . 61.3 t -65.63 -48.96 80.69 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.887 0 C-N-CA 117.245 -1.782 . . . . 0.0 113.69 -176.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.634 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.6 pp -68.49 -44.0 75.66 Favored 'General case' 0 C--N 1.289 -2.063 0 C-N-CA 120.094 -0.642 . . . . 0.0 112.156 -179.377 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.669 ' C ' HD12 ' A' ' 19' ' ' LEU . 0.4 OUTLIER -66.3 -39.19 89.15 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.99 -179.604 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.759 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 1.8 m-85 -68.45 -37.62 80.37 Favored 'General case' 0 CA--C 1.506 -0.726 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.641 -178.395 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.483 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 101.2 9.53 44.56 Favored Glycine 0 C--N 1.308 -0.974 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.046 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.697 HG22 ' CG1' ' A' ' 17' ' ' VAL . 44.6 p 55.15 66.66 1.17 Allowed 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 178.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -139.6 -22.57 0.89 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.054 179.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 9.9 mmmt -87.13 -51.41 6.01 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.646 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.634 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.0 OUTLIER -54.45 -37.11 64.8 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 122.067 0.937 . . . . 0.0 110.556 -178.85 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.48 -25.07 73.55 Favored Glycine 0 C--N 1.304 -1.215 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.587 -177.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 7.5 t -92.54 -42.89 9.44 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 111.977 0.362 . . . . 0.0 111.977 -179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 4.6 pt -91.29 -36.1 7.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 121.233 0.54 . . . . 0.0 109.917 -179.033 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.57 -24.12 69.24 Favored Glycine 0 CA--C 1.518 0.257 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -179.126 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.2 p -65.22 -41.18 94.71 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 120.771 -0.372 . . . . 0.0 111.058 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -76.02 -39.88 54.71 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.078 0.466 . . . . 0.0 109.874 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.7 mp -70.21 -45.59 66.27 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.129 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.55 -43.57 98.83 Favored Glycine 0 N--CA 1.441 -1.007 0 C-N-CA 119.545 -1.312 . . . . 0.0 110.473 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.02 -40.04 71.99 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 120.898 0.38 . . . . 0.0 111.06 179.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 12.4 t -63.99 -41.93 97.36 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 120.559 -0.456 . . . . 0.0 110.98 -178.558 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.44 -39.87 79.2 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.71 -179.528 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 18.7 pttt -59.58 -40.51 87.62 Favored 'General case' 0 C--N 1.309 -1.195 0 C-N-CA 118.591 -1.243 . . . . 0.0 107.843 -178.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -69.46 -36.82 78.07 Favored Glycine 0 N--CA 1.442 -0.92 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 179.657 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.425 ' CE1' ' CE ' ' A' ' 43' ' ' MET . 46.0 t80 -71.52 -50.71 28.67 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.552 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.563 ' O ' ' N ' ' A' ' 44' ' ' SER . 52.7 mtpt -63.65 -38.85 92.66 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.597 178.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -62.04 -37.97 86.94 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 119.981 -0.687 . . . . 0.0 110.09 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.68 -36.87 83.53 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.495 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.592 ' N ' ' SD ' ' A' ' 43' ' ' MET . 0.2 OUTLIER -94.74 -10.55 31.26 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.689 -179.615 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.563 ' N ' ' O ' ' A' ' 40' ' ' LYS . 11.7 t -58.16 -44.44 87.92 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.935 0.398 . . . . 0.0 110.126 -179.32 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.467 ' CG ' ' H ' ' A' ' 46' ' ' ASP . 44.8 t0 -85.4 -179.46 6.95 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.423 179.727 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.467 ' H ' ' CG ' ' A' ' 45' ' ' ASP . 96.7 m-20 56.15 38.11 29.52 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.279 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 -70.76 152.08 95.2 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.571 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo . . . . . 0 N--CA 1.495 1.562 0 C-N-CA 122.69 2.26 . . . . 0.0 111.71 179.563 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.49 ' C ' ' H ' ' A' ' 3' ' ' GLY . 94.9 mtp . . . . . 0 N--CA 1.492 1.629 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -78.15 29.13 1.91 Allowed Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.49 ' H ' ' C ' ' A' ' 1' ' ' MET . . . -152.54 34.66 0.82 Allowed Glycine 0 N--CA 1.451 -0.341 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 179.59 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.8 mt -53.11 130.75 14.81 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.673 0 CA-C-O 122.019 0.914 . . . . 0.0 110.265 -178.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.494 ' C ' HD12 ' A' ' 6' ' ' ILE . 53.3 m -106.14 -132.33 0.31 Allowed 'General case' 0 C--N 1.315 -0.891 0 CA-C-N 113.791 -1.549 . . . . 0.0 110.275 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.494 HD12 ' C ' ' A' ' 5' ' ' SER . 1.4 mp -104.68 -31.03 2.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.277 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 70.9 m95 -62.76 -46.97 85.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.692 179.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 59.1 mm-40 -64.35 -39.05 93.11 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.424 HD23 ' HA ' ' A' ' 9' ' ' LEU . 84.4 mt -65.08 -39.1 92.72 Favored 'General case' 0 CA--C 1.508 -0.649 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.146 178.626 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.598 ' O ' HG23 ' A' ' 14' ' ' VAL . 8.0 mt -63.38 -49.16 74.91 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.521 -176.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.516 ' O ' HG12 ' A' ' 15' ' ' ILE . 3.3 mp -67.67 -44.97 85.66 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.775 0 C-N-CA 119.508 -0.877 . . . . 0.0 109.093 178.07 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 77.1 mt -63.36 -44.36 98.98 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.526 -179.165 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.818 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -63.79 -36.46 83.96 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.203 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.598 HG23 ' O ' ' A' ' 10' ' ' LEU . 65.8 t -67.1 -43.06 88.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 C-N-CA 119.779 -0.769 . . . . 0.0 110.457 179.672 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.516 HG12 ' O ' ' A' ' 11' ' ' ILE . 33.5 mm -66.08 -43.04 92.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.127 0.489 . . . . 0.0 110.28 179.26 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.505 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -63.75 -38.04 81.27 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.558 -178.72 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.818 HG23 ' O ' ' A' ' 13' ' ' ALA . 95.0 t -65.66 -43.02 93.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 C-N-CA 118.409 -1.316 . . . . 0.0 111.868 -178.308 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.434 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 16.1 mt -62.0 -45.03 95.42 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 118.631 -1.227 . . . . 0.0 111.833 -179.106 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.889 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.78 -38.37 79.97 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -178.528 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.889 ' N ' HD12 ' A' ' 19' ' ' LEU . 1.3 m-85 -67.57 -32.44 73.2 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -177.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 94.45 8.88 59.46 Favored Glycine 0 CA--C 1.5 -0.887 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 178.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.721 HG22 HG13 ' A' ' 17' ' ' VAL . 18.0 p 56.95 27.95 13.94 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 114.27 -0.965 . . . . 0.0 112.502 178.034 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -100.57 -12.84 18.92 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.776 179.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.5 ' O ' ' N ' ' A' ' 27' ' ' SER . 15.4 mmmt -96.06 -58.43 2.09 Favored 'General case' 0 C--O 1.221 -0.438 0 CA-C-O 121.053 0.454 . . . . 0.0 110.281 179.511 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 1.086 ' H ' HD12 ' A' ' 25' ' ' LEU . 2.0 mp -44.12 -42.0 6.01 Favored 'General case' 0 CA--C 1.495 -1.144 0 CA-C-O 122.459 1.123 . . . . 0.0 110.468 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.94 -25.42 71.6 Favored Glycine 0 N--CA 1.424 -2.134 0 CA-C-N 113.49 -1.686 . . . . 0.0 110.601 -177.536 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.5 ' N ' ' O ' ' A' ' 24' ' ' LYS . 5.4 m -95.28 -35.06 11.95 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -179.484 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.472 ' N ' ' O ' ' A' ' 24' ' ' LYS . 9.2 pt -93.53 -38.17 9.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -179.578 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.2 -24.01 49.62 Favored Glycine 0 CA--C 1.521 0.417 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 61.9 p -66.38 -57.28 7.78 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.946 -0.302 . . . . 0.0 111.761 -179.353 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -67.81 -39.87 83.91 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.411 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -65.46 -44.99 85.51 Favored 'General case' 0 CA--C 1.507 -0.694 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.159 179.653 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.43 -43.43 99.34 Favored Glycine 0 N--CA 1.433 -1.54 0 N-CA-C 108.475 -1.85 . . . . 0.0 108.475 -178.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.97 -40.0 75.63 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.073 -0.564 . . . . 0.0 111.159 178.429 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 51.6 m -63.53 -43.37 97.33 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 120.408 -0.517 . . . . 0.0 110.87 -178.452 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -67.28 -39.71 83.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.64 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.0 pttt -60.02 -42.08 93.56 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 -179.209 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.68 -36.83 88.37 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 178.23 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.592 ' CE2' ' SD ' ' A' ' 43' ' ' MET . 14.8 t80 -71.94 -50.41 29.27 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 120.956 0.408 . . . . 0.0 110.642 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.564 ' O ' ' N ' ' A' ' 44' ' ' SER . 21.8 mtpp -62.74 -38.55 90.99 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.269 179.066 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -61.76 -38.3 87.49 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.475 -179.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.92 -35.8 80.82 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.194 0.521 . . . . 0.0 109.626 179.189 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.592 ' SD ' ' CE2' ' A' ' 39' ' ' PHE . 33.6 mtp -88.64 -16.87 31.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.06 -179.686 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.564 ' N ' ' O ' ' A' ' 40' ' ' LYS . 47.7 t -60.56 152.85 25.01 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.185 -179.346 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.472 ' C ' ' H ' ' A' ' 47' ' ' GLU . 99.3 m-20 56.56 94.88 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.9 0.381 . . . . 0.0 110.383 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -74.82 34.98 0.1 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.639 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.472 ' H ' ' C ' ' A' ' 45' ' ' ASP . 48.1 mt-10 50.07 65.26 7.13 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.677 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 77.7 Cg_endo . . . . . 0 C--N 1.306 -1.69 0 C-N-CA 122.925 2.417 . . . . 0.0 112.045 -179.834 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 92.5 mtp . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -99.09 18.32 56.87 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -145.86 22.39 1.79 Allowed Glycine 0 C--N 1.328 0.138 0 N-CA-C 109.116 -1.594 . . . . 0.0 109.116 179.498 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.452 HG23 ' CB ' ' A' ' 8' ' ' GLN . 22.1 mt -43.4 122.56 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.512 -0.504 0 CA-C-O 121.823 0.821 . . . . 0.0 110.463 -179.31 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -96.64 -162.42 0.95 Allowed 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 114.352 -1.295 . . . . 0.0 109.128 178.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.6 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.4 mp -68.48 -44.19 83.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 114.647 -1.16 . . . . 0.0 110.403 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.403 ' O ' HD13 ' A' ' 11' ' ' ILE . 95.8 m95 -70.92 -39.71 72.53 Favored 'General case' 0 C--N 1.316 -0.884 0 C-N-CA 120.068 -0.653 . . . . 0.0 109.773 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.452 ' CB ' HG23 ' A' ' 4' ' ' ILE . 94.2 mm-40 -64.66 -39.15 93.19 Favored 'General case' 0 N--CA 1.442 -0.85 0 C-N-CA 120.315 -0.554 . . . . 0.0 109.617 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.658 ' C ' HD12 ' A' ' 9' ' ' LEU . 0.4 OUTLIER -73.05 -38.36 66.51 Favored 'General case' 0 C--O 1.226 -0.176 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.014 179.027 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.566 ' O ' HG23 ' A' ' 14' ' ' VAL . 15.3 mt -63.31 -47.82 80.66 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.945 -0.302 . . . . 0.0 111.22 -177.613 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.403 HD13 ' O ' ' A' ' 7' ' ' TRP . 2.1 mp -66.94 -44.48 88.64 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.851 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 53.3 mt -64.42 -44.72 97.09 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.076 0 CA-C-N 115.639 -0.709 . . . . 0.0 111.271 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.694 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.84 -37.39 87.47 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.719 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.566 HG23 ' O ' ' A' ' 10' ' ' LEU . 55.3 t -67.67 -45.72 84.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 C-N-CA 119.624 -0.831 . . . . 0.0 110.697 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.5 mt -65.85 -43.88 92.97 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.717 0 CA-C-O 121.172 0.51 . . . . 0.0 111.189 -179.023 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.579 HG22 ' CD2' ' A' ' 20' ' ' PHE . 0.5 OUTLIER -64.46 -38.74 83.36 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.344 0 CA-C-N 115.284 -0.871 . . . . 0.0 109.616 -178.932 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.782 HG13 HG22 ' A' ' 22' ' ' THR . 61.0 t -65.75 -42.79 93.19 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.158 0 C-N-CA 118.571 -1.252 . . . . 0.0 111.389 -177.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 66.0 mt -61.77 -44.96 95.86 Favored 'General case' 0 C--N 1.312 -1.031 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.751 -179.02 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.875 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.55 -38.29 80.65 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 113.067 0.765 . . . . 0.0 113.067 -178.74 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.875 ' N ' HD12 ' A' ' 19' ' ' LEU . 1.2 m-85 -67.61 -31.74 71.97 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -178.224 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 90.74 2.79 71.84 Favored Glycine 0 C--N 1.318 -0.47 0 N-CA-C 109.211 -1.556 . . . . 0.0 109.211 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.782 HG22 HG13 ' A' ' 17' ' ' VAL . 5.5 p 57.19 9.09 0.63 Allowed 'General case' 0 CA--C 1.511 -0.544 0 CA-C-N 114.727 -0.737 . . . . 0.0 112.178 178.03 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 24.7 mtpp -71.76 -42.26 67.42 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.256 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.592 ' HG3' HD12 ' A' ' 25' ' ' LEU . 0.0 OUTLIER -86.57 -25.17 25.14 Favored 'General case' 0 C--O 1.221 -0.41 0 CA-C-N 116.16 -0.473 . . . . 0.0 112.017 -178.705 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.68 HD13 ' HA ' ' A' ' 22' ' ' THR . 9.7 mp -59.05 -43.45 91.68 Favored 'General case' 0 CA--C 1.49 -1.328 0 CA-C-O 121.852 0.834 . . . . 0.0 109.353 -179.669 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.82 -25.34 72.08 Favored Glycine 0 N--CA 1.424 -2.111 0 N-CA-C 108.704 -1.758 . . . . 0.0 108.704 -178.235 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.7 t -76.66 -42.26 42.55 Favored 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.216 -0.492 . . . . 0.0 111.355 179.122 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.434 HD13 ' NZ ' ' A' ' 24' ' ' LYS . 21.8 pt -91.47 -33.02 5.44 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 CA-C-O 121.404 0.621 . . . . 0.0 109.579 -179.67 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.488 ' N ' ' O ' ' A' ' 25' ' ' LEU . . . -59.46 -24.02 58.83 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 7.3 t -64.6 -42.4 95.59 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.44 -0.504 . . . . 0.0 112.148 -179.342 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -86.53 -36.19 19.1 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.4 mp -73.03 -46.34 52.48 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.129 -0.942 . . . . 0.0 111.725 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.78 -43.66 98.94 Favored Glycine 0 C--N 1.308 -1.003 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.579 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.0 -40.32 75.34 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.486 -0.357 . . . . 0.0 111.479 179.57 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.5 t -63.61 -42.84 98.17 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.195 0.521 . . . . 0.0 110.857 -178.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.1 mp -67.09 -39.76 83.92 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.753 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.487 ' HA ' ' HZ2' ' A' ' 40' ' ' LYS . 2.1 pttp -59.81 -42.71 94.08 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 118.809 -1.156 . . . . 0.0 108.301 -178.717 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.87 -36.88 87.57 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.495 -1.042 . . . . 0.0 110.495 178.549 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.612 ' CE1' ' SD ' ' A' ' 43' ' ' MET . 51.6 t80 -71.91 -53.34 13.45 Favored 'General case' 0 CA--C 1.513 -0.445 0 CA-C-O 120.684 0.278 . . . . 0.0 111.597 -179.355 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.487 ' HZ2' ' HA ' ' A' ' 37' ' ' LYS . 9.9 pttm -62.75 -38.37 90.3 Favored 'General case' 0 C--N 1.318 -0.773 0 C-N-CA 120.069 -0.652 . . . . 0.0 109.994 -179.423 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 52.9 tttp -61.47 -37.52 83.91 Favored 'General case' 0 N--CA 1.446 -0.654 0 C-N-CA 120.153 -0.619 . . . . 0.0 110.057 -179.523 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.86 -36.01 81.35 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.53 179.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.612 ' SD ' ' CE1' ' A' ' 39' ' ' PHE . 0.0 OUTLIER -88.48 -10.94 47.34 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.214 179.852 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 65.7 p -66.22 151.84 46.13 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.854 0.359 . . . . 0.0 110.527 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -134.53 131.87 38.49 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.555 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 36.0 p-10 -93.41 13.41 21.68 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.445 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 70.3 tt0 56.16 74.11 0.74 Allowed Pre-proline 0 C--N 1.32 -0.69 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.448 -179.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo . . . . . 0 C--N 1.307 -1.617 0 C-N-CA 122.691 2.261 . . . . 0.0 111.915 -179.716 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 73.3 mmm . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -80.01 31.31 2.29 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.448 ' C ' HD12 ' A' ' 4' ' ' ILE . . . 134.26 20.37 0.82 Allowed Glycine 0 CA--C 1.522 0.479 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.781 ' N ' HD12 ' A' ' 4' ' ' ILE . 2.5 mp -101.38 101.08 11.6 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 CA-C-O 121.174 0.511 . . . . 0.0 110.656 -179.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.614 ' H ' ' CD ' ' A' ' 8' ' ' GLN . 66.9 m -103.86 -163.04 0.94 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.593 179.191 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 26.1 mm -61.79 -45.78 97.94 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.315 -178.808 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.768 ' CZ2' HD11 ' A' ' 11' ' ' ILE . 6.5 t-105 -62.74 -42.0 99.46 Favored 'General case' 0 N--CA 1.434 -1.242 0 CA-C-N 115.219 -0.901 . . . . 0.0 108.756 179.338 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.614 ' CD ' ' H ' ' A' ' 5' ' ' SER . 5.9 mp0 -64.74 -38.73 91.97 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.127 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.439 HD23 ' HA ' ' A' ' 9' ' ' LEU . 32.7 mt -60.03 -37.28 79.3 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.789 178.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.598 ' O ' HG23 ' A' ' 14' ' ' VAL . 4.8 mt -61.94 -44.32 97.01 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.077 -176.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.768 HD11 ' CZ2' ' A' ' 7' ' ' TRP . 4.4 mp -66.65 -45.33 88.62 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.508 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.329 177.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.403 ' N ' ' CD1' ' A' ' 12' ' ' ILE . 1.1 mp -64.96 -44.79 96.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.448 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.776 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.18 -37.0 85.89 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.971 0.415 . . . . 0.0 110.395 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.598 HG23 ' O ' ' A' ' 10' ' ' LEU . 56.0 t -67.4 -43.77 87.43 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.39 0 C-N-CA 119.811 -0.756 . . . . 0.0 110.792 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.402 HG12 ' O ' ' A' ' 11' ' ' ILE . 4.4 mm -65.53 -43.39 94.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.26 0.552 . . . . 0.0 110.98 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.463 HG22 ' CD2' ' A' ' 20' ' ' PHE . 0.3 OUTLIER -63.54 -38.16 81.48 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.401 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.536 -178.31 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.776 HG23 ' O ' ' A' ' 13' ' ' ALA . 73.5 t -64.61 -43.67 96.72 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.381 0 C-N-CA 118.429 -1.309 . . . . 0.0 109.751 -178.404 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.588 HD21 ' O ' ' A' ' 14' ' ' VAL . 0.1 OUTLIER -63.72 -43.63 95.98 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 178.168 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.06 -43.75 94.55 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-N 114.006 -1.452 . . . . 0.0 111.605 -176.519 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.463 ' CD2' HG22 ' A' ' 16' ' ' VAL . 2.9 m-85 -68.92 -33.1 73.19 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.509 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 97.35 14.21 42.37 Favored Glycine 0 CA--C 1.502 -0.733 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 178.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.773 HG22 ' CG1' ' A' ' 17' ' ' VAL . 70.3 p 57.38 14.51 2.22 Favored 'General case' 0 CA--C 1.508 -0.664 0 CA-C-N 114.57 -0.815 . . . . 0.0 112.408 179.051 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -97.51 -31.35 12.38 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.375 -178.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 13.8 tppt? -70.96 -47.36 59.36 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 121.399 0.618 . . . . 0.0 111.477 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 1.092 ' H ' HD12 ' A' ' 25' ' ' LEU . 1.8 mp -61.0 -37.48 82.66 Favored 'General case' 0 CA--C 1.489 -1.402 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.232 -179.086 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.49 -24.79 75.66 Favored Glycine 0 N--CA 1.425 -2.053 0 CA-C-N 114.277 -1.329 . . . . 0.0 109.889 -177.451 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 75.7 m -84.81 -39.99 17.72 Favored 'General case' 0 CA--C 1.514 -0.408 0 C-N-CA 121.028 -0.269 . . . . 0.0 111.444 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 11.0 pt -93.95 -34.51 5.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.316 0.579 . . . . 0.0 109.759 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 25' ' ' LEU . . . -61.8 -24.79 64.93 Favored Glycine 0 C--O 1.226 -0.402 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.2 p -64.96 -38.94 92.62 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.686 -0.406 . . . . 0.0 111.606 -179.15 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 45.5 m-20 -87.28 -36.74 17.73 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -73.6 -46.03 49.6 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.456 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.404 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -61.92 -44.46 97.8 Favored Glycine 0 C--N 1.311 -0.854 0 C-N-CA 119.399 -1.382 . . . . 0.0 109.856 -179.105 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.68 -40.17 76.52 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.718 -0.241 . . . . 0.0 111.432 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.9 t -63.1 -42.35 99.56 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.565 -0.454 . . . . 0.0 110.528 -178.404 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.2 -39.41 81.14 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.042 178.712 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.601 ' HA ' ' HZ2' ' A' ' 40' ' ' LYS . 7.7 ttpt -59.51 -45.56 91.39 Favored 'General case' 0 N--CA 1.435 -1.175 0 C-N-CA 119.252 -0.979 . . . . 0.0 109.043 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.79 -37.11 88.3 Favored Glycine 0 CA--C 1.529 0.946 0 C-N-CA 120.05 -1.071 . . . . 0.0 110.461 178.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -71.6 -51.82 21.32 Favored 'General case' 0 CA--C 1.511 -0.528 0 CA-C-O 120.574 0.226 . . . . 0.0 111.537 -179.478 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.601 ' HZ2' ' HA ' ' A' ' 37' ' ' LYS . 8.9 pttm -62.78 -37.71 87.77 Favored 'General case' 0 C--N 1.318 -0.792 0 C-N-CA 120.207 -0.597 . . . . 0.0 110.144 -179.455 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -61.64 -36.15 79.95 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.25 -178.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.8 -35.97 82.19 Favored 'General case' 0 C--N 1.319 -0.727 0 C-N-CA 120.686 -0.405 . . . . 0.0 109.921 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.447 ' O ' ' O ' ' A' ' 44' ' ' SER . 10.3 mmt -88.81 -65.85 0.98 Allowed 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.626 -0.261 . . . . 0.0 110.418 179.624 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.453 ' N ' ' O ' ' A' ' 40' ' ' LYS . 28.1 t 53.86 164.8 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.377 -179.676 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -143.03 -49.61 0.33 Allowed 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.759 0.314 . . . . 0.0 110.72 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 41.7 p-10 -88.23 13.38 11.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.062 0.458 . . . . 0.0 110.204 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 40.56 76.02 0.54 Allowed Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.645 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_exo . . . . . 0 C--N 1.306 -1.671 0 C-N-CA 122.872 2.381 . . . . 0.0 112.155 -179.615 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 93.4 mtp . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.651 ' O ' HD21 ' A' ' 9' ' ' LEU . . . -117.73 3.12 17.53 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.129 -0.788 . . . . 0.0 111.129 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -137.04 23.53 3.18 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 110.88 -0.888 . . . . 0.0 110.88 179.763 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 9.1 mt -63.13 -49.4 83.46 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.458 0 CA-C-O 120.925 0.393 . . . . 0.0 110.739 -179.647 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.1 m -176.72 172.71 2.07 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 122.073 0.94 . . . . 0.0 109.96 179.043 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.9 mm -62.27 -49.65 83.12 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 CA-C-N 113.78 -1.555 . . . . 0.0 111.35 -179.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.516 ' CE2' HD11 ' A' ' 11' ' ' ILE . 10.8 t-105 -62.6 -38.59 90.76 Favored 'General case' 0 N--CA 1.44 -0.944 0 CA-C-N 115.421 -0.808 . . . . 0.0 109.008 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 25.7 mm-40 -64.94 -39.25 93.22 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.651 HD21 ' O ' ' A' ' 2' ' ' GLY . 29.3 mt -61.39 -38.1 85.8 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.434 178.662 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.618 ' O ' HG23 ' A' ' 14' ' ' VAL . 5.6 mt -62.09 -43.3 99.13 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.066 -176.809 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.516 HD11 ' CE2' ' A' ' 7' ' ' TRP . 5.9 mt -66.3 -45.33 89.99 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 C-N-CA 119.928 -0.709 . . . . 0.0 109.588 177.903 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.1 mp -65.8 -47.39 85.92 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.806 -179.268 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.813 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.75 -37.36 87.34 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.543 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.618 HG23 ' O ' ' A' ' 10' ' ' LEU . 45.8 t -67.38 -44.28 87.18 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.052 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.709 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 97.0 mt -65.61 -43.13 94.08 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.761 0 CA-C-O 121.33 0.586 . . . . 0.0 110.685 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.496 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -63.99 -38.17 81.72 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.589 -178.082 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.813 HG23 ' O ' ' A' ' 13' ' ' ALA . 83.2 t -65.61 -42.83 93.73 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.93 0 C-N-CA 118.449 -1.3 . . . . 0.0 111.474 -178.156 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.595 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 19.2 mt -62.49 -45.72 91.73 Favored 'General case' 0 C--N 1.319 -0.76 0 C-N-CA 119.66 -0.816 . . . . 0.0 112.075 -178.469 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.886 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.92 -38.24 79.41 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -179.315 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.886 ' N ' HD12 ' A' ' 19' ' ' LEU . 2.0 m-85 -67.79 -36.87 81.21 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 108.804 -0.814 . . . . 0.0 108.804 -178.215 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 101.65 7.41 48.27 Favored Glycine 0 CA--C 1.501 -0.837 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 178.374 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.765 ' HA ' HD13 ' A' ' 25' ' ' LEU . 18.0 p 56.41 19.74 4.26 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.77 -0.715 . . . . 0.0 112.135 178.588 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 17.0 mtmt -92.09 -25.13 18.9 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.63 -0.428 . . . . 0.0 111.006 -179.081 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.605 ' O ' ' N ' ' A' ' 27' ' ' SER . 0.9 OUTLIER -85.12 -59.85 2.21 Favored 'General case' 0 C--O 1.213 -0.856 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.828 -179.514 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 1.068 ' H ' HD12 ' A' ' 25' ' ' LEU . 2.6 mp -42.63 -39.06 2.22 Favored 'General case' 0 CA--C 1.492 -1.272 0 CA-C-O 122.503 1.145 . . . . 0.0 110.221 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.65 -25.2 70.52 Favored Glycine 0 N--CA 1.428 -1.872 0 CA-C-N 113.361 -1.745 . . . . 0.0 111.066 -178.173 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.605 ' N ' ' O ' ' A' ' 24' ' ' LYS . 8.5 t -99.23 -36.61 9.59 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -179.147 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.429 ' N ' ' O ' ' A' ' 24' ' ' LYS . 13.1 pt -92.75 -36.58 7.72 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 CA-C-O 121.296 0.57 . . . . 0.0 109.498 -179.03 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.24 -26.23 67.51 Favored Glycine 0 CA--C 1.521 0.415 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.0 p -64.7 -40.12 94.82 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.628 -179.469 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -76.4 -42.48 44.16 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 179.361 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.1 mp -66.89 -44.18 81.51 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.587 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.13 -44.31 97.39 Favored Glycine 0 N--CA 1.44 -1.063 0 C-N-CA 119.51 -1.328 . . . . 0.0 109.884 -179.097 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -72.1 -39.92 68.58 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.671 -0.265 . . . . 0.0 111.289 178.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 67.0 m -63.31 -40.7 98.06 Favored 'General case' 0 CA--C 1.515 -0.392 0 C-N-CA 120.528 -0.469 . . . . 0.0 110.551 -178.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.48 -39.15 78.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.007 179.048 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.407 ' O ' ' CB ' ' A' ' 41' ' ' LYS . 20.8 tttt -59.49 -44.98 92.93 Favored 'General case' 0 N--CA 1.432 -1.344 0 C-N-CA 119.358 -0.937 . . . . 0.0 108.598 -178.416 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.04 -36.48 93.08 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 178.62 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 87.1 t80 -71.35 -54.31 11.2 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 111.66 0.244 . . . . 0.0 111.66 -179.172 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.411 ' CG ' ' N ' ' A' ' 41' ' ' LYS . 18.9 ptmt -64.8 -39.83 94.23 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.974 179.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.411 ' N ' ' CG ' ' A' ' 40' ' ' LYS . 88.6 tttt -62.87 -36.84 84.63 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.729 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.62 -36.1 81.78 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.421 179.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 33.4 mtm -90.23 -10.71 43.31 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.843 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 96.3 p -60.98 -35.14 76.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.924 0.392 . . . . 0.0 110.298 -179.686 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.485 ' C ' ' H ' ' A' ' 47' ' ' GLU . 54.1 t0 55.06 75.1 0.33 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.423 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.451 ' O ' ' O ' ' A' ' 47' ' ' GLU . 66.7 t0 -71.44 40.62 0.07 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.334 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.485 ' H ' ' C ' ' A' ' 45' ' ' ASP . 3.6 mp0 57.21 151.18 0.06 OUTLIER Pre-proline 0 CA--C 1.533 0.326 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.708 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_exo . . . . . 0 C--N 1.316 -1.166 0 C-N-CA 122.597 2.198 . . . . 0.0 112.181 179.689 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.477 ' C ' ' H ' ' A' ' 3' ' ' GLY . 69.6 mmm . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 68.53 -10.2 1.52 Allowed Glycine 0 CA--C 1.523 0.58 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.477 ' H ' ' C ' ' A' ' 1' ' ' MET . . . -138.34 28.34 2.69 Favored Glycine 0 N--CA 1.465 0.59 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.7 mt -63.71 -44.12 98.26 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.486 0 CA-C-O 121.148 0.499 . . . . 0.0 110.179 -179.802 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.8 m -179.84 169.02 1.31 Allowed 'General case' 0 N--CA 1.44 -0.974 0 CA-C-O 121.748 0.785 . . . . 0.0 110.592 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.54 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.5 mp -63.86 -44.49 98.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-N 113.765 -1.561 . . . . 0.0 109.503 177.877 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.493 ' O ' HD12 ' A' ' 11' ' ' ILE . 29.0 m95 -62.69 -46.88 86.09 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 120.086 -0.645 . . . . 0.0 110.027 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.522 ' OE1' ' N ' ' A' ' 8' ' ' GLN . 0.7 OUTLIER -64.22 -39.04 93.15 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 -179.385 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.688 ' C ' HD12 ' A' ' 9' ' ' LEU . 0.2 OUTLIER -70.37 -37.92 74.66 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.319 178.654 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.559 ' O ' HG23 ' A' ' 14' ' ' VAL . 19.2 mt -62.82 -46.55 87.41 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.899 -177.467 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.493 HD12 ' O ' ' A' ' 7' ' ' TRP . 6.2 mt -65.84 -44.31 92.87 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.247 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 56.2 mt -63.44 -44.35 98.83 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.157 -178.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.778 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.15 -37.13 86.34 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.454 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.559 HG23 ' O ' ' A' ' 10' ' ' LEU . 73.5 t -67.53 -44.31 86.62 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 C-N-CA 119.795 -0.762 . . . . 0.0 110.489 179.58 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.427 HG12 ' O ' ' A' ' 11' ' ' ILE . 4.5 mm -65.99 -43.43 92.66 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.698 0 CA-C-O 121.129 0.49 . . . . 0.0 111.133 -179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.566 HG22 ' CD2' ' A' ' 20' ' ' PHE . 0.3 OUTLIER -63.96 -38.39 82.27 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.072 0 CA-C-N 115.362 -0.835 . . . . 0.0 109.371 -178.984 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.778 HG23 ' O ' ' A' ' 13' ' ' ALA . 79.0 t -65.4 -42.81 94.4 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.024 0 C-N-CA 118.478 -1.289 . . . . 0.0 111.64 -177.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.494 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 29.4 mt -62.42 -45.2 94.17 Favored 'General case' 0 C--N 1.317 -0.821 0 C-N-CA 118.984 -1.086 . . . . 0.0 111.721 -179.159 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.85 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -67.48 -38.46 84.42 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.818 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.85 ' N ' HD12 ' A' ' 19' ' ' LEU . 1.4 m-85 -67.73 -31.25 71.04 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -178.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 89.62 8.77 67.35 Favored Glycine 0 CA--C 1.505 -0.541 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.732 HG22 HG13 ' A' ' 17' ' ' VAL . 14.8 p 56.65 15.6 2.22 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 114.48 -0.86 . . . . 0.0 112.279 178.139 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 13.4 ptpt -82.66 -44.38 15.79 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.296 0.569 . . . . 0.0 109.68 178.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.443 ' O ' ' N ' ' A' ' 28' ' ' ILE . 2.0 mmmm -67.95 -43.97 77.84 Favored 'General case' 0 C--O 1.21 -1.012 0 CA-C-N 115.218 -0.901 . . . . 0.0 112.069 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.666 ' N ' HD12 ' A' ' 25' ' ' LEU . 6.7 mp -56.73 -36.87 70.22 Favored 'General case' 0 CA--C 1.49 -1.331 0 CA-C-O 121.876 0.846 . . . . 0.0 110.568 -178.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.28 -24.92 74.39 Favored Glycine 0 N--CA 1.422 -2.24 0 CA-C-N 114.61 -1.177 . . . . 0.0 110.669 -176.816 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 8.9 m -101.1 -33.92 9.93 Favored 'General case' 0 CA--C 1.503 -0.839 0 CA-C-O 121.166 0.508 . . . . 0.0 111.931 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.688 HG23 HD22 ' A' ' 32' ' ' LEU . 0.2 OUTLIER -91.66 -40.99 12.86 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.137 -178.772 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -53.22 -33.68 46.13 Favored Glycine 0 C--N 1.314 -0.667 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.466 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 41.8 t -64.99 -44.27 89.85 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.368 -0.533 . . . . 0.0 111.442 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -76.28 -44.79 35.54 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.371 0.605 . . . . 0.0 109.485 179.651 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.688 HD22 HG23 ' A' ' 28' ' ' ILE . 10.6 mp -67.48 -43.87 79.94 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 114.795 -1.093 . . . . 0.0 111.816 -179.458 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.33 -43.77 98.61 Favored Glycine 0 C--N 1.308 -0.985 0 C-N-CA 119.247 -1.454 . . . . 0.0 109.789 -179.682 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.27 -40.32 71.03 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.461 -0.369 . . . . 0.0 111.25 179.407 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 40.1 t -63.49 -41.98 98.56 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.223 0.535 . . . . 0.0 111.125 -178.71 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.53 -40.12 79.3 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.665 -179.727 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.2 pttt -60.07 -42.84 95.41 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -179.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.03 -36.59 92.18 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 178.578 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.6 t80 -71.65 -51.89 20.75 Favored 'General case' 0 CA--C 1.516 -0.365 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.18 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.548 ' O ' ' N ' ' A' ' 44' ' ' SER . 42.7 mmtm -64.0 -38.97 93.01 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.37 178.783 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -61.63 -36.83 81.89 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.092 -0.643 . . . . 0.0 110.14 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.69 -36.3 82.19 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.794 -179.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.458 ' O ' ' O ' ' A' ' 44' ' ' SER . 67.2 mtm -99.92 -66.86 0.88 Allowed 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.962 0.41 . . . . 0.0 110.741 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.548 ' N ' ' O ' ' A' ' 40' ' ' LYS . 25.8 t 40.24 -166.58 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.707 -179.429 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.547 ' N ' ' OG ' ' A' ' 44' ' ' SER . 98.7 m-20 53.81 33.07 16.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.57 -0.287 . . . . 0.0 110.648 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -100.59 41.74 1.16 Allowed 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.819 0.343 . . . . 0.0 110.513 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 55.3 tt0 -162.42 73.84 2.18 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.493 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_exo . . . . . 0 C--N 1.307 -1.635 0 C-N-CA 122.874 2.383 . . . . 0.0 112.089 -179.915 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 38.9 mmt . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 84.06 26.59 40.27 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.356 -0.697 . . . . 0.0 111.356 179.799 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 139.17 -11.63 3.31 Favored Glycine 0 N--CA 1.463 0.49 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.468 HG23 ' CB ' ' A' ' 8' ' ' GLN . 3.8 mp -102.04 117.04 46.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.094 0.473 . . . . 0.0 110.608 -179.773 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.484 ' C ' HD12 ' A' ' 6' ' ' ILE . 60.5 m -146.37 -88.15 0.1 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.733 179.427 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.484 HD12 ' C ' ' A' ' 5' ' ' SER . 1.6 mp -110.23 -34.57 2.5 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-O 120.768 0.318 . . . . 0.0 110.548 -179.755 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 58.6 m95 -62.56 -49.02 76.95 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 -179.456 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.468 ' CB ' HG23 ' A' ' 4' ' ' ILE . 3.0 mp0 -64.53 -38.94 92.74 Favored 'General case' 0 C--N 1.312 -1.045 0 C-N-CA 120.186 -0.606 . . . . 0.0 109.577 179.625 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.504 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 3.3 mm? -63.82 -39.25 93.8 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.953 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.569 ' O ' HG23 ' A' ' 14' ' ' VAL . 9.5 mt -63.4 -52.4 61.78 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.894 -178.415 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.469 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.5 mp -64.86 -44.58 96.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 178.495 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 71.9 mt -63.56 -45.73 96.9 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.101 0 C-N-CA 120.107 -0.637 . . . . 0.0 111.177 -179.6 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.799 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.73 -37.37 87.38 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.968 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.582 ' O ' ' HG ' ' A' ' 18' ' ' LEU . 51.6 t -67.54 -43.84 86.89 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 C-N-CA 119.823 -0.751 . . . . 0.0 110.872 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.3 mt -65.4 -42.79 94.34 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.658 0 CA-C-O 121.1 0.476 . . . . 0.0 110.225 -179.009 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.476 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -64.5 -38.43 82.59 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.345 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.917 -178.459 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.804 ' CG1' HG22 ' A' ' 22' ' ' THR . 75.1 t -63.88 -43.07 97.7 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.367 0 C-N-CA 118.544 -1.262 . . . . 0.0 111.002 -177.775 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.582 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 14.4 mt -60.8 -47.08 87.98 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 120.078 -0.649 . . . . 0.0 112.473 -178.789 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.857 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.95 -37.96 79.17 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -179.515 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.857 ' N ' HD12 ' A' ' 19' ' ' LEU . 0.8 OUTLIER -67.45 -35.99 80.28 Favored 'General case' 0 CA--C 1.519 -0.217 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -177.946 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.598 ' C ' ' H ' ' A' ' 23' ' ' LYS . . . 102.69 10.8 36.94 Favored Glycine 0 CA--C 1.501 -0.837 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 178.298 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.804 HG22 ' CG1' ' A' ' 17' ' ' VAL . 44.8 p 56.52 -1.94 0.04 OUTLIER 'General case' 0 CA--C 1.497 -1.081 0 CA-C-O 121.073 0.463 . . . . 0.0 112.138 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.598 ' H ' ' C ' ' A' ' 21' ' ' GLY . 12.6 tmtt? -84.41 -36.22 22.55 Favored 'General case' 0 N--CA 1.434 -1.252 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.006 -179.117 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.4 tppt? -63.75 -48.57 76.47 Favored 'General case' 0 N--CA 1.436 -1.126 0 CA-C-O 121.089 0.471 . . . . 0.0 110.37 179.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 1.063 ' H ' HD12 ' A' ' 25' ' ' LEU . 2.1 mp -60.27 -38.63 84.13 Favored 'General case' 0 CA--C 1.486 -1.493 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.044 -178.345 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.19 -25.62 72.78 Favored Glycine 0 N--CA 1.424 -2.124 0 CA-C-N 114.708 -1.133 . . . . 0.0 110.443 -177.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 8.1 t -81.81 -42.62 19.44 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 120.775 0.321 . . . . 0.0 111.311 179.389 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 11.3 pt -91.77 -34.53 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 CA-C-O 121.189 0.518 . . . . 0.0 109.706 -179.435 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 25' ' ' LEU . . . -62.1 -22.95 63.38 Favored Glycine 0 CA--C 1.518 0.253 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 14.0 t -64.8 -43.0 94.59 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.452 -0.499 . . . . 0.0 111.769 -179.325 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -84.42 -37.08 21.89 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -72.3 -44.34 62.88 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.173 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.4 ' N ' ' O ' ' A' ' 29' ' ' GLY . . . -61.97 -43.8 98.69 Favored Glycine 0 C--N 1.31 -0.899 0 C-N-CA 119.527 -1.32 . . . . 0.0 110.018 -179.366 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.5 -39.93 73.86 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.891 -0.324 . . . . 0.0 111.205 179.533 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 44.8 t -64.3 -41.93 96.62 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.542 -0.463 . . . . 0.0 111.288 -178.763 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.422 HG23 ' HZ2' ' A' ' 40' ' ' LYS . 1.2 mp -68.73 -38.92 79.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.205 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 3.3 pttp -59.49 -40.86 88.38 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 -178.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.07 -36.63 90.89 Favored Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 178.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -71.63 -49.71 37.46 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 121.04 0.448 . . . . 0.0 109.962 -179.472 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.545 ' O ' ' N ' ' A' ' 44' ' ' SER . 53.4 mttp -63.12 -38.57 91.71 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.471 178.528 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 12.5 ttmm -61.33 -36.99 81.69 Favored 'General case' 0 C--N 1.319 -0.748 0 C-N-CA 119.935 -0.706 . . . . 0.0 110.187 -179.613 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -67.03 -36.08 81.32 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.274 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.428 ' O ' ' OD1' ' A' ' 46' ' ' ASP . 75.2 mtm -93.62 -10.29 35.13 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.746 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.545 ' N ' ' O ' ' A' ' 40' ' ' LYS . 11.6 t -56.06 -41.04 74.45 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.944 0.402 . . . . 0.0 110.093 -179.199 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.412 ' O ' ' OD1' ' A' ' 45' ' ' ASP . 53.2 p-10 -75.08 78.61 2.24 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.36 179.706 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 43' ' ' MET . 99.0 m-20 -101.57 38.38 1.62 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.557 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -149.37 61.0 4.97 Favored Pre-proline 0 N--CA 1.464 0.235 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.559 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo . . . . . 0 C--N 1.306 -1.705 0 C-N-CA 122.845 2.363 . . . . 0.0 111.836 179.808 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.452 ' C ' HD11 ' A' ' 4' ' ' ILE . 1.2 ppp? . . . . . 0 N--CA 1.493 1.688 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -115.19 -16.59 7.13 Favored Glycine 0 N--CA 1.468 0.778 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -111.18 -44.68 0.91 Allowed Glycine 0 N--CA 1.463 0.483 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.719 ' N ' HD12 ' A' ' 4' ' ' ILE . 2.4 mp 55.13 96.9 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 CA-C-O 120.899 0.381 . . . . 0.0 111.133 179.056 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 34.9 m -92.33 -169.59 2.27 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.392 0.615 . . . . 0.0 109.574 178.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.2 mm -61.23 -46.74 96.02 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.636 -178.641 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.621 ' CE2' HD11 ' A' ' 11' ' ' ILE . 11.7 t-105 -62.82 -38.07 89.28 Favored 'General case' 0 N--CA 1.438 -1.059 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.725 178.82 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 28.6 mm-40 -64.84 -40.29 94.93 Favored 'General case' 0 CA--C 1.509 -0.61 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 178.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 72.0 mt -61.4 -37.64 84.17 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.006 178.212 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.719 ' O ' HG23 ' A' ' 14' ' ' VAL . 5.4 mt -62.12 -42.88 99.67 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.2 -176.44 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.621 HD11 ' CE2' ' A' ' 7' ' ' TRP . 6.4 mt -67.89 -45.67 83.57 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 C-N-CA 120.25 -0.58 . . . . 0.0 110.011 177.48 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.1 mp -65.49 -44.7 94.09 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.997 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.814 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.46 -36.69 85.0 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.605 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 10' ' ' LEU . 48.8 t -66.75 -45.73 87.3 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.039 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.305 -179.167 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 16.2 pt -65.97 -42.49 91.9 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-N 118.023 0.374 . . . . 0.0 110.929 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.492 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -63.47 -38.37 82.04 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.134 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.601 -178.96 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.814 HG23 ' O ' ' A' ' 13' ' ' ALA . 90.7 t -65.69 -44.34 93.42 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.803 0 C-N-CA 118.382 -1.327 . . . . 0.0 111.713 -178.648 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.595 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 23.5 mt -61.62 -46.46 89.7 Favored 'General case' 0 C--N 1.322 -0.623 0 C-N-CA 119.907 -0.717 . . . . 0.0 111.909 -179.037 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.869 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.7 pp -68.09 -38.41 82.32 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 -179.607 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.869 ' N ' HD12 ' A' ' 19' ' ' LEU . 2.0 m-85 -67.64 -37.7 82.8 Favored 'General case' 0 CA--C 1.517 -0.324 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -177.77 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.408 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 102.81 6.07 46.82 Favored Glycine 0 CA--C 1.499 -0.953 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 178.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.751 ' HA ' HD13 ' A' ' 25' ' ' LEU . 18.5 p 57.88 19.2 5.56 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 114.964 -0.618 . . . . 0.0 112.281 178.279 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -93.16 -19.93 20.98 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.535 -179.355 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.602 ' O ' ' N ' ' A' ' 27' ' ' SER . 1.0 OUTLIER -89.81 -60.39 1.95 Allowed 'General case' 0 C--O 1.211 -0.958 0 CA-C-O 121.178 0.513 . . . . 0.0 110.706 -179.775 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 1.047 ' H ' HD12 ' A' ' 25' ' ' LEU . 2.6 mp -42.26 -39.43 2.09 Favored 'General case' 0 CA--C 1.491 -1.304 0 CA-C-O 122.495 1.141 . . . . 0.0 110.149 -179.532 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -74.78 -25.83 68.67 Favored Glycine 0 N--CA 1.426 -1.988 0 CA-C-N 113.246 -1.797 . . . . 0.0 111.02 -178.18 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.602 ' N ' ' O ' ' A' ' 24' ' ' LYS . 8.3 m -99.09 -34.18 10.5 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 112.438 0.532 . . . . 0.0 112.438 -179.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.467 ' N ' ' O ' ' A' ' 24' ' ' LYS . 13.0 pt -94.26 -36.05 6.78 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 CA-C-O 121.483 0.658 . . . . 0.0 109.533 -179.107 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.44 -27.52 71.85 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.679 -0.968 . . . . 0.0 110.679 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.0 p -64.83 -41.27 95.88 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.68 -0.408 . . . . 0.0 111.848 -179.121 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -78.61 -40.97 32.93 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 179.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.3 mp -68.65 -45.92 70.52 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.551 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.51 -44.0 97.29 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -69.76 -40.23 76.24 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.366 -0.417 . . . . 0.0 111.364 179.196 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 43.3 m -63.63 -40.79 97.77 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.531 -0.467 . . . . 0.0 111.216 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.67 -40.93 79.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.073 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 16.2 pttt -60.24 -43.48 96.05 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.66 -36.91 92.0 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.614 -0.994 . . . . 0.0 110.614 178.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.593 ' CZ ' ' SD ' ' A' ' 43' ' ' MET . 39.9 t80 -71.67 -50.69 28.19 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-O 120.946 0.403 . . . . 0.0 110.516 -179.604 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.564 ' O ' ' N ' ' A' ' 44' ' ' SER . 66.4 mmtt -63.97 -38.99 93.09 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 120.252 -0.579 . . . . 0.0 110.325 179.181 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 49.3 mtpt -61.97 -37.16 83.71 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.239 -179.663 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.54 -35.89 81.35 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.523 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.593 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 6.0 mtp -100.7 -69.82 0.76 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.711 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.564 ' N ' ' O ' ' A' ' 40' ' ' LYS . 0.9 OUTLIER 28.35 -88.03 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.635 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.16 179.853 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.504 ' N ' ' O ' ' A' ' 43' ' ' MET . 90.2 m-20 -134.07 -175.78 3.96 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.559 178.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 47' ' ' GLU . 42.0 t0 60.54 39.18 18.39 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.602 -0.272 . . . . 0.0 110.64 -179.791 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.425 ' C ' ' O ' ' A' ' 46' ' ' ASP . 51.7 mt-10 -32.5 96.43 0.09 OUTLIER Pre-proline 0 N--CA 1.47 0.535 0 O-C-N 123.485 0.491 . . . . 0.0 111.002 179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo . . . . . 0 N--CA 1.496 1.657 0 C-N-CA 122.158 1.906 . . . . 0.0 112.318 -178.948 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.482 ' HG3' ' H ' ' A' ' 3' ' ' GLY . 4.5 tpt . . . . . 0 N--CA 1.488 1.426 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 116.46 3.93 18.27 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.482 ' H ' ' HG3' ' A' ' 1' ' ' MET . . . 94.08 9.78 59.15 Favored Glycine 0 N--CA 1.464 0.535 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.525 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.481 HG22 ' N ' ' A' ' 5' ' ' SER . 30.4 mt -59.07 -113.45 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.523 -0.339 . . . . 0.0 110.545 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.481 ' N ' HG22 ' A' ' 4' ' ' ILE . 38.4 m -157.98 -164.48 1.53 Allowed 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -178.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.1 mm -96.92 -45.5 12.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.872 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.725 ' CE2' HD11 ' A' ' 11' ' ' ILE . 9.5 t-105 -62.67 -36.61 83.44 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.617 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 21.3 mm-40 -64.47 -38.88 92.57 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 86.6 mt -63.03 -37.66 88.07 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.747 178.374 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.612 ' O ' HG23 ' A' ' 14' ' ' VAL . 5.2 mt -62.58 -42.89 99.84 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.13 -177.055 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.725 HD11 ' CE2' ' A' ' 7' ' ' TRP . 7.8 mt -66.95 -45.54 87.02 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.95 0 C-N-CA 119.698 -0.801 . . . . 0.0 109.51 177.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 67.1 mt -65.66 -47.56 85.71 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.806 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.327 -179.719 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.837 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.55 -37.34 87.21 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.4 -179.764 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.612 HG23 ' O ' ' A' ' 10' ' ' LEU . 40.6 t -67.67 -44.25 86.17 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 C-N-CA 119.748 -0.781 . . . . 0.0 110.973 179.721 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 91.8 mt -65.27 -42.28 93.54 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.834 0 CA-C-O 120.993 0.425 . . . . 0.0 110.395 -179.087 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.502 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -64.25 -38.4 82.41 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.113 0 CA-C-N 115.322 -0.854 . . . . 0.0 110.11 -178.836 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.837 HG23 ' O ' ' A' ' 13' ' ' ALA . 87.1 t -64.56 -42.6 95.64 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.257 0 C-N-CA 118.389 -1.325 . . . . 0.0 111.131 -177.351 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.565 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 20.8 mt -62.08 -47.18 85.83 Favored 'General case' 0 C--N 1.316 -0.887 0 C-N-CA 119.819 -0.752 . . . . 0.0 112.566 -178.573 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.849 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -68.01 -38.41 82.56 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.897 -179.579 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.849 ' N ' HD12 ' A' ' 19' ' ' LEU . 0.7 OUTLIER -68.07 -32.14 72.27 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -178.3 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 93.9 5.79 62.44 Favored Glycine 0 CA--C 1.504 -0.61 0 C-N-CA 120.209 -0.996 . . . . 0.0 111.044 178.523 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.776 HG22 ' CG1' ' A' ' 17' ' ' VAL . 14.4 p 58.39 26.93 14.71 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.161 -0.519 . . . . 0.0 112.202 178.558 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 50.2 pttt -96.97 -33.09 11.7 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.878 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 16.6 mmmt -77.45 -52.78 8.53 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.72 -0.392 . . . . 0.0 111.498 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 1.071 ' H ' HD12 ' A' ' 25' ' ' LEU . 1.9 mp -48.75 -39.08 23.61 Favored 'General case' 0 CA--C 1.489 -1.374 0 CA-C-O 122.336 1.065 . . . . 0.0 110.476 -179.32 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.91 -25.79 70.72 Favored Glycine 0 N--CA 1.426 -2.003 0 CA-C-N 114.092 -1.413 . . . . 0.0 111.111 -177.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 7.2 t -94.0 -39.65 10.53 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 111.915 0.339 . . . . 0.0 111.915 -179.718 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 7.5 pt -89.8 -37.47 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 CA-C-O 121.387 0.613 . . . . 0.0 109.675 -179.133 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.32 -27.05 68.64 Favored Glycine 0 C--O 1.228 -0.224 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 -179.111 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 78.1 p -64.91 -42.01 95.1 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 120.544 -0.462 . . . . 0.0 111.219 -179.444 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 66.7 t0 -76.63 -41.04 47.38 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.289 0.566 . . . . 0.0 109.846 179.728 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.5 mp -68.68 -45.82 70.68 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.024 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.56 -43.82 98.45 Favored Glycine 0 C--N 1.308 -1.018 0 C-N-CA 119.463 -1.351 . . . . 0.0 110.031 -179.55 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.07 -40.25 75.14 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.82 0.343 . . . . 0.0 111.148 179.646 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.6 t -63.94 -42.01 97.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.132 0.491 . . . . 0.0 111.248 -178.742 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.48 -39.42 78.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.615 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 17.9 pttt -59.32 -40.35 86.0 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 -178.108 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -69.81 -37.09 75.37 Favored Glycine 0 N--CA 1.442 -0.903 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -71.61 -49.16 42.8 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-O 121.114 0.483 . . . . 0.0 109.762 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.53 ' O ' ' N ' ' A' ' 44' ' ' SER . 47.5 mtpt -63.01 -38.6 91.83 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.558 178.566 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 14.2 tmtt? -61.75 -36.68 81.71 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 119.773 -0.771 . . . . 0.0 109.853 -178.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.89 -36.44 82.29 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.052 179.713 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . . . . . . . . . 75.9 mtm -92.42 -10.92 36.25 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.488 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.53 ' N ' ' O ' ' A' ' 40' ' ' LYS . 41.4 t -61.89 148.89 42.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.275 -179.666 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 56.25 44.9 24.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.539 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 51.4 p30 -74.4 46.2 0.26 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.7 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 68.9 mt-10 52.02 71.47 1.48 Allowed Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.621 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo . . . . . 0 C--N 1.306 -1.659 0 C-N-CA 122.756 2.304 . . . . 0.0 112.054 -179.994 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.647 ' HA ' HD11 ' A' ' 4' ' ' ILE . 91.5 mtp . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -111.2 24.47 16.04 Favored Glycine 0 N--CA 1.467 0.75 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.49 ' C ' HD13 ' A' ' 4' ' ' ILE . . . -130.93 19.97 4.87 Favored Glycine 0 CA--C 1.519 0.326 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 179.517 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.685 ' N ' HD13 ' A' ' 4' ' ' ILE . 0.0 OUTLIER -103.23 -82.23 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.851 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.775 ' N ' HE21 ' A' ' 8' ' ' GLN . 41.2 m 67.44 -80.0 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 114.931 -1.031 . . . . 0.0 112.341 179.381 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.609 ' N ' HD12 ' A' ' 6' ' ' ILE . 1.6 mp -92.94 -30.85 4.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.786 -178.622 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 91.8 m95 -62.27 -41.01 98.1 Favored 'General case' 0 CA--C 1.507 -0.685 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.748 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.775 HE21 ' N ' ' A' ' 5' ' ' SER . 5.6 pt20 -64.28 -39.48 94.01 Favored 'General case' 0 C--O 1.215 -0.725 0 C-N-CA 118.572 -1.251 . . . . 0.0 108.152 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.425 ' O ' ' CB ' ' A' ' 13' ' ' ALA . 76.6 mt -68.59 -38.49 80.71 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.166 179.376 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.648 ' O ' HG23 ' A' ' 14' ' ' VAL . 18.7 mt -63.28 -49.27 74.72 Favored 'General case' 0 C--N 1.314 -0.935 0 C-N-CA 120.076 -0.65 . . . . 0.0 111.371 -176.022 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.462 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.7 mp -67.19 -44.33 87.81 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 178.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.424 HD13 ' O ' ' A' ' 8' ' ' GLN . 1.0 OUTLIER -65.07 -44.56 95.74 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.878 -179.387 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.846 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.77 -36.53 84.6 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.825 -179.762 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.648 HG23 ' O ' ' A' ' 10' ' ' LEU . 54.8 t -67.03 -45.03 87.87 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.826 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.442 -178.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 15.9 pt -66.23 -42.56 91.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 CA-C-O 121.05 0.452 . . . . 0.0 110.827 179.645 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.502 ' HA ' HD21 ' A' ' 19' ' ' LEU . 0.3 OUTLIER -63.54 -38.12 81.38 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.905 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 -179.324 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.846 HG23 ' O ' ' A' ' 13' ' ' ALA . 94.4 t -65.52 -43.72 94.25 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 C-N-CA 118.557 -1.257 . . . . 0.0 111.654 -178.303 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.518 ' HG ' ' O ' ' A' ' 14' ' ' VAL . 21.3 mt -61.82 -47.09 86.66 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 119.566 -0.854 . . . . 0.0 111.57 -178.853 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.851 HD12 ' N ' ' A' ' 20' ' ' PHE . 4.6 pp -67.06 -38.21 85.41 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -179.221 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.851 ' N ' HD12 ' A' ' 19' ' ' LEU . 1.2 m-85 -67.55 -35.83 79.81 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 -177.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.425 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 98.79 8.04 54.76 Favored Glycine 0 CA--C 1.501 -0.821 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 178.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.736 HG22 ' CG1' ' A' ' 17' ' ' VAL . 19.0 p 57.7 27.1 13.85 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 114.309 -0.945 . . . . 0.0 112.52 178.239 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 55.3 mtpt -100.0 -19.82 16.38 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.686 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.503 ' O ' ' N ' ' A' ' 27' ' ' SER . 14.5 mmmt -88.66 -56.91 3.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.125 0.488 . . . . 0.0 110.622 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 1.064 ' H ' HD12 ' A' ' 25' ' ' LEU . 2.3 mp -45.58 -39.83 8.07 Favored 'General case' 0 CA--C 1.495 -1.173 0 CA-C-O 122.473 1.13 . . . . 0.0 110.291 179.804 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.82 -24.84 73.3 Favored Glycine 0 N--CA 1.424 -2.105 0 CA-C-N 113.568 -1.651 . . . . 0.0 110.472 -177.397 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.503 ' N ' ' O ' ' A' ' 24' ' ' LYS . 7.1 t -97.32 -35.98 10.54 Favored 'General case' 0 CA--C 1.519 -0.235 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 -179.639 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 8.7 pt -92.22 -37.21 8.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 CA-C-O 121.358 0.599 . . . . 0.0 109.412 -179.347 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.4 -27.39 65.59 Favored Glycine 0 CA--C 1.522 0.484 0 N-CA-C 110.734 -0.947 . . . . 0.0 110.734 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.3 t -64.76 -41.13 96.12 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.931 -0.308 . . . . 0.0 111.652 -179.388 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 53.3 m-20 -74.15 -43.65 56.6 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.53 0.681 . . . . 0.0 109.208 179.475 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.6 mp -65.82 -44.28 86.08 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.789 -1.096 . . . . 0.0 111.553 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.52 -45.18 96.39 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 119.411 -1.376 . . . . 0.0 109.823 -179.204 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.6 -39.81 73.6 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.651 -0.274 . . . . 0.0 111.309 179.164 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 39.4 t -63.19 -41.69 99.23 Favored 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 120.528 -0.469 . . . . 0.0 110.406 -178.247 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.02 -39.27 79.47 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.715 179.027 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 24.3 tttt -59.87 -43.72 94.57 Favored 'General case' 0 C--N 1.309 -1.17 0 C-N-CA 119.287 -0.965 . . . . 0.0 108.463 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.97 -36.6 91.23 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 178.18 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -71.59 -50.77 27.81 Favored 'General case' 0 CA--C 1.52 -0.182 0 CA-C-O 120.805 0.336 . . . . 0.0 110.291 -179.621 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.521 ' O ' ' N ' ' A' ' 44' ' ' SER . 53.2 mtpt -63.43 -38.52 91.46 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.37 178.646 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -61.74 -39.11 90.41 Favored 'General case' 0 C--N 1.32 -0.705 0 C-N-CA 120.138 -0.625 . . . . 0.0 110.102 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -67.02 -35.98 81.1 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.551 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.433 ' O ' ' O ' ' A' ' 44' ' ' SER . 76.2 mtm -90.34 -65.92 0.97 Allowed 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 121.049 0.452 . . . . 0.0 110.548 179.797 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.521 ' N ' ' O ' ' A' ' 40' ' ' LYS . 60.7 p 41.98 -167.53 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.706 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -94.69 108.47 20.46 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.818 0.342 . . . . 0.0 110.242 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -97.86 22.79 8.74 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 121.059 0.457 . . . . 0.0 110.547 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 57.5 mt-10 47.37 73.16 1.05 Allowed Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.43 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 74.6 Cg_endo . . . . . 0 C--N 1.307 -1.63 0 C-N-CA 122.856 2.371 . . . . 0.0 111.946 -179.903 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.496 ' O ' ' CD1' ' A' ' 12' ' ' ILE . 98.0 mmm . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -120.85 -9.44 7.52 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.034 -0.827 . . . . 0.0 111.034 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.34 -2.07 66.11 Favored Glycine 0 N--CA 1.463 0.441 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 26.0 mt -62.66 -47.68 91.78 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 115.335 -0.432 . . . . 0.0 110.296 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.8 m -175.41 -164.97 0.15 Allowed 'General case' 0 N--CA 1.442 -0.872 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.521 ' CG2' ' N ' ' A' ' 7' ' ' TRP . 1.5 tp -88.72 -49.07 14.47 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 114.988 -1.005 . . . . 0.0 111.012 179.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.528 ' CD1' ' C ' ' A' ' 7' ' ' TRP . 2.0 t-105 -62.15 -38.42 88.93 Favored 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -179.262 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 13.7 mm-40 -64.31 -38.75 92.16 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 179.639 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.826 ' O ' HD12 ' A' ' 9' ' ' LEU . 0.2 OUTLIER -70.33 -38.03 74.82 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.423 178.933 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.558 ' O ' HG23 ' A' ' 14' ' ' VAL . 1.2 tt -62.71 -47.03 85.4 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.971 -175.607 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.45 HD11 ' CE2' ' A' ' 7' ' ' TRP . 2.0 mp -65.01 -43.94 96.04 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 177.51 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.496 ' CD1' ' O ' ' A' ' 1' ' ' MET . 72.9 mt -63.37 -44.51 99.03 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.065 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.547 -178.671 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.873 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.23 -37.25 86.82 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.923 -179.241 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.558 HG23 ' O ' ' A' ' 10' ' ' LEU . 78.6 t -67.02 -44.05 88.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 C-N-CA 120.545 -0.462 . . . . 0.0 111.139 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.453 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 58.7 mt -66.62 -43.19 90.57 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.285 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 178.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.471 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.5 t -64.01 -42.27 95.16 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.681 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.881 -179.046 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.873 HG23 ' O ' ' A' ' 13' ' ' ALA . 60.1 t -65.93 -44.92 92.29 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.118 0 C-N-CA 118.281 -1.368 . . . . 0.0 112.774 -177.376 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.518 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.4 pp -72.65 -42.87 63.89 Favored 'General case' 0 C--N 1.293 -1.857 0 C-N-CA 120.054 -0.659 . . . . 0.0 109.842 178.761 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.733 ' C ' HD13 ' A' ' 19' ' ' LEU . 2.6 tm? -64.37 -41.29 96.79 Favored 'General case' 0 N--CA 1.443 -0.806 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.617 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.471 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 5.6 m-85 -69.0 -39.47 79.31 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 118.741 -1.183 . . . . 0.0 108.749 179.17 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.478 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 105.15 11.9 28.63 Favored Glycine 0 N--CA 1.467 0.75 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 179.025 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.73 HG22 ' CG1' ' A' ' 17' ' ' VAL . 50.4 p 57.31 44.42 21.89 Favored 'General case' 0 CA--C 1.499 -0.983 0 CA-C-N 115.371 -0.414 . . . . 0.0 112.062 178.304 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -127.19 -18.38 4.56 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.593 -0.73 . . . . 0.0 111.551 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 9.6 tppt? -86.44 -48.38 8.47 Favored 'General case' 0 N--CA 1.447 -0.625 0 CA-C-O 121.008 0.432 . . . . 0.0 110.08 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.711 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.1 OUTLIER -62.43 -36.76 83.42 Favored 'General case' 0 CA--C 1.505 -0.768 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.682 -178.839 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.42 -24.64 75.96 Favored Glycine 0 N--CA 1.437 -1.24 0 N-CA-C 109.914 -1.275 . . . . 0.0 109.914 -176.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 7.6 t -84.75 -42.74 14.92 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 121.104 -0.238 . . . . 0.0 111.592 179.66 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.416 HD13 HG21 ' A' ' 28' ' ' ILE . 8.6 pt -94.08 -35.94 6.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 121.228 0.537 . . . . 0.0 110.034 -179.417 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.526 ' N ' ' O ' ' A' ' 25' ' ' LEU . . . -62.06 -22.68 62.99 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 -179.502 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.9 t -64.79 -42.54 94.99 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.703 -0.399 . . . . 0.0 111.548 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 94.3 m-20 -76.32 -41.18 49.32 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.338 0.59 . . . . 0.0 109.614 179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 8.0 mp -68.33 -44.43 75.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.556 179.75 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.0 -44.08 97.92 Favored Glycine 0 N--CA 1.443 -0.853 0 C-N-CA 119.363 -1.399 . . . . 0.0 109.99 -179.001 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -70.73 -39.87 73.11 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.719 0.295 . . . . 0.0 111.413 179.27 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 11.0 t -63.22 -41.9 99.19 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.646 -0.422 . . . . 0.0 110.69 -178.439 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -68.78 -39.17 79.78 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.009 178.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 23.9 tttt -59.69 -44.65 93.57 Favored 'General case' 0 N--CA 1.435 -1.223 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 -178.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.39 -36.61 92.88 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 178.06 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.62 ' CE2' ' SD ' ' A' ' 43' ' ' MET . 38.3 t80 -71.8 -51.78 20.85 Favored 'General case' 0 CA--C 1.512 -0.495 0 CA-C-O 120.991 0.424 . . . . 0.0 110.406 -179.373 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.511 ' O ' ' N ' ' A' ' 44' ' ' SER . 48.8 mtpt -62.62 -39.1 92.75 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.717 179.454 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 42.8 mtmt -61.58 -39.1 89.97 Favored 'General case' 0 C--N 1.319 -0.75 0 C-N-CA 119.043 -1.063 . . . . 0.0 109.911 -179.73 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.84 -36.33 82.09 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.322 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.62 ' SD ' ' CE2' ' A' ' 39' ' ' PHE . 0.0 OUTLIER -89.07 -12.27 41.7 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.527 179.239 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.511 ' N ' ' O ' ' A' ' 40' ' ' LYS . 46.8 t -61.35 -43.79 98.27 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.051 0.453 . . . . 0.0 110.246 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -89.06 113.55 24.68 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.514 179.715 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 41.1 p-10 -95.25 14.44 22.25 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.064 0.459 . . . . 0.0 110.801 -179.71 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 -168.92 75.33 0.76 Allowed Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.663 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_exo . . . . . 0 C--N 1.307 -1.643 0 C-N-CA 122.783 2.322 . . . . 0.0 111.999 179.962 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.499 ' SD ' ' N ' ' A' ' 1' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.451 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -143.19 87.12 0.18 Allowed Glycine 0 C--N 1.33 0.233 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.894 -179.588 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 87.92 26.95 27.65 Favored Glycine 0 CA--C 1.519 0.295 0 N-CA-C 110.499 -1.041 . . . . 0.0 110.499 179.365 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 12.7 mm -63.33 -48.13 88.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.328 -0.436 . . . . 0.0 110.727 -179.236 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.5 m 177.49 177.64 0.34 Allowed 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 122.07 0.938 . . . . 0.0 109.789 178.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.524 ' HA ' HD23 ' A' ' 9' ' ' LEU . 16.9 mm -69.84 -47.87 67.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 CA-C-N 113.346 -1.752 . . . . 0.0 110.88 179.364 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.588 ' CE2' HD11 ' A' ' 11' ' ' ILE . 22.4 t-105 -65.42 -39.39 92.07 Favored 'General case' 0 N--CA 1.432 -1.345 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.248 -179.519 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 22.0 mm-40 -65.84 -41.45 91.74 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.061 0.458 . . . . 0.0 110.8 179.58 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.683 ' C ' HD12 ' A' ' 9' ' ' LEU . 0.4 OUTLIER -63.41 -36.74 84.72 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.724 179.453 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.628 ' O ' HG23 ' A' ' 14' ' ' VAL . 6.3 mt -62.03 -42.39 99.11 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.013 -177.13 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.588 HD11 ' CE2' ' A' ' 7' ' ' TRP . 7.8 mt -65.2 -44.18 95.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 177.538 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 69.7 mt -63.96 -44.37 97.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.313 -179.019 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.868 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -65.12 -37.53 87.76 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.133 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.628 HG23 ' O ' ' A' ' 10' ' ' LEU . 64.8 t -67.1 -44.54 87.98 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.372 0 C-N-CA 120.829 -0.348 . . . . 0.0 111.35 -178.732 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 16.1 pt -67.12 -42.86 88.77 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.11 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 178.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.473 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.7 t -63.71 -41.63 93.24 Favored 'Isoleucine or valine' 0 CA--C 1.476 -1.882 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.981 -179.213 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.868 HG23 ' O ' ' A' ' 13' ' ' ALA . 61.5 t -66.49 -50.11 69.67 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.984 0 C-N-CA 117.149 -1.821 . . . . 0.0 113.11 -177.19 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.497 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.0 OUTLIER -66.34 -44.52 83.08 Favored 'General case' 0 C--N 1.302 -1.492 0 C-N-CA 119.209 -0.996 . . . . 0.0 112.01 179.722 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.651 ' C ' HD12 ' A' ' 19' ' ' LEU . 0.4 OUTLIER -65.59 -38.24 88.93 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.442 179.962 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.473 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 3.0 m-85 -68.01 -43.91 77.75 Favored 'General case' 0 CA--C 1.515 -0.381 0 C-N-CA 119.221 -0.992 . . . . 0.0 108.501 -179.487 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.504 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 111.71 11.12 17.68 Favored Glycine 0 C--N 1.316 -0.559 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 178.715 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.739 HG22 ' CG1' ' A' ' 17' ' ' VAL . 59.5 p 56.42 35.09 25.36 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 114.863 -0.668 . . . . 0.0 112.784 178.18 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 56.3 mtpt -116.26 -20.32 9.83 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.811 -0.632 . . . . 0.0 111.792 -179.576 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 tppt? -83.47 -52.08 6.81 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-O 121.175 0.512 . . . . 0.0 110.466 -179.741 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.748 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.2 OUTLIER -59.35 -36.73 76.26 Favored 'General case' 0 CA--C 1.501 -0.933 0 CA-C-O 121.907 0.86 . . . . 0.0 111.285 -178.882 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.51 -24.51 76.11 Favored Glycine 0 N--CA 1.433 -1.525 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -177.257 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 7.3 t -86.33 -42.59 13.58 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 179.446 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 13.2 pt -93.66 -36.59 7.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 C-N-CA 120.353 -0.539 . . . . 0.0 109.899 -179.456 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 25' ' ' LEU . . . -61.36 -23.99 63.07 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 -179.672 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 38.8 t -64.57 -42.47 95.62 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.745 0.307 . . . . 0.0 111.237 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -69.94 -44.01 70.42 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.519 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.406 ' N ' HD12 ' A' ' 32' ' ' LEU . 8.1 mp -65.12 -44.4 88.85 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.149 -0.932 . . . . 0.0 111.413 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.31 -44.39 97.01 Favored Glycine 0 N--CA 1.438 -1.214 0 C-N-CA 119.292 -1.432 . . . . 0.0 109.986 -179.077 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.21 -40.06 71.36 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.529 -0.336 . . . . 0.0 111.414 179.076 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.8 t -63.65 -41.29 98.25 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 120.666 -0.413 . . . . 0.0 111.141 -178.389 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.12 -40.34 80.5 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.798 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.5 pttt -60.28 -43.19 96.44 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 -179.679 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.97 -36.68 92.37 Favored Glycine 0 CA--C 1.519 0.342 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.488 ' CZ ' ' CE ' ' A' ' 43' ' ' MET . 66.6 t80 -71.51 -52.23 19.42 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.625 ' O ' ' N ' ' A' ' 44' ' ' SER . 66.0 mmtt -62.91 -38.15 89.81 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.154 178.73 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -60.94 -35.64 77.26 Favored 'General case' 0 C--N 1.312 -1.029 0 C-N-CA 119.631 -0.827 . . . . 0.0 109.909 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.06 -35.73 81.32 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.141 -179.311 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.488 ' CE ' ' CZ ' ' A' ' 39' ' ' PHE . 6.3 ptp -121.6 -55.29 1.93 Allowed 'General case' 0 N--CA 1.475 0.793 0 CA-C-O 121.364 0.602 . . . . 0.0 111.293 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.625 ' N ' ' O ' ' A' ' 40' ' ' LYS . 4.8 t 62.24 134.88 0.01 OUTLIER 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.717 -179.145 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -87.54 140.13 29.83 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.699 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 44.8 p-10 -90.16 12.09 18.97 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-O 121.317 0.58 . . . . 0.0 110.375 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 49.13 75.07 0.7 Allowed Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.177 -0.919 . . . . 0.0 110.295 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo . . . . . 0 C--N 1.308 -1.581 0 C-N-CA 122.809 2.339 . . . . 0.0 112.224 -179.753 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.519 ' C ' ' H ' ' A' ' 3' ' ' GLY . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.96 22.92 0.88 Allowed Glycine 0 CA--C 1.525 0.701 0 C-N-CA 120.437 -0.887 . . . . 0.0 110.992 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.519 ' H ' ' C ' ' A' ' 1' ' ' MET . . . -150.03 26.36 1.14 Allowed Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.635 -0.986 . . . . 0.0 110.635 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 5.0 mt -41.44 112.82 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.022 0.439 . . . . 0.0 110.871 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.799 ' C ' HE22 ' A' ' 8' ' ' GLN . 16.6 m -154.88 -78.45 0.1 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.882 -179.699 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.737 ' N ' HE22 ' A' ' 8' ' ' GLN . 3.5 mm -109.24 -29.5 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.402 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.763 -179.484 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 38.5 m95 -62.0 -45.33 94.06 Favored 'General case' 0 C--O 1.22 -0.489 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -178.593 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.921 HE21 ' H ' ' A' ' 9' ' ' LEU . 0.0 OUTLIER -63.8 -38.96 93.03 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 119.737 -0.785 . . . . 0.0 109.485 178.72 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.921 ' H ' HE21 ' A' ' 8' ' ' GLN . 78.8 mt -64.45 -38.21 90.24 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.264 179.727 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.642 ' O ' HG23 ' A' ' 14' ' ' VAL . 20.7 mt -63.3 -48.27 78.78 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.805 -176.596 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.501 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.8 mp -67.92 -44.58 85.03 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 C-N-CA 119.662 -0.815 . . . . 0.0 109.142 178.212 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -65.08 -47.59 87.22 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 C-N-CA 120.055 -0.658 . . . . 0.0 110.566 -179.432 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.857 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -65.85 -38.07 87.88 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 -179.545 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.642 HG23 ' O ' ' A' ' 10' ' ' LEU . 62.8 t -67.78 -44.29 85.73 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.625 0 C-N-CA 120.173 -0.611 . . . . 0.0 111.171 -178.824 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.47 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 0.9 OUTLIER -66.28 -44.05 91.35 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.385 0 O-C-N 123.353 0.408 . . . . 0.0 110.053 179.485 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.414 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.3 t -64.02 -41.99 94.24 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.721 0 CA-C-N 115.107 -0.951 . . . . 0.0 109.964 -178.578 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.857 HG23 ' O ' ' A' ' 13' ' ' ALA . 59.6 t -66.14 -45.22 90.89 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.909 0 C-N-CA 118.03 -1.468 . . . . 0.0 112.672 -177.043 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.431 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.1 pp -71.23 -42.85 68.36 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.157 177.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.677 ' C ' HD13 ' A' ' 19' ' ' LEU . 2.5 tm? -64.67 -41.49 96.04 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.908 -179.171 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.414 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 6.1 m-85 -68.97 -38.62 79.47 Favored 'General case' 0 CA--C 1.513 -0.465 0 C-N-CA 119.014 -1.074 . . . . 0.0 108.623 178.78 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.499 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 104.76 11.28 30.92 Favored Glycine 0 C--N 1.315 -0.614 0 CA-C-N 115.01 -0.995 . . . . 0.0 111.104 178.521 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.725 HG22 ' CG1' ' A' ' 17' ' ' VAL . 51.2 p 58.68 43.24 19.1 Favored 'General case' 0 CA--C 1.505 -0.763 0 CA-C-N 115.25 -0.475 . . . . 0.0 111.917 178.872 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -124.94 -20.19 5.03 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.4 -179.802 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 8.9 tppt? -84.99 -49.63 8.16 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-O 121.091 0.472 . . . . 0.0 110.496 179.826 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.767 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.1 OUTLIER -61.63 -36.83 81.88 Favored 'General case' 0 CA--C 1.505 -0.766 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.044 -178.792 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.26 -24.62 76.1 Favored Glycine 0 N--CA 1.435 -1.432 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -177.343 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.4 t -84.85 -42.49 15.03 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 111.607 0.225 . . . . 0.0 111.607 179.519 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 11.4 pt -94.91 -36.69 7.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 120.272 -0.571 . . . . 0.0 110.088 -179.443 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 25' ' ' LEU . . . -63.8 -24.42 68.22 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 -179.5 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 10.9 t -64.61 -42.71 95.36 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 120.771 0.32 . . . . 0.0 111.332 -179.698 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 94.9 m-20 -70.58 -43.63 69.04 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.341 0.591 . . . . 0.0 109.481 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.8 mp -65.47 -44.75 86.17 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.426 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.37 -45.07 95.85 Favored Glycine 0 N--CA 1.439 -1.157 0 C-N-CA 119.444 -1.36 . . . . 0.0 109.94 -179.118 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.39 -39.69 71.03 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.577 -0.312 . . . . 0.0 111.566 179.265 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 48.4 t -63.34 -41.79 98.9 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-O 121.125 0.488 . . . . 0.0 110.324 -178.322 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 1.2 mp -69.19 -39.4 79.23 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.931 179.032 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 15.7 tttp -60.09 -44.08 95.05 Favored 'General case' 0 C--N 1.309 -1.152 0 C-N-CA 119.343 -0.943 . . . . 0.0 108.614 -179.043 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.68 -36.54 91.44 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 178.389 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 64.2 t80 -71.65 -51.83 21.1 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-O 120.76 0.314 . . . . 0.0 110.462 -179.564 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.533 ' O ' ' N ' ' A' ' 44' ' ' SER . 23.7 mtpp -62.7 -38.05 88.9 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.375 179.135 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -61.02 -36.73 80.29 Favored 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 120.098 -0.641 . . . . 0.0 110.226 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.43 -36.19 82.17 Favored 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.37 -179.591 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.605 ' C ' ' H ' ' A' ' 45' ' ' ASP . 5.4 mmt -97.32 -67.25 0.86 Allowed 'General case' 0 N--CA 1.467 0.412 0 CA-C-O 120.992 0.425 . . . . 0.0 110.728 179.323 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.533 ' N ' ' O ' ' A' ' 40' ' ' LYS . 13.8 t 53.68 0.48 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.797 -179.063 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.605 ' H ' ' C ' ' A' ' 43' ' ' MET . 98.4 m-20 -64.64 -42.83 95.2 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.876 0.37 . . . . 0.0 110.706 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.4 ' OD1' ' O ' ' A' ' 46' ' ' ASP . 66.7 t0 -82.04 42.9 0.75 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.974 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -49.75 146.53 7.33 Favored Pre-proline 0 CA--C 1.536 0.404 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.428 -179.559 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 80.0 Cg_exo . . . . . 0 N--CA 1.49 1.274 0 C-N-CA 122.281 1.987 . . . . 0.0 112.098 179.85 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.427 ' SD ' ' N ' ' A' ' 1' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 . . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -80.54 36.11 2.24 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 111.656 -0.578 . . . . 0.0 111.656 -179.608 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.526 ' O ' ' NE2' ' A' ' 8' ' ' GLN . . . 138.52 -9.19 3.45 Favored Glycine 0 N--CA 1.463 0.474 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.536 HG23 ' CB ' ' A' ' 8' ' ' GLN . 4.0 mp -99.58 117.79 45.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.051 0.453 . . . . 0.0 110.628 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.425 ' O ' HD23 ' A' ' 9' ' ' LEU . 18.1 m -144.91 -85.68 0.13 Allowed 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.664 179.409 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.5 mm -112.63 -33.55 2.17 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.915 -179.169 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 55.2 m95 -62.54 -48.97 77.16 Favored 'General case' 0 C--O 1.221 -0.423 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 -179.588 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . 0.536 ' CB ' HG23 ' A' ' 4' ' ' ILE . 0.5 OUTLIER -64.13 -38.43 91.05 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.608 179.847 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.507 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 3.2 mm? -62.8 -39.08 93.16 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.874 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.544 ' O ' HG23 ' A' ' 14' ' ' VAL . 8.9 mt -63.76 -51.77 63.39 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.6 -178.335 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.485 ' H ' HD12 ' A' ' 11' ' ' ILE . 3.5 mp -65.62 -44.49 93.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 178.372 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 70.8 mt -63.72 -45.3 97.73 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.15 0 C-N-CA 120.479 -0.488 . . . . 0.0 111.337 -179.667 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.865 ' O ' HG23 ' A' ' 17' ' ' VAL . . . -64.95 -38.79 92.12 Favored 'General case' 0 C--N 1.32 -0.713 0 O-C-N 123.381 0.425 . . . . 0.0 110.975 -179.323 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.544 HG23 ' O ' ' A' ' 10' ' ' LEU . 70.7 t -67.54 -43.15 87.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 C-N-CA 120.566 -0.453 . . . . 0.0 110.562 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.452 ' O ' ' CB ' ' A' ' 19' ' ' LEU . 96.7 mt -66.25 -43.35 91.78 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.322 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.453 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.5 ' O ' ' HB2' ' A' ' 20' ' ' PHE . 1.4 t -63.72 -42.2 95.18 Favored 'Isoleucine or valine' 0 CA--C 1.481 -1.684 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.319 -178.68 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.865 HG23 ' O ' ' A' ' 13' ' ' ALA . 61.4 t -66.02 -45.11 91.62 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.883 0 C-N-CA 118.253 -1.379 . . . . 0.0 112.672 -176.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.527 HD12 ' N ' ' A' ' 19' ' ' LEU . 1.3 pp -72.39 -43.16 64.32 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 119.702 -0.799 . . . . 0.0 109.949 178.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.698 ' C ' HD13 ' A' ' 19' ' ' LEU . 2.6 tm? -64.4 -41.44 96.64 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.923 -1.035 . . . . 0.0 110.313 -179.63 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.5 ' HB2' ' O ' ' A' ' 16' ' ' VAL . 5.0 m-85 -69.02 -35.98 77.25 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 118.879 -1.129 . . . . 0.0 108.957 179.019 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.482 ' O ' ' OG1' ' A' ' 22' ' ' THR . . . 97.44 11.96 49.76 Favored Glycine 0 N--CA 1.465 0.593 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.703 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.701 HG22 ' CG1' ' A' ' 17' ' ' VAL . 42.8 p 55.72 69.49 0.73 Allowed 'General case' 0 CA--C 1.506 -0.713 0 CA-C-N 114.604 -0.798 . . . . 0.0 112.445 178.364 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 49.6 mtpt -139.87 -25.53 0.81 Allowed 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.873 179.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 11.2 mmmt -85.8 -53.03 5.38 Favored 'General case' 0 C--O 1.221 -0.444 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.728 179.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.623 ' H ' HD12 ' A' ' 25' ' ' LEU . 0.1 OUTLIER -53.05 -37.33 61.49 Favored 'General case' 0 CA--C 1.505 -0.784 0 CA-C-O 121.817 0.818 . . . . 0.0 110.642 -178.992 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -73.67 -25.22 72.73 Favored Glycine 0 N--CA 1.438 -1.219 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 -178.296 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 13.8 m -93.46 -39.76 10.71 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 -179.527 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.2 pt -94.19 -34.9 5.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.193 0.521 . . . . 0.0 110.017 -179.011 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.16 -26.26 71.44 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.3 t -64.7 -43.06 94.68 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.657 -179.643 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -76.43 -41.0 49.13 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.347 0.594 . . . . 0.0 109.64 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.678 ' O ' HD13 ' A' ' 36' ' ' ILE . 7.6 mp -68.4 -46.61 69.51 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.062 -0.972 . . . . 0.0 111.575 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.93 -44.0 98.43 Favored Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -179.16 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -71.12 -40.39 71.45 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.825 179.057 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 58.4 m -64.0 -40.8 97.18 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.898 -179.342 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.678 HD13 ' O ' ' A' ' 32' ' ' LEU . 1.6 mp -68.19 -41.57 84.12 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.485 -179.433 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.4 ' HG2' ' N ' ' A' ' 38' ' ' GLY . 16.6 pttt -60.08 -43.35 95.56 Favored 'General case' 0 C--N 1.308 -1.203 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 -179.144 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.4 ' N ' ' HG2' ' A' ' 37' ' ' LYS . . . -69.7 -36.78 75.93 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 110.599 -1.001 . . . . 0.0 110.599 178.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.581 ' CE2' ' SD ' ' A' ' 43' ' ' MET . 24.4 t80 -71.64 -49.26 41.66 Favored 'General case' 0 CA--C 1.514 -0.432 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.845 -178.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 44' ' ' SER . 9.8 mptt -67.06 -39.07 86.82 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.484 178.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.405 ' O ' ' OG ' ' A' ' 44' ' ' SER . 63.4 tttp -61.65 -36.65 81.41 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 119.72 -0.792 . . . . 0.0 109.865 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -68.59 -35.92 78.02 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.502 179.758 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.581 ' SD ' ' CE2' ' A' ' 39' ' ' PHE . 26.4 mtp -88.64 -19.81 25.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.856 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.514 ' N ' ' O ' ' A' ' 40' ' ' LYS . 89.6 p -50.92 135.34 24.58 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.204 -179.761 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.449 ' OD1' ' N ' ' A' ' 46' ' ' ASP . 68.1 t0 -167.73 132.37 1.84 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.901 0.381 . . . . 0.0 110.749 -179.679 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.449 ' N ' ' OD1' ' A' ' 45' ' ' ASP . 56.9 t0 51.79 32.88 10.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.117 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 64.5 mt-10 -68.79 151.37 97.28 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.556 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_exo . . . . . 0 N--CA 1.488 1.189 0 C-N-CA 122.424 2.083 . . . . 0.0 112.05 179.776 . . . . . . . . 0 0 . 1 stop_ save_